TW201015069A - Markers for detection of gastric cancer - Google Patents

Abstract

Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be over-expressed in gastric tumor tissue and other tumor tissue, and thus can be used as markers for gastric and other types of cancer. GTM proteins can be released from cancer cells, and can reach sufficiently high concentrations in the serum and/or other fluids to permit their detection. Thus, methods and test kits for detection and quantification of GTM can provide a valuable tool for diagnosis of gastric cancer.

Description

201015069 VI. Description of the Invention: TECHNICAL FIELD OF THE INVENTION The present invention relates to the detection of cancer. In particular, the invention relates to the use of genetic and/or protein markers for detecting cancer and, more particularly, for detecting genetic and/or protein markers of gastric cancer. [Prior Art] When cancer is detected and treated early, the survival of cancer patients is greatly improved. In the case of gastric cancer, patients diagnosed with early disease, 9〇% ® annual survival, compared with approximately 10% of patients diagnosed with advanced disease. However, the vast majority of patients with gastric cancer currently have advanced disease. Therefore, the development of early diagnosis of gastric cancer can lead to improved patient prognosis. Identifying markers associated with specific cancers in biological samples, including body fluids such as blood, urine, peritoneal rinses, and fecal extracts, provides a valuable means of early diagnosis of cancer, leading to early treatment and improved prognosis. Specialized cancer markers also provide tools to monitor disease and track the efficacy of surgery, radiation therapy, and chemotherapy. However, for many major cancers, the available markers suffer from insufficient sensitivity and specificity. For example, the most commonly used gastric cancer markers cal9_9, ca72_4 and domain hairy embryonic antigen (CEA) detect only about 15-50% of any stage of gastric tumors' and decline to about 2-11% for early disease. Therefore, a very high frequency pseudo-negative test can cause the patient and the health care physician to believe that no disease is present, but in fact the patient may have a serious cancer that requires immediate attention. In addition, these markers may give a false positive signal in up to 1/3 of individuals with benign gastric disease 145138.doc 201015069. SUMMARY OF THE INVENTION Therefore, there is an urgent need for a preferred method of detecting the presence of cancer. The present invention provides methods, compositions, and devices that provide for the detection of early cancer' and reduce the frequency of false positive and false negative test results. In certain embodiments, molecular analysis can be used to identify genes that are overexpressed in gastric limb tissue as compared to non-malignant gastric tissue. Such assays include microarray and quantitative polymerase chain reaction (qPCR) methods. In this paper, cancer genes and proteins encoded by those genes are referred to as gastric tumor markers (GTM). It should be understood that the term GTM does not require that the marker be specific to gastric tumors only. Instead, it can be used in other types of tumors, including malignant or non-malignant tumors, including the stomach, bladder, colorectum, pancreas, ovaries, skin (such as melanoma), liver, esophagus, endometrium, and brain cancer. Increase the performance of GTM. However, it should be understood that the term (^1^1 does not include the prior art markers cal9-9, ca72-4 and CEA. Some GTMs are sufficiently over-expressed to diagnose gastric cancer with high reliability, while in other cases Excessive performance of two or more GTMs can provide a reliable diagnosis of gastric cancer. In some embodiments, a microarray method can be used to detect a pattern of overexpression of one or more cancer-related genes. In a specific embodiment, the presence of a marker that is overexpressed in a tumor or other biological sample can be confirmed using a quantitative polymerase chain reaction (qPCR). Some specific embodiments of the GTM assay disclosed herein are highly selective. The way 'overexpressed in tumor cells, and rarely overexpressed in non-tumor 145138.doc 201015069 cells, allows selective and accurate detection of cancer using only one measure of over-expressed GTM. In other embodiments, two, three or more GTMs can be detected in the sample and provide greater diagnostic validity. The encoded protein can be screened by or excised from the cell. Selected genes. These proteins, either alone or in combination with each other, have a serum or body fluid marker for diagnosing gastric cancer, or are used as markers for monitoring established diseases. Proteins can be processed using methods known in the art. Detection of markers, including the use of monoclonal antibodies, multiple antisera, and analogs thereof, using radioimmunoassay (RIA), protein wafers or suspension arrays. [Embodiment] Definitions Before describing specific embodiments of the invention in detail, It would be useful to provide some definitions of the nouns used herein. The term GTM or gastric tumor marker " or >gtm family member" means the gene, gene fragment 'RNA, RNA fragment, Protein or protein fragments, or other molecules that are associated with it, do not include molecules known in the prior art to be associated with gastric cancer, cal9_9, ca72_4, and CEA. Examples of GTMs are included below. The term "marker" means A molecule that is qualitatively or quantitatively associated with the presence of a biological phenomenon. An example of a marker is GTMs, however "a marker" Also included are metabolites, by-products, whether directly or indirectly related to conditions hidden under the mechanism. "qPCR" - the meaning of the specified amount of polymerase chain reaction. 145138.doc 201015069 "performance" Generating mRNA from a gene or a portion of a gene also includes the production of a protein encoded by an RNA or a gene or a portion of a gene, and more includes the presence of a detection material associated with performance. For example, binding to a ligand, such as an antibody and a gene or other nucleotide, The binding of a protein or protein fragment and the coloration of the binding partner are also included in the scope of the term "performance". Therefore, increasing the density of spots on immune dots, such as Western blots, is also included in the range of nouns "performance" hidden under biomolecules. "CPN2" - Word means human carboxypeptidase N, polypeptide 2,83 kDa chain; and carboxypeptidase N. "HAPLN4" - The word means human hyaluronan glycoprotein linked protein 4 . "MMP12" - The word means human matrix metalloproteinase 12. "INHBA" - The word means human statin, beta Α (also includes activin A, activin ΑΒ or alpha polypeptide). "IGFBP7" - The word means human insulin-like growth factor 7. "GGH" - The word means human gamma-amidoxime hydrolase (also known as conjugase, folylpolygammsiglutamyl hydrolase). "L£PRE1" - The word means human proteoglycan rich in leucine acid (also known as leprecan l). "CST4" - The word means human cysteine protease inhibitor S. "SFRP4" - The word means the human secreted frizzled protein 4 ° "ASPN" means the human asporin (also known as LRR class 1). 145138.doc -6 · 201015069 • The word "CGREF1M or "CGR11" - means a human cell growth regulator with EF hand function site 1. "KLK" - The word means human kallikrein 1 , variant 1 or human kallikrein 10, variant 2 or both, unless otherwise specified. The term "TIMP1" means a human tissue inhibitor of metalloproteinase 1 (also known as erythroid potentiating activity or collagenase inhibitor). β SPARC" - word means human secreted protein, acidic Rich in cysteine (also known as osteonectin) 〇"TGFBI" means human transforming growth factor, β_induced, 68 kDa 〇"EFEMP2" Humans contain EGF and other fibulin extracellular matrix proteins 2. LUM" - Word means human Lumiken (}umican). "SNN" - Word means human Sterling (stann(4). Φ &quot The term SPP1" means that human secretory phosphoprotein U is also known as osteopontin or bone sialic acid protein I or early tau lymphocyte activation 1). ''CSPG2' - word means human chondroitin sulfate protein Polysaccharide 2 (also known as versican). "ASAm" - the word means human N_ stilbene amide amine amine hydrolase, variant 1 or N-mercaptosphingosine guanamine hydrolase, variant 2 or thiosphingosine guanamine hydrolase Both variants 1 and 2 (also known as acidic neural guanylase, variants 1 and 2). ° 145138.doc 201015069 "PRSS11" - The word means human protease, serine 11 (also known as IGF binding serine protease). "SFRP2" - The word means human secretory curl-related protein 2. "?1^八20123" - The word means human phospholipase 8 2, and 118 groups. "SPON2" - The word means human spondin 2, an extracellular matrix protein. "OLFM1" - Word means human olfactomedin l. "TSRC1" - The word means a repeat of the human thrombospondin containing 1. "THBS2" - The word means human thrombospondin 2 . "Adelieken" means DKFZp564I1922. "CST2" - The word means the human cysteine protease inhibitor SA. "CST1" - The word means the human cysteine protease inhibitor SN. The term "LOXL2" means human adenosine oxidase-like enzyme 2. The term "TG" means human scorpion globulin. "TGFB1" - The word means human transforming growth factor, βΐ. "SERPINH1" - The word means human serine or cysteine protease inhibitor, a grade Η (also known as heat shock protein 47, member 1, or collagen-binding protein 1). The term "SERPINB5" means human serine or cysteine protease inhibitor, grade Β (also known as ovalbumin, member 5). The word "CEACAM5" or "CEA" means human cancer Embryonic antigen-related cell adhesion molecule 5 .

The term "ΜΜΡ2" means human matrix metalloproteinase 2 (also known as gelatinase A 145138.doc 201015069 . or 72 kDa gelatinase or 72 kDa type IV collagenase). "PCSK5" means human protein Proto-transformase subtilisin/kexin type 5 It should be understood that the above nouns may mean proteins, DNA sequences and/or RNA sequences. It should also be understood that the above terms may also mean The same sequence of non-human proteins, DNA and/or RNA are described. Description of the Invention of the Invention A marker for detecting and evaluating a cancer comprising gastric cancer is provided which has greater reliability in detecting gastric cancer than prior art markers. Regarding the term "reliability", we include the lack of false positives and/or false negatives. Therefore, the higher the reliability of the marker, the more false positives and/or false negatives associated with the diagnosis using the marker. Thus, in some embodiments, a marker is provided that allows detection of gastric cancer with a reliability that is about 50% higher than the reliability of prior art markers. In other embodiments, a ratio is provided. A marker of about 70% higher reliability; in another specific embodiment, it is higher than about 73%; in another specific embodiment, it is higher than about 80%; in another specific embodiment , higher than about 9 〇〇 / 0; in another specific embodiment, higher than about 95%; in other specific embodiments, higher than about 98%; and in some embodiments, Approximately 100% reliable markers. Therefore, we have surprisingly found that the emergence of many genes and proteins is associated with gastroenteroma. Therefore, gene products (such as nucleotides, such as mRNA) can be used, as well as from such Translating nucleotides Detection of white matter and peptides to diagnose tumors, such as gastric tumors. Array analysis of samples taken from patients with gastric tumors and non-malignant tissues of the same sputum has been guided to this amazing discovery. 'In many stomach tumors, a specific map of the overexpression of certain genes is associated with disease. Antibodies that are elevated against cancer markers can also be used to detect cancer markers. Therefore, 'by analyzing multiple cancer markers Presence and content can increase the sensitivity of the diagnosis' while reducing the frequency of false positive and/or false negative results. General Methods for Cancer Detection The following methods use members of the GTM family to detect cancer, including non-restrictive gastric cancer. Methods • Microarrays using oligonucleotide probes that are selective for the GTM gene product • Real-time quantitative PCR (qPCR) of tumor and normal samples using marker-specific primers and probes. • Enzyme Linked Immunoassay (ELIS A) • Immunohistochemistry for gastric tumor and lymph node metastasis using anti-marker antibodies • Use anti-standard Antibody to immunohistochemistry of other tumors, including but not limited to colorectal, pancreas, ovary, melanoma, liver, esophagus, bladder, endometrium, and brain. • Before and after surgery to remove tumors In the serum of patients with gastric cancer, 'immunological tests are performed on members of the marker family. · In individuals derived from healthy individuals and suffering from non-malignant diseases such as gastritis, ulcers, stomach 145138.doc -10· 201015069 metaplastic and dysplastic individuals In the serum, perform immunoassays for members of the marker family. • In patients with other cancers including but not limited to colorectal, pancreas, nest, melanoma, liver, esophagus, bladder, endometrium and brain To perform immunoassays for members of the marker family. • Detection of markers in body fluids, including serum, lymph, peritoneal fluid, cerebrospinal fluid, synovial fluid, and the like. Immunological detection of members of the marker family is performed in gastric juice, peritoneal washings, urine, and feces from patients with gastric cancer. Array methods and/or qPCR are used. • Use a computer to analyze arrays or qPCR data. Raw data were collected and analyzed for fold change by comparing the performance of gastric tumor genes with the extent to which the same genes were expressed in non-tumor tissues. A threshold is established to conclude that the performance is increased (e.g., l_5x increase, 2-fold increase, and in other embodiments, a 3-fold increase, a 4-fold increase, or a 5-fold increase). It will be appreciated that other thresholds for determining that an increased performance has occurred may be selected without departing from the scope of the invention. Further analysis of tumor gene expression involves matching the genes showing increased performance to known performance profiles of gastric tumors to provide a diagnosis of the tumor. » In certain aspects, the invention provides a method of detecting cancer comprising: (a) providing a biological sample; and (b) detecting excessive performance of a gtm family member in the sample. In other aspects, the invention encompasses the step of detecting excessive expression of GTM mRNA. In other views, the invention encompasses the step of detecting excessive expression of a GTM protein. 145138.doc 201015069 In a still further aspect, the invention encompasses the step of detecting excessive expression of a GTM peptide. In a still further aspect, the invention includes a device for detecting a GTM, comprising: a substrate having a GTM capture reagent thereon; and a detector coupled to the substrate, the detector capable of detecting a GTM associated with the capture reagent Wherein the capture reagent comprises an oligonucleotide or an antibody. Additional perspectives include kits for detecting cancer, including: Substance; GTM capture reagents, including one or more GTM-specific nucleotides and GTM-specific antibodies; and instructions for use. A still further aspect of the invention comprises a method of detecting GTM using qPCR, comprising: a forward primer specific to the GTM; a reverse primer specific to the GTM; a PCR reagent; a reaction vial; and instructions for use. Additional aspects of the invention include a kit for detecting the presence of a GTM protein or peptide, comprising: a substrate having a capture reagent for the GTM protein or peptide; an antibody specific for the GTM protein or peptide; capable of indicating that it has been associated with the GTM protein or Reagents for peptide-bound antibodies; 145138.doc -12- 201015069 and instructions for use. An additional aspect of the invention encompasses a method of making a monoclonal antibody, comprising the steps of: In a further step, the invention comprises a method of detecting gastric cancer comprising the steps of: providing a sample from a patient suspected of having gastric cancer; The presence of GTM protein was measured using ELISA. As described in this article, by measuring the performance of one or more tumor-specific markers, the completion of tumor detection, we unexpectedly found that the correlation between the increase in GTMs performance and the diagnosis of gastric cancer is extremely High: = The least significant association detected has a large 6χ1〇.6? value. At a P value of less than 20' many associations are significant. With such high significance, it may not be necessary to detect increased performance in more than one GTM. However, the lengthy GTMs in the present invention allow for the detection of gastric cancer with increased reliability. The methods provided herein also include highly sensitive assays. Qpc玟 is extremely sensitive and can be used to detect very low copy numbers (eg, “100) gene products in samples. With such sensitivity, it is possible to perform very early detection of events related to gastric cancer. A squat-like method to evaluate the appropriateness of various methods for molecular confirmation of markers associated with gastric tumors. Swollen collection 145138.doc -13· 201015069 from Seoul National University Hospital, Korea and Dunedin

In the surgical specimens removed from the Hospital, New Zealand, gastric swollen, tumor samples and non-malignant stomach tissues were collected. Based on the signs, the findings of the science, and the histological examination of the organization*, the diagnosis of gastric cancer is carried out. RNA Extraction In some embodiments, the performance of genes associated with gastric tumors is analyzed by determining changes in RNA from samples obtained from tumors. Frozen surgical specimens were embedded in OCT media. A 60 micron piece was cut from the tissue block using a microtome, homogenized in a TriReagent: water (3:1) mixture, and then extracted by gas chromatography. Total RNA was then purified from the liquid phase using the RNeasyTM program (Qiagen). RNA was also extracted from 16 cancer cell lines and pooled as reference RNA. Microarray slide preparation Epoxy coated slides were obtained from MWG Biotech AG, Ebersberg, Germany' and approximately 30,000 50-body oligonucleotides were printed using a Gene Machines microarray robot according to the manufacturer's draft. The relevant oligonucleotides, as well as the alignment number (MWG oligo#) of the NCBI mRNA and protein reference sequences, are presented in Figure 2. The complete DNA sequence of the GTM of the present invention is shown below. RNA labeling and hybridization in a reaction containing 5-(3-aminoallyl)-2'-deoxyuridine-5'-triphosphate, transcribed from 10 μg of total RNA using Superscriptll reverse transcriptase (Invitrogen) cDNA. The reaction was then deionized in a Microcon column and then incubated with Cy3 or Cy5 145138.doc -14-201015069 for 1 hour at room temperature in a bicarbonate buffer solution. The unincorporated dye was removed using a Qiaquick column (Qiagen) and the sample was concentrated to 15 microliters in a SpeedVac. The Cy3 and Cy5 labeled cDNAs were then denatured with Ambion ULTRAhyb buffer solution for 2 minutes at 100 °C and hybridized to the microarray slides for 16 hours at 42 °C in the hybridization chamber. The slides were then rinsed and scanned twice on an Axon 4000A scanner set to 2 output to produce raw fluorescent data for gene expression. Standardization procedure to compare the performance of cancer genes from tumors and non-cancerous tissues, by subtracting the local background fluorescence intensity' to correct the intermediate fluorescence intensity detected by GenepixTM software, and to exclude background correction intensity below 〇 Point. To make standardization more convenient' Logarithmically convert the intensity ratio and the overall dot intensity. For dye and spatial skew, use the local regression provided in the l〇cfittm suit soft palate to correct the intensity ratio of the logarithmic transformation. Regarding the overall dot intensity and position, the logarithmic conversion intensity ratio is returned to φ. The residual of the local regression provides a corrected log-fold change. For quality control, the ratio of each standardized microarray is plotted against dot intensity and localization. The dot pattern is then visually inspected for the remaining processed products. In addition, the variation analysis (AN〇VA) mode was also applied to detect needle-to-tip skew. Insert all ‘normalized results and parameters into the database for statistical analysis. Statistical Analysis By measuring the fold change between the arrays, it was confirmed that there was a statistically significant change in gene expression in the tumor sample versus positive tissue. To complete the work 145138.doc -15- 201015069 'proportional l〇g2 (proportion), so that each array has the same overall standard deviation. The standardization process reduces the variability within the average tissue type. Further conversion of l〇g2 (ratio) is made such that each oligonucleotide has an intermediate value of ’ to make the visual inspection result easier. Then use the level-check based on the fold change to improve the robustness of the noise. The assay consists of two steps: (1) calculating the grade of the fold change (Rfc) within the array, and (Η) subtracting the median value (Rfc) of the normal tissue from the median value (Rfc) of the tumor tissue. The difference between the two intermediate value levels defines the score of the multiple change level that appears in Figure 2. Two additional statistical tests can be performed on the normalized data: 1) student's t-test for both samples, with or without Bonferroni adjustment' and 2) Wilcoxon assay. Statistical analysis of beam fabric combinations To determine the use of a combination of two or three markers to identify the value of tumor and non-malignant samples, so that qPCR data from 40 pairs of samples (tumor and non-malignant samples are obtained from the same Patients) received the following analysis. The standard distribution of non-malignant and tumor samples was generated using sample mean and standard deviation'. It is then determined that the value taken from the tumor performance data will exceed a defined threshold in the non-malignant distribution (eg, greater than 50%, 70%, 73%, 80%, 90%, 95°/., 98%, 99%, or 100). Probability (ie sensitivity) of %). As for the combination of markers, a probability that at least one of the markers exceeds a threshold is determined. 145138.doc •16- 201015069 ο 4f male _Opoolllvauo8luvoowlull VU0I330WH1000IV00DV101W0VUV —ιο,ονιΰ,Ηιΰινον3νν80νΰΙ.3ιοισ^ VOOIWUOBUOOVBIOVOH ooalaovDOVSVQDOOV. '0' «u<UOOOOH<OOUHH<o<80H^ iui10voviui1viuiv1ioi8iuiuv0vv3iu'iui05^ OOVBIOBVauuvuIwuaLLYyuolov·oouvollvocoov'-'v'-'vooi. One. 0W00V0; 33VIUII8IVIUI30I5 ν1νγονογνοιυιον8νο8ιοιννο1ιο, 10Η · IIBIvv'uloxlooDYVVlvlolvovvlul5l <: lolvow5 VYOVOVWVlolulolvovoolvlol8, u, lov'uli olollvu '-' xlcmaLolvoD '-' IIBIlvvl printed owllollovoIVWVVlullu'oi, LLVlullolvv ^ lplmlvoowl vuluuloov: OIVlu'lgllv31VDVlulvlu'lvIBI -5550lqlv001aL3volovov8guo 8D9lulvolovlv3lulllouloowoov · Iwovoovovuollwuloovooloyon OOHOXXOV3wvovyovloloxowovlulD5 ^ usoaoauapuapsu^saa^ 01WHWHV011UI10UIUIWVUI0'10V01VVV0011 ▲ — <Nm to w>s〇r-ooo»om Pair «T^5tiWrNfN{srs<N<N<Nf^fnmmf^f^p〇fnfnf<i^i· ^ ^ ^ ^ V001V1V01D11WD01D11D01 ODOVUWUVlaLLUVOOOXlal

VOVVVOOIDIVOVISIIOVVOOO VVWOOVHOVUlowuwuovuvol Ο0018νυν10ννυ100νυνυ1 lOOOVOOIXDDOIVOOVOVOi 0v3vl DDlull0v3vuv018ui VO vowoovuDOHwulwuu:! 0X10V8D0U1VO1D8 οϋνννυχοννννϋινοονονοΗονι D081vlowoolol3uv8 vwauloolvuvlvulvuvoovuvi ΗΗΰυ < Η < υ < υΗΗυ8 < 8ΗΡ_

VDOloolooouQ

>WVW£ VD011JJ 31ΙΧυν310100νυ311νονοονν a lovo!Duloovlvovlvu100.LU00vl one

HvovuxlDV81D08wvloli 00VJLLL§H0vyxxDu1013xxi

VDOLLOVloollivvoDUOWI ΗΗΗυΗυυυυΗ<υΗΗΟ«ΟΟΗυΗ_ 8ν1νννο1χ8ϋ001υυ10νι

10VUVU10D0018VU101I $ - = 2 2 91 2 61 οε ιζ One + ιέβ*

voovwaLLVUVUVOOVWVavlYW

DuauolvolwoolovuDO νοο1χ0νν8ϋ0νυυυ1ονι

W0108D01WUS10I

8VU0§WU0V3100VUI OOLUVOOlDololvIvolvuwuvl ulloxouvoloouwovlovoilol

DolDlvolovlvu3Hollulxvol v§lluolauDOVuu§v 18vlvuvolvolooHulaLD8l 08<8ί<ΗΗυο<οο<ο<υο_ νννυ01038ννννοουι 1υυνυυν80ν8ν!00υι 3110VDO01DV3vl01DU31131l

W10V118U300V0831I 0ν1ν1υυ08νυνΗυνοονν001ι «ΟΗΗϋ<ϋουΗΟΟΗΗ80<ο_ <uutouoo<8uod_

W1V00V8LLLLVU8V3U1I

1101WDUVU1VD101V8100I υο.Ιγννο88111υ1νννννι ulvovuluoaLV80ivolil 1« 轚*铋¥„wi*蛘昧蝽蛘昧蝽.·豸^赛奶*1*

Is —s00SH IE 62αε—

Le s--s0SH

i-oo-OOSH

leslo-OOSH lEsioos

IE°°06S-00SH iv sdsu •-lsu

HOO

Ladol

03TM

Isas §1 3X3 -dym

I

1HVWV

3HVdS i ZSHH1 01 1503

9eMIdiHHOT ISJOl 2wud

iHHH 々dyis vans lddw

ISOL *

(al*tl)lw-ylgIE 3VS,NSe**Shan 黹啪 黹啪 淮 ^ ^ ^ · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

谫达^粜澹攻雄*-f*_N zfc-°*g箕"*雎*令(♦^sl-l*also 咖逭雄费3^-5^^^,-^ -111^资隹Class»- $. gf* 馕 馕 迤 迤 迤 · · y y y y y y y 屮 屮 屮 屮 屮 屮 屮 屮 屮 屮 屮 - * * Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji Ji *Shratter "Ύ容轚1-•屮B^^1-»18 145I38.doc -17· 201015069

Quantitative Real-Time PCR In other embodiments, immediate or quantitative PCR (qPCR) can be used for absolute or relative quantification of the number of PCR template copies. TaqmanTM probes and primer sets were designed using Primer Express V 2.0TM (Applied Biosystems). Where possible, all potential junction variants are included in the resulting extension region, and the extension region preferentially provides the region covered by the MWG-Biotech-derived microarray oligonucleotide. Alternatively, use these if you want to represent the target gene by including the 88&丫-〇11-〇6111&11£11'1^ performance array (Applied Biosystems). In Table 1 and in Fig. 1, the names of the genes, symbols, and Applied Biosystems" requirements for the determination of the qPCR, the advancement primer, the reverse primer, and the probe sequence are shown. In the assays designed in the company, the primer concentration was titrated using the SYBR green marker draft and cDNA prepared from the reference RNA. The expansion was performed on the ABI PrismTM 7000 Sequence Detection System under standard cyclization conditions. When a single amplified product was observed in the dissociation curve, a 5'FAM-3TAMRA phosphate needle (Proligo) with an optimum primer concentration and a final concentration of 250 nM was used to generate a standard curve in the range of more than 625-fold. In the subsequent measurement, an assay providing a standard curve having a regression coefficient of more than 0.98 was used. It will be appreciated that in other embodiments, the regression coefficients need not be as high. More specifically, any standard curve can be used as long as the regression coefficient is high enough to allow a statistically significant determination of the difference in performance. In alternative embodiments, such regression coefficients can be above about 0.7, above about 0.8, above about 0.9, or above about 0.95. Assays were performed on two 96-well plates, with a single cDNA representing each 145138.doc -18-201015069 RNA samples. Each plate contains duplicate reference cDNA standard curves, exceeding the 625-fold concentration range. The analysis included calculation of ACT (target gene ct_average reference cDNA CT). ACT is proportional to the change in the negative l〇g2 multiple. Then calculate the 1〇§2 fold change relative to the intermediate non-malignant l〇g2 fold change (ratio to fold change-intermediate standard l〇g2 fold change and then cluster these fold changes into frequency categories and make a chart. Cancer Identification Microarray analysis of the gene uses Cy5 to identify RNA from 58 gastric tumors and w non-malignant ("normal") gastric tissue samples, and reference nucleotides labeled with Cy3 in duplicate or triplicate Hybridization. After standardization, the change in performance was estimated in each of 29,718 genes by three measurements: (1)^ # ik: the median value of the gene in the tumor sample divided by the non-malignant test The ratio of the median values in the sample. The (Η) fold change level and (iii) the statistical probability of significant fold change were observed. The immunological analysis of the cancer marker gene can be used to understand the antibodies (single or multiple plants) that are resistant to GTM. GTM can be tested using several types of immunological methods. Radioimmunoassay (RIA) is well known in the art and can be used in fluid or tumor extracts. Measure and quantify GTM proteins. In addition, 'protein wafers and/or suspension arrays can also be fabricated, in which antibodies against GTM are placed on the substrate, such as glass or plastic surfaces. Samples can be applied to the wafer surface or to the suspension array. The GTM present in the sample is bound to the antibody. After the unbound antibody is removed by rinsing, the second antibody against GTM can be used to develop GTM. Production of antibodies and proteins 145138.doc -19· 201015069 Wafers, and methods of suspending arrays, are known in the art and need not be further described herein. For gastric malignant selection, in certain embodiments, biological fluids, including serum The cancer marker was found. The degree of (1) the presence of a signal sequence characteristic of the secreted protein or incision from the outside of the membrane' (ii) the intermediate degree of overexpression (fold change) in the tumor compared with the non-malignant control group, Iii) an intermediate change in the level of performance between the tumor and the non-malignant control group, and (iv) an overlap between the range of performance in the tumor and the non-malignant control group Based on the degree, select serum markers from the array data. All 29 GTMs are known to have a signal peptide sequence at the 5' end of their codon sequence. The signal sequence targets the GTM protein and is transported through the serosa to the extracellular compartment (Gunner Von Heijne, Journal of Molecular Biology 173: 243-251 (1984)). Furthermore, none of the GTMs have a penetrating membrane sequence motif which will result in the full length of the protein being retained in the serosa. As a result, all GTM markers of the invention The substance may be secreted into the extracellular space 'and thus may be in contact with the blood supply, taken up by the capillaries or transported into the lymphatic system' and then into the blood supply. As a result, these tumor-derived markers will all appear in the gold solution. Next, if >50% of the tumor samples showed a degree of expression within 95% of the non-malignant range, the gene was excluded. In tumor samples, changes in the extent of overexpression not only reflect tumor heterogeneity, but also the extent to which tumor samples are contaminated by "normal" tissues, including muscle, stromal cells, and non-malignant epithelial glands. The change on. ,, normal, pollution range from 5 to 7〇%, median 145138.doc •20· 201015069 approximately 25%. Exclude other genes because of their high relative expression in hematopoietic cells or elevated expression in metaplastic stomach tissue. It can be appreciated that depending on the extent of contamination by normal cells or cells that normally exhibit the marker, different threshold ranges can be selected to provide adequate separation of the cancer source from the normal source. We found useful GTMs including the following markers of genes (DNA), complementary DNA (cDNA), RNA, proteins and protein fragments: carboxypeptidase N, peptide 2, 83 kDa chain (also known as carboxypeptidase N (CPN2) ), matrix metalloproteinase 12 (MMP12), statin ("INHBA"), insulin-like growth factor 7 (nIGFBP7"), γ-amidoxime hydrolase ("GGH"), leucine-rich amide Acid proteoglycan ("LEPRE1"), cysteine protease inhibitor S ("CST4"), secretory curly-related protein 4 ("SFRP4"), Aspen cloud ("ASPN"), with Cell growth regulator ("CGREF1"), kallikrein 10 ("KLK10"), tissue inhibitor of metalloproteinase 1 ("TIMP1"), secretory acidic rich half of EF hand function site 1 Cystein acid protein ("SPARC"), transforming growth factor, β-induced ("TGFBI"), containing EGF, etc. - phenanthrene extracellular matrix protein 2 ("EFEMP2"), Lumiken ("LUM"), Sterling ("SNN"), secretory phosphoprotein 1 (&quo t;SPP1"), chondroitin sulfate proteoglycan 2 ("CSPG2"), N-mercaptosphingosine guanamine hydrolase ("ASAH1"), serine protease 11 ("PRSS11"), secretory curl - related protein 2 ("SFRP2"), phospholipase A2, XIIB group ("PLA2G12B"), stritin 2, extracellular matrix protein ("SPON2"), olfactory medlar l("〇LFMl" ), a thrombospondin repeat containing 1 ("TSRC1"), human thrombospondin 2 ("THBS2"), Adelikan, cysteine protease inhibitor SA ("CST2"), cysteine Amino acid protease 145138.doc -21- 201015069 Inhibitor SN ("CST1"), adenine oxidase-like enzyme 2 ("LOXL2"), thyroglobulin ("TG"), transforming growth factor, Pi("TGFBl"), serine or cysteine protease inhibitor, level H ("SERPINH1"), serine or cysteine protease inhibitor, level B ("SERPINB5"), Matrix metalloproteinase 2 ("MMP2"), proprotein convertase subtilisin / Kaixin 5 Type ("PCSK5"), and hyaluronic acid glycoprotein-linked protein 4 ("HAPLN4"). DNA The DNA sequence of the GTM of the present invention is shown below, together with confirmation information. Matrix metalloproteinase 12 >gi j 4505206丨ref丨NM_002426.1丨human matrix metalloproteinase 12 (macrophage elastase) (MMP12), mRNA丨qPCR advancement_introduction matches [75 8..780] | qPCR reverse _Introduction matches [888..864] | qPCR probe matches [786..815]

TAGAAGTTTACAATGAAGTTTCTTCTAATACTGCTCCTGCAGGCCA CTGCTTCTGGAGCTCTTCCCCTGAACAGCTCTACAAGCCTGGAAAAAAAT AATGTGCTATTTGGTGAGAGATACTTAGAAAAATTTTATGGCCTTGAGATA AACAAACTTCCAGTGACAAAAATGAAATATAGTGGAAACTTAATGAAGG Q AAAAAATCCAAGAAATGCAGCACTTCTTGGGTCTGAAAGTGACCGGGCAA CTGGACACATCTACCCTGGAGATGATGCACGCACCTCGATGTGGAGTCCC CGATCTCCATCATTTCAGGGAAATGCCAGGGGGGCCCGTATGGAGGAAAC ATTATATCACCTACAGAATCAATAATTACACACCTGACATGAACCGTGAG GATGTTGACTACGCAATCCGGAAAGCTTTCCAAGTATGGAGTAATGTTAC CCCCTTGAAATTCAGCAAGATTAACACAGGCATGGCTGACATTTTGGTGG TTTTTGCCCGTGGAGCTCATGGAGACTTCCATGCTTTTGATGGCAAAGGTG GAATCCTAGCCCATGCTTTTGGACCTGGATCTGGCATTGGAGGGGATGCA CATTTCGATGAGGACGAATTCTGGACTACACATTCAGGAGGCACAAACTT GTTCCTCACTGCTGTTCACGAGATTGGCCATTCCTTAGGTCTTGGCCATTCT AGTGATCCAAAGGCTGTAATGTTCCCCACCTACAAATATGTCGACATCAA CACATTTCGCCTCTCTGCTGATGACATACGTGGCATTCAGTCCCTGTATGG AGACCCAAAAGAGAACCAACGCTTGCCAAATCCTGACAATTCAGAACCAG CTCTCTGTGACCCCAATTTGAGTTTTGATGCTGTCACTACCGTGGGAAATA AGATCTTTTTCTTCAAAGACAGGTTCTTCTGGCTGAAGGTTTCTGAGAGAC CAAAGACCAGTGTTAATTTAATTTCTT CCTTATGGCCAACCTTGCCATCTG GCATTGAAGCTGCTTATGAAATTGAAGCCAGAAATCAAGTTTTTCTTTTTA 145138.doc -22- 201015069

AAGATGACAAATACTGGTTAATTAGCAATTTAAGACCAGAGCCAAATTAT

CCCAAGAGCATACATTCTTTTGGTTTTCCTAACTTTGTGAAAAAAATTGAT

GCAGCTGTTTTTAACCCACGTTTTTATAGGACCTACTTCTTTGTAGATAAC

CAGTATTGGAGGTATGATGAAAGGAGACAGATGATGGACCCTGGTTATCC

CAAACTGATTACCAAGAACTTCCAAGGAATCGGGCCTAAAATTGATGCAG

TCTTCTATTCTAAAAACAAATACTACTATTTCTTCCAAGGATCTAACCAAT

TTGAATATGACTTCCTACTCCAACGTATCACCAAAACACTGAAAAGCAAT

AGCTGGTTTGGTTGTTAGAAATGGTGTAATTAATGGTTTTTGTTAGTTCAC

TTCAGCTTAATAAGTATTTATTGCATATTTGCTATGTCCTCAGTGTACCACT

ACTTAGAGATATGTATCATAAAAATAAAATCTGTAAACCATAGGTAATGA

TTATATAAAATACATAATATTTTTCAATTTTGAAAACTCTAATTGTCCATTC

TTGCTTGACTCTACTATTAAGTTTGAAAATAGTTACCTTCAAAGCAAGATA

ATTCTATTTGAAGCATGCTCTGTAAGTTGCTTCCTAACATCCTTGGACTGA

GAAATTATACTTACTTCTGGCATAACTAAAATTAAGTATATATATTTTGGC TCAAATAAAATTG Sequence No. 67

Inhibin PA

>gi|4504698|ref|NM_002192.l| Human inhibin, βΑ (activin A, activinΑΒα polypeptide) (ΙΝΗΒΑ), mRNA I qPCR is determined in accordance with [457..481]

TCCACACACACAAAAAACCTGCGCGTGAGGGGGGAGGAAAAGCAG

GGCCTTTAAAAAGGCAATCACAACAACTTTTGCTGCCAGGATGCCCTTGCT

TTGGCTGAGAGGATTTCTGTTGGCAAGTTGCTGGATTATAGTGAGGAGTTC

CCCCACCCCAGGATCCGAGGGGCACAGCGCGGCCCCCGACTGTCCGTCCT

GTGCGCTGGCCGCCCTCCCAAAGGATGTACCCAACTCTCAGCCAGAGATG

GTGGAGGCCGTCAAGAAGCACATTTTAAACATGCTGCACTTGAAGAAGAG

ACCCGATGTCACCCAGCCGGTACCCAAGGCGGCGCTTCTGAACGCGATCA

GAAAGCTTCATGTGGGCAAAGTCGGGGAGAACGGGTATGTGGAGATAGA

GGATGACATTGGAAGGAGGGCAGAAATGAATGAACTTATGGAGCAGACC

TCGGAGATCATCACGTTTGCCGAGTCAGGAACAGCCAGGAAGACGCTGCA

CTTCGAGATTTCCAAGGAAGGCAGTGACCTGTCAGTGGTGGAGCGTGCAG

AAGTCTGGCTCTTCCTAAAAGTCCCCAAGGCCAACAGGACCAGGACCAAA

GTCACCATCCGCCTCTTCCAGCAGCAGAAGCACCCGCAGGGCAGCTTGGA

CACAGGGGAAGAGGCCGAGGAAGTGGGCTTAAAGGGGGAGAGGAGTGA

ACTGTTGCTCTCTGAAAAAGTAGTAGACGCTCGGAAGAGCACCTGGCATG

TCTTCCCTGTCTCCAGCAGCATCCAGCGGTTGCTGGACCAGGGCAAGAGC

TCCCTGGACGTTCGGATTGCCTGTGAGCAGTGCCAGGAGAGTGGCGCCAG

CTTGGTTCTCCTGGGCAAGAAGAAGAAGAAAGAAGAGGAGGGGGAAGGG

AAAAAGAAGGGCGGAGGTGAAGGTGGGGCAGGAGCAGATGAGGAAAAG

GAGCAGTCGCACAGACCTTTCCTCATGCTGCAGGCCCGGCAGTCTGAAGA

CCACCCTCATCGCCGGCGTCGGCGGGGCTTGGAGTGTGATGGCAAGGTCA

ACATCTGCTGTAAGAAACAGTTCTTTGTCAGTTTCAAGGACATCGGCTGGA

ATGACTGGATCATTGCTCCCTCTGGCTATCATGCCAACTACTGCGAGGGTG

AGTGCCCGAGCCATATAGCAGGCACGTCCGGGTCCTCACTGTCCTTCCACT

CAACAGTCATCAACCACTACCGCATGCGGGGCCATAGCCCCTTTGCCAAC

CTCAAATCGTGCTGTGTGCCCACCAAGCTGAGACCCATGTCCATGTTGTAC

TATGATGATGGTCAAAACATCATCAAAAAGGACATTCAGAACATGATCGT 145138.doc -23- 201015069

GGAGGAGTGTGGGTGCTCATAGAGTTGCCCAGCCCAGGGGGAAAGGGAG

CAAGAGTTGTCCAGAGAAGACAGTGGCAAAATGAAGAAATTTTTAAGGTT

TCTGAGTTAACCAGAAAAATAGAAATTAAAAACAAAACAAAACAAAAAA

AAAAACAAAAAAAAACAAAAGTAAATTAAAAACAAACCTGATGAAACAG

ATGAAACAGATGAAGGAAGATGTGGAAATCTTAGCCTGCCTTAGCCAGGG

CTCAGAGATGAAGCAGTGAAGAGACAGATTGGGAGGGAAAGGGAGAATG

GTGTACCCTTTATTTCTTCTGAAATCACACTGATGACATCAGTTGTTTAAA

CGGGGTATTGTCCTTTCCCCCCTTGAGGTTCCCTTGTGAGCTTGAATCAAC

CAATCTGATCTGCAGTAGTGTGGACTAGAACAACCCAAATAGCATCTAGA

AAGCCATGAGTTTGAAAGGGCCCATCACAGGCACTTTCCTAGCCTAAT Sequence No. 68 Insulin-like Growth Factor 7 >gi | 4504618 | ref丨NM_001553.1 | Human Insulin Growth Factor 7 (IGFBP7), mRNA | qPCR Advance—Introduction Matches with [470..487]|9? and reverse primer foot _ [567..546] Matches | 41 > € 11 and the probe [492..517] Matches GCCGCTGCCACCGCACCCCGCCATGGAGCGGCCGTCGCTGCGCGCC CTGCTCCTCGGCGCCGCTGGGCTGCTGCTCCTGCTCCTGCCCCTCTCCTCTT CCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGCCCGCCCC TGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGC TGCCCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGC CGGCAGGGGGTACTGCGCGCCGGGCATGGAGTGCGTGAAGAGCCGCAAG AGGCGGAAGGGTAAAGCCGGGGCAGCAGCCGGCGGTCCGGGTGTAAGCG GCGTGTGCGTGTGCAAGAGCCGCTACCCGGTGTGCGGCAGCGACGGCACC ACCTACCCGAGCGGCTGCCAGCTGCGCGCCGCCAGCCAGAGGGCCGAGA GCCGCGGGGAGAAGGCCATCACCCAGGTCAGCAAGGGCACCTGCGAGCA AGGTCCTTCCATAGTGACGCCCCCCAAGGACATCTGGAATGTCACTGGTG CCCAGGTGTACTTGAGCTGTGAGGTCATCGGAATCCCGACACCTGTCCTCA ❿ TCTGGAACAAGGTAAAAAGGGGTCACTATGGAGTTCAAAGGACAGAACT CCTGCCTGGTGACCGGGACAACCTGGCCATTCAGACCCGGG GTGGCCCAG AAAAGCATGAAGTAACTGGCTGGGTGCTGGTATCTCCTCTAAGTAAGGAA GATGCTGGAGAATATGAGTGCCATGCATCCAATTCCCAAGGACAGGCTTC AGCATCAGCAAAAATTACAGTGGTTGATGCCTTACATGAAATACCAGTGA AAAAAGGTGAAGGTGCCGAGCTATAAACCTCCAGAATATTATTAGTCTGC ATGGTTAAAAGTAGTCATGGATAACTACATTACCTGTTCTTGCCTAATAAG TTTCTTTTAATCCAATCCACTAACACTTTAGTTATATTCACTGGTTTTACAC AGAGAAATACAAAATAAAGATCACACATCAAGACTATCTACAAAAATTTA TTATATATTTACAGAAGAAAAGCATGCATATCATTAAACAAATAAAATAC TTTTTATCACAAAAAAAAAAAAAAAA Serial No. 69 γ_ hub amine acyl hydrolase > gi 4503986 Shu Shu Shu ref ΝΜ_003878.1 | human γ- hub acyl hydrolase amine 145138.doc -24- 201015069 (engagement Enzyme, Foley poly-gamma glutamine hydrolase) (GGH), mRNA|qPCR Advance_Introduction matches [53 1..547] I qPCR reverse-introduction matches [611..587] | qPCR probe and [549..577]matching TGCCGCAGCCCCCGCCCGCCCGCAGAGCTTTTGAAAGGCGGCGGG AGGCGGCGAGCGCCATGGCCAGTCCGGGCTGCCTGCTGTGCGTGCTGGGC CTGCTACTCTGCGGGGCGGCGAGCCTCGAGCTGTCTAGACCCCACGGCGA CACCGCCAAGAAGCCCATCATCGGAATATTAATGCAAAAATGCCGTAATA AAGTCATGAAAAACTATGGAAGATACTATATTGCTGCGTCATATGT AAAG TACTTGGAGTCTGCAGGTGCGAGAGTTGTACCAGTAAGGCTGGATCTTAC AGAGAAAGACTATGAAATACTTTTCAAATCTATTAATGGAATCCTTTTCCC TGGAGGAAGTGTTGACCTCAGACGCTCAGATTATGCTAAAGTGGCCAAAA TATTTTATAACTTGTCCATACAGAGTTTTGATGATGGAGACTATTTTCCTGT GTGGGGCACATGCCTTGGATTTGAAGAGCTTTCACTGCTGATTAGTGGAG AGTGCTTATTAACTGCCACAGATACTGTTGACGTGGCAATGCCGCTGAACT TCACTGGAGGTCAATTGCACAGCAGAATGTTCCAGAATTTTCCTACTGAGT TGTTGCTGTCATTAGCAGTAGAACCTCTGACTGCCAATTTCCATAAGTGGA GCCTCTCCGTGAAGAATTTTACAATGAATGAAAAGTTAAAGAAGTTTTTC AATGTCTTAACTACAAATACAGATGGCAAGATTGAGTTTATTTCAACAAT GGAAGGATATAAGTATCCAGTATATGGTGTCCAGTGGCATCCAGAGAAAG CACCTTATGAGTGGAAGAATTTGGATGGCATTTCCCATGCACCTAATGCTG TGAAAACCGCATTTTATTTAGCAGAGTTTTTTGTTAATGAAGCTCGGAAAA ACAACCATCATTTTAAATCTGAATCTGAAGAGGAGAAAGCATTGATTTAT CAGTTCAGTCCAATTTATACTGGAAATATTTCTTCATTTCAGCAATGTTAC ATATTTGATTGAAAGTCTTCAATTTGTTAACAGAGCAAATTTGAATAATTC CATGATTAAACTGTTAGAATAACTTGCTACTCATGGCAAGATTAGGAAGT CACAGATTCTTTTCTATAATGTGCCTGGCTCTGATTCTTCATTATGTATGTG ACTATTTATATAACATTAGATAATTAAATAGTGAGACATAAATAGAGTGC TTTTTCATGGAAAA GCCTTCTTATATCTGAAGATTGAAAAATAAATTTACT GAAATACAAAAAAAAAAAAAAA Sequence No. 70

>gi| 21361917丨ref |ΝΜ_022356·2|Protein rich in leucine acid lysine (Lipken), (LEPRE1), mRNA | qPCR Advance—primer matches [813..836]|qPCR and reverse primer _ [894..872] Matches | qPCR probe with [841..870] Matches GGTGGCGGGTGGCTGGCGGTTCCGTTAGGTCTGAGGGAGCGATGG CGGTACGCGCGTTGAAGCTGCTGACCACACTGCTGGCTGTCGTGGCCGCT GCCTCCCAAGCCGAGGTCGAGTCCGAGGCAGGATGGGGCATGGTGACGCC TGATCTGCTCTTCGCCGAGGGGACCGCAGCCTACGCGCGCGGGGACTGGC CCGGGGTGGTCCTGAGCATGGAACGGGCGCTGCGCTCCCGGGCAGCCCTC CGCGCCCTTCGCCTGCGCTGCCGCACCCAGTGTGCCGCCGACTTCCCGTGG leucine proline-enriched proteoglycan of 1 145138.doc -25- 201015069

GAGCTGGACCCCGACTGGTCCCCCAGCCCGGCCCAGGCCTCGGGCGCCGC

CGCCCTGCGCGACCTGAGCTTCTTCGGGGGCCTTCTGCGTCGCGCTGCCTG

CCTGCGCCGCTGCCTCGGGCCGCCGGCCGCCCACTCGCTCAGCGAAGAGA

TGGAGCTGGAGTTCCGCAAGCGGAGCCCCTACAACTACCTGCAGGTCGCC

TACTTCAAGATCAACAAGTTGGAGAAAGCTGTTGCTGCAGCACACACCTT

CTTCGTGGGCAATCCTGAGCACATGGAAATGCAGCAGAACCTAGACTATT

ACCAAACCATGTCTGGAGTGAAGGAGGCCGACTTCAAGGATCTTGAGACT

CAACCCCATATGCAAGAATTTCGACTGGGAGTGCGACTCTACTCAGAGGA

ACAGCCACAGGAAGCTGTGCCCCACCTAGAGGCGGCGCTGCAAGAATACT

TTGTGGCCTATGAGGAGTGCCGTGCCCTCTGCGAAGGGCCCTATGACTAC

GATGGCTACAACTACCTTGAGTACAACGCTGACCTCTTCCAGGCCATCAC

AGATCATTACATCCAGGTCCTCAACTGTAAGCAGAACTGTGTCACGGAGC

TTGCTTCCCACCCAAGTCGAGAGAAGCCCTTTGAAGACTTCCTCCCATCGC

ATTATAATTATCTGCAGTTTGCCTACTATAACATTGGGAATTATACACAGG

CTGTTGAATGTGCCAAGACCTATCTTCTCTTCTTCCCCAATGACGAGGTGA

TGAACCAAAATTTGGCCTATTATGCAGCTATGCTTGGAGAAGAACACACC

AGATCCATCGGCCCCCGTGAGAGTGCCAAGGAGTACCGACAGCGAAGCCT

ACTGGAAAAAGAACTGCTTTTCTTCGCTTATGATGTTTTTGGAATTCCCTTT

GTGGATCCGGATTCATGGACTCCAGGAGAAGTGATTCCCAAGAGATTGCA

AGAGAAACAGAAGTCAGAACGGGAAACAGCCGTACGCATCTCCCAGGAG

ATTGGGAACCTTATGAAGGAAATCGAGACCCTTGTGGAAGAGAAGACCA

AGGAGTCACTGGATGTGAGCAGACTGACCCGGGAAGGTGGCCCCCTGCTG

TATGAAGGCATCAGTCTCACCATGAACTCCAAACTCCTGAATGGTTCCCA

GCGGGTGGTGATGGACGGCGTAATCTCTGACCACGAGTGTCAGGAGCTGC

AGAGACTGACCAATGTGGCAGCAACCTCAGGAGATGGCTACCGGGGTCA

GACCTCCCCACATACTCCCAATGAAAAGTTCTATGGTGTCACTGTCTTCAA

AGCCCTCAAGCTGGGGCAAGAAGGCAAAGTTCCTCTGCAGAGTGCCCACC

TGTACTACAACGTGACGGAGAAGGTGCGGCGCATCATGGAGTCCTACTTC

CGCCTGGATACGCCCCTCTACTTTTCCTACTCTCATCTGGTGTGCCGCACT

GCCATCGAAGAGGTCCAGGCAGAGAGGAAGGATGATAGTCATCCAGTCC

ACGTGGACAACTGCATCCTGAATGCCGAGACCCTCGTGTGTGTCAAAGAG

CCCCCAGCCTACACCTTCCGCGACTACAGCGCCATCCTTTACCTAAATGGG

GACTTCGATGGCGGAAACTTTTATTTCACTGAACTGGATGCCAAGACCGT

GACGGCAGAGGTGCAGCCTCAGTGTGGAAGAGCCGTGGGATTCTCTTCAG

GCACTGAAAACCCACATGGAGTGAAGGCTGTCACCAGGGGGCAGCGCTGT

GCCATCGCCCTGTGGTTCACCCTGGACCCTCGACACAGCGAGCGGGTGAG

AGCAGCTCGAGCGGGTGAGAGCAGCTGGTGCTGTGGTGACCCGTTCCCAG

AGCGCCCTTGGTTTGCCTTTCTCTTCCCCAAATCCCATTGCCAGTGGCTGA

GACACGAAAGGAGCACTTGGGACACCAGCTCCAACGCCCTGTCATTATGG

TCACATTGCCTTGTCCTCCCTGGGCCTGCTGTGAACGGGATCCAGGTGGGG

AAAGAGGTCAAGACAGGGAGCGATGCTGAGTTCTTGGTTCCCTCCTTGGG

CCCCACTTCAGCTGTCCTTTTCCAGAGAGTAGGACCTGCTGGGAAGGAGA

TGAGCCTGGGGCCATTAAGGAACCTTCCTTGTCCCCTGGGAAGTAGCAGC

TGAGAGATAGCGAGTGTCTGGAGCGGAGGCCTCTCTGAATGGGCAGGGGT

TTGTCCTTGCAGGACAGGGTGCAGGCAGATGACCTGGTGAAGATGCTCTT

CAGCCCAGAAGAGATGGTCCTCTCCCAGGAGCAGCCCCTGGATGCCCAGC

AGGGCCCCCCCGAACCTGCACAAGAGTCTCTCTCAGAGAGTGAATCGAAG

CCCAAGGATGAGCTATGACAGCGTCCAGGTCAGACGGATGGGTGACTAGA

CCCATGGAGAGGAACTCTTCTGCACTCTGAGCTGGCCAGCCCCTCGGGGC

TGCAGAGCAGTGAGCCTACATCTGCCACTCAGCCGAGGGGACCCTGCTCA

CAGCCTTCTACATGGTGCTACTGCTCTTGGAGTGGACATGACCAGACACC 145138.doc -26- 201015069

GCACCCCCTGGATCTGGCTGAGGGCTCAGGACACAGGCCCAGCCACCCCC

AGGGGCCTCCACAGGCCGCTGCATAACAGCGATACAGTACTTAAGTGTCT

GTGTAGACAACCAAAGAATAAATGATTCATGGTTTTTTTT Sequence No. 71 Cysteine protease inhibition Xie s > gi丨19882254丨ref丨ΝΜ_001899·2丨 Human cysteine protease inhibitor 8 (€3丁4), 〇1«^八|9? 11 Advance_Introduction matches [343..361]|4?〇1 Reverse_Introduction matches [434..411]|9?1111 Probe matches [3 82..410]

GGCTCTCACCCTCCTCTCCTGCAGCTCCAGCTTTGTGCTCTGCCTCT GAGGAGACCATGGCCCGGCCTCTGTGTACCCTGCTACTCCTGATGGCTACC CTGGCTGGGGCTCTGGCCTCGAGCTCCAAGGAGGAGAATAGGATAATCCC AGGTGGCATCTATGATGCAGACCTCAATGATGAGTGGGTACAGCGTGCCC TTCACTTCGCCATCAGCGAGTACAACAAGGCCACCGAAGATGAGTACTAC AGACGCCCGCTGCAGGTGCTGCGAGCCAGGGAGCAGACCTTTGGGGGGGT GAATTACTTCTTCGACGTAGAGGTGGGCCGCACCATATGTACCAAGTCCC AGCCCAACTTGGACACCTGTGCCTTCCATGAACAGCCAGAACTGCAGAAG AAACAGTTGTGCTCTTTCGAGATCTACGAAGTTCCCTGGGAGGACAGAAT GTCCCTGGTGAATTCCAGGTGTCAAGAAGCCTAGGGGTCTGTGCCAGGCC AGTCACACCGACCACCACCCACTCCCACCCACTGTAGTGCTCCCACCCCTG GACTGGTGGCCCCCACCCTGCGGGAGGCCTCCCCATGTGCCTGTGCCAAG AGACAGACAGAGAAGGCTGCAGGAGTCCTTTGTTGCTCAGCAGGGCGCTC TGCCCTCCCTCCTTCCTTCTTGCTTCTAATAGACCTGGTACATGGTACACAC ACCCCCACCTCCTGCAATTAAACAGTAGCATCGCC No. 72 secreted frizzled protein handcuffs off sequence 4 ❹ > gi | 8400733 | ref Shu Shu ΝΜ_003014.2 human secreted frizzled related protein 4 (SFRP4), mRNA | qPCR is matched with [1079..1103] when requested in the context.

GGCGGGTTCGCGCCCCGAAGGCTGAGAGCTGGCGCTGCTCGTGCCC

TGTGTGCCAGACGGCGGAGCTCCGCGGCCGGACCCCGCGGCCCCGCTTTG

CTGCCGACTGGAGTTTGGGGGAAGAAACTCTCCTGCGCCCCAGAAGATTT

CTTCCTCGGCGAAGGGACAGCGAAAGATGAGGGTGGCAGGAAGAGAAGG

CGCTTTCTGTCTGCCGGGGTCGCAGCGCGAGAGGGCAGTGCCATGTTCCTC

TCCATCCTAGTGGCGCTGTGCCTGTGGCTGCACCTGGCGCTGGGCGTGCGC

GGCGCGCCCTGCGAGGCGGTGCGCATCCCTATGTGCCGGCACATGCCCTG

GAACATCACGCGGATGCCCAACCACCTGCACCACAGCACGCAGGAGAAC

GCCATCCTGGCCATCGAGCAGTACGAGGAGCTGGTGGACGTGAACTGCAG

CGCCGTGCTGCGCTTCTTCTTCTGTGCCATGTACGCGCCCATTTGCACCCT

GGAGTTCCTGCACGACCCTATCAAGCCGTGCAAGTCGGTGTGCCAACGCG 145138.doc •27- 201015069

CGCGCGACGACTGCGAGCCCCTCATGAAGATGTACAACCACAGCTGGCCC GAAAGCCTGGCCTGCGACGAGCTGCCTGTCTATGACCGTGGCGTGTGCAT TTCGCCTGAAGCCATCGTCACGGACCTCCCGGAGGATGTTAAGTGGATAG ACATCACACCAGACATGATGGTACAGGAAAGGCCTCTTGATGTTGACTGT AAACGCCTAAGCCCCGATCGGTGCAAGTGTAAAAAGGTGAAGCCAACTTT GGCAACGTATCTCAGCAAAAACTACAGCTATGTTATTCATGCCAAAATAA AAGCTGTGCAGAGGAGTGGCTGCAATGAGGTCACAACGGTGGTGGATGTA AAAGAGATCTTCAAGTCCTCATCACCCATCCCTCGAACTCAAGTCCCGCTC ATTACAAATTCTTCTTGCCAGTGTCCACACATCCTGCCCCATCAAGATGTT CTCATCATGTGTTACGAGTGGCGTTCAAGGATGATGCTTCTTGAAAATTGC TTAGTTGAAAAATGGAGAGATCAGCTTAGTAAAAGATCCATACAGTGGGA AGAGAGGCTGCAGGAACAGCGGAGAACAGTTCAGGACAAGAAGAAAACA GCCGGGCGCACCAGTCGTAGTAATCCCCCCAAACCAAAGGGAAAGCCTCC TGCTCCCAAACCAGCCAGTCCCAAGAAGAACATTAAAACTAGGAGTGCCC AGAAGAGAACAAACCCGAAAAGAGTGTGAGCTAACTAGTTTCCAAAGCG GAGACTTCCGACTTCCTTACAGGATGAGGCTGGGCATTGCCTGGGACAGC CTATGTAAGGCCATGTGCCCCTTGCCCTAACAACTCACTGCAGTGCTCTTC ATAGACACATCTTGCAGCATTTTTCTTAAGGCTATGCTTCAGTTTTTCTTTG TAAGCCATCACAAGCCATAGTGGTAGGTTTGCCCTTTGGTACAGAAGGTG AGTTAAAGCTGGTGGAAAAGGCTTATT GCATTGCATTCAGAGTAACCTGT GTGCATACTCTAGAAGAGTAGGGAAAATAATGCTTGTTACAATTCGACCT AATATGTGCATTGTAAAATAAATGCCATATTTCAAACAAAACACGTAATT TTTTTACAGTATGTTTTATTACCTTTTGATATCTGTTGTTGCAATGTTAGTG ATGTTTTAAAATGTGATGAAAATATAATGTTTTTAAGAAGGAACAGTAGT GGAATGAATGTTAAAAGATCTTTATGTGTTTATGGTCTGCAGAAGGATTTT TGTGATGAAAGGGGATTTTTTGAAAAATTAGAGAAGTAGCATATGGAAAA TTATAATGTGTTTTTTTACCAATGACTTCAGTTTCTGTTTTTAGCTAGAAAC TTAAAAACAAAAATAATAATAAAGAAAAATAAATAAAAAGGAGAGGCAG ACAATGTCTGGATTCCTGTTTTTTGGTTACCTGATTTCCATGATCATGATGC TTCTTGTCAACACCCTCTTAAGCAGCACCAGAAACAGTGAGTTTGTCTGTA CCATTAGGAGTTAGGTACTAATTAGTTGGCTAATGCTCAAGTATTTTATAC CCACAAGAGAGGTATGTCACTCATCTTACTTCCCAGGACATCCACCCTGA GAATAATTTGACAAGCTTAAAAATGGCCTTCATGTGAGTGCCAAATTTTGT TTTTCTTCATTTAAATATTTTCTTTGCCTAAATACATGTGAGAGGAGTTAA ATATAAATGTACAGAGAGGAAAGTTGAGTTCCACCTCTGAAATGAGAATT ACTTGACAGTTGGGATACTTTAATCAGAAAAAAAGAACTTATTTGCAGCA TTTTATCAACAAATTTCATAATTGTGGACAATTGGAGGCATTTATTTTAAA AAACAATTTTATTGGCCTTTTGCTAACACAGTAAGCATGTATTTTATAAGG CATTCAATAAATGCACAACGCCCAAAGGAAATAAAATCCTATCTAA TCCT ACTCTCCACTACACAGAGGTAATCACTATTAGTATTTTGGCATATTATTCT CCAGGTGTTTGCTTATGCACTTATAAAATGATTTGAACAAATAAAACTAG GAACCTGTATACATGTGTTTCATAACCTGCCTCCTTTGCTTGGCCCTTTATT GAGATAAGTTTTCCTGTCAAGAAAGCAGAAACCATCTCATTTCTAACAGC TGTGTTATATTCCATAGTATGCATTACTCAACAAACTGTTGTGCTATTGGA TACTTAGGTGGTTTCTTCACTGACAATACTGAATAAACATCTCACCGGAAT TC Serial No. 73 Asi Bo Yun

>gi丨41350213丨ref丨NM_017680.3丨Human Aspen Cloud (LRR 145138.doc -28- 201015069 Type) (ASPN), mRNA I qPCR Forward-Introduction Matches with [798..823]|9?011 Reverse _Introduction matches [934..912]|4?011 probe matches [842..875]

AGTACTAACATGGACTAATCTGTGGGAGCAGTTTATTCCAGTATCA

CCCAGGGTGCAGCCACACCAGGACTGTGTTGAAGGGTGTTTTTTTTCTTTT

AAATGTAATACCTCCTCATCTTTTCTTCTTACACAGTGTCTGAGAACATTT

ACATTATAGATAAGTAGTACATGGTGGATAACTTCTACTTTTAGGAGGACT

ACTCTCTTCTGACAGTCCTAGACTGGTCTTCTACACTAAGACACCATGAAG

GAGTATGTGCTCCTATTATTCCTGGCTTTGTGCTCTGCCAAACCCTTCTTTA

GCCCTTCACACATCGCACTGAAGAATATGATGCTGAAGGATATGGAAGAC

ACAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAGGA

CAACTCTCTTTTTCCAACAAGAGAGCCAAGAAGCCATTTTTTTCCATTTGA

TCTGTTTCCAATGTGTCCATTTGGATGTCAGTGCTATTCACGAGTTGTACA

TTGCTCAGATTTAGGTTTGACCTCAGTCCCAACCAACATTCCATTTGATAC

TCGAATGCTTGATCTTCAAAACAATAAAATTAAGGAAATCAAAGAAAATG

ATTTTAAAGGACTCACTTCACTTTATGGTCTGATCCTGAACAACAACAAGC

TAACGAAGATTCACCCAAAAGCCTTTCTAACCACAAAGAAGTTGCGAAGG

CTGTATCTGTCCCACAATCAACTAAGTGAAATACCACTTAATCTTCCCAAA

TCATTAGCAGAACTCAGAATTCATGAAAATAAAGTTAAGAAAATACAAAA

GGACACATTCAAAGGAATGAATGCTTTACACGTTTTGGAAATGAGTGCAA

ACCCTCTTGATAATAATGGGATAGAGCCAGGGGCATTTGAAGGGGTGACG

GTGTTCCATATCAGAATTGCAGAAGCAAAACTGACCTCAGTTCCTAAAGG

CTTACCACCAACTTTATTGGAGCTTCACTTAGATTATAATAAAATTTCAAC

AGTGGAACTTGAGGATTTTAAACGATACAAAGAACTACAAAGGCTGGGCC

TAGGAAACAACAAAATCACAGATATCGAAAATGGGAGTCTTGCTAACATA

CCACGTGTGAGAGAAATACATTTGGAAAACAATAAACTAAAAAAAATCCC

TTCAGGATTACCAGAGTTGAAATACCTCCAGATAATCTTCCTTCATTCTAA

TTCAATTGCAAGAGTGGGAGTAAATGACTTCTGTCCAACAGTGCCAAAGA

TGAAGAAATCTTTATACAGTGCAATAAGTTTATTCAACAACCCGGTGAAA

TACTGGGAAATGCAACCTGCAACATTTCGTTGTGTTTTGAGCAGAATGAGT

GTTCAGCTTGGGAACTTTGGAATGTAATAATTAGTAATTGGTAATGTCCAT

TTAATATAAGATTCAAAAATCCCTACATTTGGAATACTTGAACTCTATTAA

TAATGGTAGTATTATATATACAAGCAAATATCTATTCTCAAGTGGTAAGTC

CACTGACTTATTTTATGACAAGAAATTTCAACGGAATTTTGCCAAACTATT

GATACATAAGGGTTGAGAGAAACAAGCATCTATTGCAGTTTCTTTTTGCGT

ACAAATGATCTTACATAAATCTCATGCTTGACCATTCCTTTCTTCATAACA

AAAAAGTAAGATATTCGGTATTTAACACTTTGTTATCAAGCATATTTTAAA

AAGAACTGTACTGTAAATGGAATGCTTGACTTAGCAAAATTTGTGCTCTTT

CATTTGCTGTTAGAAAAACAGAATTAACAAAGACAGTAATGTGAAGAGTG

CATTACACTATTCTTATTCTTTAGTAACTTGGGTAGTACTGTAATATTTTTA

ATCATCTTAAAGTATGATTTGATATAATCTTATTGAAATTACCTTATCATG

TCTTAGAGCCCGTCTTTATGTTTAAAACTAATTTCTTAAAATAAAGCCTTC

AGTAAATGTTCATTACCAACTTGATAAATGCTACTCATAAGAGCTGGTTTG

GGGCTATAGCATATGCTTTTTTTTTTTTAATTATTACCTGATTTAAAAATCT

CTGTAAAAACGTGTAGTGTTTCATAAAATCTGTAACTCGCATTTTAATGAT

CCGCTATTATAAGCTTTTAATAGCATGAAAATTGTTAGGCTATATAACATT

GCCACTTCAACTCTAAGGAATATTTTTGAGATATCCCTTTGGAAGACCTTG 145138.doc -29- 201015069

CTTGGAAGAGCCTGGACACTAACAATTCTACACCAAATTGTCTCTTCAAAT

ACGTATGGACTGGATAACTCTGAGAAACACATCTAGTATAACTGAATAAG

CAGAGCATCAAATTAAACAGACAGAAACCGAAAGCTCTATATAAATGCTC

AGAGTTCTTTATGTATTTCTTATTGGCATTCAACATATGTAAAATCAGAAA

ACAGGGAAATTTTCATTAAAAATATTGGTTTGAAATAAAAAAAAAAAAAA Sequence No. 74 Cell growth regulation with EF hand function site 1

>gi | 33589823 | ref 丨NM—006569.2 | Human cell growth regulator (CGREF1) with EF hand function site 1 , mRNA | qPCR advance _ primer matched with [378..394] | qPCR reverse-introduction and [455 ..43 1] Matching | qPCR probes match [396..415]❻

CGCGCAGCCCCTCCGGCCGCGGGCGCAGCGGGGGCGCTGGTGGAG

CTGCGAAGGGCCAGGTCCGGCGGGCGGGGCGGCGGCTGGCACTGGCTCC

GGACTCTGCCCGGCCAGGGCGGCGGCTCCAGCCGGGAGGGCGACGTGGA

GCGGCCACGTGGAGCGGCCCGGGGGAGGCTGGCGGCGGGAGGCGAGGCG

CGGGCGGCGCAGCAGCCAGGAGCGCCCACGGAGCTGGACCCCCAGAGCC

GCGCGGCGCCGCAGCAGTTCCAGGAAGGATGTTACCTTTGACGATGACAG

TGTTAATCCTGCTGCTGCTCCCCACGGGTCAGGCTGCCCCAAAGGATGGA

GTCACAAGGCCAGACTCTGAAGTGCAGCATCAGCTCCTGCCCAACCCCTT

CCAGCCAGGCCAGGAGCAGCTCGGACTTCTGCAGAGCTACCTAAAGGGAC

TAGGAAGGACAGAAGTGCAACTGGAGCATCTGAGCCGGGAGCAGGTTCT

CCTCTACCTCTTTGCCCTCCATGACTATGACCAGAGTGGACAGCTGGATGG

CCTGGAGCTGCTGTCCATGTTGACAGCTGCTCTGGCCCCTGGAGCTGCCAA

CTCTCCTACCACCAACCCGGTGATATTGATAGTGGACAAAGTGCTCGAGA

CGCAGGACCTGAATGGGGATGGGCTCATGACCCCTGCTGAGCTCATCAAC

TTCCCGGGAGTAGCCCTCAGGCACGTGGAGCCCGGAGAGCCCCTTGCTCC

ATCTCCTCAGGAGCCACAAGCTGTTGGAAGGCAGTCCCTATTAGCTAAAA

GCCCATTAAGACAAGAAACACAGGAAGCCCCTGGTCCCAGAGAAGAAGC

AAAGGGCCAGGTAGAGGCCAGAAGGGAGTCTTTGGATCCTGTCCAGGAG

CCTGGGGGCCAGGCAGAGGCTGATGGAGATGTTCCAGGGCCCAGAGGGG

AAGCTGAGGGCCAGGCAGAGGCTAAAGGAGATGCCCCTGGGCCCAGAGG

GGAAGCTGGGGGCCAGGCAGAGGCTGAAGGAGATGCCCCCGGGCCCAGA

GGGGAAGCTGGGGGCCAGGCAGAGGCCAGGGAGAATGGAGAGGAGGCC

AAGGAACTTCCAGGGGAAACACTGGAGTCTAAGAACACCCAAAATGACTT

TGAGGTGCACATTGTTCAAGTGGAGAATGATGAGATCTAGATCTTGAAGA

TACAGGTACCCCACGAAGTCTCAGTGCCAGAACATAAGCCCTGAAGTGGG

CAGGGGAAATGTACGCTGGGACAAGGACCATCTCTGTGCCCCCTGTCTGG

TCCCAGTAGGTATCAGGTCTTTCTGTGCAGCTCAGGGAGACCCTAAGTTAA

GGGGCAGATTACCAATAAAGAACTGAATGAATTCATCCCCCCGGGCCACC

TCTCTACCCGTCCAGCCTGCCCAGACCCTCTCAGAGGAACGGGGTTGGGG

ACCGAAAGGACAGGGATGCCGCCTGCCCAGTGTTTCTGGGCCTCACGGTG

CTCCGGCAGCAGAGCGCATGGTGCTAGCCATGGCCGGCTGCAGAGGACCC

AGTGAGGAAAGCTCAGTCTATCCCTGGGCCCCAAACCCTCACCGGTTCCC

CCTCACCTGGTGTTCAGACACCCCATGCTCTCCTGCAGCTCAGGGCAGGTG

ACCCCATCCCCAGTAATATTAATCATCACTAGAACTTTTTGAGAGCCTTGT 145138.doc •30· 201015069

ACACATCAGGCATCATGCTGGGCATTTTATATATGATTTTATCCTCACAAT

AATTCTGTAGCCAAGCAGAATTGGTTCCATTTGACAGATGAAGAAATTGA

GGCAGATTGCGTTAAGTGCTGTACCCTAAGGTGATATGCAGCTAATTAAA

TGGCAGATTTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA sequence No. 75 kallikrein 10, transcriptional change ttl >gi 丨22208981 I ref 丨ΝΜ_002776·3 I human kallikrein 10 (KLK10), transcript variant 1, mRNA | qPCR advancement_引子与[851 ..874] Matching | qPCR Reverse-Introduction matches [950..931] | qPCR probe matches [890..914]

CATCCTGCCACCCCTAGCCTTGCTGGGGACGTGAACCCTCTCCCCG CGCCTGGGAAGCCTTCTTGGCACCGGGACCCGGAGAATCCCCACGGAAGC CAGTTCCAAAAGGGATGAAAAGGGGGCGTTTCGGGCACTGGGAGAAGCC TGTATTCCAGGGCCCCTCCCAGAGCAGGAATCTGGGACCCAGGAGTGCCA GCCTCACCCACGCAGATCCTGGCCATGAGAGCTCCGCACCTCCACCTCTCC GCCGCCTCTGGCGCCCGGGCTCTGGCGAAGCTGCTGCCGCTGCTGATGGC GCAACTCTGGGCCGCAGAGGCGGCGCTGCTCCCCCAAAACGACACGCGCT TGGACCCCGAAGCCTATGGCTCCCCGTGCGCGCGCGGCTCGCAGCCCTGG CAGGTCTCGCTCTTCAACGGCCTCTCGTTCCACTGCGCGGGTGTCCTGGTG GACCAGAGTTGGGTGCTGACGGCCGCGCACTGCGGAAACAAGCCACTGTG GGCTGGAGTAGGGGATGACCACCTGCTGCTTCTTCAGGGAGAGCAGCTCC GCCGGACCACTCGCTCTGTTGTCCATCCCAAGTACCACCAGGGCTCAGGC CCCATCCTGCCAAGGCGAACGGATGAGCACGATCTCATGTTGCTGAAGCT GGCCAGGCCCGTAGTGCTGGGGCCCCGCGTCCGGGCCCTGCAGCTTCCCT ACCGCTGTGCTCAGCCCGGAGACCAGTGCCAGGTTGCTGGCTGGGGCACC ACGGCCGCCCGGAGAGTGAAGTACAACAAGGGCCTGACCTGCTCCAGCAT CACTATCCTGAGCCCTAAAGAGTGTGAGGTCTTCTACCCTGGCGTGGTCAC CAACAACATGATATGTGCTGGACTGGACCGGGGCCAGGACCCTTGCCAGA GTGACTCTGGAGGCCCCCTGGTCTGTGACGAGACCCTCCAAGGCATCCTCT CGTGGGGTGTTTACCCCTGTGGCTCTGCCCAG CATCCAGCTGTCTACACCC AGATCTGCAAATACATGTCCTGGATCAATAAAGTCATACGCTCCAACTGA TCCAGATGCTACGCTCCAGCTGATCCAGATGTTATGCTCCTGCTGATCCAG ATGCCCAGAGGCTCCATCGTCCATCCTCTTCCTCCCCAGTCGGCTGAACTC TCCCCTTGTCTGCACTGTTCAAACCTCTGCCGCCCTCCACACCTCTAAACA TCTCCCCTCTCACCTCATTCCCCCACCTATCCCCATTCTCTGCCTGTACTGA AGCTGAAATGCAGGAAGTGGTGGCAAAGGTTTATTCCAGAGAAGCCAGG AAGCCGGTCATCACCCAGCCTCTGAGAGCAGTTACTGGGGTCACCCAACC TGACTTCCTCTGCCACTCCCTGCTGTGTGACTTTGGGCAAGCCAAGTGCCC TCTCTGAACCTCAGTTTCCTCATCTGCAAAATGGGAACAATGACGTGCCTA CCTCTTAGACATGTTGTGAGGAGACTATGATATAACATGTGTATGTAAATC TTCATGGTGATTGTCATGTAAGGCTTAACACAGTGGGTGGTGAGTTCTGAC TAAAGGTTACCTGTTGTCGTGA Serial No. 76 kallikrein 10, transcript variant Jin 2 145138.doc • 31- 201015069 > gi 22208983 Shu Shu Shu ref NM_145888.1 Shu human kallikrein Enzyme 10 (KLK10), transcript variant 2, mRNA|qPCR advance _ primer matched with [714..737] | 4? ft. reverse _ primer matched with [813..794] | 9? 0 anisotropic probe and [ 753..777] match

ACCAGCGGCAGACCACAGGCAGGGCAGAGGCACGTCTGGGTCCCC TCCCTCCTTCCTATCGGCGACTCCCAGGATCCTGGCCATGAGAGCTCCGCA CCTCCACCTCTCCGCCGCCTCTGGCGCCCGGGCTCTGGCGAAGCTGCTGCC GCTGCTGATGGCGCAACTCTGGGCCGCAGAGGCGGCGCTGCTCCCCCAAA ACGACACGCGCTTGGACCCCGAAGCCTATGGCTCCCCGTGCGCGCGCGGC TCGCAGCCCTGGCAGGTCTCGCTCTTCAACGGCCTCTCGTTCCACTGCGCG GGTGTCCTGGTGGACCAGAGTTGGGTGCTGACGGCCGCGCACTGCGGAAA CAAGCCACTGTGGGCTCGAGTAGGGGATGACCACCTGCTGCTTCTTCAGG GAGAGCAGCTCCGCCGGACCACTCGCTCTGTTGTCCATCCCAAGTACCAC ❿ CAGGGCTCAGGCCCCATCCTGCCAAGGCGAACGGATGAGCACGATCTCAT GTTGCTGAAGCTGGCCAGGCCCGTAGTGCTGGGGCCCCGCGTCCGGGCCC TGCAGCTTCCCTACCGCTGTGCTCAGCCCGGAGACCAGTGCCAGGTTGCTG GCTGGGGCACCACGGCCGCCCGGAGAGTGAAGTACAACAAGGGCCTGAC CTGCTCCAGCATCACTATCCTGAGCCCTAAAGAGTGTGAGGTCTTCTACCC TGGCGTGGTCACCAACAACATGATATGTGCTGGACTGGACCGGGGCCAGG ACCCTTGCCAGAGTGACTCTGGAGGCCCCCTGGTCTGTGACGAGACCCTC CAAGGCATCCTCTCGTGGGGTGTTTACCCCTGTGGCTCTGCCCAGCATCCA GCTGTCTACACCCAGATCTGCAAATACATGTCCTGGATCAATAAAGTCAT ACGCTCCAACTGATCCAGATGCTACGCTCCAGCTGATCCAGATGTTATGCT CCTGCTGATCCAGATGCCCAGAGGCT CCATCGTCCATCCTCTTCCTCCCCA GTCGGCTGAACTCTCCCCTTGTCTGCACTGTTCAAACCTCTGCCGCCCTCC ACACCTCTAAACATCTCCCCTCTCACCTCATTCCCCCACCTATCCCCATTCT CTGCCTGTACTGAAGCTGAAATGCAGGAAGTGGTGGCAAAGGTTTATTCC AGAGAAGCCAGGAAGCCGGTCATCACCCAGCCTCTGAGAGCAGTTACTGG GGTCACCCAACCTGACTTCCTCTGCCACTCCCTGCTGTGTGACTTTGGGCA AGCCAAGTGCCCTCTCTGAACCTCAGTTTCCTCATCTGCAAAATGGGAACA U ATGACGTGCCTACCTCTTAGACATGTTGTGAGGAGACTATGATATAACAT GTGTATGTAAATCTTCATGGTGATTGTCATGTAAGGCTTAACACAGTGGGT GGTGAGTTCTGACTAAAGGTTACCTGTTGTCGTGA Serial No. 77 Red metalloproteinase inhibitor of knitting 1 > gi 4507508 Bu ef Shu Shu Shu NM_003254.1 of human tissue inhibitor of metalloproteinase (erythroid lineage synergistic activity , collagenase inhibitor) (TIMP1), mRNA | qPCR advance _ primer matches [221..241] | qPCR reverse-primer matches [359..340] | qPCR probe matches [25 1..283]

AGGGGCCTTAGCGTGCCGCATCGCCGAGATCCAGCGCCCAGAGAG 145138.doc -32- 201015069 ACACCAGAGAACCCACCATGGCCCCCTTTGAGCCCCTGGCTTCTGGCATCC TGTTGTTGCTGTGGCTGATAGCeCCCAGCAGGGCCTGCACCTGTGTCCCAC CCCACCCACAGACGGCCTTCTGCAATTCCGACCTCGTCATCAGGGCCAAG TTCGTGGGGACACCAGAAGTCAACCAGACCACCTTATACCAGCGTTATGA GATCAAGATGACCAAGATGTATAAAGGGTTCCAAGCCTTAGGGGATGCCG CTGACATCCGGTTCGTCTACACCCCCGCCATGGAGAGTGTCTGCGGATACT TCCACAGGTCCCACAACCGCAGCGAGGAGTTTCTCATTGCTGGAAAACTG CAGGATGGACTCTTGCACATCACTACCTGCAGTTTCGTGGCTCCCTGGAAC AGCCTGAGCTTAGCTCAGCGCCGGGGCTTCACCAAGACCTACACTGTTGG CTGTGAGGAATGCACAGTGTTTCCCTGTTTATCCATCCCCTGCAAACTGCA GAGTGGCACTCATTGCTTGTGGACGGACCAGCTCCTCCAAGGCTCTGAAA AGGGCTTCCAGTCCCGTCACCTTGCCTGCCTGCCTCGGGAGCCAGGGCTGT GCACCTGGCAGTCCCTGCGGTCCCAGATAGCCTGAATCCTGCCCGGAGTG GAACTGAAGCCTGCACAGTGTCCACCCTGTTCCCACTCCCATCTTTCTTCC GGACAATGAAATAAAGAGTTACCACCCAGC Serial No. 78 secreted protein acidic and rich in cysteine

>gi| 48675 809丨ref |NM_003 118.2丨human secreted protein, acidic, rich in cysteine (osteonectin) (SPARC), 1111^^入|9?«1 advancement_introduction and [ 788..810] Matching|9?€11 Reverse_Introduction matches [915..898] | qPCR probe matches [818..839]

GTTGCCTGTCTCTAAACCCCTCCACATTCCCGCGGTCCTTCAGACTG

CCCGGAGAGCGCGCTCTGCCTGCCGCCTGCCTGCCTGCCACTGAGGGTTCC

CAGCACCATGAGGGCCTGGATCTTCTTTCTCCTTTGCCTGGCCGGGAGGGC

CTTGGCAGCCCCTCAGCAAGAAGCCCTGCCTGATGAGACAGAGGTGGTGG

AAGAAACTGTGGCAGAGGTGACTGAGGTATCTGTGGGAGCTAATCCTGTC

CAGGTGGAAGTAGGAGAATTTGATGATGGTGCAGAGGAAACCGAAGAGG

AGGTGGTGGCGGAAAATCCCTGCCAGAACCACCACTGCAAACACGGCAA

GGTGTGCGAGCTGGATGAGAACAACACCCCCATGTGCGTGTGCCAGGACC

CCACCAGCTGCCCAGCCCCCATTGGCGAGTTTGAGAAGGTGTGCAGCAAT

GACAACAAGACCTTCGACTCTTCCTGCCACTTCTTTGCCACAAAGTGCACC

CTGGAGGGCACCAAGAAGGGCCACAAGCTCCACCTGGACTACATCGGGCC

TTGCAAATACATCCCCCCTTGCCTGGACTCTGAGCTGACCGAATTCCCCCT

GCGCATGCGGGACTGGCTCAAGAACGTCCTGGTCACCCTGTATGAGAGGG

ATGAGGACAACAACCTTCTGACTGAGAAGCAGAAGCTGCGGGTGAAGAA

GATCCATGAGAATGAGAAGCGCCTGGAGGCAGGAGACCACCCCGTGGAG

CTGCTGGCCCGGGACTTCGAGAAGAACTATAACATGTACATCTTCCCTGTA

CACTGGCAGTTCGGCCAGCTGGACCAGCACCCCATTGACGGGTACCTCTC

CCACACCGAGCTGGCTCCACTGCGTGCTCCCCTCATCCCCATGGAGCATTG

CACCACCCGCTTTTTCGAGACCTGTGACCTGGACAATGACAAGTACATCG

CCCTGGATGAGTGGGCCGGCTGCTTCGGCATCAAGCAGAAGGATATCGAC

AAGGATCTTGTGATCTAAATCCACTCCTTCCACAGTACCGGATTCTCTCTT

TAACCCTCCCCTTCGTGTTTCCCCCAATGTTTAAAATGTTTGGATGGTTTGT

TGTTCTGCCTGGAGACAAGGTGCTAACATAGATTTAAGTGAATACATTAA

CGGTGCTAAAAATGAAAATTCTAACCCAAGACATGACATTCTTAGCTGTA

ACTTAACTATTAAGGCCTTTTCCACACGCATTAATAGTCCCATTTTTCTCTT 145138.doc -33- 201015069

GCCATTTGTAGCTTTGCCCATTGTCTTATTGGCACATGGGTGGACACGGAT

CTGCTGGGCTCTGCCTTAAACACACATTGCAGCTTCAACTTTTCTCTTTAGT

GTTCTGTTTGAAACTAATACTTACCGAGTCAGACTTTGTGTTCATTTCATTT

CAGGGTCTTGGCTGCCTGTGGGCTTCCCCAGGTGGCCTGGAGGTGGGCAA

AGGGAAGTAACAGACACACGATGTTGTCAAGGATGGTTTTGGGACTAGAG

GCTCAGTGGTGGGAGAGATCCCTGCAGAACCCACCAACCAGAACGTGGTT

TGCCTGAGGCTGTAACTGAGAGAAAGATTCTGGGGCTGTGTTATGAAAAT

ATAGACATTCTCACATAAGCCCAGTTCATCACCATTTCCTCCTTTACCTTTC

AGTGCAGTTTCTTTTCACATTAGGCTGTTGGTTCAAACTTTTGGGAGCACG

GACTGTCAGTTCTCTGGGAAGTGGTCAGCGCATCCTGCAGGGCTTCTCCTC

CTCTGTCTTTTGGAGAACCAGGGCTCTTCTCAGGGGCTCTAGGGACTGCCA

GGCTGTTTCAGCCAGGAAGGCCAAAATCAAGAGTGAGATGTAGAAAGTTG

TAAAATAGAAAAAGTGGAGTTGGTGAATCGGTTGTTCTTTCCTCACATTTG

GATGATTGTCATAAGGTTTTTAGCATGTTCCTCCTTTTCTTCACCCTCCCCT

TTTTTCTTCTATTAATCAAGAGAAACTTCAAAGTTAATGGGATGGTCGGAT

CTCACAGGCTGAGAACTCGTTCACCTCCAAGCATTTCATGAAAAAGCTGC

TTCTTATTAATCATACAAACTCTCACCATGATGTGAAGAGTTTCACAAATC

CTTCAAAATAAAAAGTAATGACTTAGAAACTGCCTTCCTGGGTGATTTGC

ATGTGTCTTAGTCTTAGTCACCTTATTATCCTGACACAAAAACACATGAGC

ATACATGTCTACACATGACTACACAAATGCAAACCTTTGCAAACACATTA

TGCTTTTGCACACACACACCTGTACACACACACCGGCATGTTTATACACAG

GGAGTGTATGGTTCCTGTAAGCACTAAGTTAGCTGTTTTCATTTAATGACC

TGTGGTTTAACCCTTTTGATCACTACCACCATTATCAGCACCAGACTGAGC

AGCTATATCCTTTTATTAATCATGGTCATTCATTCATTCATTCATTCACAAA

ATATTTATGATGTATTTACTCTGCACCAGGTCCCATGCCAAGCACTGGGGA

CACAGTTATGGCAAAGTAGACAAAGCATTTGTTCATTTGGAGCTTAGAGT

CCAGGAGGAATACATTAGATAATGACACAATCAAATATAAATTGCAAGAT

GTCACAGGTGTGATGAAGGGAGAGTAGGAGAGACCATGAGTATGTGTAA

CAGGAGGACACAGCATTATTCTAGTGCTGTACTGTTCCGTACGGCAGCCA

CTACCCACATGTAACTTTTTAAGATTTAAATTTAAATTAGTTAACATTCAA

AACGCAGCTCCCCAATCACACTAGCAACATTTCAAGTGCTTGAGAGCCAT

GCATGATTAGTGGTTACCCTATTGAATAGGTCAGAAGTAGAATCTTTTCAT

CATCACAGAAAGTTCTATTGGACAGTGCTCTTCTAGATCATCATAAGACTA

CAGAGCACTTTTCAAAGCTCATGCATGTTCATCATGTTAGTGTCGTATTTT ❹

GAGCTGGGGTTTTGAGACTCCCCTTAGAGATAGAGAAACAGACCCAAGAA

ATGTGCTCAATTGCAATGGGCCACATACCTAGATCTCCAGATGTCATTTCC

CCTCTCTTATTTTAAGTTATGTTAAGATTACTAAAACAATAAAAGCTCCTA

AAAAATCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA sequence No. 79 transforming growth factor, p-induced > gi丨4507466丨ref丨ΝΜ_000358·1丨 human transforming growth factor, β-induced, 68 kDa (TGFBI), mRNA|qPCR in the context of The measurement matches the [170..194]

GCTTGCCCGTCGGTCGCTAGCTCGCTCGGTGCGCGTCGTCCCGCTCC

ATGGCGCTCTTCGTGCGGCTGCTGGCTCTCGCCCTGGCTCTGGCCCTGGGC

CCCGCCGCGACCCTGGCGGGTCCCGCCAAGTCGCCCTACCAGCTGGTGCT 145138.doc • 34· 201015069

GCAGCACAGCAGGCTCCGGGGCCGCCAGCACGGCCCCAACGTGTGTGCTG TGCAGAAGGTTATTGGCACTAATAGGAAGTACTTCACCAACTGCAAGCAG TGGTACCAAAGGAAAATCTGTGGCAAATCAACAGTCATCAGCTACGAGTG CTGTCCTGGATATGAAAAGGTCCCTGGGGAGAAGGGCTGTCCAGCAGCCC TACCACTCTCAAACCTTTACGAGACCCTGGGAGTCGTTGGATCCACCACCA CTCAGCTGTACACGGACCGCACGGAGAAGCTGAGGCCTGAGATGGAGGG GCCCGGCAGCTTCACCATCTTCGCCCCTAGCAACGAGGCCTGGGCCTCCTT GCCAGCTGAAGTGCTGGACTCCCTGGTCAGCAATGTCAACATTGAGCTGC TCAATGCCCTCCGCTACCATATGGTGGGCAGGCGAGTCCTGACTGATGAG CTGAAACACGGCATGACCCTCACCTCTATGTACCAGAATTCCAACATCCA GATCCACCACTATCCTAATGGGATTGTAACTGTGAACTGTGCCCGGCTCCT GAAAGCCGACCACCATGCAACCAACGGGGTGGTGCACCTCATCGATAAGG TCATCTCCACCATCACCAACAACATCCAGCAGATCATTGAGATCGAGGAC ACCTTTGAGACCCTTCGGGCTGCTGTGGCTGCATCAGGGCTCAACACGAT GCTTGAAGGTAACGGCCAGTACACGCTTTTGGCCCCGACCAATGAGGCCT TCGAGAAGATCCCTAGTGAGACTTTGAACCGTATCCTGGGCGACCCAGAA GCCCTGAGAGACCTGCTGAACAACCACATCTTGAAGTCAGCTATGTGTGC TGAAGCCATCGTTGCGGGGCTGTCTGTAGAGACCCTGGAGGGCACGACAC TGGAGGTGGGCTGCAGCGGGGACATGCTCACTATCAACGGGAAGGCGATC ATCTCCAATAAAGACATCCTAGCCACCAA CGGGGTGATCCACTACATTGA TGAGCTACTCATCCCAGACTCAGCCAAGACACTATTTGAATTGGCTGCAG AGTCTGATGTGTCCACAGCCATTGACCTTTTCAGACAAGCCGGCCTCGGCA ATCATCTCTCTGGAAGTGAGCGGTTGACCCTCCTGGCTCCCCTGAATTCTG TATTCAAAGATGGAACCCCTCCAATTGATGCCCATACAAGGAATTTGCTTC GGAACCACATAATTAAAGACCAGCTGGCCTCTAAGTATCTGTACCATGGA CAGACCCTGGAAACTCTGGGCGGCAAAAAACTGAGAGTTTTTGTTTATCG TAATAGCCTCTGCATTGAGAACAGCTGCATCGCGGCCCACGACAAGAGGG GGAGGTACGGGACCCTGTTCACGATGGACCGGGTGCTGACCCCCCCAATG GGGACTGTCATGGATGTCCTGAAGGGAGACAATCGCTTTAGCATGCTGGT AGCTGCCATCCAGTCTGCAGGACTGACGGAGACCCTCAACCGGGAAGGAG TCTACACAGTCTTTGCTCCCACAAATGAAGCCTTCCGAGCCCTGCCACCAA GAGAACGGAGCAGACTCTTGGGAGATGCCAAGGAACTTGCCAACATCCTG AAATACCACATTGGTGATGAAATCCTGGTTAGCGGAGGCATCGGGGCCCT GGTGCGGCTAAAGTCTCTCCAAGGTGACAAGCTGGAAGTCAGCTTGAAAA ACAATGTGGTGAGTGTCAACAAGGAGCCTGTTGCCGAGCCTGACATCATG GCCACAAATGGCGTGGTCCATGTCATCACCAATGTTCTGCAGCCTCCAGCC AACAGACCTCAGGAAAGAGGGGATGAACTTGCAGACTCTGCGCTTGAGAT CTTCAAACAAGCATCAGCGTTTTCCAGGGCTTCCCAGAGGTCTGTGCGACT AGCCCCTGTCTATCAAAAGTTATTAGAGAGGATGAAGCATTAGCTTGAAG CAC TACAGGAGGAATGCACCACGGCAGCTCTCCGCCAATTTCTCTCAGAT TTCCACAGAGACTGTTTGAATGTTTTCAAAACCAAGTATCACACTTTAATG TACATGGGCCGCACCATAATGAGATGTGAGCCTTGTGCATGTGGGGGAGG AGGGAGAGAGATGTACTTTTTAAATCATGTTCCCCCTAAACATGGCTGTTA ACCCACTGCATGCAGAAACTTGGATGTCACTGCCTGACATTCACTTCCAGA GAGGACCTATCCCAAATGTGGAATTGACTGCCTATGCCAAGTCCCTGGAA AAGGAGCTTCAGTATTGTGGGGCTCATAAAACATGAATCAAGCAATCCAG CCTCATGGGAAGTCCTGGCACAGTTTTTGTAAAGCCCTTGCACAGCTGGA GAAATGGCATCATTATAAGCTATGAGTTGAAATGTTCTGTCAAATGTGTCT CACATCTACACGTGGCTTGGAGGCTTTTATGGGGCCCTGTCCAGGTAGAA AAGAAATGGTATGTAGAGCTTAGATTTCCCTATTGTGACAGAGCCATGGT GTGTTTGTAATAATAAAACCAAAGAAACATA serial No. 80 145138.doc -35- 201015069 containing EGF like - Feibu Lin Qu extracellular matrix protein 2 > gi | 8393298 Bu ef | NM_01693 8.1 | containing human EGF and the like - phenemicin extracellular matrix protein 2 (EFEMP2), mRNA | qPCR is determined in the context of the requirements and [1248·. 1272]

CAAGCTTGGCACGAGGGCAGGCATTGCCCGAGCCAGCCGAGCCGC CAGAGCCGCGGGCCGCGCGGGTGTCGCGGGCCCAACCCCAGGATGCTCCC CTGCGCCTCCTGCCTACCCGGGTCTCTACTGCTCTGGGCGCTGCTACTGTT GCTCTTGGGATCAGCTTCTCCTCAGGATTCTGAAGAGCCCGACAGCTACAC GGAATGCACAGATGGCTATGAGTGGGACCCAGACAGCCAGCACTGCCGG GATGTCAACGAGTGTCTGACCATCCCTGAGGCCTGCAAGGGGGAAATGAA GTGCATCAACCAGTACGGGGGCTACTTGTGCCTGCCCCGCTCCGCTGCCGT CATCAACGACCTACACGGCGAGGGACCCCCGCCACCAGTGCCTCCCGCTC AACACCCCAACCCCTGCCCACCAGGCTATGAGCCCGACGATCAGGACAGC TGTGTGGATGTGGACGAGTGTGCCCAGGCCCTGCACGACTGTCGCCCCAG CCAGGACTGCCATAACTTGCCTGGCTCCTATCAGTGCACCTGCCCTGATGG TTACCGCAAGATCGGGCCCGAGTGTGTGGACATAGACGAGTGCCGCTACC GCTACTGCCAGCACCGCTGCGTGAACCTGCCTGGCTCCTTCCGCTGCCAGT GCGAGCCGGGCTTCCAGCTGGGGCCTAACAACCGCTCCTGTGTTGATGTG AACGAGTGTGACATGGGGGCCCCATGCGAGCAGCGCTGCTTCAACTCCTA TGGGACCTTCCTGTGTCGCTGCCACCAGGGCTATGAGCTGCATCGGGATG GCTTCTCCTGCAGTGATATTGATGAGTGTAGCTACTCCAGCTACCTCTGTC AGTACCGCTGCGTCAACGAGCCAGGCCGTTTCTCCTGCCACTGCCCACAG GGTTACCAGCTGCTGGCCACACGCCTCTGCCAAGACATTGATGAGTGTGA GTCTGGTGCGCACCAGTGCTCCGAGGCCCAA Sequence No. 81 ACCTGTGTCAACTTCCATG GGGGCTACCGCTGCGTGGACACCAACCGCTGCGTGGAGCCCTACATCCAG GTCTCTGAGAACCGCTGTCTCTGCCCGGCCTCCAACCCTCTATGTCGAGAG CAGCCTTCATCCATTGTGCACCGCTACATGACCATCACCTCGGAGCGGAG AGTACCCGCTGACGTGTTCCAGATCCAGGCGACCTCCGTCTACCCCGGTGC CTACAATGCCTTTCAGATCCGTGCTGGAAACTCGCAGGGGGACTTTTACAT TAGGCAAATCAACAACGTCAGCGCCATGCTGGTCCTCGCCCGGCCGGTGA CGGGCCCCCGGGAGTACGTGCTGGACCTGGAGATGGTCACCATGAATTCC CTCATGAGCTACCGGGCCAGCTCTGTACTGAGGCTCACCGTCTTTGTAGGG GCCTACACCTTCTGAGGAGCAGGAGGGAGCCACCCTCCCTGCAGCTACCC TAGCTGAGGAGCCTGTTGTGAGGGGCAGAATGAGAAAGGCCCAGGGGCC CCCATTGACAGGAGCTGGGAGCTCTGCACCACGAGCTTCAGTCACCCCGA GAGGAGAGGAGGTAACGAGGAGGGCGGACTCCAGGCCCCGGCCCAGAGA TTTGGACTTGGCTGGCTTGCAGGGGTCCTAAGAAACTCCACTCTGGACAG CGCCAGGAGGCCCTGGGTTCCATTCCTAACTCTGCCTCAAACTGTACATTT GGATAAGCCCTAGTAGTTCCCTGGGCCTGTTTTTCTATAAAACGAGGCAAC TGG Lumi Ken > gi | 21359858 | ref Shu ΝΜ_002345 · 2 | human Lumi Ken (LUM), 145138.doc -36- 201015069 1111^八|4?€11 Advance_Introduction matches [61..84]|4?01 Reverse_Introduction matches [182..162] I qPCR probe matches [117.. 152]

GTATCACTCAGAATCTGGCAGCCAGTTCCGTCCTGACAGAGTTCAC AGCATATATTGGTGGATTCTTGTCCATAGTGCATCTGCTTTAAGAATTAAC GAAAGCAGTGTCAAGACAGTAAGGATTCAAACCATTTGCCAAAAATGAGT CTAAGTGCATTTACTCTCTTCCTGGCATTGATTGGTGGTACCAGTGGCCAG TACTATGATTATGATTTTCCCCTATCAATTTATGGGCAATCATCACCAAAC TGTGCACCAGAATGTAACTGCCCTGAAAGCTACCCAAGTGCCATGTACTG TGATGAGCTGAAATTGAAAAGTGTACCAATGGTGCCTCCTGGAATCAAGT ATCTTTACCTTAGGAATAACCAGATTGACCATATTGATGAAAAGGCCTTTG AGAATGTAACTGATCTGCAGTGGCTCATTCTAGATCACAACCTTCTAGAA AACTCCAAGATAAAAGGGAGAGTTTTCTCTAAATTGAAACAACTGAAGAA GCTGCATATAAACCACAACAACCTGACAGAGTCTGTGGGCCCACTTCCCA AATCTCTGGAGGATCTGCAGCTTACTCATAACAAGATCACAAAGCTGGGC TCTTTTGAAGGATTGGTAAACCTGACCTTCATCCATCTCCAGCACAATCGG CTGAAAGAGGATGCTGTTTCAGCTGCTTTTAAAGGTCTTAAATCACTCGAA TACCTTGACTTGAGCTTCAATCAGATAGCCAGACTGCCTTCTGGTCTCCCT GTCTCTCTTCTAACTCTCTACTTAGACAACAATAAGATCAGCAACATCCCT GATGAGTATTTCAAGCGTTTTAATGCATTGCAGTATCTGCGTTTATCTCAC AACGAACTGGCTGATAGTGGAATACCTGGAAATTCTTTCAATGTGTCATCC CTGGTTGAGCTQGATCTGTCCTATAACAAGCTTAAAAACATACCAACTGTC AATGAAAACCTTGAAAACTATTAC CTGGAGGTCAATCAACTTGAGAAGTT TGACATAAAGAGCTTCTGCAAGATCCTGGGGCCATTATCCTACTCCAAGA TCAAGCATTTGCGTTTGGATGGCAATCGCATCTCAGAAACCAGTCTTCCAC CGGATATGTATGAATGTCTACGTGTTGCTAACGAAGTCACTCTTAATTAAT ATCTGTATCCTGGAACAATATTTTATGGTTATGTTTTTCTGTGTGTCAGTTT TCATAGTATCCATATTTTATTACTGTTTATTACTTCCATGAATTTTAAAATC TGAGGGAAATGTTTTGTAAACATTTATTTTTTTTAAAGAAAAGATGAAAG GCAGGCCTATTTCATCACAAGAACACACACATATACACGAATAGACATCA AACTCAATGCTTTATTTGTAAATTTAGTGTTTTTTTATTTCTACTGTCAAAT GATGTGCAAAACCTTTTACTGGTTGCATGGAAATCAGCCAAGTTTTATAAT CCTTAAATCTTAATGTTCCTCAAAGCTTGGATTAAATACATATGGATGTTA CTCTCTTGCACCAAATTATCTTGATACATTCAAATTTGTCTGGTTAAAAAA TAGGTGGTAGATATTGAGGCCAAGAATATTGCAAAATACATGAAGCTTCA TGCACTTAAAGAAGTATTTTTAGAATAAGAATTTGCATACTTACCTAGTGA AACTTTTCTAGAATTATTTTTCACTCTAAGTCATGTATGTTTCTCTTTGATT ATTTGCATGTTATGTTTAATAAGCTACTAGCAAAATAAAACATAGCAAAT GAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA No. 82 Sequence Site Ning > gi | 29893560 ref Shu Shu ΝΜ_003498 · 3 | human Site Ning (SNN),

mRNA

AGCGGGGCCGGACCGGGCGGGCGGAGCCGGGCCCGCGGGGCTGCT

GCGGGGCGATCGGGCCGGGCCGCTGCCGCGCCATGGACTCCCGTGTCCAG

CCTGAGTTCCAGCCTCACTGAGTGGCCACCCCCAAAGTGCTGCCAGCCGA 145138.doc -37- 201015069

GGAAGCCCCCAGCACTGACCATGTCTATTATGGACCACAGCCCCACCACG

GGCGTGGTCACAGTCATCGTCATCCTCATTGCCATCGCGGCCCTGGGGGCC

TTGATCCTGGGCTGCTGGTGCTACCTGCGGCTGCAGCGCATCAGCCAGTCA

GAGGACGAGGAGAGCATCGTGGGGGATGGGGAGACCAAGGAACCCTTCC

TGCTGGTGCAGTATTCGGCCAAGGGACCGTGCGTGGAGAGAAAGGCCAA

GCTGATGACTCCCAACGGCCCGGAAGTCCACGGCTGAGCCAGGATGCAAG

GCTCCTGGTCCTGTTTGCAGCCGGCCAAGAGGCGCTGGGAGGGGCAAAAC

CATACGGATGCGCTGCTGTCTGAGAGGAAGGGCTGACACTTGCTGGCATG

GCCTCTGCGGGCTTCGTCATCGCATGCACTGATGCCCGGGGACCTGGCTGT

CCTGGGCTTCCCCTCGGCCTCCAGGTGAGGCTGCCCATTGCAGGCACTGG

GCAGGCCTGACCTTGCTGGGGCTCATGGCCCTGTAGCGCTTTTGTTACTTG

AATGTCTAGCTGAGCCTGTTTTTGATGGAGCTACTACTGTAATGCGTGAAC

TAACAAACCTGTGAACTGTAAATAGGCCCCTGGAAGCACGTGCTTAAGCC

GTTTTGCTGATTTTTAAAAATATCATCTAGCGCACACGGGACTGGTATTCT

GGCTGTACTAATGACAAGCTGAGTCAAGACCCTGGAGGGTCATAGGCTTG

TAAAGGCCCACGCCACACTCGGCAGGGGTCTCTCATGTGTGTCCATCTGC

GTGTATGTCAAGGAAGTGAGATGCCAATTTGGGGTCTTGAGGCTGACCAG

TTGGGGTGCTTGGGTGATCTCTGCTTCATTAGTCATGGGTGGAAGAAAAA

CCACACCCCCCGCACCCCTCCGTTCTTTCTGCATAGACTCACTTGTTAAAT

AGCAGTTCTGTTGAGAGTGGAGTTACTGCAGGGAAGCTACCGGACCTGCC

TGGGAGCCAGTGAAGGGCGAGTCAGGGCACGCGTCCTGGAGGCTGCCAG

CGTCCTTGTAGCAGAGCAGTTTCTTGCCGCTTGGGTCTTCAGCACGCCAAG

CCCCCCACCAACCCTCCACCCCGAGTGAAGGCTTCGCTGAAATTGCTTTGG

TCCTCATAGAGCCTGTGGTGGCTACTTTTGGTCTGAAACCCACTTGGCCCA

GGAAAGAGAAAAGGTTGTATGTTTTGTGTTGGTGTTTCCTATTTTCTGCAC

TGGAGGGGAGGGGACTGTTGAGGTTCTGTCTTTTTTCTTCTTTTCCTCTTCC

CTCTTCACATCACTTGGCTTCCTTTCCTCTCTGATGACCGTCCGCCTATGGG

GTTCTGACTTCACTTTCCTCAGCGGGTCTCCAGTCCCCTGACCCAGCTCTA

AAGGCACTTAGGACCCAGGGAACATTTCTCACGTGCACATTCCCCTAAGA

GCCACCAGACTGCTTCCTGCCAGCCTGTGCTTGCGGCAGGGAGCCGGGGC

AGGGCAGAGGTGAACTTGAAGTTCAGGACTTGACTCTCCCACAGGTGGTG

AGCTGGTGGCTCTCTGGTGAGCTAGTGTCTCCACAGCCTGTCTCCAAGGCC

TCCCCTATGTACATTTCAGTGAGCTCACTTTGATTTTTAATCCCACCACAA

GCACATACTAATTTTATTTATGATTCAAATGTGACTCGTGCCTGCCCATCC

CTGTAATAGATGGAAGGTCAGCCCCGGCTTAACCACAGAGCACTGGCCCT

TCATGGCTGAGCTCAGAGCTCTGGCCTCCTGCTCAGACTAAAGGCACCTCC

TCTGGCCTCACCCAAGCCTCTTCTAAAAACCATGTTGAATGAATCCACGTT

CTGGAACCCCGAGGCGGGAGAAGTAGGGAGCTGTTCGTTTAAGCAGCATA

CACCTAAATTGGGGGTTTAAACATTAAGTAGGAGCTTGGGGTGGAAGAGG

GACAGCCGGCTGGGCCACCTGAGCAGAAGGTGGTAATGAAACACCTCAG

CTGGGCTCTTGGGAGACCTTAGGAAGCAGGAGAGGCAACACCTCTGGCTA

CTGATGGTGTGGCAAGTTCAGAAGAGGTGGTGGTGGGGTAGGCGTGATGT

CAGCAGAAGCCCTGCAGGCTGGGTGGGCAGGACACGTGGTGGGGGCCAC

TGAAACCAGGCCTAGGAGGGAGAACAAGTTCCAAAGGTGCCGACTGGAA

GAAGGGGGTAAAAGTTTGCTTTGGTGAGTGAGAAAAGGCTGGGGCGTGTG

ATCCATCCCCTCACGTTTCAGAACTTCCAGGCTTTCTACCTCGACTCTCAC

CACAGCCAGCACATACACCTAGGCTGTTTTTCCTTCCTCCACACCTGAGGG

ACGCAGCAACAGCTAGGATCTGCATTTTCAGGTTCCGAGCCTGACCCCTG

GAACTGACCAGCGCTCGATTGTCAGCCTTGGCCTGGGGTTTTGACCTTGCC

AGTGAAGTTTCGGTTTTGAAGTGATTAAATGTCACTTCCTCATCAGTTTCA

CTTCTGGAGGTTTTCTTATCCTACTCCCTGGTGCCAGGGACGTACCTGGGA 145138.doc -38 - 201015069 GTTTGAATCAGGCCCATTTGAGCGTGGCAGCCGTGTTGGGTGAAGGTCCG GGGCTCGGTGAGGCACTGGGGGGGTTTTCGGGAGGAAAATGAAAATGCTT CTAGAATGAGTGAACCACATCATAGCTCTCACTGTTTTTTCAATAGCTACT TTTTTTAGCAGACACCAGAGCCACACTCAAATGGCTAAGTAGGTTATGAC CTCTCTGGATTATTTTTGAATGCCCAACTGTTGCATTCAAGTTTTCTGACTA ATAAGAAATTAAGCATTCATCCTTCGTATCACTGCAGAAGCAACAGTGGG GGCACAGGGAGGGAACTCTTGACACTGAGCCACTAAAATATGGACTAATT TTTTGGACAAATCTTCAAACGGACTGTGCTACTGTATTTGTCTCAAAGCTA CCAAGTTTGTGCAATAAGTGGAAGGGATGTCATCCTTCTTCAATAAATGCT GAATGACATTCAAGCTGATTTTCTAGACCACTGAGAAAATCTTTATTTACA ATAAATTTCAATAAAATTTGCATAAATATATTCCCAAAAAAAAAAAAAAA AAAAAAGAAAAAAAAAAAAA Serial No. 83 secreted phosphoprotein 1

>gi I 38146097 I ref I NM_000582_2 I Human secretory phosphoprotein 1 (osteogenic protein, bone sialic acid protein I, early T-lymphocyte activation 1) (SPP1), mRNA|qPCR is determined at the time of request and [253..277] Matching

CTCCCTGTGTTGGTGGAGGATGTCTGCAGCAGCATTTAAATTCTGG

GAGGGCTTGGTTGTCAGCAGCAGCAGGAGGAGGCAGAGCACAGCATCGT

CGGGACCAGACTCGTCTCAGGCCAGTTGCAGCCTTCTCAGCCAAACGCCG

ACCAAGGAAAACTCACTACCATGAGAATTGCAGTGATTTGCTTTTGCCTCC

TAGGCATCACCTGTGCCATACCAGTTAAACAGGCTGATTCTGGAAGTTCTG

AGGAAAAGCAGCTTTACAACAAATACCCAGATGCTGTGGCCACATGGCTA

AACCCTGACCCATCTCAGAAGCAGAATCTCCTAGCCCCACAGACCCTTCC

AAGTAAGTCCAACGAAAGCCATGACCACATGGATGATATGGATGATGAA

GATGATGATGACCATGTGGACAGCCAGGACTCCATTGACTCGAACGACTC

TGATGATGTAGATGACACTGATGATTCTCACCAGTCTGATGAGTCTCACCA

TTCTGATGAATCTGATGAACTGGTCACTGATTTTCCCACGGACCTGCCAGC

AACCGAAGTTTTCACTCCAGTTGTCCCCACAGTAGACACATATGATGGCC

GAGGTGATAGTGTGGTTTATGGACTGAGGTCAAAATCTAAGAAGTTTCGC

AGACCTGACATCCAGTACCCTGATGCTACAGACGAGGACATCACCTCACA

CATGGAAAGCGAGGAGTTGAATGGTGCATACAAGGCCATCCCCGTTGCCC

AGGACCTGAACGCGCCTTCTGATTGGGACAGCCGTGGGAAGGACAGTTAT

GAAACGAGTCAGCTGGATGACCAGAGTGCTGAAACCCACAGCCACAAGC

AGTCCAGATTATATAAGCGGAAAGCCAATGATGAGAGCAATGAGCATTCC

GATGTGATTGATAGTCAGGAACTTTCCAAAGTCAGCCGTGAATTCCACAG

CCATGAATTTCACAGCCATGAAGATATGCTGGTTGTAGACCCCAAAAGTA

AGGAAGAAGATAAACACCTGAAATTTCGTATTTCTCATGAATTAGATAGT

GCATCTTCTGAGGTCAATTAAAAGGAGAAAAAATACAATTTCTCACTTTG

CATTTAGTCAAAAGAAAAAATGCTTTATAGCAAAATGAAAGAGAACATGA

AATGCTTCTTTCTCAGTTTATTGGTTGAATGTGTATCTATTTGAGTCTGGAA

ATAACTAATGTGTTTGATAATTAGTTTAGTTTGTGGCTTCATGGAAACTCC

CTGTAAACTAAAAGCTTCAGGGTTATGTCTATGTTCATTCTATAGAAGAAA

TGCAAACTATCACTGTATTTTAATATTTGTTATTCTCTCATGAATAGAAATT

TATGTAGAAGCAAACAAAATACTTTTACCCACTTAAAAAGAGAATATAAC 145138.doc -39- 201015069 ATTTTATGTCACTATAATCTTTTGTTTTTTAAGTTAGTGTATATTTTGTTGT chondroitin GATTATCTTTTTGTGGTGTGAATAAATCTTTTATCTTGAATGTAATAAGAA TTTGGTGGTGTCAATTGCTTATTTGTTTTCCCACGGTTGTCCAGCAATTAAT AAAACATAACCTTTTTTACTGCCTAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAA Serial No. 84 sulfate proteoglycan 2 > gi 21361115 Shu Shu Shu ref NM_004385.2 | human chondroitin sulfate proteoglycan 2 (Fu Xiken) (CSPG2), mRNA | qPCR Advance - Primer matches [10087.. 101 06] | qPCR Reverse-Introduction matches [101 85·. 10 163] | qPCR probe matches [10 139·. 101 61]

GCTGCCCCGAGCCTTTCTGGGGAAGAACTCCAGGCGTGCGGACGCA

ACAGCCGAGAACATTAGGTGTTGTGGACAGGAGCTGGGACCAAGATCTTC

GGCCAGCCCCGCATCCTCCCGCATCTTCCAGCACCGTCCCGCACCCTCCGC

ATCCTTCCCCGGGCCACCACGCTTCCTATGTGACCCGCCTGGGCAACGCCG

AACCCAGTCGCGCAGCGCTGCAGTGAATTTTCCCCCCAAACTGCAATAAG

CCGCCTTCCAAGGCCAAGATGTTCATAAATATAAAGAGCATCTTATGGAT

GTGTTCAACCTTAATAGTAACCCATGCGCTACATAAAGTCAAAGTGGGAA

AAAGCCCACCGGTGAGGGGCTCCCTCTCTGGAAAAGTCAGCCTACCTTGT

CATTTTTCAACGATGCCTACTTTGCCACCCAGTTACAACACCAGTGAATTT

CTCCGCATCAAATGGTCTAAGATTGAAGTGGACAAAAATGGAAAAGATTT

GAAAGAGACTACTGTCCTTGTGGCCCAAAATGGAAATATCAAGATTGGTC

AGGACTACAAAGGGAGAGTGTCTGTGCCCACACATCCCGAGGCTGTGGGC

GATGCCTCCCTCACTGTGGTCAAGCTGCTGGCAAGTGATGCGGGTCTTTAC

CGCTGTGACGTCATGTACGGGATTGAAGACACACAAGACACGGTGTCACT

GACTGTGGATGGGGTTGTGTTTCACTACAGGGCGGCAACCAGCAGGTACA

CACTGAATTTTGAGGCTGCTCAGAAGGCTTGTTTGGACGTTGGGGCAGTC

ATAGCAACTCCAGAGCAGCTCTTTGCTGCCTATGAAGATGGATTTGAGCA

GTGTGACGCAGGCTGGCTGGCTGATCAGACTGTCAGATATCCCATCCGGG

CTCCCAGAGTAGGCTGTTATGGAGATAAGATGGGAAAGGCAGGAGTCAG

GACTTATGGATTCCGTTCTCCCCAGGAAACTTACGATGTGTATTGTTATGT

GGATCATCTGGATGGTGATGTGTTCCACCTCACTGTCCCCAGTAAATTCAC

CTTCGAGGAGGCTGCAAAAGAGTGTGAAAACCAGGATGCCAGGCTGGCA

ACAGTGGGGGAACTCCAGGCGGCATGGAGGAACGGCTTTGACCAGTGCG

ATTACGGGTGGCTGTCGGATGCCAGCGTGCGCCACCCTGTGACTGTGGCC

AGGGCCCAGTGTGGAGGTGGTCTACTTGGGGTGAGAACCCTGTATCGTTT

TGAGAACCAGACAGGCTTCCCTCCCCCTGATAGCAGATTTGATGCCTACTG

CTTTAAACCTAAAGAGGCTACAACCATCGATTTGAGTATCCTCGCAGAAA

CTGCATCACCCAGTTTATCCAAAGAACCACAAATGGTTTCTGATAGAACT

ACACCAATCATCCCTTTAGTTGATGAATTACCTGTCATTCCAACAGAGTTC

CCTCCCGTGGGAAATATTGTCAGTTTTGAACAGAAAGCCACAGTCCAACC

TCAGGCTATCACAGATAGTTTAGCCACCAAATTACCCACACCTACTGGCA

GTACCAAGAAGCCCTGGGATATGGATGACTACTCACCTTCTGCTTCAGGA

CCTCTTGGAAAGCTAGACATATCAGAAATTAAGGAAGAAGTGCTCCAGAG

TACAACTGGCGTCTCTCATTATGCTACGGATTCATGGGATGGTGTCGTGGA

AGATAAACAAACACAAGAATCGGTTACACAGATTGAACAAATAGAAGTG 145138.doc • 40· 201015069

GGTCCTTTGGTAACATCTATGGAAATCTTAAAGCACATTCCTTCCAAGGAA

TTCCCTGTAACTGAAACACCATTGGTAACTGCAAGAATGATCCTGGAATC

CAAAACTGAAAAGAAAATGGTAAGCACTGTTTCTGAATTGGTAACCACAG

GTCACTATGGATTCACCTTGGGAGAAGAGGATGATGAAGACAGAACACTT

ACAGTTGGATCTGATGAGAGCACCTTGATCTTTGACCAAATTCCTGAAGTC

ATTACGGTGTCAAAGACTTCAGAAGACACCATCCACACTCATTTAGAAGA

CTTGGAGTCAGTCTCAGCATCCACAACTGTTTCCCCTTTAATTATGCCTGA

TAATAATGGATCATCCATGGATGACTGGGAAGAGAGACAAACTAGTGGTA

GGATAACGGAAGAGTTTCTTGGCAAATATCTGTCTACTACACCTTTTCCAT

CACAGCATCGTACAGAAATAGAATTGTTTCCTTATTCTGGTGATAAAATAT

TAGTAGAGGGAATTTCCACAGTTATTTATCCTTCTCTACAAACAGAAATGA

CACATAGAAGAGAAAGAACAGAAACACTAATACCAGAGATGAGAACAGA

TACTTATACAGATGAAATACAAGAAGAGATCACTAAAAGTCCATTTATGG

GAAAAACAGAAGAAGAAGTCTTCTCTGGGATGAAACTCTCTACATCTCTC

TCAGAGCCAATTCATGTTACAGAGTCTTCTGTGGAAATGACCAAGTCTTTT

GATTTCCCAACATTGATAACAAAGTTAAGTGCAGAGCCAACAGAAGTAAG

AGATATGGAGGAAGACTTTACAGCAACTCCAGGTACTACAAAATATGATG

AAAATATTACAACAGTGCTTTTGGCCCATGGTACTTTAAGTGTTGAAGCAG

CCACTGTATCAAAATGGTCATGGGATGAAGATAATACAACATCCAAGCCT

TTAGAGTCTACAGAACCTTCAGCCTCTTCAAAATTGCCCCCTGCCTTACTC

ACAACTGTGGGGATGAATGGAAAGGATAAAGACATCCCAAGTTTCACTGA

AGATGGAGCAGATGAATTTACTCTTATTCCAGATAGTACTCAAAAGCAGT

TAGAGGAGGTTACTGATGAAGACATAGCAGCCCATGGAAAATTCACAATT

AGATTTCAGCCAACTACATCAACTGGTATTGCAGAAAAGTCAACTTTGAG

AGATTCTACAACTGAAGAAAAAGTTCCACCTATCACAAGCACTGAAGGCC

AAGTTTATGCAACCATGGAAGGAAGTGCTTTGGGTGAAGTAGAAGATGTG

GACCTCTCTAAGCCAGTATCTACTGTTCCCCAATTTGCACACACTTCAGAG

GTGGAAGGATTAGCATTTGTTAGTTATAGTAGCACCCAAGAGCCTACTAC

TTATGTAGACTCTTCCCATACCATTCCTCTTTCTGTAATTCCCAAGACAGA

CTGGGGAGTGTTAGTACCTTCTGTTCCATCAGAAGATGAAGTTCTAGGTGA

ACCCTCTCAAGACATACTTGTCATTGATCAGACTCGCCTTGAAGCGACTAT

TTCTCCAGAAACTATGAGAACAACAAAAATCACAGAGGGAACAACTCAG

GAAGAATTCCCTTGGAAAGAACAGACTGCAGAGAAACCAGTTCCTGCTCT

CAGTTCTACAGCTTGGACTCCCAAGGAGGCAGTAACACCACTGGATGAAC

AAGAGGGCGATGGATCAGCATATACAGTCTCTGAAGATGAATTGTTGACA

GGTTCTGAGAGGGTCCCAGTTTTAGAAACAACTCCAGTTGGAAAAATTGA

TCACAGTGTGTCTTATCCACCAGGTGCTGTAACTGAGCACAAAGTGAAAA

CAGATGAAGTGGTAACACTAACACCACGCATTGGGCCAAAAGTATCTTTA

AGTCCAGGGCCTGAACAAAAATATGAAACAGAAGGTAGTAGTACAACAG

GATTTACATCATCTTTGAGTCCTTTTAGTACCCACATTACCCAGCTTATGG

AAGAAACCACTACTGAGAAAACATCCCTAGAGGATATTGATTTAGGCTCA

GGATTATTTGAAAAGCCCAAAGCCACAGAACTCATAGAATTTTCAACAAT

CAAAGTCACAGTTCCAAGTGATATTACCACTGCCTTCAGTTCAGTAGACA

GACTTCACACAACTTCAGCATTCAAGCCATCTTCCGCGATCACTAAGAAA

CCACCTCTCATCGACAGGGAACCTGGTGAAGAAACAACCAGTGACATGGT

AATCATTGGAGAATCAACATCTCATGTTCCTCCCACTACCCTTGAAGATAT

TGTAGCCAAGGAAACAGAAACCGATATTGATAGAGAGTATTTCACGACTT

CAAGTCCTCCTGCTACACAGCCAACAAGACCACCCACTGTGGAAGACAAA

GAGGCCTTTGGACCTCAGGCGCTTTCTACGCCACAGCCCCCAGCAAGCAC

AAAATTTCACCCTGACATTAATGTTTATATTATTGAGGTCAGAGAAAATAA

GACAGGTCGAATGAGTGATTTGAGTGTAATTGGTCATCCAATAGATTCAG 145138.doc -41 - 201015069

AATCTAAAGAAGATGAACCTTGTAGTGAAGAAACAGATCCAGTGCATGAT

CTAATGGCTGAAATTTTACCTGAATTCCCTGACATAATTGAAATAGACCTA

TACCACAGTGAAGAAAATGAAGAAGAAGAAGAAGAGTGTGCAAATGCTA

CTGATGTGACAACCACCCCATCTGTGCAGTACATAAATGGGAAGCATCTC

GTTACCACTGTGCCCAAGGACCCAGAAGCTGCAGAAGCTAGGCGTGGCCA

GTTTGAAAGTGTTGCACCTTCTCAGAATTTCTCGGACAGCTCTGAAAGTGA

TACTCATCCATTTGTAATAGCCAAAACGGAATTGTCTACTGCTGTGCAACC

TAATGAATCTACAGAAACAACTGAGTCTCTTGAAGTTACATGGAAGCCTG

AGACTTACCCTGAAACATCAGAACATTTTTCAGGTGGTGAGCCTGATGTTT

TCCCCACAGTCCCATTCCATGAGGAATTTGAAAGTGGAACAGCCAAAAAA

GGGGCAGAATCAGTCACAGAGAGAGATACTGAAGTTGGTCATCAGGCAC

ATGAACATACTGAACCTGTATCTCTGTTTCCTGAAGAGTCTTCAGGAGAGA

TTGCCATTGACCAAGAATCTCAGAAAATAGCCTTTGCAAGGGCTACAGAA

GTAACATTTGGTGAAGAGGTAGAAAAAAGTACTTCTGTCACATACACTCC

CACTATAGTTCCAAGTTCTGCATCAGCATATGTTTCAGAGGAAGAAGCAG

TTACCCTAATAGGAAATCCTTGGCCAGATGACCTGTTGTCTACCAAAGAA

AGCTGGGTAGAAGCAACTCCTAGACAAGTTGTAGAGCTCTCAGGGAGTTC

TTCGATTCCAATTACAGAAGGCTCTGGAGAAGCAGAAGAAGATGAAGATA

CAATGTTCACCATGGTAACTGATTTATCACAGAGAAATACTACTGATACA

CTCATTACTTTAGACACTAGCAGGATAATCACAGAAAGCTTTTTTGAGGTT

CCTGCAACCACCATTTATCCAGTTTCTGAACAACCTTCTGCAAAAGTGGTG

CCTACCAAGTTTGTAAGTGAAACAGACACTTCTGAGTGGATTTCCAGTACC

ACTGTTGAGGAAAAGAAAAGGAAGGAGGAGGAGGGAACTACAGGTACGG

CTTCTACATTTGAGGTATATTCATCTACACAGAGATCGGATCAATTAATTT

TACCCTTTGAATTAGAAAGTCCAAATGTAGCTACATCTAGTGATTCAGGTA

CCAGGAAAAGTTTTATGTCCTTGACAACACCAACACAGTCTGAAAGGGAA

ATGACAGATTCTACTCCTGTCTTTACAGAAACAAATACATTAGAAAATTTG

GGGGCACAGACCACTGAGCACAGCAGTATCCATCAACCTGGGGTTCAGGA

AGGGCTGACCACTCTCCCACGTAGTCCTGCCTCTGTCTTTATGGAGCAGGG

CTCTGGAGAAGCTGCTGCCGACCCAGAAACCACCACTGTTTCTTCATTTTC

ATTAAACGTAGAGTATGCAATTCAAGCCGAAAAGGAAGTAGCTGGCACTT

TGTCTCCGCATGTGGAAACTACATTCTCCACTGAGCCAACAGGACTGGTTT

TGAGTACAGTAATGGACAGAGTAGTTGCTGAAAATATAACCCAAACATCC

AGGGAAATAGTGATTTCAGAGCGATTAGGAGAACCAAATTATGGGGCAG

AAATAAGGGGCTTTTCCACAGGTTTTCCTTTGGAGGAAGATTTCAGTGGTG

ACTTTAGAGAATACTCAACAGTGTCTCATCCCATAGCAAAAGAAGAAACG

GTAATGATGGAAGGCTCTGGAGATGCAGCATTTAGGGACACCCAGACTTC

ACCATCTACAGTACCTACTTCAGTTCACATCAGTCACATATCTGACTCAGA

AGGACCCAGTAGCACCATGGTCAGCACTTCAGCCTTCCCCTGGGAAGAGT

TTACATCCTCAGCTGAGGGCTCAGGTGAGCAACTGGTCACAGTCAGCAGC

TCTGTTGTTCCAGTGCTTCCCAGTGCTGTGCAAAAGTTTTCTGGTACAGCT

TCCTCCATTATCGACGAAGGATTGGGAGAAGTGGGTACTGTCAATGAAAT

TGATAGAAGATCCACCATTTTACCAACAGCAGAAGTGGAAGGTACGAAAG

CTCCAGTAGAGAAGGAGGAAGTAAAGGTCAGTGGCACAGTTTCAACAAA

CTTTCCCCAAACTATAGAGCCAGCCAAATTATGGTCTAGGCAAGAAGTCA

ACCCTGTAAGACAAGAAATTGAAAGTGAAACAACATCAGAGGAACAAAT

TCAAGAAGAAAAGTCATTTGAATCCCCTCAAAACTCTCCTGCAACAGAAC

AAACAATCTTTGATTCACAGACATTTACTGAAACTGAACTCAAAACCACA

GATTATTCTGTACTAACAACAAAGAAAACTTACAGTGATGATAAAGAAAT

GAAGGAGGAAGACACTTCTTTAGTTAACATGTCTACTCCAGATCCAGATG

CAAATGGCTTGGAATCTTACACAACTCTCCCTGAAGCTACTGAAAAGTCA 145138.doc -42- 201015069

CATTTTTTCTTAGCTACTGCATTAGTAACTGAATCTATACCAGCTGAACAT

GTAGTCACAGATTCACCAATCAAAAAGGAAGAAAGTACAAAACATTTTCC

GAAAGGCATGAGACCAACAATTCAAGAGTCAGATACTGAGCTCTTATTCT

CTGGACTGGGATCAGGAGAAGAAGTTTTACCTACTCTACCAACAGAGTCA

GTGAATTTTACTGAAGTGGAACAAATCAATAACACATTATATCCCCACAC

TTCTCAAGTGGAAAGTACCTCAAGTGACAAAATTGAAGACTTTAACAGAA

TGGAAAATGTGGCAAAAGAAGTTGGACCACTCGTATCTCAAACAGACATC

TTTGAAGGTAGTGGGTCAGTAACCAGCACAACATTAATAGAAATTTTAAG

TGACACTGGAGCAGAAGGACCCACGGTGGCACCTCTCCCTTTCTCCACGG

ACATCGGACATCCTCAAAATCAGACTGTCAGGTGGGCAGAAGAAATCCAG

ACTAGTAGACCACAAACCATAACTGAACAAGACTCTAACAAGAATTCTTC

AACAGCAGAAATTAACGAAACAACAACCTCATCTACTGATTTTCTGGCTA

GAGCTTATGGTTTTGAAATGGCCAAAGAATTTGTTACATCAGCACCAAAA

CCATCTGACTTGTATTATGAACCTTCTGGAGAAGGATCTGGAGAAGTGGA

TATTGTTGATTCATTTCACACTTCTGCAACTACTCAGGCAACCAGACAAGA

AAGCAGCACCACATTTGTTTCTGATGGGTCCCTGGAAAAACATCCTGAGG

TGCCAAGCGCTAAAGCTGTTACTGCTGATGGATTCCCAACAGTTTCAGTGA

TGCTGCCTCTTCATTCAGAGCAGAACAAAAGCTCCCCTGATCCAACTAGC

ACACTGTCAAATACAGTGTCATATGAGAGGTCCACAGACGGTAGTTTCCA

AGACCGTTTCAGGGAATTCGAGGATTCCACCTTAAAACCTAACAGAAAAA

AACCCACTGAAAATATTATCATAGACCTGGACAAAGAGGACAAGGATTTA

ATATTGACAATTACAGAGAGTACCATCCTTGAAATTCTACCTGAGCTGAC

ATCGGATAAAAATACTATCATAGATATTGATCATACTAAACCTGTGTATG

AAGACATTCTTGGAATGCAAACAGATATAGATACAGAGGTACCATCAGAA

CCACATGACAGTAATGATGAAAGTAATGATGACAGCACTCAAGTTCAAGA

GATCTATGAGGCAGCTGTCAACCTTTCTTTAACTGAGGAAACATTTGAGG

GCTCTGCTGATGTTCTGGCTAGCTACACTCAGGCAACACATGATGAATCA

ATGACTTATGAAGATAGAAGCCAACTAGATCACATGGGCTTTCACTTCAC

AACTGGGATCCCTGCTCCTAGCACAGAAACAGAATTAGACGTTTTACTTCC

CACGGCAACATCCCTGCCAATTCCTCGTAAGTCTGCCACAGTTATTCCAGA

GATTGAAGGAATAAAAGCTGAAGCAAAAGCCCTGGATGACATGTTTGAAT

CAAGCACTTTGTCTGATGGTCAAGCTATTGCAGACCAAAGTGAAATAATA

CCAACATTGGGCCAATTTGAAAGGACTCAGGAGGAGTATGAAGACAAAA

AACATGCTGGTCCTTCTTTTCAGCCAGAATTCTCTTCAGGAGCTGAGGAGG

CATTAGTAGACCATACTCCCTATCTAAGTATTGCTACTACCCACCTTATGG

ATCAGAGTGTAACAGAGGTGCCTGATGTGATGGAAGGATCCAATCCCCCA

TATTACACTGATACAACATTAGCAGTTTCAACATTTGCGAAGTTGTCTTCT

CAGACACCATCATCTCCCCTCACTATCTACTCAGGCAGTGAAGCCTCTGGA

CACACAGAGATCCCCCAGCCCAGTGCTCTGCCAGGAATAGACGTCGGCTC

ATCTGTAATGTCCCCACAGGATTCTTTTAAGGAAATTCATGTAAATATTGA

AGCAACTTTCAAACCATCAAGTGAGGAATACCTTCACATAACTGAGCCTC

CCTCTTTATCTCCTGACACAAAATTAGAACCTTCAGAAGATGATGGTAAAC

CTGAGTTATTAGAAGAAATGGAAGCTTCTCCCACAGAACTTATTGCTGTG

GAAGGAACTGAGATTCTCCAAGATTTCCAAAACAAAACCGATGGTCAAGT

TTCTGGAGAAGCAATCAAGATGTTTCCCACCATTAAAACACCTGAGGCTG

GAACTGTTATTACAACTGCCGATGAAATTGAATTAGAAGGTGCTACACAG

TGGCCACACTCTACTTCTGCTTCTGCCACCTATGGGGTCGAGGCAGGTGTG

GTGCCTTGGCTAAGTCCACAGACTTCTGAGAGGCCCACGCTTTCTTCTTCT

CCAGAAATAAACCCTGAAACTCAAGCAGCTTTAATCAGAGGGCAGGATTC

CACGATAGCAGCATCAGAACAGCAAGTGGCAGCGAGAATTCTTGATTCCA

ATGATCAGGCAACAGTAAACCCTGTGGAATTTAATACTGAGGTTGCAACA 145138.doc -43- 201015069 billion CCACCATTTTCCCTTCTGGAGACTTCTAATGAAACAGATTTCCTGATTGGC ATTAATGAAGAGTCAGTGGAAGGCACGGCAATCTATTTACCAGGACCTGA TCGCTGCAAAATGAACCCGTGCCTTAACGGAGGCACCTGTTATCCTACTG AAACTTCCTACGTATGCACCTGTGTGCCAGGATACAGCGGAGACCAGTGT GAACTTGATTTTGATGAATGTCACTCTAATCCCTGTCGTAATGGAGCCACT TGTGTTGATGGTTTTAACACATTCAGGTGCCTCTGCCTTCCAAGTTATGTT GGTGCACTTTGTGAGCAAGATACCGAGACATGTGACTATGGCTGGCACAA ATTCCAAGGGCAGTGCTACAAATACTTTGCCCATCGACGCACATGGGATG CAGCTGAACGGGAATGCCGTCTGCAGGGTGCCCATCTCACAAGCATCCTG TCTCACGAAGAACAAATGTTTGTTAATCGTGTGGGCCATGATTATCAGTGG ATAGGCCTCAATGACAAGATGTTTGAGCATGACTTCCGTTGGACTGATGG CAGCACACTGCAATACGAGAATTGGAGACCCAACCAGCCAGACAGCTTCT TTTCTGCTGGAGAAGACTGTGTTGTAATCATTTGGCATGAGAATGGCCAGT GGAATGATGTTCCCTGCAATTACCATCTCACCTATACGTGCAAGAAAGGA ACAGTTGCTTGCGGCCAGCCCCCTGTTGTAGAAAATGCCAAGACCTTTGG AAAGATGAAACCTCGTTATGAAATCAACTCCCTGATTAGATACCACTGCA AAGATGGTTTCATTCAACGTCACCTTCCAACTATCCGGTGCTTAGGAAATG GAAGATGGGCTATACCTAAAATTACCTGCATGAACCCATCTGCATA CCAA AGGACTTATTCTATGAAATACTTTAAAAATTCCTCATCAGCAAAGGACAA TTCAATAAATACATCCAAACATGATCATCGTTGGAGCCGGAGGTGGCAGG AGTCGAGGCGCTGATCCCTAAAATGGCGAACATGTGTTTTCATCATTTCAG CCAAAGTCCTAACTTCCTGTGCCTTTCCTATGACCTCGAGAAGTAATTATC AGTTGGTTTGGATTTTTGGACCACCGTTCAGTCATTTTGGGTTGCCGTGCT CCCAAAACATTTTAAATGAAAGTATTGGCATTCAAAAAGACAGCAGACAA AATGAAAGAAAATGAGAGCAGAAAGTAAGCATTTCCAGCCTATCTAATTT CTTTAGTTTTCTATTTGCCTCCAGTGCAGTCCATTTCCTAATGTATACCAGC CTACTGTACTATTTAAAATGCTCAATTTCAGCACCGATGGCCATGTAAATA AGATGATTTAATGTTGATTTTAATCCTGTATATAAAATAAAAAGTCACAAT GAGTTTGGGCATATTTAATGATGATTATGGAGCCTTAGAGGTCTTTAATCA TTGGTTCGGCTGCTTTTATGTAGTTTAGGCTGGAAATGGTTTCACTTGCTCT TTGACTGTCAGCAAGACTGAAGATGGCTTTTCCTGGACAGCTAGAAAACA CAAAATCTTGTAGGTCATTGCACCTATCTCAGCCATAGGTGCAGTTTGCTT CTACATGATGCTAAAGGCTGCGAATGGGATCCTGATGGAACTAAGGACTC CAATGTCGAACTCTTCTTTGCTGCATTCCTTTTTCTTCACTTACAAGAAAGG CCTGAATGGAGGACTTTTCTGTAACCAGG Serial No. 85 N- Dukes yl sphingosine yeast dipped Zhi hydrolase 1 > gi | 30089929 | ref Shu NM_0043 15.2 | human N- acyl Sphingosine guanamine hydrolase Acidic neuropterinase 1 (ASAH1), transcriptional 艎2, mRNA | qPCR advance-primer matches [1212..1228] | qPCR reverse-primer matches [1290.· 1266] I qPCR probe and [1233 .. 1260] Matching

GGACTTTGAAATCCAACCCGGTCACCTACCCGCGCGACTGTGTCCA

CGGATGGCACGAAAGCCAAGCGAGTCCCCCTGCCGAGCTACTCGCGTCCG

CCTCCTCCCAAGCTGAGCTCTGCTCCGCCCACCTGAGTCCTTCGCCAGTTA

GGAGGAAACACAGCCGCTTAATGAACTGCTGCATCGGGCTGGGAGAGAA

AGCTCGCGGGTCCCACCGGGCCTCCTACCCAAGTCTCAGCGCGCTTTTCAC 145138.doc • 44· 201015069

CGAGGCCTCAATTCTGGGATTTGGCAGCTTTGCTGTGAAAGCCCAATGGA CAGAGGACTGCAGAAAATCAACCTATCCTCCTTCAGGACCAACGTACAGA GGTGCAGTTCCATGGTACACCATAAATCTTGACTTACCACCCTACAAAAG ATGGCATGAATTGATGCTTGACAAGGCACCAATGCTAAAGGTTATAGTGA ATTCTCTGAAGAATATGATAAATACATTCGTGCCAAGTGGAAAAGTTATG CAGGTGGTGGATGAAAAATTGCCTGGCCTACTTGGCAACTTTCCTGGCCCT TTTGAAGAGGAAATGAAGGGTATTGCCGCTGTTACTGATATACCTTTAGG AGAGATTATTTCATTCAATATTTTTTATGAATTATTTACCATTTGTACTTCA ATAGTAGCAGAAGACAAAAAAGGTCATCTAATACATGGGAGAAACATGG ATTTTGGAGTATTTCTTGGGTGGAACATAAATAATGATACCTGGGTCATAA CTGAGCAACTAAAACCTTTAACAGTGAATTTGGATTTCCAAAGAAACAAC AAAACTGTCTTCAAGGCTTCAAGCTTTGCTGGCTATGTGGGCATGTTAACA GGATTCAAACCAGGACTGTTCAGTCTTACACTGAATGAACGTTTCAGTATA AATGGTGGTTATCTGGGTATTCTAGAATGGATTCTGGGAAAGAAAGATGC CATGTGGATAGGGTTCCTCACTAGAACAGTTCTGGAAAATAGCACAAGTT ATGAAGAAGCCAAGAATTTATTGACCAAGACCAAGATATTGGCCCCAGCC TACTTTATCCTGGGAGGCAACCAGTCTGGGGAAGGTTGTGTGATTACACG AGACAGAAAGGAATCATTGGATGTATATGAACTCGATGCTAAGCAGGGTA GATGGTATGTGGTACAAACAAATTATGACCGTTGGAAACATCCCTTCTTCC TTGATGATCGCAGAACGCCTGCAAA GATGTGTCTGAACCGCACCAGCCAA GAGAATATCTCATTTGAAACCATGTATGATGTCCTGTCAACAAAACCTGTC CTCAACAAGCTGACCGTATACACAACCTTGATAGATGTTACCAAAGGTCA ATTCGAAACTTACCTGCGGGACTGCCCTGACCCTTGTATAGGTTGGTGAGC ACACGTCTGGCCTACAGAATGCGGCCTCTGAGACATGAAGACACCATCTC CATGTGACCGAACACTGCAGCTGTCTGACCTTCCAAAGACTAAGACTCGC GGCAGGTTCTCTTTGAGTCAAAAGCTTGTCTTCGTCCATCTGTTGACAAAT GACAGACCTTTTTTTTTCCCCCATCAGTTGATTTTTCTTATTTACAGATAAC TTCTTTAGGGGAAGTAAAACAGTCATCTAGAATTCACTGAGTTTTGTTTCA CTTTGACATTTGGGGATCTGGTGGGCAGTCGAACCATGGTGAACTCCACCT CCGTGGAATAAATGGAGATTCAGCGTGGGTGTTGAATCCAGCACGTCTGT GTGAGTAACGGGACAGTAAACACTCCACATTCTTCAGTTTTTCACTTCTAC CTACATATTTGTATGTTTTTCTGTATAACAGCCTTTTCCTTCTGGTTCTAAC TGCTGTTAAAATTAATATATCATTATCTTTGCTGTTATTGACAGCGATATA ATTTTATTACATATGATTAGAGGGATGAGACAGACATTCACCTGTATATTT CTTTTAATGGGCACAAAATGGGCCCTTGCCTCTAAATAGCACTTTTTGGGG TTCAAGAAGTAATCAGTATGCAAAGCAATCTTTTATACAATAATTGAAGT GTTCCCTTTTTCATAATTACTGTACTTCCCAGTAACCCTAAGGAAGTTGCT AACTTAAAAAACTGCATCCCACGTTCTGTTAATTTAGTAAATAAACAAGTC AAAGACTTGTGGAAAATAGGAAGTGAACCCATATTTTAAAT TCTCATAAG TAGCATTCATGTAATAAACAGGTTTTTAGTTTGTTCTTCAGATTGATAGGG AGTTTTAAAGAAATTTTAGTAGTTACTAAAATTATGTTACTGTATTTTTCA GAAATCAAACTGCTTATGAAAAGTACTAATAGAACTTGTTAACCTTTCTAA CCTTCACGATTAACTGTGAAATGTACGTCATTTGTGCAAGACCGTTTGTCC ACTTCATTTTGTATAATCACAGTTGTGTTCCTGACACTCAATAAACAGTCA TTGGAAAGAGTGCCAGTCAGCAGTCATGCA Serial No. 86 N- dipped dipped amine group sphingosine yeast hydrolase Chong transcript variant 1 1 > gi | 30089927 Shu ref | NM_177924.1 Shu human sphingosine N- acyl hydrolysis Amides Enzyme (Acid Neural-Reductase) 1 (ASAH1), Transcriptional Variant 2, 145138.doc •45- 201015069 1111?^八|9?€11 Advance_Introduction matches [1050..1066]|4?〇11 Reverse _ primer matches [1128.. 1104] I qPCR probe matches [1071.. 1098]

GGCTCTTCTTTGCCTCTGCTGGAGTCCGGGGAGTGGCGTTGGCTGCT

AGAGCGATGCCGGGCCGGAGTTGCGTCGCCTTAGTCCTCCTGGCTGCCGC

CGTCAGCTGTGCCGTCGCGCAGCACGCGCCGCCGTGGACAGAGGACTGCA

GAAAATCAACCTATCCTCCTTCAGGACCAACGTACAGAGGTGCAGTTCCA

TGGTACACGATAAATCTTGACTTACCACCCTACAAAAGATGGCATGAATT

GATGCTTGACAAGGCACCAATGCTAAAGGTTATAGTGAATTCTCTGAAGA

ATATGATAAATACATTCGTGCCAAGTGGAAAAGTTATGCAGGTGGTGGAT

GAAAAATTGCCTGGCCTACTTGGCAACTTTCCTGGCCCTTTTGAAGAGGAA

ATGAAGGGTATTGCCGCTGTTACTGATATACCTTTAGGAGAGATTATTTCA

TTCAATATTTTTTATGAATTATTTACCATTTGTACTTCAATAGTAGCAGAA

GACAAAAAAGGTCATCTAATACATGGGAGAAACATGGATTTTGGAGTATT

TCTTGGGTGGAACATAAATAATGATACCTGGGTCATAACTGAGCAACTAA

AACCTTTAACAGTGAATTTGGATTTCCAAAGAAACAACAAAACTGTCTTC

AAGGCTTCAAGCTTTGCTGGCTATGTGGGCATGTTAACAGGATTCAAACC

AGGACTGTTCAGTCTTACACTGAATGAACGTTTCAGTATAAATGGTGGTTA

TCTGGGTATTCTAGAATGGATTCTGGGAAAGAAAGATGCCATGTGGATAG

GGTTCCTCACTAGAACAGTTCTGGAAAATAGCACAAGTTATGAAGAAGCC

AAGAATTTATTGACCAAGACCAAGATATTGGCCCCAGCCTACTTTATCCTG

GGAGGCAACCAGTCTGGGGAAGGTTGTGTGATTACACGAGACAGAAAGG

AATCATTGGATGTATATGAACTCGATGCTAAGCAGGGTAGATGGTATGTG

GTACAAACAAATTATGACCGTTGGAAACATCCCTTCTTCCTTGATGATCGC

AGAACGCCTGCAAAGATGTGTCTGAACCGCACCAGCCAAGAGAATATCTC

ATTTGAAACCATGTATGATGTCCTGTCAACAAAACCTGTCCTCAACAAGCT

GACCGTATACACAACCTTGATAGATGTTACCAAAGGTCAATTCGAAACTT

ACCTGCGGGACTGCCCTGACCCTTGTATAGGTTGGTGAGCACACGTCTGG

CCTACAGAATGCGGCCTCTGAGACATGAAGACACCATCTCCATGTGACCG

AACACTGCAGCTGTCTGACCTTCCAAAGACTAAGACTCGCGGCAGGTTCT

CTTTGAGTCAAAAGCTTGTCTTCGTCCATCTGTTGACAAATGACAGACCTT

TTTTTTTCCCCCATCAGTTGATTTTTCTTATTTACAGATAACTTCTTTAGGG

GAAGTAAAACAGTCATCTAGAATTCACTGAGTTTTGTTTCACTTTGACATT

TGGGGATCTGGTGGGCAGTCGAACCATGGTGAACTCCACCTCCGTGGAAT

AAATGGAGATTCAGCGTGGGTGTTGAATCCAGCACGTCTGTGTGAGTAAC

GGGACAGTAAACACTCCACATTCTTCAGTTTTTCACTTCTACCTACATATT

TGTATGTTTTTCTGTATAACAGCCTTTTCCTTCTGGTTCTAACTGCTGTTAA

AATTAATATATCATTATCTTTGCTGTTATTGACAGCGATATAATTTTATTAC

ATATGATTAGAGGGATGAGACAGACATTCACCTGTATATTTCTTTTAATGG

GCACAAAATGGGCCCTTGCCTCTAAATAGCACTTTTTGGGGTTCAAGAAG

TAATCAGTATGCAAAGCAATCTTTTATACAATAATTGAAGTGTTCCCTTTT

TCATAATTACTGTACTTCCCAGTAACCCTAAGGAAGTTGCTAACTTAAAAA

ACTGCATCCCACGTTCTGTTAATTTAGTAAATAAACAAGTCAAAGACTTGT

GGAAAATAGGAAGTGAACCCATATTTTAAATTCTCATAAGTAGCATTCAT

GTAATAAACAGGTTTTTAGTTTGTTCTTCAGATTGATAGGGAGTTTTAAAG

AAATTTTAGTAGTTACTAAAATTATGTTACTGTATTTTTCAGAAATCAAAC

TGCTTATGAAAAGTACTAATAGAACTTGTTAACCTTTCTAACCTTCACGAT

TAACTGTGAAATGTACGTCATTTGTGCAAGACCGTTTGTCCACTTCATTTT

GTATAATCACAGTTGTGTTCCTGACACTCAATAAACAGTCATTGGAAAGA 14S138.doc -46- 201015069 GTGCCAGTCAGCAGTCATGCA Sequence No. 87 Protease, Serine 11 >gi|21327712 ef丨ΝΜ_002775·2|Human Protease, Serine 11 (IGF Binding) (PRSS11), mRNA 丨qPCR Advance _ The primer matches [103 0.. 1048] 丨 qPCR reverse—the primer matches [1106·· 1083] | qPCR probe matches [1080.· 1050]

CCGGCCCTCGCCCTGTCCGCCGCCACCGCCGCCGCCGCCAGAGTCG

CCATGCAGATCCCGCGCGCCGCTCTTCTCCCGCTGCTGCTGCTGCTGCTGG

CGGCGCCCGCCTCGGCGCAGCTGTCCCGGGCCGGCCGCTCGGCGCCTTTG

GCCGCCGGGTGCCCAGACCGCTGCGAGCCGGCGCGCTGCCCGCCGCAGCC

GGAGCACTGCGAGGGCGGCCGGGCCCGGGACGCGTGCGGCTGCTGCGAG

GTGTGCGGCGCGCCCGAGGGCGCCGCGTGCGGCCTGCAGGAGGGCCCGTG

CGGCGAGGGGCTGCAGTGCGTGGTGCCCTTCGGGGTGCCAGCCTCGGCCA

CGGTGCGGCGGCGCGCGCAGGCCGGCCTCTGTGTGTGCGCCAGCAGCGAG

CCGGTGTGCGGCAGCGACGCCAACACCTACGCCAACCTGTGCCAGCTGCG

CGCCGCCAGCCGCCGCTCCGAGAGGCTGCACCGGCCGCCGGTCATCGTCC

TGCAGCGCGGAGCCTGCGGCCAAGGGCAGGAAGATCCCAACAGTTTGCGC

CATAAATATAACTTTATCGCGGACGTGGTGGAGAAGATCGCCCCTGCCGT

GGTTCATATCGAATTGTTTCGCAAGCTTCCGTTTTCTAAACGAGAGGTGCC

GGTGGCTAGTGGGTCTGGGTTTATTGTGTCGGAAGATGGACTGATCGTGA

CAAATGCCCACGTGGTGACCAACAAGCACCGGGTCAAAGTTGAGCTGAAG

AACGGTGCCACTTACGAAGCCAAAATCAAGGATGTGGATGAGAAAGCAG

ACATCGCACTCATCAAAATTGACCACCAGGGCAAGCTGCCTGTCCTGCTG

CTTGGCCGCTCCTCAGAGCTGCGGCCGGGAGAGTTCGTGGTCGCCATCGG

AAGCCCGTTTTCCCTTCAAAACACAGTCACCACCGGGATCGTGAGCACCA

CCCAGCGAGGCGGCAAAGAGCTGGGGCTCCGCAACTCAGACATGGACTA

CATCCAGACCGACGCCATCATCAACTATGGAAACTCGGGAGGCCCGTTAG

TAAACCTGGACGGTGAAGTGATTGGAATTAACACTTTGAAAGTGACAGCT

GGAATCTCCTTTGCAATCCCATCTGATAAGATTAAAAAGTTCCTCACGGAG

TCCCATGACCGACAGGCCAAAGGAAAAGCCATCACCAAGAAGAAGTATA

TTGGTATCCGAATGATGTCACTCACGTCCAGCAAAGCCAAAGAGCTGAAG

GACCGGCACCGGGACTTCCCAGACGTGATCTCAGGAGCGTATATAATTGA

AGTAATTCCTGATACCCCAGCAGAAGCTGGTGGTCTCAAGGAAAACGACG

TCATAATCAGCATCAATGGACAGTCCGTGGTCTCCGCCAATGATGTCAGC

GACGTCATTAAAAGGGAAAGCACCCTGAACATGGTGGTCCGCAGGGGTA

ATGAAGATATCATGATCACAGTGATTCCCGAAGAAATTGACCCATAGGCA

GAGGCATGAGCTGGACTTCATGTTTCCCTCAAAGACTCTCCCGTGGATGAC

GGATGAGGACTCTGGGCTGCTGGAATAGGACACTCAAGACTTTTGACTGC

CATTTTGTTTGTTCAGTGGAGACTCCCTGGCCAACAGAATCCTTCTTGATA

GTTTGCAGGCAAAACAAATGTAATGTTGCAGATCCGCAGGCAGAAGCTCT

GCCCTTCTGTATCCTATGTATGCAGTGTGCTTTTTCTTGCCAGCTTGGGCCA

TTCTTGCTTAGACAGTCAGCATTTGTCTCCTCCTTTAACTGAGTCATCATCT

TAGTCCAACTAATGCAGTCGATACAATGCGTAGATAGAAGAAGCCCCACG

GGAGCCAGGATGGGACTGGTCGTGTTTGTGCTTTTCTCCAAGTCAGCACCC

AAAGGTCAATGCACAGAGACCCCGGGTGGGTGAGCGCTGGCTTCTCAAAC 145138.doc -47- 201015069 GGCCGAAGTTGCCTCTTTTAGGAATCTCTTTGGAATTGGGAGCACGATGAC TCTGAGTTTGAGCTATTAAAGTACTTCTTACACATTG Sequence No. 88 Secretory Curl-related Protein 2 >gi | 42656988丨ref | XM_050625.4丨Human Secretory Curl-related Protein 2 (3?1^>2) , 1111 ^ eight |?? 9 «1 forward _ Introduction and [686..703] match | qPCR reverse primer _ and [750..728] match | qPCR probes [705 * .726] match CCGGGTCGGAGCCCCCCGGAGCTGCGCGCGGGCTTGCAGCGCCTCG CCCGCGCTGTCCTCCCGGTGTCCCGCTTCTCCGCGCCCCAGCCGCCGGCTG CCAGCTTTTCGGGGCCCCGAGTCGCACCCAGCGAAGAGAGCGGGCCCGGG ACAAGCTCGAACTCCGGCCGCCTCGCCCTTCCCCGGCTCCGCTCCCTCTGC _ CCCCTCGGGGTCGCGCGCCCACGATGCTGCAGGGCCCTGGCTCGCTGCTG CTGCTCTTCCTCGCCTCGCACTGCTGCCTGGGCTCGGCGCGCGGGCTCTTC CTCTTTGGCCAGCCCGACTTCTCCTACAAGCGCAGCAATTGCAAGCCCATC CCTGCCAACCTGCAGCTGTGCCACGGCATCGAATACCAGAACATGCGGCT GCCCAACCTGCTGGGCCACGAGACCATGAAGGAGGTGCTGGAGCAGGCC GGCGCTTGGATCCCGCTGGTCATGAAGCAGTGCCACCCGGACACCAAGAA GTTCCTGTGCTCGCTCTTCGCCCCCGTCTGCCTCGATGACCTAGACGAGAC CATCCA GCCATGCCACTCGCTCTGCGTGCAGGTGAAGGACCGCTGCGCCC CGGTCATGTCCGCCTTCGGCTTCCCCTGGCCCGACATGCTTGAGTGCGACC GTTTCCCCCAGGACAACGACCTTTGCATCCCCCTCGCTAGCAGCGACCACC TCCTGCCAGCCACCGAGGAAGCTCCAAAGGTATGTGAAGCCTGCAAAAAT AAAAATGATGATGACAACGACATAATGGAAACGCTTTGTAAAAATGATTT TGCACTGAAAATAAAAGTGAAGGAGATAACCTACATCAACCGAGATACC AAAATCATCCTGGAGACCAAGAGCAAGACCATTTACAAGCTGAACGGTGT GTCCGAAAGGGACCTGAAGAAATCGGTGCTGTGGCTCAAAGACAGCTTGC AGTGCACCTGTGAGGAGATGAACGACATCAACGCGCCCTATCTGGTCATG GGACAGAAACAGGGTGGGGAGCTGGTGATCACCTCGGTGAAGCGGTGGC ❹ AGAAGGGGCAGAGAGAGTTCAAGCGCATCTCCCGCAGCATCCGCAAGCT GCAGTGCTAGTCCCGGCATCCTGATGGCTCCGACAGGCCTGCTCCAGAGC ACGGCTGACCATTTCTGCTCCGGGATCTCAGCTCCCGTTCCCCAAGCACAC TCCTAGCTGCTCCAGTGTCAGCCTGGGCAGCTTCCCCCTGCCTTTTGCACG TTTGCATCCCCAGCATTTCCTGAGTTATAAGGCCACAGGAGTGGATAGCTG TTTTCACCTAAAGGAAAAGCCCACCCGAATCTTGTAGAAATATTCAAACT AATAAAATCATGAATATTTTTATGAAGTTTAAAAA Serial No. 89 phospholipase A2, XIIB group > gi | 45505134 ref Shu Shu Shu NM_032562.2 human phospholipase A2,

XIIB group (PLA2G12B), mRNA

TGTCCCTGGAATTCTGGGACACTGGCTGGGGTTTGAGGAGAGAAGC

CAGTACCTACCTGGCTGCAGGATGAAGCTGGCCAGTGGCTTCTTGGTTTTG 145138.doc •48- 201015069

TGGCTCAGCCTTGGGGGTGGCCTGGCTCAGAGCGACACGAGCCCTGACAC GGAGGAGTCCTATTCAGACTGGGGCCTTCGGCACCTCCGGGGAAGCTTTG AATCCGTCAATAGCTACTTCGATTCTTTTCTGGAGCTGCTGGGAGGGAAGA ATGGAGTCTGTCAGTACAGGTGCCGATATGGAAAGGCACCAATGCCCAGA CCTGGCTACAAGCCCCAAGAGCCCAATGGCTGCGGCTCCTATTTCCTGGGT CTCAAGGTACCAGAAAGTATGGACTTGGGCATTCCAGCAATGACAAAGTG CTGCAACCAGCTGGATGTCTGTTATGACACTTGCGGTGCCAACAAATATC GCTGTGATGCAAAATTCCGATGGTGTCTCCACTCGATCTGCTCTGACCTTA AGCGGAGTCTGGGCTTTGTCTCCAAAGTGGAAGCAGCCTGTGATTCCCTG GTTGACACTGTGTTCAACACCGTGTGGACCTTGGGCTGCCGCCCCTTTATG AATAGTCAGCGGGCAGCTTGCATCTGTGCAGAGGAGGAGAAGGAAGAGT TATGAGGAAGAAGTGATTCCTTCCTGGTTTTGAGTGACACCACAGCTGTCA GCCTTCAAGATGTCAAGTCTTCGAGTCAGCGTGACTCATTCATTCTTCCAA CAGTTTGGACACCACAAAGCAGGAGAAAGGGAACATTTTTCTACAGCTGG AAAGTGAGTCCTATCCTTTGAGGAAATTTGAAAAAAGACATGGAGTGGTT TGAAAGCTACTCTTCATTTAAGACTGCTCTCCCCAACCAAGACACATTTGC CTGGAAATTCAGTTCTTAGCTTAAAGACTAAAATGCAAGCAAACCCTGCA ATTCCTGGACCTGATAGTTATATTCATGAGTGAAATTGTGGGGAGTCCAGC CATTTGGGAGGCAATGACTTTCTGCTGGCCCATGTTTCAGTTGCCAGTAAG CTTCTCACATTTAATAAAGTGTA CTTTTTAGAACATT Sequence No. 90 s pentin 2, extracellular matrix protein >gi | 6912681 ef|NM_012445.1 丨 human statin 2, extracellular

Matrix protein (SPON2), mRNA

GCACGAGGGAAGAGGGTGATCCGACCCGGGGAAGGTCGCTGGGCA

GGGCGAGTTGGGAAAGCGGCAGCCCCCGCCGCCCCCGCAGCCCCTTCTCC

TCCTTTCTCCCACGTCCTATCTGCCTCTCGCTGGAGGCCAGGCCGTGCAGC

ATCGAAGACAGGAGGAACTGGAGCCTCATTGGCCGGCCCGGGGCGCCGG

CCTCGGGCTTAAATAGGAGCTCCGGGCTCTGGCTGGGACCCGACCGCTGC

CGGCCGCGCTCCCGCTGCTCCTGCCGGGTGATGGAAAACCCCAGCCCGGC

CGCCGCCCTGGGCAAGGCCCTCTGCGCTCTCCTCCTGGCCACTCTCGGCGC

CGCCGGCCAGCCTCTTGGGGGAGAGTCCATCTGTTCCGCCAGAGCCCCGG

CCAAATACAGCATCACCTTCACGGGCAAGTGGAGCCAGACGGCCTTCCCC

AAGCAGTACCCCCTGTTCCGCCCCCCTGCGCAGTGGTCTTCGCTGCTGGGG

GCCGCGCATAGCTCCGACTACAGCATGTGGAGGAAGAACCAGTACGTCAG

TAACGGGCTGCGCGACTTTGCGGAGCGCGGCGAGGCCTGGGCGCTGATGA

AGGAGATCGAGGCGGCGGGGGAGGCGCTGCAGAGCGTGCACGCGGTGTT

TTCGGCGCCCGCCGTCCCCAGCGGCACCGGGCAGACGTCGGCGGAGCTGG

AGGTGCAGCGCAGGCACTCGCTGGTCTCGTTTGTGGTGCGCATCGTGCCC

AGCCCCGACTGGTTCGTGGGCGTGGACAGCCTGGACCTGTGCGACGGGGA

CCGTTGGCGGGAACAGGCGGCGCTGGACCTGTACCCCTACGACGCCGGGA

CGGACAGCGGCTTCACCTTCTCCTCCCCCAACTTCGCCACCATCCCGCAGG

ACACGGTGACCGAGATAACGTCCTCCTCTCCCAGCCACCCGGCCAACTCC

TTCTACTACCCGCGGCTGAAGGCCCTGCCTCCCATCGCCAGGGTGACACTG

GTGCGGCTGCGACAGAGCCCCAGGGCCTTCATCCCTCCCGCCCCAGTCCT

GCCCAGCAGGGACAATGAGATTGTAGACAGCGCCTCAGTTCCAGAAACGC

CGCTGGACTGCGAGGTCTCCCTGTGGTCGTCCTGGGGACTGTGCGGAGGC

CACTGTGGGAGGCTCGGGACCAAGAGCAGGACTCGCTACGTCCGGGTCCA 145138.doc -49- 201015069

GCCCGCCAACAACGGGAGCCCCTGCCCCGAGCTCGAAGAAGAGGCTGAG

TGCGTCCCTGATAACTGCGTCTAAGACCAGAGCCCCGCAGCCCCTGGGGC

CCCCGGAGCCATGGGGTGTCGGGGGCTCCTGTGCAGGCTCATGCTGCAGG

CGGCCGAGGCACAGGGGGTTTCGCGCTGCTCCTGACCGCGGTGAGGCCGC

GCCGACCATCTCTGCACTGAAGGGCCCTCTGGTGGCCGGCACGGGCATTG

GGAAACAGCCTCCTCCTTTCCCAACCTTGCTTCTTAGGGGCCCCCGTGTCC

CGTCTGCTCTCAGCCTCCTCCTCCTGCAGGATAAAGTCATCCCCAAGGCTC

CAGCTACTCTAAATTATGGTCTCCTTATAAGTTATTGCTGCTCCAGGAGAT

TGTCCTTCATCGTCCAGGGGCCTGGCTCCCACGTGGTTGCAGATACCTCAG

ACCTGGTGCTCTAGGCTGTGCTGAGCCCACTCTCCCGAGGGCGCATCCAA

GCGGGGGCCACTTGAGAAGTGAATAAATGGGGCGGTTTCGGAAGCGTCA

GTGTTTCCATGTTATGGATCTCTCTGCGTTTGAATAAAGACTATCTCTGTTG CTCAC Sequence No. 91 噢托美定1, Transcription 3

>gi| 34335282 |ref|NM_058199.2| Human Bromometemidine

l (OLFMl), transcript variant 3, mRNA CCCGCCCCCGCCCCTTCCGAGCAAACTTTTGGCACCCACCGCAGCC CAGCGCGCGTTCGTGCTCCGCAGGGCGCGCCTCTCTCCGCCAATGCCAGG CGCGCGGGGGAGCCATTAGGAGGCGAGGAGAGAGGAGGGCGCAGCTCCC GCCCAGCCCAGCCCTGCCCAGCCCTGCCCGGAGGCAGACGCGCCGGAACC GGGACGCGATAAATATGCAGAGCGGAGGCTTCGCGCAGCAGAGCCCGCG CGCCGCCCGCTCCGGGTGCTGAATCCAGGCGTGGGGACACGAGCCAGGCG CCGCCGCCGGAGCCAGCGGAGCCGGGGCCAGAGCCGGAGCGCGTCCGCG TCCACGCAGCCGCCGGCCGGCCAGCACCCAGGGCCCTGCATGCCAGGTCG TTGGAGGTGGCAGCGAGACATGCACCCGGCCCGGAAGCTCCTCAGCCTCC TCTTCCTCATCCTGATGGGCACTGAACTCACTCAAAATAAAAGAGAAAAC AAAGCAGAGAAGATGGGAGGGCCAGAGAGCGAGAGGAAGACCACAGGA GAGAAGACACTGAACGAGCTTCCCTTGTTTTGCCTGGAAGCCCACGCTGG CTCCCTGGCTCTGCCCAGGATGTGCAGTCCAAATCCCAATCCAGCAGTGG GGTTATGTCGTCCCGCTTACCCTCAGAGCCCTTCTCCTGGTGCTGCCCAGA CGATCAGCCAGTCCCTCCTGGAGAGGTTCTGCATGGCCTCTAGGAGAGAA GTTTTCTTGGCCCCAGGAAGGCCTGGTGGAGGGTGGTGGTTGTGCACTGTT GCTGGACAGATGCATTCATTCATGTGCACACACACACACACACATGCACA CACAGGGGAGCAGATACCTGCAGAGAAGAGCCAACCAGGTCCTGATTAG TGGCAAGCTGCCCCACAAAGGGCTATGCCTGTGTCTTATTGAGACACCTTG GCAAAG AGATGGCTGATTCTGGGTGGTCCTGGACATGGCCGCACCCAAGG GCCCTCCAAGCCTTAATGGCACCCTGAAGCCTCCATGCCCAGGCCAAAAG ATGCTTTTCCTCCCTAAAAAAAAAAAAAAAAAAA Preface ij No. 92 Repeats of thrombospondin containing 1

>gi丨38〇169〇3丨ref丨NM_019〇32.2丨 Human-containing platelet reactive protein repeat (TSRC1), mRNA

GGGGCCCCAGTGGCCGCCGCGGAGCGAGGTTGCCTGGAGAGAGCG 145138.doc -50- 201015069

CCTGGGCGCAGAAGGGTTAACGGGCCACCGGGGGCTCGCAGAGCAGGAG

GGTGCTCTCGGACGGTGTGTCCCCCACTGCACTGCTGAACTTGGAGGACA

GGGTCGCCGCGAGGGACGCAGAGAGCACCCTCCACGCCCAGATGCCTGCG

TAGTTTTTGTGACCAGTCCGCTCCTGCCTCCCCCTGGGGCAGTAGAGGGGG

AGCGATGGAGAACTGGACTGGCAGGCCCTGGCTGTATCTGCTGCTGCTTC

TGTCCCTCCCTCAGCTCTGCTTGGATCAGGAGGTGTTGTCCGGACACTCTC

TTCAGACACCTACAGAGGAGGGCCAGGGCCCCGAAGGTGTCTGGGGACCT

TGGGTCCAGTGGGCCTCTTGCTCCCAGCCCTGCGGGGTGGGGGTGCAGCG

CAGGAGCCGGACATGTCAGCTCCCTACAGTGCAGCTCCACCCGAGTCTGC

CCCTCCCTCCCCGGCCCCCAAGACATCCAGAAGCCCTCCTCCCCCGGGGCC

AGGGTCCCAGACCCCAGACTTCTCCAGAAACCCTCCCCTTGTACAGGACA

CAGTCTCGGGGAAGGGGTGGCCCACTTCGAGGTCCCGCTTCCCACCTAGG

GAGAGAGGAGACCCAGGAGATTCGAGCGGCCAGGAGGTCCCGGCTTCGA

GACCCCATCAAGCCAGGAATGTTCGGTTATGGGAGAGTGCCCTTTGCATT

GCCACTGCACCGGAACCGCAGGCACCCTCGGAGCCCACCCAGATCTGAGC

TGTCCCTGATCTCTTCTAGAGGGGAAGAGGCTATTCCGTCCCCTACTCCAA

GAGCAGAGCCATTCTCCGCAAACGGCAGCCCCCAAACTGAGCTCCCTCCC

ACAGAACTGTCTGTCCACACCCCATCCCCCCAAGCAGAACCTCTAAGCCC

TGAAACTGCTCAGACAGAGGTGGCCCCCAGAACCAGGCCTGCCCCCCTAC

GGCATCACCCCAGAGCCCAGGCCTCTGGCACAGAGCCCCCCTCACCCACG

CACTCCTTAGGAGAAGGTGGCTTCTTCCGTGCATCCCCTCAGCCACGAAG

GCCAAGTTCCCAGGGTTGGGCCAGTCCCCAGGTAGCAGGGAGACGCCCTG

ATCCTTTTCCTTCGGTCCCTCGGGGCCGAGGCCAGCAGGGCCAAGGGCCTT

GGGGAACGGGGGGGACTCCTCACGGGCCCCGCCTGGAGCCTGACCCTCAG

CACCCGGGCGCCTGGCTGCCCCTGCTGAGCAACGGCCCCCATGCCAGCTC

CCTCTGGAGCCTCTTTGCTCCCAGTAGCCCTATTCCAAGATGTTCTGGGGA

GAGTGAACAGCTAAGAGCCTGCAGCCAAGCGCCCTGCCCCCCTGAGCAGC

CAGACCCCCGGGCCCTGCAGTGCGCAGCCTTTAACTCCCAGGAATTCATG

GGCCAGCTGTATCAGTGGGAGCCCTTCACTGAAGTCCAGGGCTCCCAGCG

CTGTGAACTGAACTGCCGGCCCCGTGGCTTCCGCTTCTATGTCCGTCACAC

TGAAAAGGTCCAGGATGGGACCCTGTGTCAGCCTGGAGCCCCTGACATCT

GTGTGGCTGGACGCTGTCTGAGCCCCGGCTGTGATGGGATCCTTGGCTCTG

GCAGGCGTCCTGATGGCTGTGGAGTCTGTGGGGGTGATGATTCTACCTGTC

GCCTTGTTTCGGGGAACCTCACTGACCGAGGGGGCCCCCTGGGCTATCAG

AAGATCTTGTGGATTCCAGCGGGAGCCTTGCGGCTCCAGATTGCCCAGCT

CCGGCCTAGCTCCAACTACCTGGCACTTCGTGGCCCTGGGGGCCGGTCCAT

CATCAATGGGAACTGGGCTGTGGATCCCCCTGGGTCCTACAGGGCCGGCG

GGACCGTCTTTCGATATAACCGTCCTCCCAGGGAGGAGGGCAAAGGGGAG

AGTCTGTCGGCTGAAGGCCCCACCACCCAGCCTGTGGATGTCTATATGATC

TTTCAGGAGGAAAACCCAGGCGTTTTTTATCAGTATGTCATCTCTTCACCT

CCTCCAATCCTTGAGAACCCCACCCCAGAGCCCCCTGTCCCCCAGCTTCAG

CCGGAGATTCTGAGGGTGGAGCCCCCACTTGCTCCGGCACCCCGCCCAGC

CCGGACCCCAGGCACCCTCCAGCGTCAGGTGCGGATCCCCCAGATGCCCG

CCCCGCCCCATCCCAGGACACCCCTGGGGTCTCCAGCTGCGTACTGGAAA

CGAGTGGGACACTCTGCATGCTCAGCGTCCTGCGGGAAAGGTGTCTGGCG

CCCCATTTTCCTCTGCATCTCCCGTGAGTCGGGAGAGGAACTGGATGAAC

GCAGCTGTGCCGCGGGTGCCAGGCCCCCAGCCTCCCCTGAACCCTGCCAC

GGCACCCCATGCCCCCCATACTGGGAGGCTGGCGAGTGGACATCCTGCAG

CCGCTCCTGTGGCCCCGGCACCCAGCACCGCCAGCTGCAGTGCCGGCAGG

AATTTGGGGGGGGTGGCTCCTCGGTGCCCCCGGAGCGCTGTGGACATCTC

CCCCGGCCCAACATCACCCAGTCTTGCCAGCTGCGCCTCTGTGGCCATTGG 145138.doc -51- 201015069 ❹ GAAGTTGGCTCTCCTTGGAGCCAGTGCTCCGTGCGGTGCGGCCGGGGCCA GAGAAGCCGGCAGGTTCGCTGTGTTGGGAACAACGGTGATGAAGTGAGC GAGCAGGAGTGTGCGTCAGGCCCCCCGCAGCCCCCCAGCAGAGAGGCCTG TGACATGGGGCCCTGTACTACTGCCTGGTTCCACAGCGACTGGAGCTCCA AGTGCTCAGCCGAGTGTGGGACGGGAATCCAGCGGCGCTCTGTGGTCTGC CTTGGGAGTGGGGCAGCCCTCGGGCCAGGCCAGGGGGAAGCAGGAGCAG GAACTGGGCAGAGCTGTCCAACAGGAAGCCGGCCCCCTGACATGCGCGCC TGCAGCCTGGGGCCCTGTGAGAGAACTTGGCGCTGGTACACAGGGCCCTG GGGTGAGTGCTCCTCCGAATGTGGCTCTGGCACACAGCGTAGAGACATCA TCTGTGTATCCAAACTGGGGACGGAGTTCAACGTGACTTCTCCGAGCAAC TGTTCTCACCTCCCCAGGCCCCCTGCCCTGCAGCCCTGTCAAGGGCAGGCC TGCCAGGACCGATGGTTTTCCACGCCCTGGAGCCCATGTTCTCGCTCCTGC CAAGGGGGAACGCAGACACGGGAGGTCCAGTGCCTGAGCACCAACCAGA CCCTCAGCACCCGATGCCCTCCTCAACTGCGGCCCTCCAGGAAGCGCCCCT GTAACAGCCAACCCTGCAGCCAGCGCCCTGATGATCAATGCAAGGACAGC TCTCCACATTGCCCCCTGGTGGTACAGGCCCGGCTCTGCGTCTACCCCTAC TACACAGCCACCTGTTGCCGCTCTTGCGCACATGTCCTGGAGCGGTCTCCC CAGGATCCCTCCTGAAAGGGGTCCGGGGCACCTTCACGGTTTTCTGTGC CA CCATCGGTCACCCATTGATCGGCCCACTCTGAACCCCCTGGCTCTCCAGCC TGTCCCAGTCTCAGCAGGGATGTCCTCCAGGTGACAGAGGGTGGCAAGGT GACTGACACAAAGTGACTTTCAGGGCTGTGGTCAGGCCCATGTGGTGGTG TGATGGGTGTGTGCACATATGCCTCAGGTGTGCTTTTGGGACTGCATGGAT ATGTGTGTGCTCAAACGTGTATCACTTTTCAAAAAGAGGTTACACAGACT GAGAAGGACAAGACCTGTTTCCTTGAGACTTTCCTAGGTGGAAAGGAAAG CAAGTCTGCAGTTCCTTGCTAATCTGAGCTACTTAGAGTGTGGTCTCCCCA CCAACTCCAGTTTTGTGCCCTAAGCCTCATTTCTCATGTTCAGACCTCACA TCTTCTAAGCCGCCCTGTGTCTCTGACCCCTTCTCATTTGCCTAGTATCTCT GCCCCTGCCTCCCTAATTAGCTAGGGCTGGGGTCAGCCACTGCCAATCCTG CCTTACTCAGGAAGGCAGGAGGAAAGAGACTGCCTCTCCAGAGCAAGGC CCAGCTGGGCAGAGGGTGAAAAAGAGAAATGTGAGCATCCGCTCCCCCA CCACCCCGCCCAGCCCCTAGCCCCACTCCCTGCCTCCTGAAATGGTTCCCA CCCAGAACTAATTTATTTTTTATTAAAGATGGTCATGACAAATGAAAAAA AAAAAAAAAAAAA Serial No. 93

Human thrombospondin 2 >gi丨403 17627 | ref | ΝΜ_003247·2丨 Human Human Thrombospondin 2 (1'11882), 1111^^八|9?€11 Advance_Introduction matches [3558..3580] qPCR reverse-introduction matches [3682..3655] 1 qPCR probe matches [3597..3623]

GAGGAGGAGACGGCATCCAGTACAGAGGGGCTGGACTTGGACCCC

TGCAGCAGCCCTGCACAGGAGAAGCGGCATATAAAGCCGCGCTGCCCGG

GAGCCGCTCGGCCACGTCCACCGGAGCATCCTGCACTGCAGGGCCGGTCT

CTCGCTCCAGCAGAGCCTGCGCCTTTCTGACTCGGTCCGGAACACTGAAA

CCAGTCATCACTGCATCTTTTTGGCAAACCAGGAGCTCAGCTGCAGGAGG

CAGGATGGTCTGGAGGCTGGTCCTGCTGGCTCTGTGGGTGTGGCCCAGCA

CGCAAGCTGGTCACCAGGACAAAGACACGACCTTCGACCTTTTCAGTATC 145138.doc •52· 201015069

AGCAACATCAACCGCAAGACCATTGGCGCCAAGCAGTTCCGCGGGCCCGA

CCCCGGCGTGCCGGCTTACCGCTTCGTGCGCTTTGACTACATCCCACCGGT

GAACGCAGATGACCTCAGCAAGATCACCAAGATCATGCGGCAGAAGGAG

GGCTTCTTCCTCACGGCCCAGCTCAAGCAGGACGGCAAGTCCAGGGGCAC

GCTGTTGGCTCTGGAGGGCCCCGGTCTCTCCCAGAGGCAGTTCGAGATCG

TCTCCAACGGCCCCGCGGACACGCTGGATCTCACCTACTGGATTGACGGC

ACCCGGCATGTGGTCTCCCTGGAGGACGTCGGCCTGGCTGACTCGCAGTG

GAAGAACGTCACCGTGCAGGTGGCTGGCGAGACCTACAGCTTGCACGTGG

GCTGCGACCTCATAGACAGCTTCGCTCTGGACGAGCCCTTCTACGAGCAC

CTGCAGGCGGAAAAGAGCCGGATGTACGTGGCCAAAGGCTCTGCCAGAG

AGAGTCACTTCAGGGGTTTGCTTCAGAACGTCCACCTAGTGTTTGAAAACT

CTGTGGAAGATATTCTAAGCAAGAAGGGTTGCCAGCAAGGCCAGGGAGCT

GAGATCAACGCCATCAGTGAGAACACAGAGACGCTGCGCCTGGGTCCGCA

TGTCACCACCGAGTACGTGGGCCCCAGCTCGGAGAGGAGGCCCGAGGTGT

GCGAACGCTCGTGCGAGGAGCTGGGAAACATGGTCCAGGAGCTCTCGGG

GCTCCACGTCCTCGTGAACCAGCTCAGCGAGAACCTCAAGAGAGTGTCGA

ATGATAACCAGTTTCTCTGGGAGCTCATTGGTGGCCCTCCTAAGACAAGG

AACATGTCAGCTTGCTGGCAGGATGGCCGGTTCTTTGCGGAAAATGAAAC

GTGGGTGGTGGACAGCTGCACCACGTGTACCTGCAAGAAATTTAAAACCA

TTTGCCACCAAATCACCTGCCCGCCTGCAACCTGCGCCAGTCCATCCTTTG

TGGAAGGCGAATGCTGCCCTTCCTGCCTCCACTCGGTGGACGGTGAGGAG

GGCTGGTCTCCGTGGGCAGAGTGGACCCAGTGCTCCGTGACGTGTGGCTC

TGGGACCCAGCAGAGAGGCCGGTCCTGTGACGTCACCAGCAACACCTGCT

TGGGGCCCTCCATCCAGACACGGGCTTGCAGTCTGAGCAAGTGTGACACC

CGCATCCGGCAGGACGGCGGCTGGAGCCACTGGTCACCTTGGTCTTCATG

CTCTGTGACCTGTGGAGTTGGCAATATCACACGCATCCGTCTCTGCAACTC

CCCAGTGCCCCAGATGGGGGGCAAGAATTGCAAAGGGAGTGGCCGGGAG

ACCAAAGCCTGCCAGGGCGCCCCATGCCCAATCGATGGCCGCTGGAGCCC

CTGGTCCCCGTGGTCGGCCTGCACTGTCACCTGTGCCGGTGGGATCCGGG

AGCGCACCCGGGTCTGCAACAGCCCTGAGCCTCAGTACGGAGGGAAGGCC

TGCGTGGGGGATGTGCAGGAGCGTCAGATGTGCAACAAGAGGAGCTGCC

CCGTGGATGGCTGTTTATCCAACCCCTGCTTCCCGGGAGCCCAGTGCAGCA

GCTTCCCCGATGGGTCCTGGTCATGCGGCTCCTGCCCTGTGGGCTTCTTGG

GCAATGGCACCCACTGTGAGGACCTGGACGAGTGTGCCCTGGTCCCCGAC

ATCTGCTTCTCCACCAGCAAGGTGCCTCGCTGTGTCAACACTCAGCCTGGC

TTCCACTGCCTGCCCTGCCCGCCCCGATACAGAGGGAACCAGCCCGTCGG

GGTCGGCCTGGAAGCAGCCAAGACGGAAAAGCAAGTGTGTGAGCCCGAA

AACCCATGCAAGGACAAGACACACAACTGCCACAAGCACGCGGAGTGCA

TCTACCTGGGCCACTTCAGCGACCCCATGTACAAGTGCGAGTGCCAGACA

GGCTACGCGGGCGACGGGCTCATCTGCGGGGAGGACTCGGACCTGGACG

GCTGGCCCAACCTCAATCTGGTCTGCGCCACCAACGCCACCTACCACTGC

ATCAAGGATAACTGCCCCCATCTGCCAAATTCTGGGCAGGAAGACTTTGA

CAAGGACGGGATTGGCGATGCCTGTGATGATGACGATGACAATGACGGTG

TGACCGATGAGAAGGACAACTGCCAGCTCCTCTTCAATCCCCGCCAGGCT

GACTATGACAAGGATGAGGTTGGGGACCGCTGTGACAACTGCCCTTACGT

GCACAACCCTGCCCAGATCGACACAGACAACAATGGAGAGGGTGACGCC

TGCTCCGTGGACATTGATGGGGACGATGTCTTCAATGAACGAGACAATTG

TCCCTACGTCTACAACACTGACCAGAGGGACACGGATGGTGACGGTGTGG

GGGATCACTGTGACAACTGCCCCCTGGTGCACAACCCTGACCAGACCGAC

GTGGACAATGACCTTGTTGGGGACCAGTGTGACAACAACGAGGACATAGA

TGACGACGGCCACCAGAACAACCAGGACAACTGCCCCTACATCTCCAACG 145138.doc -53- 201015069

CCAACCAGGCTGACCATGACAGAGACGGCCAGGGCGACGCCTGTGACCCT

GATGATGACAACGATGGCGTCCCCGATGACAGGGACAACTGCCGGCTTGT

GTTCAACCCAGACCAGGAGGACTTGGACGGTGATGGACGGGGTGATATTT

GTAAAGATGATTTTGACAATGACAACATCCCAGATATTGATGATGTGTGT

CCTGAAAACAATGCCATCAGTGAGACAGACTTCAGGAACTTCCAGATGGT

CCCCTTGGATCCCAAAGGGACCACCCAAATTGATCCCAACTGGGTCATTC

GCCATCAAGGCAAGGAGCTGGTTCAGACAGCCAACTCGGACCCCGGCATC

GCTGTAGGTTTTGACGAGTTTGGGTCTGTGGACTTCAGTGGCACATTCTAC

GTAAACACTGACCGGGACGACGACTATGCCGGCTTCGTCTTTGGTTACCA

GTCAAGCAGCCGCTTCTATGTGGTGATGTGGAAGCAGGTGACGCAGACCT

ACTGGGAGGACCAGCCCACGCGGGCCTATGGCTACTCCGGCGTGTCCCTC

AAGGTGGTGAACTCCACCACGGGGACGGGCGAGCACCTGAGGAACGCGC

TGTGGCACACGGGGAACACGCCGGGGCAGGTGCGAACCTTATGGCACGA

CCCCAGGAACATTGGCTGGAAGGACTACACGGCCTATAGGTGGCACCTGA

CTCACAGGCCCAAGACTGGCTACATCAGAGTCTTAGTGCATGAAGGAAAA

CAGGTCATGGCAGACTCAGGACCTATCTATGACCAAACCTACGCTGGCGG

GCGGCTGGGTCTATTTGTCTTCTCTCAAGAAATGGTCTATTTCTGAGACCT

CAAGTACGAATGCAGAGATATTTAAACAAGATTTGCTGCATTTCCGGCAA

TGCCCTGTGCATGCCATGGTCCCTAGACACCTCAGTTCATTGTGGTCCTTG

TGGCTTCTCTCTCTAGCAGCACCTCCTGTCCCTTGACCTTAACTCTGATGGT

TCTTCACCTCCTGCCAGCAACCCCAAACCCAAGTGCCTTCAGAGGATAAA

TATCAATGGAACTCAGAGATGAACATCTAACCCACTAGAGGAAACCAGTT

TGGTGATATATGAGACTTTATGTGGAGTGAAAATTGGGCATGCCATTACA

TTGCTTTTTCTTGTTTGTTTAAAAAGAATGACGTTTACATATAAAATGTAA

TTACTTATTGTATTTATGTGTATATGGAGTTGAAGGGAATACTGTGCATAA

GCCATTATGATAAATTAAGCATGAAAAATATTGCTGAACTACTTTTGGTGC

TTAAAGTTGTCACTATTCTTGAATTAGAGTTGCTCTACAATGACACACAAA

TCCCATTAAATAAATTATAAACAAGGGTCAATTCAAATTTGAAGTAATGTT

TTAGTAAGGAGAGATTAGAAGACAACAGGCATAGCAAATGACATAAGCT

ACCGATTAACTAATCGGAACATGTAAAACAGTTACAAAAATAAACGAACT

CTCCTCTTGTCCTACAATGAAAGCCCTCATGTGCAGTAGAGATGCAGTTTC

ATCAAAGAACAAACATCCTTGCAAATGGGTGTGACGCGGTTCCAGATGTG

GATTTGGCAAAACCTCATTTAAGTAAAAGGTTAGCAGAGCAAAGTGCGGT

GCTTTAGCTGCTGCTTGTGCCGCTGTGGCGTCGGGGAGGCTCCTGCCTGAG

CTTCCTTCCCCAGCTTTGCTGCCTGAGAGGAACCAGAGCAGACGCACAGG

CCGGAAAAGGCGCATCTAACGCGTATCTAGGCTTTGGTAACTGCGGACAA

GTTGCTTTTACCTGATTTGATGATACATTTCATTAAGGTTCCAGTTATAAAT

ATTTTGTTAATATTTATTAAGTGACTATAGAATGCAACTCCATTTACCAGT

AACTTATTTTAAATATGCCTAGTAACACATATGTAGTATAATTTCTAGAAA

CAAACATCTAATAAGTATATAATCCTGTGAAAATATGAGGCTTGATAATA

TTAGGTTGTCACGATGAAGCATGCTAGAAGCTGTAACAGAATACATAGAG

AATAATGAGGAGTTTATGATGGAACCTTAAATATATAATGTTGCCAGCGA

TTTTAGTTCAATATTTGTTACTGTTATCTATCTGCTGTATATGGAATTCTTT

TAATTCAAACGCTGAAAAGAATCAGCATTTAGTCTTGCCAGGCACACCCA

ATAATCAGTCATGTGTAATATGCACAAGTTTGTTTTTGTTTTTGTTTTTTTT

GTTGGTTGGTTTGTTTTTTTGCTTTAAGTTGCATGATCTTTCTGCAGGAAAT

AGTCACTCATCCCACTCCACATAAGGGGTTTAGTAAGAGAAGTCTGTCTGT

CTGATGATGGATAGGGGGCAAATCTTTTTCCCCTTTCTGTTAATAGTCATC

ACATTTCTATGCCAAACAGGAACAATCCATAACTTTAGTCTTAATGTACAC

ATTGCATTTTGATAAAATTAATTTTGTTGTTTCCTTTGAGGTTGATCGTTGT

GTTGTTGTTTTGCTGCACTTTTTACTTTTTTGCGTGTGGAGCTGTATTCCCG 145138.doc -54- 201015069 AGACCAACGAAGCGTTGGGATACTTCATTAAATGTAGCGACTGTCAACAG CGTGCAGGTTTTCTGTTTCTGTGTTGTGGGGTCAACCGTACAATGGTGTGG GAGTGACGATGATGTGAATATTTAGAATGTACCATATTTTTTGTAAATTAT TTATGTTTTTCTAAACAAATTTATCGTATAGGTTGATGAAACGTCATGTGT TTTGCCAAAGACTGTAAATATTTATTTATGTGTTCACATGGTCAAAATTTC ACCACTGAAACCCTGCACTTAGCTAGAACCTCATTTTTAAAGATTAACAAC AGGAAATAAATTGTAAAAAAGGTTTTCTATACATGAAAAAAAAAAAAAA AAAA Serial No. 94 Adelaide Milliken > gi | l8390318 | ref | NM_0015419.l | human Adelaide Milliken (DKFZp564I1922), mRNA | qPCR around In the text, the measurement is matched with [694·.718] when requested.

❹ ATGCCCAAGCGCGCGCACTGGGGGGCCCTCTCCGTGGTGCTGATCC

TGCTTTGGGGCCATCCGCGAGTGGCGCTGGCCTGCCCGCATCCTTGTGCCT GCTACGTCCCCAGCGAGGTCCACTGCACGTTCCGATCCCTGGCTTCCGTGC CCGCTGGCATTGCTAGACACGTGGAAAGAATCAATTTGGGGTTTAATAGC ATACAGGCCCTGTCAGAAACCTCATTTGCAGGACTGACCAAGTTGGAGCT ACTTATGATTCACGGCAATGAGATCCCAAGCATCCCCGATGGAGCTTTAA GAGACCTCAGCTCTCTTCAGGTTTTCAAGTTCAGCTACAACAAGCTGAGA GTGATCACAGGACAGACCCTCCAGGGTCTCTCTAACTTAATGAGGCTGCA CATTGACCACAACAAGATCGAGTTTATCCACCCTCAAGCTTTCAACGGCTT AACGTCTCTGAGGCTACTCCATTTGGAAGGAAATCTCCTCCACCAGCTGCA CCCCAGCACCTTCTCCACGTTCACATTTTTGGATTATTTCAGACTCTCCACC ATAAGGCACCTCTACTTAGCAGAGAACATGGTTAGAACTCTTCCTGCCAG CATGCTTCGGAACATGCCGCTTCTGGAGAATCTTTACTTGCAGGGAAATCC GTGGACCTGCGATTGTGAGATGAGATGGTTTTTGGAATGGGATGCAAAAT CCAGAGGAATTCTGAAGTGTAAAAAGGACAAAGCTTATGAAGGCGGTCA GTTGTGTGCAATGTGCTTCAGTCCAAAGAAGTTGTACAAACATGAGATAC cunning ACAAGCTGAAGGACATGACTTGTCTGAAGCCTTCAATAGAGTCCCCTCTG

Zero AGACAGAACAGGAGCAGGAGTATTGAGGAGGAGCAAGAACAGGAAGAG

GATGGTGGCAGCCAGCTCATCCTGGAGAAATTCCAACTGCCCCAGTGGAG CATCTCTTTGAATATGACCGACGAGCACGGGAACATGGTGAACTTGGTCT GTGACATCAAGAAACCAATGGATGTGTACAAGATTCACTTGAACCAAACG GATCCTCCAGATATTGACATAAATGCAACAGTTGCCTTGGACTTTGAGTGT CCAATGACCCGAGAAAACTATGAAAAGCTATGGAAATTGATAGCATACTA CAGTGAAGTTCCCGTGAAGCTACACAGAGAGCTCATGCTCAGCAAAGACC CCAGAGTCAGCTACCAGTACAGGCAGGATGCTGATGAGGAAGCTCTTTAC TACACAGGTGTGAGAGCCCAGATTCTTGCAGAACCAGAATGGGTCATGCA GCCATCCATAGATATCCAGCTGAACCGACGTCAGAGTACGGCCAAGAAGG TGCTACTTTCCTACTACACCCAGTATTCTCAAACAATATCCACCAAAGATA CAAGGCAGGCTCGGGGCAGAAGCTGGGTAATGATTGAGCCTAGTGGAGCT GTGCAAAGAGATCAGACTGTCCTGGAAGGGGGTCCATGCCAGTTGAGCTG CAACGTGAAAGCTTCTGAGAGTCCATCTATCTTCTGGGTGCTTCCAGATGG CTCCATCCTGAAAGCGCCCATGGATGACCCAGACAGCAAGTTCTCCATTCT CAGCAGTGGCTGGCTGAGGATCAAGTCCATGGAGCCATCTGACTCAGGCT TGTACCAGTGCATTGCTCAAGTGAGGGATGAAATGGACCGCATGGTATAT 145138.doc • 55 · 201015069

AGGGTACTTGTGCAGTCTCCCTCCACTCAGCCAGCCGAGAAAGACACAGT

GACAATTGGCAAGAACCCAGGGGAGTCGGTGACATTGCCTTGCAATGCTT

TAGCAATACCCGAAGCCCACCTTAGCTGGATTCTTCCAAACAGAAGGATA

ATTAATGATTTGGCTAACACATCACATGTATACATGTTGCCAAATGGAACT

CTTTCCATCCCAAAGGTCCAAGTCAGTGATAGTGGTTACTACAGATGTGTG

GCTGTCAACCAGCAAGGGGCAGACCATTTTACGGTGGGAATCACAGTGAC

CAAGAAAGGGTCTGGCTTGCCATCCAAAAGAGGCAGACGCCCAGGTGCA

AAGGCTCTTTCCAGAGTCAGAGAAGACATCGTGGAGGATGAAGGGGGCTC

GGGCATGGGAGATGAAGAGAACACTTCAAGGAGACTTCTGCATCCAAAG

GACCAAGAGGTGTTCCTCAAAACAAAGGATGATGCCATCAATGGAGACA

AGAAAGCCAAGAAAGGGAGAAGAAAGCTGAAACTCTGGAAGCATTCGGA

AAAAGAACCAGAGACCAATGTTGCAGAAGGTCGCAGAGTGTTTGAATCTA

GACGAAGGATAAACATGGCAAACAAACAGATTAATCCGGAGCGCTGGGC

TGATATTTTAGCCAAAGTCCGTGGGAAAAATCTCCCTAAGGGCACAGAAG

TACCCCCGTTGATTAAAACCACAAGTCCTCCATCCTTGAGCCTAGAAGTCA

CACCACCTTTTCCTGCTGTTTCTCCCCCCTCAGCATCTCCTGTGCAGACAGT

AACCAGTGCTGAAGAATCCTCAGCAGATGTACCTCTACTTGGTGAAGAAG

AGCACGTTTTGGGTACCATTTCCTCAGCCAGCATGGGGCTAGAACACAAC

CACAATGGAGTTATTCTTGTTGAACCTGAAGTAACAAGCACACCTCTGGA

GGAAGTTGTTGATGACCTTTCTGAGAAGACTGAGGAGATAACTTCCACTG

AAGGAGACCTGAAGGGGACAGCAGCCCCTACACTTATATCTGAGCCTTAT

GAACCATCTCCTACTCTGCACACATTAGACACAGTCTATGAAAAGCCCAC

CCATGAAGAGACGGCAACAGAGGGTTGGTCTGCAGCAGATGTTGGATCGT

CACCAGAGCCCACATCCAGTGAGTATGAGCCTCCATTGGATGCTGTCTCCT

TGGCTGAGTCTGAGCCCATGCAATACTTTGACCCAGATTTGGAGACTAAG

TCACAACCAGATGAGGATAAGATGAAAGAAGACACCTTTGCACACCTTAC

TCCAACCCCCACCATCTGGGTTAATGACTCCAGTACATCACAGTTATTTGA

GGATTCTACTATAGGGGAACCAGGTGTCCCAGGCCAATCACATCTACAAG

GACTGACAGACAACATCCACCTTGTGAAAAGTAGTCTAAGCACTCAAGAC

ACCTTACTGATTAAAAAGGGTATGAAAGAGATGTCTCAGACACTACAGGG

AGGAAATATGCTAGAGGGAGACCCCACACACTCCAGAAGTTCTGAGAGTG

AGGGCCAAGAGAGCAAATCCATCACTTTGCCTGACTCCACACTGGGTATA

ATGAGCAGTATGTCTCCAGTTAAGAAGCCTGCGGAAACCACAGTTGGTAC

CCTCCTAGACAAAGACACCACAACAGTAACAACAACACCAAGGCAAAAA ❹

GTTGCTCCGTCATCCACCATGAGCACTCACCCTTCTCGAAGGAGACCCAAC

GGGAGAAGGAGATTACGCCCCAACAAATTCCGCCACCGGCACAAGCAAA

CCCCACCCACAACTTTTGCCCCATCAGAGACTTTTTCTACTCAACCAACTC

AAGCACCTGACATTAAGATTTCAAGTCAAGTGGAGAGTTCTCTGGTTCCTA

CAGCTTGGGTGGATAACACAGTTAATACCCCCAAACAGTTGGAAATGGAG

AAGAATGCAGAACCCACATCCAAGGGAACACCACGGAGAAAACACGGGA

AGAGGCCAAACAAACATCGATATACCCCTTCTACAGTGAGCTCAAGAGCG

TCCGGATCCAAGCCCAGCCCTTCTCCAGAAAATAAACATAGAAACATTGT

TACTCCCAGTTCAGAAACTATACTTTTGCCTAGAACTGTTTCTCTGAAAAC

TGAGGGCCCTTATGATTCCTTAGATTACATGACAACCACCAGAAAAATAT

ATTCATCTTACCCTAAAGTCCAAGAGACACTTCCAGTCACATATAAACCCA

CATCAGATGGAAAAGAAATTAAGGATGATGTTGCCACAAATGTTGACAAA

CATAAAAGTGACATTTTAGTCACTGGTGAATCAATTACTAATGCCATACCA

ACTTCTCGCTCCTTGGTCTCCACTATGGGAGAATTTAAGGAAGAATCCTCT

CCTGTAGGCTTTCCAGGAACTCCAACCTGGAATCCCTCAAGGACGGCCCA

GCCTGGGAGGCTACAGACAGACATACCTGTTACCACTTCTGGGGAAAATC

TTACAGACCCTCCCCTTCTTAAAGAGCTTGAGGATGTGGATTTCACTTCCG 145138.doc 56- 201015069

AGTTTTTGTCCTCTTTGACAGTCTCCACACCATTTCACCAGGAAGAAGCTG

GTTCTTCCACAACTCTCTCAAGCATAAAAGTGGAGGTGGCTTCAAGTCAG

GCAGAAACCACCACCCTTGATCAAGATCATCTTGAAACCACTGTGGCTAT

TCTCCTTTCTGAAACTAGACCACAGAATCACACCCCTACTGCTGCCCGGAT

GAAGGAGCCAGCATCCTCGTCCCCATCCACAATTCTCATGTCTTTGGGACA

AACCACCACCACTAAGCCAGCACTTCCCAGTCCAAGAATATCTCAAGCAT

CTAGAGATTCCAAGGAAAATGTTTTCTTGAATTATGTGGGGAATCCAGAA

ACAGAAGCAACCCCAGTCAACAATGAAGGAACACAGCATATGTCAGGGC

CAAATGAATTATCAACACCCTCTTCCGACCGGGATGCATTTAACTTGTCTA

CAAAGCTGGAATTGGAAAAGCAAGTATTTGGTAGTAGGAGTCTACCACGT

GGCCCAGATAGCCAACGCCAGGATGGAAGAGTTCATGCTTCTCATCAACT

AACCAGAGTCCCTGCCAAACCCATCCTACCAACAGCAACAGTGAGGCTAC

CTGAAATGTCCACACAAAGCGCTTCCAGATACTTTGTAACTTCCCAGTCAC

CTCGTCACTGGACCAACAAACCGGAAATAACTACATATCCTTCTGGGGCT

TTGCCAGAGAACAAACAGTTTACAACTCCAAGATTATCAAGTACAACAAT

TCCTCTCCCATTGCACATGTCCAAACCCAGCATTCCTAGTAAGTTTACTGA

GCGAAGAACTGACCAATTCAATGGTTACTCCAAAGTGTTTGGAAATAACA

ACATCCCTGAGGCAAGAAACCCAGTTGGAAAGCCTCCCAGTCCAAGAATT

CCTCATTATTCCAATGGAAGACTCCCTTTCTTTACCAACAAGACTCTTTCTT

TTCCACAGTTGGGAGTCACCCGGAGACCCCAGATACCCACTTCTCCTGCCC

CAGTAATGAGAGAGAGAAAAGTTATTCCAGGTTCCTACAACAGGATACAT

TCCCATAGCACCTTCCATCTGGACTTTGGCCCTCCGGCACCTCCGTTGTTG

CACACTCCGCAGACCACGGGATCACCCTCAACTAACTTACAGAATATCCC

TATGGTCTCTTCCACCCAGAGTTCTATCTCCTTTATAACATCTTCTGTCCAG

TCCTCAGGAAGCTTCCACCAGAGCAGCTCAAAGTTCTTTGCAGGAGGACC

TCCTGCATCCAAATTCTGGTCTCTTGGGGAAAAGCCCCAAATCCTCACCAA

GTCCCCACAGACTGTGTCCGTCACCGCTGAGACAGACACTGTGTTCCCCTG

TGAGGCAACAGGAAAACCAAAGCCTTTCGTTACTTGGACAAAGGTTTCCA

CAGGAGCTCTTATGACTCCGAATACCAGGATACAACGGTTTGAGGTTCTC

AAGAACGGTACCTTAGTGATACGGAAGGTTCAAGTACAAGATCGAGGCCA

GTATATGTGCACCGCCAGCAACCTGCACGGCCTGGACAGGATGGTGGTCT

TGCTTTCGGTCACCGTGCAGCAACCTCAAATCCTAGCCTCCCACTACCAGG

ACGTCACTGTCTACCTGGGAGACACCATTGCAATGGAGTGTCTGGCCAAA

GGGACCCCAGCCCCCCAAATTTCCTGGATCTTCCCTGACAGGAGGGTGTG

GCAAACTGTGTCCCCCGTGGAGAGCCGCATCACCCTGCACGAAAACCGGA

CCCTTTCCATCAAGGAGGCGTCCTTCTCAGACAGAGGCGTCTATAAGTGC

GTGGCCAGCAATGCAGCCGGGGCGGACAGCCTGGCCATCCGCCTGCACGT

GGCGGCACTGCCCCCCGTTATCCACCAGGAGAAGCTGGAGAACATCTCGC

TGCCCCCGGGGCTCAGCATTCACATTCACTGCACTGCCAAGGCTGCGCCCC

TGCCCAGCGTGCGCTGGGTGCTCGGGGACGGTACCCAGATCCGCCCCTC

CAGTTCCTCCACGGGAACTTGTTTGTTTTCCCCAACGGGACGCTCTACATC

CGCAACCTCGCGCCCAAGGACAGCGGGCGCTATGAGTGCGTGGCCGCCAA

CCTGGTAGGCTCCGCGCGCAGGACGGTGCAGCTGAACGTGCAGCGTGCAG

CAGCCAACGCGCGCATCACGGGCACCTCCCCGCGGAGGACGGACGTCAG

GTACGGAGGAACCCTCAAGCTGGACTGCAGCGCCTCGGGGGACCCCTGGC

CGCGCATCCTCTGGAGGCTGCCGTCCAAGAGGATGATCGACGCGCTCTTC

AGTTTTGATAGCAGAATCAAGGTGTTTGCCAATGGGACCCTGGTGGTGAA

ATCAGTGACGGACAAAGATGCCGGAGATTACCTGTGCGTAGCTCGAAATA

AGGTTGGTGATGACTACGTGGTGCTCAAAGTGGATGTGGTGATGAAACCG

GCCAAGATTGAACACAAGGAGGAGAACGACCACAAAGTCTTCTACGGGG

GTGACCTGAAAGTGGACTGTGTGGCCACCGGGCTTCCCAATCCCGAGATC 145138.doc -57- 201015069

TCCTGGAGCCTCCCAGACGGGAGTCTGGTGAACTCCTTCATGCAGTCGGA

TGACAGCGGTGGACGCACCAAGCGCTATGTCGTCTTCAACAATGGGACAC

TCTACTTTAACGAAGTGGGGATGAGGGAGGAAGGAGACTACACCTGCTTT

GCTGAAAATCAGGTCGGGAAGGACGAGATGAGAGTCAGAGTCAAGGTGG

TGACAGCGCCCGCCACCATCCGGAACAAGACTTACTTGGCGGTTCAGGTG

CCCTATGGAGACGTGGTCACTGTAGCCTGTGAGGCCAAAGGAGAACCCAT

GCCCAAGGTGACTTGGTTGTCCCCAACCAACAAGGTGATCCCCACCTCCTC

TGAGAAGTATCAGATATACCAAGATGGCACTCTCCTTATTCAGAAAGCCC

AGCGTTCTGACAGCGGCAACTACACCTGCCTGGTCAGGAACAGCGCGGGA

GAGGATAGGAAGACGGTGTGGATTCACGTCAACGTCCAGCCACCCAAGAT

CAACGGTAACCCCAACCCCATCACCACCGTGCGGGAGATAGCAGCCGGGG

GCAGTCGGAAACTGATTGACTGCAAAGCTGAAGGCATCCCCACCCCGAGG

GTGTTATGGGCTTTTCCCGAGGGTGTGGTTCTGCCAGCTCCATACTATGGA

AACCGGATCACTGTCCATGGCAACGGTTCCCTGGACATCAGGAGTTTGAG

GAAGAGCGACTCCGTCCAGCTGGTATGCATGGCACGCAACGAGGGAGGG

GAGGCGAGGTTGATCGTGCAGCTCACTGTCCTGGAGCCCATGGAGAAACC

CATCTTCCACGACCCGATCAGCGAGAAGATCACGGCCATGGCGGGCCACA

CCATCAGCCTCAACTGCTCTGCCGCGGGGACCCCGACACCCAGCCTGGTG

TGGGTCCTTCCCAATGGCACCGATCTGCAGAGTGGACAGCAGCTGCAGCG

CTTCTACCACAAGGCTGACGGCATGCTACACATTAGCGGTCTCTCCTCGGT

GGACGCTGGGGCCTACCGCTGCGTGGCCCGCAATGCCGCTGGCCACACGG

AGAGGCTGGTCTCCCTGAAGGTGGGACTGAAGCCAGAAGCAAACAAGCA

GTATCATAACCTGGTCAGCATCATCAATGGTGAGACCCTGAAGCTCCCCT

GCACCCCTCCCGGGGCTGGGCAGGGACGTTTCTCCTGGACGCTCCCCAAT

GGCATGCATCTGGAGGGCCCCCAAACCCTGGGACGCGTTTCTCTTCTGGA

CAATGGCACCCTCACGGTTCGTGAGGCCTCGGTGTTTGACAGGGGTACCT

ATGTATGCAGGATGGAGACGGAGTACGGCCCTTCGGTCACCAGCATCCCC

GTGATTGTGATCGCCTATCCTCCCCGGATCACCAGCGAGCCCACCCCGGTC

ATCTACACCCGGCCCGGGAACACCGTGAAACTGAACTGCATGGCTATGGG

GATTCCCAAAGCTGACATCACGTGGGAGTTACCGGATAAGTCGCATCTGA

AGGCAGGGGTTCAGGCTCGTCTGTATGGAAACAGATTTCTTCACCCCCAG

GGATCACTGACCATCCAGCATGCCACACAGAGAGATGCCGGCTTCTACAA

GTGCATGGCAAAAAACATTCTCGGCAGTGACTCCAAAACAACTTACATCC

ACGTCTTCTGAAATGTGGATTCCAGAATGATTGCTTAGGAACTGACAACA

AAGCGGGGTTTGTAAGGGAAGCCAGGTTGGGGAATAGGAGCTCTTAAATA

ATGTGTCACAGTGCATGGTGGCCTCTGGTGGGTTTCAAGTTGAGGTTGATC

TTGATCTACAATTGTTGGGAAAAGGAAGCAATGCAGACACGAGAAGGAG

GGCTCAGCCTTGCTGAGACACTTTCTTTTGTGTTTACATCATGCCAGGGGC

TTCATTCAGGGTGTCTGTGCTCTGACTGCAATTTTTCTTCTTTTGCAAATGC

CACTCGACTGCCTTCATAAGCGTCCATAGGATATCTGAGGAACATTCATCA

AAAATAAGCCATAGACATGAACAACACCTCACTACCCCATTGAAGACGCA

TCACCTAGTTAACCTGCTGCAGTTTTTACATGATAGACTTTGTTCCAGATT

GACAAGTCATCTTTCAGTTATTTCCTCTGTCACTTCAAAACTCCAGCTTGC

CCAATAAGGATTTAGAACCAGAGTGACTGATATATATATATATATTTTAAT

TCAGAGTTACATACATACAGCTACCATTTTATATGAAAAAAGAAAAACAT

TTCTTCCTGGAACTCACTTTTTATATAATGTTTTATATATATATTTTTTCCTT

TCAAATCAGACGATGAGACTAGAAGGAGAAATACTTTCTGTCTTATTAAA

ATTAATAAATTATTGGTCTTTACAAGACTTGGATACATTACAGCAGACATG

GAAATATAATTTTAAAAAATTTCTCTCCAACCTCCTTCAAATTCAGTCACC

ACTGTTATATTACCTTCTCCAGGAACCCTCCAGTGGGGAAGGCTGCGATAT

TAGATTTCCTTGTATGCAAAGTTTTTGTTGAAAGCTGTGCTCAGAGGAGGT 145138.doc -58 - 201015069

GAGAGGAGAGGAAGGAGAAAACTGCATCATAACTTTACAGAATTGAATC

TAGAGTCTTCCCCGAAAAGCCCAGAAACTTCTCTGCAGTATCTGGCTTGTC

CATCTGGTCTAAGGTGGCTGCTTCTTCCCCAGCCATGAGTCAGTTTGTGCC

CATGAATAATACACGACCTGTTATTTCCATGACTGCTTTACTGTATTTTTA

AGGTCAATATACTGTACATTTGATAATAAAATAATATTCTCCCAAAAAAA

AAA Sequence No. 95 Cysteine protease inhibitor SA >gi| 19882252|ref丨ΝΜ_001322·2|Human cysteine protease

Inhibitor 8 into (〇8丁2), 111^^人|9?€11 Advance_Introduction matches [302..320] | qPCR reverse _ primer matches [393..370] | qPCR probe and [ 341..369] match

GCCTCCGAGGAGACCATGGCCTGGCCCCTGTGCACCCTGCTGCTCC

TGCTGGCCACCCAGGCTGTGGCCCTGGCCTGGAGCCCCCAGGAGGAGGAC

AGGATAATCGAGGGTGGCATCTATGATGCAGACCTCAATGATGAGCGGGT

ACAGCGTGCCCTTCACTTTGTCATCAGCGAGTATAACAAGGCCACTGAAG

ATGAGTACTACAGACGCCTGCTGCGGGTGCTACGAGCCAGGGAGCAGATC

GTGGGCGGGGTGAATTACTTCTTCGACATAGAGGTGGGCCGAACCATATG

TACCAAGTCCCAGCCCAACTTGGACACCTGTGCCTTCCATGAACAGCCAG

AACTGCAGAAGAAACAGTTGTGCTCTTTCCAGATCTACGAAGTTCCCTGG

GAGGACAGAATGTCCCTGGTGAATTCCAGGTGTCAAGAAGCCTAGGGATC

TGTGCCAGGGAGTCACACTGACCACCTCCTACTCCCACCCCTTGTAGTGCT

CCCACCCCTGGACTGGTGGCCCCCACCCTGTGGGAGGTCTCCCCATGCACC

TGCAGCAGGAGAAGACAGAGAAGGCTGCAGGAGGCCTTTGTTGCTCAGC

AGGGGACTCTGCCCTCCCTCCTTCCTTTTGCTTCTCATAGCCCTGGTACATG

GTACACACACCCCCACCTCCTGCAATTAAACAGTAGCATCACCTC Sequence No. 96

Cysteine protease inhibitor SN >gi| 19882250丨ref |NM_001898.2丨 Human cysteine protease inhibitor SN (CST1), mRNA| qPCR advance_引子 matches [358..376] | qPCR reverse _Introduction matches [449..426] | qPCR probe matches [397..425]

GGGCTCCCTGCCTCGGGCTCTCACCCTCCTCTCCTGCAGCTCCAGCT

TTGTGCTCTGCCTCTGAGGAGACCATGGCCCAGTATCTGAGTACCCTGCTG

CTCCTGCTGGCCACCCTAGCTGTGGCCCTGGCCTGGAGCCCCAAGGAGGA

GGATAGGATAATCCCGGGTGGCATCTATAACGCAGACCTCAATGATGAGT

GGGTACAGCGTGCCCTTCACTTCGCCATCAGCGAGTATAACAAGGCCACC

AAAGATGACTACTACAGACGTCCGCTGCGGGTACTAAGAGCCAGGCAACA 145138.doc • 59 · 201015069 GACCGTTGGGGGGGTGAATTACTTCTTCGACGTAGAGGTGGGCCGCACCA TATGTACCAAGTCCCAGCCCAACTTGGACACCTGTGCCTTCCATGAACAGC CAGAACTGCAGAAGAAACAGTTGTGCTCTTTCGAGATCTACGAAGTTCCC TGGGAGAACAGAAGGTCCCTGGTGAAATCCAGGTGTCAAGAATCCTAGGG ATCTGTGCCAGGCCATTCGCACCAGCCACCACCCACTCCCACCCCCTGTAG TGCTCCCACCCCTGGACTGGTGGCCCCCACCCTGCGGGAGGCCTCCCCATG TGCCTGCGCCAAGAGACAGACAGAGAAGGCTGCAGGAGTCCTTTGTTGCT CAGCAGGGCGCTCTGCCCTCCCTCCTTCCTTCTTGCTTCTAATAGCCCTGGT ACATGGTACACACCCCCCCACCTCCTGCAATTAAACAGTAGCATCGCCTCC CTCTGAAAAAAAAAAAAAAAAAAAAAAA sequence bad 'J difficult slope No. 97 Dukes oxidase - Enzyme Class 2 > gi | 45 05010 Shu Shu ref NM_002318.1 | amine from human醯 oxidase-class 2 (LOXL2), mRNA | qPCR advance _ primer matches [2205..2223] | qPCR reverse _ primer matches [2286..2269] | qPCR probe matches _ [2261..2229]

ACTCCAGCGCGCGGCTACCTACGCTTGGTGCTTGCTTTCTCCAGCCA

TCGGAGACCAGAGCCGCCCCCTCTGCTCGAGAAAGGGGCTCAGCGGCGGC

GGAAGCGGAGGGGGACCACCGTGGAGAGCGCGGTCCCAGCCCGGCCACT

GCGGATCCCTGAAACCAAAAAGCTCCTGCTGCTTCTGTACCCCGCCTGTCC

CTCCCAGCTGCGCAGGGCCCCTTCGTGGGATCATCAGCCCGAAGACAGGG

ATGGAGAGGCCTCTGTGCTCCCACCTCTGCAGCTGCCTGGCTATGCTGGCC

CTCCTGTCCCCCCTGAGCCTGGCACAGTATGACAGCTGGCCCCATTACCCC

GAGTACTTCCAGCAACCGGCTCCTGAGTATCACCAGCCCCAGGCCCCCGC

CAACGTGGCCAAGATTCAGCTGCGCCTGGCTGGGCAGAAGAGGAAGCAC

AGCGAGGGCCGGGTGGAGGTGTACTATGATGGCCAGTGGGGCACCGTGTG

CGATGACGACTTCTCCATCCACGCTGCCCACGTCGTCTGCCGGGAGCTGG

GCTATGTGGAGGCCAAGTCCTGGACTGCCAGCTCCTCCTACGGCAAGGGA

GAAGGGCCCATCTGGTTAGACAATCTCCACTGTACTGGCAACGAGGCGAC

CCTTGCAGCATGCACCTCCAATGGCTGGGGCGTCACTGACTGCAAGCACA

CGGAGGATGTCGGTGTGGTGTGCAGCGACAAAAGGATTCCTGGGTTCAAA

TTTGACAATTCGTTGATCAACCAGATAGAGAACCTGAATATCCAGGTGGA

GGACATTCGGATTCGAGCCATCCTCTCAACCTACCGCAAGCGCACCCCAG

TGATGGAGGGCTACGTGGAGGTGAAGGAGGGCAAGACCTGGAAGCAGAT

CTGTGACAAGCACTGGACGGCCAAGAATTCCCGCGTGGTCTGCGGCATGT

TTGGCTTCCCTGGGGAGAGGACATACAATACCAAAGTGTACAAAATGTTT

GCCTCACGGAGGAAGCAGCGCTACTGGCCATTCTCCATGGACTGCACCGG

CACAGAGGCCCACATCTCCAGCTGCAAGCTGGGCCCCCAGGTGTCACTGG

ACCCCATGAAGAATGTCACCTGCGAGAATGGGCTGCCGGCCGTGGTGAGT

TGTGTGCCTGGGCAGGTCTTCAGCCCTGACGGACCCTCGAGATTCCGGAA

AGCATACAAGCCAGAGCAACCCCTGGTGCGACTGAGAGGCGGTGCCTACA

TCGGGGAGGGCCGCGTGGAGGTGCTCAAAAATGGAGAATGGGGGACCGT

CTGCGACGACAAGTGGGACCTGGTGTCGGCCAGTGTGGTCTGCAGAGAGC

TGGGCTTTGGGAGTGCCAAAGAGGCAGTCACTGGCTCCCGACTGGGGCAA

GGGATCGGACCCATCCACCTCAACGAGATCCAGTGCACAGGCAATGAGAA

GTCCATTATAGACTGCAAGTTCAATGCCGAGTCTCAGGGCTGCAACCACG 145138.doc •60· 201015069

AGGAGGATGCTGGTGTGAGATGCAACACCCCTGCCATGGGCTTGCAGAAG AAGCTGCGCCTGAACGGCGGCCGCAATCCCTACGAGGGCCGAGTGGAGGT GCTGGTGGAGAGAAACGGGTCCCTTGTGTGGGGGATGGTGTGTGGCCAAA ACTGGGGCATCGTGGAGGCCATGGTGGTCTGCCGCCAGCTGGGCCTGGGA TTCGCCAGCAACGCCTTCCAGGAGACCTGGTATTGGCACGGAGATGTCAA CAGCAACAAAGTGGTCATGAGTGGAGTGAAGTGCTCGGGAACGGAGCTG TCCCTGGCGCACTGCCGCCACGACGGGGAGGACGTGGCCTGCCCCCAGGG CGGAGTGCAGTACGGGGCCGGAGTTGCCTGCTCAGAAACCGCCCCTGACC TGGTCCTCAATGCGGAGATGGTGCAGCAGACCACCTACCTGGAGGACCGG CCCATGTTCATGCTGCAGTGTGCCATGGAGGAGAACTGCCTCTCGGCCTCA GCCGCGCAGACCGACCCCACCACGGGCTACCGCCGGCTCCTGCGCTTCTC CTCCCAGATCCACAACAATGGCCAGTCCGACTTCCGGCCCAAGAACGGCC GCCACGCGTGGATCTGGCACGACTGTCACAGGCACTACCACAGCATGGAG GTGTTCACCCACTATGACCTGCTGAACCTCAATGGCACCAAGGTGGCAGA GGGCCACAAGGCCAGCTTCTGCTTGGAGGACACAGAATGTGAAGGAGAC ATCCAGAAGAATTACGAGTGTGCCAACTTCGGCGATCAGGGCATCACCAT GGGCTGCTGGGACATGTACCGCCATGACATCGACTGCCAGTGGGTTGACA TCACTGACGTGCCCCCTGGAGACTACCTGTTCCAGGTTGTTATTAACCCCA ACTTCGAGGTTGCAGAATCCGATTACTCCAACAACATCATGAAATGCAGG AGCCGCTATGACGGCCACCGCATCTGGATGT ACAACTGCCACATAGGTGG TTCCTTCAGCGAAGAGACGGAAAAAAAGTTTGAGCACTTCAGCGGGCTCT TAAACAACCAGCTGTCCCCGCAGTAAAGAAGCCTGCGTGGTCAACTCCTG TCTTCAGGCCACACCACATCTTCCATGGGACTTCCCCCCAACAACTGAGTC TGAACGAATGCCACGTGCCCTCACCCAGCCCGGCCCCCACCCTGTCCAGA CCCCTACAGCTGTGTCTAAGCTCAGGAGGAAAGGGACCCTCCCATCATTC ATGGGGGGCTGCTACCTGACCCTTGGGGCCTGAGAAGGCCTTGGGGGGGT GGGGTTTGTCCACAGAGCTGCTGGAGCAGCACCAAGAGCCAGTCTTGACC GGGATGAGGCCCACAGACAGGTTGTCATCAGCTTGTCCCATTCAAGCCAC CGAGCTCACCACAGACACAGTGGAGCCGCGCTCTTCTCCAGTGACACGTG GACAAATGCGGGCTCATCAGCCCCCCCAGAGAGGGTCAGGCCGAACCCCA TTTCTCCTCCTCTTAGGTCATTTTCAGCAAACTTGAATATCTAGACCTCTCT TCCAATGAAACCCTCCAGTCTATTATAGTCACATAGATAATGGTGCCACGT GTTTTCTGATTTGGTGAGCTCAGACTTGGTGCTTCCCTCTCCACAACCCCC ACCCCTTGTTTTTCAAGATACTATTATTATATTTTCACAGACTTTTGAAGCA CAAATTTATTGGCATTTAATATTGGACATCTGGGCCCTTGGAAGTACAAAT CTAAGGAAAAACCAACCCACTGTGTAAGTGACTCATCTTCCTGTTGTTCCA ATTCTGTGGGTTTTTGATTCAACGGTGCTATAACCAGGGTCCTGGGTGACA GGGCGCTCACTGAGCACCATGTGTCATCACAGACACTTACACATACTTGA AACTTGGAATAAAAGAAAGATTTATG thyroid serial No. 98 Globulin >gi| 33589851丨ref |NM_003235.3丨 Human thyroglobulin (TG), mRNA | qPCR Advance_Introduction matches [886..905] | qPCR Reverse_Introduction matches [962..941]| qPCR probe matches [915..939]

GCAGTGGTTTCTCCTCCTTCCTCCCAGGAAGGGCCAGGAAAATGGC

CCTGGTCCTGGAGATCTTCACCCTGCTGGCCTCCATCTGCTGGGTGTCGGC

CAATATCTTCGAGTACCAGGTTGATGCCCAGCCCCTTCGTCCCTGTGAGCT 145138.doc •61· 201015069

GCAGAGGGAAACGGCCTTTCTGAAGCAAGCAGACTACGTGCCCCAGTGTG

CAGAGGATGGCAGCTTCCAGACTGTCCAGTGCCAGAACGACGGCCGCTCC

TGCTGGTGTGTGGGTGCCAACGGCAGTGAAGTGCTGGGCAGCAGGCAGCC

AGGACGGCCTGTGGCTTGTCTGTCATTTTGTCAGCTACAGAAACAGCAGA

TCTTACTGAGTGGCTACATTAACAGCACAGACACCTCCTACCTCCCTCAGT

GTCAGGATTCAGGGGACTACGCGCCTGTTCAGTGTGATGTGCAGCATGTC

CAGTGCTGGTGTGTGGACGCAGAGGGGATGGAGGTGTATGGGACCCGCCA

GCTGGGGAGGCCAAAGCGATGTCCAAGGAGCTGTGAAATAAGAAATCGT

CGTCTTCTCCACGGGGTGGGAGATAAGTCACCACCCCAGTGTTCTGCGGA

GGGAGAGTTTATGCCTGTCCAGTGCAAATTTGTCAACACCACAGACATGA

TGATTTTTGATCTGGTCCACAGCTACAACAGGTTTCCAGATGCATTTGTGA

CCTTCAGTTCCTTCCAGAGGAGGTTCCCTGAGGTATCTGGGTATTGCCACT

GTGCTGACAGCCAAGGGCGGGAACTGGCTGAGACAGGTTTGGAGTTGTTA

CTGGATGAAATTTATGACACCATTTTTGCTGGCCTGGACCTTCCTTCCACC

TTCACTGAAACCACCCTGTACCGGATACTGCAGAGACGGTTCCTCGCAGTT

CAATCAGTCATCTCTGGCAGATTCCGATGCCCCACAAAATGTGAAGTGGA

GCGGTTTACAGCAACCAGCTTTGGTCACCCCTATGTTCCAAGCTGCCGCCG

AAATGGCGACTATCAGGCGGTGCAGTGCCAGACGGAAGGGCCCTGCTGGT

GTGTGGACGCCCAGGGGAAGGAAATGCATGGAACCCGGCAGCAAGGGGA

GCCGCCATCTTGTGCTGAAGGCCAATCTTGTGCCTCCGAAAGGCAGCAGG

CCTTGTCCAGACTCTACTTTGGGACCTCAGGCTACTTCAGCCAGCACGACC

TGTTCTCTTCCCCAGAGAAAAGATGGGCCTCTCCAAGAGTAGCCAGATTT

GCCACATCCTGCCCACCCACGATCAAGGAGCTCTTTGTGGACTCTGGGCTT

CTCCGCCCAATGGTGGAGGGACAGAGCCAACAGTTTTCTGTCTCAGAAAA

TCTTCTCAAAGAAGCCATCCGAGCAATTTTTCCCTCCCGAGGGCTGGCTCG

TCTTGCCCTTCAGTTTACCACCAACCCAAAGAGACTCCAGCAAAACCTTTT

TGGAGGGAAATTTTTGGTGAATGTTGGCCAGTTTAACTTGTCTGGAGCCCT

TGGCACAAGAGGCACATTTAACTTCAGTCAATTTTTCCAGCAACTTGGTCT

TGCAAGCTTCTTGAATGGAGGGAGACAAGAAGATTTGGCCAAGCCACTCT

CTGTGGGATTAGATTCAAATTCTTCCACAGGAACCCCTGAAGCTGCTAAG

AAGGATGGTACTATGAATAAGCCAACTGTGGGCAGCTTTGGCTTTGAAAT

TAACCTACAAGAGAACCAAAATGCCCTCAAATTCCTTGCTTCTCTCCTGGA

GCTTCCAGAATTCCTTCTCTTCTTGCAACATGCTATCTCTGTGCCAGAAGA

TGTGGCAAGAGATTTAGGTGATGTGATGGAAACGGTACTCGACTCCCAGA

CCTGTGAGCAGACACCTGAAAGGCTATTTGTCCCATCATGCACGACAGAA

GGAAGCTATGAGGATGTCCAATGCTTTTCCGGAGAGTGCTGGTGTGTGAA

TTCCTGGGGCAAAGAGCTTCCAGGCTCAAGAGTCAGAGATGGACAGCCAA

GGTGCCCCAGAGACTGTGAAAAGCAAAGGGCTCGCATGCAAAGCCTCATG

GGCAGCCAGCCTGCTGGCTCCACCTTGTTTGTCCCTGCTTGTACTAGTGAG

GGACATTTCCTGCCTGTCCAGTGCTTCAACTCAGAGTGCTACTGTGTTGAT

GCTGAGGGTCAGGCCATTCCTGGAACTCGAAGTGCAATAGGGAAGCCCAA

GAAATGCCCCACGCCCTGTCAATTACAGTCTGAGCAAGCTTTCCTCAGGA

CGGTGCAGGCCCTGCTCTCTAACTCCAGCATGCTACCCACCCTTTCCGACA

CCTACATCCCACAGTGCAGCACCGATGGGCAGTGGAGACAAGTGCAATGC

AATGGGCCTCCTGAGCAGGTCTTCGAGTTGTACCAACGATGGGAGGCTCA

GAACAAGGGCCAGGATCTGACGCCTGCCAAGCTGCTAGTGAAGATCATGA

GCTACAGAGAAGCAGCTTCCGGAAACTTCAGTCTCTTTATTCAAAGTCTGT

ATGAGGCTGGCCAGCAAGATGTCTTCCCGGTGCTGTCACAATACCCTTCTC

TGCAAGATGTCCCACTAGCAGCACTGGAAGGGAAACGGCCCCAGCCCAG

GGAGAATATCCTCCTGGAGCCCTACCTCTTCTGGCAGATCTTAAATGGCCA

ACTCAGCCAATACCCGGGGTCCTACTCAGACTTCAGCACTCCTTTGGCACA 145138.doc -62- 201015069

TTTTGATCTTCGGAACTGCTGGTGTGTGGATGAGGCTGGCCAAGAACTGG

AAGGAATGCGGTCTGAGCCAAGCAAGCTCCCAACGTGTCCTGGCTCCTGT

GAGGAAGCAAAGCTCCGTGTACTGCAGTTCATTAGGGAAACGGAAGAGA

TTGTTTCAGCTTCCAACAGTTCTCGGTTCCCTCTGGGGGAGAGTTTCCTGG

TGGCCAAGGGAATCCGGCTGAGGAATGAGGACCTCGGCCTTCCTCCGCTC

TTCCCGCCCCGGGAGGCTTTCGCGGAGTTTCTGCGTGGGAGTGATTACGCC

ATTCGCCTGGCGGCTCAGTCTACCTTAAGCTTCTATCAGAGACGCCGCTTT

TCCCCGGACGACTCGGCTGGAGCATCCGCCCTTCTGCGGTCGGGCCCCTAC

ATGCCACAGTGTGATGCGTTTGGAAGTTGGGAGCCTGTGCAGTGCCACGC

TGGGACTGGGCACTGCTGGTGTGTAGATGAGAAAGGAGGGTTCATCCCTG

GCTCACTGACTGCCCGCTCTCTGCAGATTCCACAGTGCCCGACAACCTGCG

AGAAATCTCGAACCAGTGGGCTGCTTTCCAGTTGGAAACAGGCTAGATCC

CAAGAAAACCCATCTCCAAAAGACCTGTTCGTCCCAGCCTGCCTAGAAAC

AGGAGAATATGCCAGGCTGCAGGCATCGGGGGCTGGCACCTGGTGTGTGG

ACCCTGCATCAGGAGAAGAGTTGCGGCCTGGCTCGAGCAGCAGTGCCCAG

TGCCCAAGCCTCTGCAATGTGCTCAAGAGTGGAGTCCTCTCTAGGAGAGT

CAGCCCAGGCTATGTCCCAGCCTGCAGGGCAGAGGATGGGGGCTTTTCCC

CAGTGCAATGTGACCAGGCCCAGGGCAGCTGCTGGTGTGTCATGGACAGC

GGAGAAGAGGTGCCTGGGACGCGCGTGACCGGGGGCCAGCCCGCCTGTG

AGAGCCCGCGGTGTCCGCTGCCATTCAACGCGTCGGAGGTGGTTGGTGGA

ACAATCCTGTGTGAGACAATCTCGGGCCCCACAGGCTCTGCCATGCAGCA

GTGCCAATTGCTGTGCCGCCAAGGCTCCTGGAGCGTGTTTCCACCAGGGC

CATTGATATGTAGCCTGGAGAGCGGACGCTGGGAGTCACAGCTGCCTCAG

CCCCGGGCCTGCCAACGGCCCCAGCTGTGGCAGACCATGCAGACCCAAGG

GCACTTTCAGCTCCAGCTCCCGCCGGGCAAGATGTGCAGTGCTGACTACG

CGGGTTTGCTGCAGACTTTCCAGGTTTTCATATTGGATGAGCTGACAGCCC

GCGGCTTCTGCCAGATCCAGGTGAAGACTTTTGGCACCCTGGTTTCCATTC

CTGTCTGCAACAACTCCTCTGTGCAGGTGGGTTGTCTGACCAGGGAGCGTT

TAGGAGTGAATGTTACATGGAAATCACGGCTTGAGGACATCCCAGTGGCT

TCTCTTCCTGACTTACATGACATTGAGAGAGCCTTGGTGGGCAAGGATCTC

CTTGGGCGCTTCACAGATCTGATCCAGAGTGGCTCATTCCAGCTTCATCTG

GACTCCAAGACGTTCCCAGCGGAAACCATCCGCTTCCTCCAAGGGGACCA

CTTTGGCACCTCTCCTAGGACACGGTTTGGGTGCTCGGAAGGATTCTACCA

AGTCTTGACAAGTGAGGCCAGTCAGGACGGACTGGGATGCGTTAAGTGCC

ATGAAGGAAGCTATTCCCAAGATGAGGAATGCATTCCTTGTCCTGTTGGA

TTCTACCAAGAACAGGCAGGGAGCTTGGCCTGTGTCCCATGTCCTGTGGG

CAGAACGACCATTTCTGCCGGAGCTTTCAGCCAGACTCACTGTGTCACTGA

CTGTCAGAGGAACGAAGCAGGCCTGCAATGTGACCAGAATGGCCAGTATC gagccagccagaaggAcaggggcagtgggaaggccttctgtgtggacgg

CGAGGGGCGGAGGCTGCCATGGTGGGAAACAGAGGCCCCTCTTGAGGAC

TCACAGTGTTTGATGATGCAGAAGTTTGAGAAGGTTCCAGAATCAAAGGT

GATCTTCGACGCCAATGCTCCTGTGGCTGTCAGATCCAAAGTTCCTGATTC

TGAGTTCCCCGTGATGCAGTGCTTGACAGATTGCACAGAGGACGAGGCCT

GCAGCTTCTTCACCGTGTCCACGACGGAGCCAGAGATTTCCTGTGATTTCT

ATGCTTGGACAAGTGACAATGTTGCCTGCATGACTTCTGACCAGAAACGA

GATGCACTGGGGAACTCAAAGGCCACCAGCTTTGGAAGTCTTCGCTGCCA

GGTGAAAGTGAGGAGCCATGGTCAAGATTCTCCAGCTGTGTATTTGAAAA

AGGGCCAAGGATCCACCACAACACTTCAGAAACGCTTTGAACCCACTGGT

TTCCAAAACATGCTTTCTGGATTGTACAACCCCATTGTGTTCTCAGCCTCA

GGAGCCAATCTAACCGATGCTCACCTCTTCTGTCTTCTTGCATGCGACCGT

GATCTGTGTTGCGATGGCTTCGTCCTCACACAGGTTCAAGGAGGTGCCATC 14S138.doc -63- 201015069

ATCTGTGGGTTGCTGAGCTCACCCAGTGTCCTGCTTTGTAATGTCAAAGAC

TGGATGGATCCCTCTGAAGCCTGGGCTAATGCTACATGTCCTGGTGTGACA

TATGACCAGGAGAGCCACCAGGTGATATTGCGTCTTGGAGACCAGGAGTT

CATCAAGAGTCTGACACCCTTAGAAGGAACTCAAGACACCTTTACCAATT

TTCAGCAGGTTTATCTCTGGAAAGATTCTGACATGGGGTCTCGGCCTGAGT

CTATGGGATGTAGAAAAAACACAGTGCCAAGGCCAGCATCTCCAACAGA

AGCAGGTTTGACAACAGAACTTTTCTCCCCTGTGGACCTCAACCAGGTCAT

TGTCAATGGAAATCAATCACTATCCAGCCAGAAGCACTGGCTTTTCAAGC

ACCTGTTTTCAGCCCAGCAGGCAAACCTATGGTGCCTTTCTCGTTGTGTGC

AGGAGCACTCTTTCTGTCAGCTCGCAGAGATAACAGAGAGTGCATCCTTG

TACTTCACCTGCACCCTCTACCCAGAGGCACAGGTGTGTGATGACATCATG

GAGTCCAATACCCAGGGCTGCAGACTGATCCTGCCTCAGATGCCAAAGGC

CCTGTTCCGGAAGAAAGTTATACTGGAAGATAAAGTGAAGAACTTTTACA

CTCGCCTGCCGTTCCAAAAACTGATGGGGATATCCATTAGAAATAAAGTG

CCCATGTCTGAAAAATCTATTTCTAATGGGTTCTTTGAATGTGAACGACGG

TGCGATGCGGACCCATGCTGCACTGGCTTTGGATTTCTAAATGTTTCCCAG

TTAAAAGGAGGAGAGGTGACATGTCTCACTCTGAACAGCTTGGGAATTCA

GATGTGCAGTGAGGAGAATGGAGGAGCCTGGCGCATTTTGGACTGTGGCT

CTCCTGACATTGAAGTCCACACCTATCCCTTCGGATGGTACCAGAAGCCCA

TTGCTCAAAATAATGCTCCCAGTTTTTGCCCTTTGGTTGTTCTGCCTTCCCT

CACAGAGAAAGTGTCTCTGGAATCGTGGCAGTCCCTGGCCCTCTCTTCAGT

GGTTGTTGATCCATCCATTAGGCACTTTGATGTTGCCCATGTCAGCACTGC

TGCCACCAGCAATTTCTCTGCTGTCCGAGACCTCTGTTTGTCGGAATGTTC

CCAACATGAGGCCTGTCTCATCACCACTCTGCAAACCCAACTCGGGGCTG

TGAGATGTATGTTCTATGCTGATACTCAAAGCTGCACACATAGTCTGCAGG

GTCGGAACTGCCGACTTCTGCTTCGTGAAGAGGCCACCCACATCTACCGG

AAGCCAGGAATCTCTCTGCTCAGCTATGAGGCATCTGTACCTTCTGTGCCC

ATTTCCACCCATGGCCGGCTGCTGGGCAGGTCCCAGGCCATCCAGGTGGG

TACCTCATGGAAGCAAGTGGACCAGTTCCTTGGAGTTCCATATGCTGCCCC

GCCCCTGGCAGAGAGGCACTTCCAGGCACCAGAGCCCTTGAACTGGACAG

GCTCCTGGGATGCCAGCAAGCCAAGGGCCAGCTGCTGGCAGCCAGGCACC

AGAACATCCACGTCTCCTGGAGTCAGTGAAGATTGTTTGTATCTCAATGTG

TTCATCCCTCAGAATGTGGCCCCTAACGCGTCTGTGCTGGTGTTCTTCCAC

AACACCATGGACAGGGAGGAGAGTGAAGGATGGCCGGCTATCGACGGCT

CCTTCTTGGCTGCTGTTGGCAACCTCATCGTGGTCACTGCCAGCTACCGAG

TGGGTGTCTTCGGCTTCCTGAGTTCTGGATCCGGAGAGGTGAGTGGCAACT

GGGGGCTGCTGGACCAGGTGGCGGCTCTGACCTGGGTGCAGACCCACATC

CGAGGATTTGGCGGGGACCCTCGGCGCGTGTCCCTGGCAGCAGACCGTGG

CGGGGCTGATGTGGCCAGCATCCACCTTCTCACGGCCAGGGCCACCAACT

CCCAACTTTTCCGGAGAGCTGTGCTGATGGGAGGCTCCGCACTCTCCCCGG

CCGCCGTCATCAGCCATGAGAGGGCTCAGCAGCAGGCAATTGCTTTGGCA

AAGGAGGTCAGTTGCCCCATGTCATCCAGCCAAGAAGTGGTGTCCTGCCT

CCGCCAGAAGCCTGCCAATGTCCTCAATGATGCCCAGACCAAGCTCCTGG

CCGTGAGTGGCCCTTTCCACTACTGGGGTCCTGTGATCGATGGCCACTTCC

TCCGTGAGCCTCCAGCCAGAGCACTGAAGAGGTCTTTATGGGTAGAGGTC

GATCTGCTCATTGGGAGTTCTCAGGACGACGGGCTCATCAACAGAGCAAA

GGCTGTGAAGCAATTTGAGGAAAGTCGAGGCCGGACCAGTAGCAAAACA

GCCTTTTACCAGGCACTGCAGAATTCTCTGGGTGGCGAGGACTCAGATGC

CCGCGTCGAGGCTGCTGCTACATGGTATTACTCTCTGGAGCACTCCACGGA

TGACTATGCCTCCTTCTCCCGGGCTCTGGAGAATGCCACCCGGGACTACTT

TATCATCTGCCCTATAATCGACATGGCCAGTGCCTGGGCAAAGAGGGCCC 145138.doc -64- 201015069

GAGGAAACGTCTTCATGTACCATGCTCCTGAAAACTACGGCCATGGCAGC

CTGGAGCTGCTGGCGGATGTTCAGTTTGCCTTGGGGCTTCCCTTCTACCCA

GCCTACGAGGGGCAGTTTTCTCTGGAGGAGAAGAGCCTGTCGCTGAAAAT

CATGCAGTACTTTTCCCACTTCATCAGATCAGGAAATCCCAACTACCCTTA

TGAGTTCTCACGGAAAGTACCCACATTTGCAACCCCCTGGCCTGACTTTGT

ACCCCGTGCTGGTGGAGAGAACTACAAGGAGTTCAGTGAGCTGCTCCCCA

ATCGACAGGGCCTGAAGAAAGCCGACTGCTCCTTCTGGTCCAAGTACATC

TCGTCTCTGAAGACATCTGCAGATGGAGCCAAGGGCGGGCAGTCAGCAGA

GAGTGAAGAGGAGGAGTTGACGGCTGGATCTGGGCTAAGAGAAGATCTC

CTAAGCCTCCAGGAACCAGGCTCTAAGACCTACAGCAAGTGACCAGCCCT

TGAGCTCCCCAAAAACCTCACCCGAGGCTGCCCACTATGGTCATCTTTTTC

TCTAAAATAGTTACTTACCTTCAATAAAGTATCTACATGCGGTG Sequence No. 99 Transforming growth factor, pi

>gi丨10863 872 I ref丨NM_000660.1丨 Human transforming growth factor, β 1 (Camurati-Engelmann) (TGFB1), 111«^八|91^11forward_引引与[1651 ..1668] Matching|4?€11 Reverse_Introduction matches [153 9.. 1557] | qPCR probe matches [1687.. 1713]

ACCTCCCTCCGCGGAGCAGCCAGACAGCGAGGGCCCCGGCCGGGG

GCAGGGGGGACGCCCCGTCCGGGGCACCCCCCCCGGCTCTGAGCCGCCCG

CGGGGCCGGCCTCGGCCCGGAGCGGAGGAAGGAGTCGCCGAGGAGCAGC

CTGAGGCCCCAGAGTCTGAGACGAGCCGCCGCCGCCCCCGCCACTGCGGG

GAGGAGGGGGAGGAGGAGCGGGAGGAGGGACGAGCTGGTCGGGAGAAG

AGGAAAAAAACTTTTGAGACTTTTCCGTTGCCGCTGGGAGCCGGAGGCGC

GGGGACCTCTTGGCGCGACGCTGCCCCGCGAGGAGGCAGGACTTGGGGAC

CCCAGACCGCCTCCCTTTGCCGCCGGGGACGCTTGCTCCCTCCCTGCCCCC

TACACGGCGTCCCTCAGGCGCCCCCATTCCGGACCAGCCCTCGGGAGTCG

CCGACCCGGCCTCCCGCAAAGACTTTTCCCCAGACCTCGGGCGCACCCCCT

GCACGCCGCCTTCATCCCCGGCCTGTCTCCTGAGCCCCCGCGCATCCTAGA

CCCTTTCTCCTCCAGGAGACGGATCTCTCTCCGACCTGCCACAGATCCCCT

ATTCAAGACCACCCACCTTCTGGTACCAGATCGCGCCCATCTAGGTTATTT

CCGTGGGATACTGAGACACCCCCGGTCCAAGCCTCCCCTCCACCACTGCG

CCCTTCTCCCTGAGGAGCCTCAGCTTTCCCTCGAGGCCCTCCTACCTTTTGC

CGGGAGACCCCCAGCCCCTGCAGGGGCGGGGCCTCCCCACCACACCAGCC

CTGTTCGCGCTCTCGGCAGTGCCGGGGGGCGCCGCCTCCCCCATGCCGCCC

TCCGGGCTGCGGCTGCTGCCGCTGCTGCTACCGCTGCTGTGGCTACTGGTG

CTGACGCCTGGCCCGCCGGCCGCGGGACTATCCACCTGCAAGACTATCGA

CATGGAGCTGGTGAAGCGGAAGCGCATCGAGGCCATCCGCGGCCAGATCC

TGTCCAAGCTGCGGCTCGCCAGCCCCCCGAGCCAGGGGGAGGTGCCGCCC

GGCCCGCTGCCCGAGGCCGTGCTCGCCCTGTACAACAGCACCCGCGACCG

GGTGGCCGGGGAGAGTGCAGAACCGGAGCCCGAGCCTGAGGCCGACTAC

TACGCCAAGGAGGTCACCCGCGTGCTAATGGTGGAAACCCACAACGAAAT

CTATGACAAGTTCAAGCAGAGTACACACAGCATATATATGTTCTTCAACA

CATCAGAGCTCCGAGAAGCGGTACCTGAACCCGTGTTGCTCTCCCGGGCA

GAGCTGCGTCTGCTGAGGAGGCTCAAGTTAAAAGTGGAGCAGCACGTGGA 145138.doc -65- 201015069

GCTGTACCAGAAATACAGCAACAATTCCTGGCGATACCTCAGCAACCGGC

TGCTGGCACCCAGCGACTCGCCAGAGTGGTTATCTTTTGATGTCACCGGAG

TTGTGCGGCAGTGGTTGAGCCGTGGAGGGGAAATTGAGGGCTTTCGCCTT

AGCGCCCACTGCTCCTGTGACAGCAGGGATAACACACTGCAAGTGGACAT

CAACGGGTTCACTACCGGCCGCCGAGGTGACCTGGCCACCATTCATGGCA

TGAACCGGCCTTTCCTGCTTCTCATGGCCACCCCGCTGGAGAGGGCCCAGC

ATCTGCAAAGCTCCCGGCACCGCCGAGCCCTGGACACCAACTATTGCTTC

AGCTCCACGGAGAAGAACTGCTGCGTGCGGCAGCTGTACATTGACTTCCG

CAAGGACCTCGGCTGGAAGTGGATCCACGAGCCCAAGGGCTACCATGCCA

ACTTCTGCCTCGGGCCCTGCCCCTACATTTGGAGCCTGGACACGCAGTACA

GCAAGGTCCTGGCCCTGTACAACCAGCATAACCCGGGCGCCTCGGCGGCG

CCGTGCTGCGTGCCGCAGGCGCTGGAGCCGCTGCCCATCGTGTACTACGT

GGGCCGCAAGCCCAAGGTGGAGCAGCTGTCCAACATGATCGTGCGCTCCT

GCAAGTGCAGCTGAGGTCCCGCCCCGCCCCGCCCCGCCCCGGCAGGCCCG

GCCCCACCCCGCCCCGCCCCCGCTGCCTTGCCCATGGGGGCTGTATTTAAG

GACACCGTGCCCCAAGCCCACCTGGGGCCCCATTAAAGATGGAGAGAGG

ACTGCGGATCTCTGTGTCATTGGGCGCCTGCCTGGGGTCTCCATCCCTGAC

GTTCCCCCACTCCCACTCCCTCTCTCTCCCTCTCTGCCTCCTCCTGCCTGTC

TGCACTATTCCTTTGCCCGGCATCAAGGCACAGGGGACCAGTGGGGAACA

CTACTGTAGTTAGATCTATTTATTGAGCACCTTGGGCACTGTTGAAGTGCC

TTACATTAATGAACTCATTCAGTCACCATAGCAACACTCTGAGATGGCAG

GGACTCTGATAACACCCATTTTAAAGGTTGAGGAAACAAGCCCAGAGAGG

TTAAGGGAGGAGTTCCTGCCCACCAGGAACCTGCTTTAGTGGGGGATAGT

GAAGAAGACAATAAAAGATAGTAGTTCAGGCCAGGCGGGGTGCTCACGC

CTGTAATCCTAGCACTTTTGGGAGGCAGAGATGGGAGGATACTTGAATCC

AGGCATTTGAGACCAGCCTGGGTAACATAGTGAGACCCTATCTCTACAAA

ACACTTTTAAAAAATGTACACCTGTGGTCCCAGCTACTCTGGAGGCTAAG

GTGGGAGGATCACTTGATCCTGGGAGGTCAAGGCTGCAG Sequence No. 100 serine protease inhibitor, located in 贝, 成贝1 >gi丨3 2454740丨ref丨ΝΜ_001235.2丨 Human serine (or cysteine) protease inhibitor, level Η ( Heat shock protein 47), member 1, (collagen binding protein 1) (SERPINH1), mRNA | qPCR is determined in the context of the requirements and matches [184..208]

TCTTTGGCTTTTTTTGGCGGAGCTGGGGCGCCCTCCGGAAGCGTTTC

CAACTTTCCAGAAGTTTCTCGGGACGGGCAGGAGGGGGTGGGGACTGCCA

TATATAGATCCCGGGAGCAGGGGAGCGGGCTAAGAGTAGAATCGTGTCGC

GGCTCGAGAGCGAGAGTCACGTCCCGGCGCTAGCCCAGCCCGACCCAGGC

CCACCGTGGTGCACGCAAACCACTTCCTGGCCATGCGCTCCCTCCTGCTTC

TCAGCGCCTTCTGCCTCCTGGAGGCGGCCCTGGCCGCCGAGGTGAAGAAA

CCTGCAGCCGCAGCAGCTCCTGGCACTGCGGAGAAGTTGAGCCCCAAGGC

GGCCACGCTTGCCGAGCGCAGCGCCGGCCTGGCCTTCAGCTTGTACCAGG

CCATGGCCAAGGACCAGGCAGTGGAGAACATCCTGGTGTCACCCGTGGTG

GTGGCCTCGTCGCTAGGGCTCGTGTCGCTGGGCGGCAAGGCGACCACGGC

GTCGCAGGCCAAGGCAGTGCTGAGCGCCGAGCAGCTGCGCGACGAGGAG 145138.doc -66- 201015069

GTGCACGCCGGCCTGGGCGAGCTGCTGCGCTCACTCAGCAACTCCACGGC GCGCAACGTGACCTGGAAGCTGGGCAGCCGACTGTACGGACCCAGCTCAG TGAGCTTCGCTGATGACTTCGTGCGCAGCAGCAAGCAGCACTACAACTGC GAGCACTCCAAGATCAACTTCCGCGACAAGCGCAGCGCGCTGCAGTCCAT CAACGAGTGGGCCGCGCAGACCACCGACGGCAAGCTGCCCGAGGTCACC AAGGACGTGGAGCGCACGGACGGCGCCCTGCTAGTCAACGCCATGTTCTT CAAGCCACACTGGGATGAGAAATTCCACCACAAGATGGTGGACAACCGTG GCTTCATGGTGACTCGGTCCTATACCGTGGGTGTCATGATGATGCACCGGA CAGGCCTCTACAACTACTACGACGACGAGAAGGAAAAGCTGCAAATCGTG GAGATGCCCCTGGCCCACAAGCTCTCCAGCCTCATCATCCTCATGCCCCAT CACGTGGAGCCTCTCGAGCGCCTTGAAAAGCTGCTAACCAAAGAGCAGCT GAAGATCTGGATGGGGAAGATGCAGAAGAAGGCTGTTGCCATCTCCTTGC CCAAGGGTGTGGTGGAGGTGACCCATGACCTGCAGAAACACCTGGCTGGG CTGGGCCTGACTGAGGCCATTGACAAGAACAAGGCCGACTTGTCACGCAT GTCAGGCAAGAAGGACCTGTACCTGGCCAGCGTGTTCCACGCCACCGCCT TTGAGTTGGACACAGATGGCAACCCCTTTGACCAGGACATCTACGGGCGC GAGGAGCTGCGCAGCCCCAAGCTGTTCTACGCCGACCACCCCTTCATCTTC CTAGTGCGGGACACCCAAAGCGGCTCCCTGCTATTCATTGGGCGCCTGGT CCGGCCTAAGGGTGACAAGATGCGAGACGAGTTATAGGGCCTCAGGGTGC ACACAGGATGGCAGGAGGCATCCAAAGGC TCCTGAGACACATGGGTGCT ATTGGGGTTGGGGGGGAGGTGAGGTACCAGCCTTGGATACTCCATGGGGT GGGGGTGGAAAAACAGACCGGGGTTCCCGTGTGCCTGAGCGGACCTTCCC AGCTAGAATTCACTCCACTTGGACATGGGCCCCAGATACCATGATGCTGA GCCCGGAAACTCCACATCCTGTGGGACCTGGGCCATAGTCATTCTGCCTGC CCTGAAAGTCCCAGATCAAGCCTGCCTCAATCAGTATTCATATTTATAGCC AGGTACCTTCTCACCTGTGAGACCAAATTGAGCTAGGGGGGTCAGCCAGC CCTCTTCTGACACTAAAACACCTCAGCTGCCTCCCCAGCTCTATCCCAACC TCTCCCAACTATAAAACTAGGTGCTGCAGCCCCTGGGACCAGGCACCCCC AGAATGACCTGGCCGCAGTGAGGCGGATTGAGAAGGAGCTCCCAGGAGG GGCTTCTGGGCAGACTCTGGTCAAGAAGCATCGTGTCTGGCGTTGTGGGG ATGAACTTTTTGTTTTGTTTCTTCCTTTTTTAGTTCTTCAAAGATAGGGAGG GAAGGGGGAACATGAGCCTTTGTTGCTATCAATCCAAGAACTTATTTGTA CATTTTTTTTTTCAATAAAACTTTTCCAATGACATTTTGTTGGAGCGTGGAA AAAA Serial No. 101 serine protease inhibitor, Sui position B, Pui 5 > gi | 450578 8 | ref | NM_002639.1 | human serine (or cysteine) protease inhibitor, rank B (ovalbumin), member 5 (SERPINB5), mRNA|qPCR advancement_probe matched with [36..56]|qPCR reverse_introduction and [106..86 ] Matching | qPCR probes with [60..80] Match

GGCACGAGTTGTGCTCCTCGCTTGCCTGTTCCTTTTCCGCATTT

CCAGGATAACTGTGACTCCAGGCCCGCAATGGATGCCCTGCAACTAGCAA

ATTCGGCTTTTGCCGTTGATCTGTTCAAACAACTATGTGAAAAGGAGCCAC

TGGGCAATGTCCTCTTCTCTCCAATCTGTCTCTCCACCTCTCTGTCACTTGC

TCAAGTGGGTGCTAAAGGTGACACTGCAAATGAAATTGGACAGGTTCTTC

ATTTTGAAAATGTCAAAGATATACCCTTTGGATTTCAAACAGTAACATCGG 145138.doc -67- 201015069

ATGTAAACAAACTTAGTTCCTTTTACTCACTGAAACTAATCAAGCGGCTCT

ACGTAGACAAATCTCTGAATCTTTCTACAGAGTTCATCAGCTCTACGAAGA

GACCCTATGCAAAGGAATTGGAAACTGTTGACTTCAAAGATAAATTGGAA

GAAACGAAAGGTCAGATCAACAACTCAATTAAGGATCTCACAGATGGCCA

CTTTGAGAACATTTTAGCTGACAACAGTGTGAACGACCAGACCAAAATCC

TTGTGGTTAATGCTGCCTACTTTGTTGGCAAGTGGATGAAGAAATTTCCTG

AATCAGAAACAAAAGAATGTCCTTTCAGACTCAACAAGACAGACACCAA

ACCAGTGCAGATGATGAACATGGAGGCCACGTTCTGTATGGGAAACATTG

ACAGTATCAATTGTAAGATCATAGAGCTTCCTTTTCAAAATAAGCATCTCA

GCATGTTCATCCTACTACCCAAGGATGTGGAGGATGAGTCCACAGGCTTG

GAGAAGATTGAAAAACAACTCAACTCAGAGTCACTGTCACAGTGGACTAA

TCCCAGCACCATGGCCAATGCCAAGGTCAAACTCTCCATTCCAAAATTTA

AGGTGGAAAAGATGATTGATCCCAAGGCTTGTCTGGAAAATCTAGGGCTG

AAACATATCTTCAGTGAAGACACATCTGATTTCTCTGGAATGTCAGAGAC

CAAGGGAGTGGCCCTATCAAATGTTATCCACAAAGTGTGCTTAGAAATAA

CTGAAGATGGTGGGGATTCCATAGAGGTGCCAGGAGCACGGATCCTGCAG

CACAAGGATGAATTGAATGCTGACCATCCCTTTATTTACATCATCAGGCAC

AACAAAACTCGAAACATCATTTTCTTTGGCAAATTCTGTTCTCCTTAAGTG

GCATAGCCCATGTTAAGTCCTCCCTGACTTTTCTGTGGATGCCGATTTCTG

TAAACTCTGCATCCAGAGATTCATTTTCTAGATACAATAAATTGCTAATGT

TGCTGGATCAGGAAGCCGCCAGTACTTGTCATATGTAGCCTTCACACAGA

TAGACCTTTTTTTTTTTCCAATTCTATCTTTTGTTTCCTTTTTTCCCATAAGA

CAATGACATACGCTTTTAATGAAAAGGAATCACGTTAGAGGAAAAATATT

TATTCATTATTTGTCAAATTGTCCGGGGTAGTTGGCAGAAATACAGTCTTC

CACAAAGAAAATTCCTATAAGGAAGATTTGGAAGCTCTTCTTCCCAGCAC

TATGCTTTCCTTCTTTGGGATAGAGAATGTTCCAGACATTCTCGCTTCCCTG

AAAGACTGAAGAAAGTGTAGTGCATGGGACCCACGAAACTGCCCTGGCTC

CAGTGAAACTTGGGCACATGCTCAGGCTACTATAGGTCCAGAAGTCCTTA

TGTTAAGCCCTGGCAGGCAGGTGTTTATTAAAATTCTGAATTTTGGGGATT

TTCAAAAGATAATATTTTACATACACTGTATGTTATAGAACTTCATGGATC

AGATCTGGGGCAGCAACCTATAAATCAACACCTTAATATGCTGCAACAAA

ATGTAGAATATTCAGACAAAATGGATACATAAAGACTAAGTAGCCCATAA

GGGGTCAAAATTTGCTGCCAAATGCGTATGCCACCAACTTACAAAAACAC

TTCGTTCGCAGAGCTTTTCAGATTGTGGAATGTTGGATAAGGAATTATAGA CCTCTAGTAGCTGAAATGCAAGACCCCAAGAGGAAGTTCAGATCTTAATA ❿

TAAATTCACTTTCATTTTTGATAGCTGTCCCATCTGGTCATGTGGTTGGCAC

TAGACTGGTGGCAGGGGCTTCTAGCTGACTCGCACAGGGATTCTCACAAT

AGCCGATATCAGAATTTGTGTTGAAGGAACTTGTCTCTTCATCTAATATGA

TAGCGGGAAAAGGAGAGGAAACTACTGCCTTTAGAAAATATAAGTAAAG

TGATTAAAGTGCTCACGTTACCTTGACACATAGTTTTTCAGTCTATGGGTT

TAGTTACTTTAGATGGCAAGCATGTAACTTATATTAATAGTAATTTGTAAA

GTTGGGTGGATAAGCTATCCCTGTTGCCGGTTCATGGATTACTTCTCTATA

AAAAATATATATTTACCAAAAAATTTTGTGACATTCCTTCTCCCATCTCTT

CCTTGACATGCATTGTAAATAGGTTCTTCTTGTTCTGAGATTCAATATTGA

ATTTCTCCTATGCTATTGACAATAAAATATTATTGAACTACC Sequence No. 102 Carcinoembryonic Antigen-associated Cell Adhesion Molecule 5 >gi丨113 86170丨ref丨NM_004363.1丨 Human Carcinoembryonic Antigen-Related 145138.doc -68 - 201015069 Cell Adhesion Molecule 5 (CEACAM5 ), mRNA| qPCR is matched with [2128..21 52] when requested in the context.

CTCAGGGCAGAGGGAGGAAGGACAGCAGACCAGACAGTCACAGC

AGCCTTGACAAAACGTTCCTGGAACTCAAGCTCTTCTCCACAGAGGAGGA

CAGAGCAGACAGCAGAGACCATGGAGTCTCCCTCGGCCCCTCCCCACAGA

TGGTGCATCCCCTGGCAGAGGCTCCTGCTCACAGCCTCACTTCTAACCTTC

TGGAACCCGCCCACCACTGCCAAGCTCACTATTGAATCCACGCCGTTCAAT

GTCGCAGAGGGGAAGGAGGTGCTTCTACTTGTCCACAATCTGCCCCAGCA

TCTTTTTGGCTACAGCTGGTACAAAGGTGAAAGAGTGGATGGCAACCGTC

AAATTATAGGATATGTAATAGGAACTCAACAAGCTACCCCAGGGCCCGCA

TACAGTGGTCGAGAGATAATATACCCCAATGCATCCCTGCTGATCCAGAA

CATCATCCAGAATGACACAGGATTCTACACCCTACACGTCATAAAGTCAG

ATCTTGTGAATGAAGAAGCAACTGGCCAGTTCCGGGTATACCCGGAGCTG

CCCAAGCCCTCCATCTCCAGCAACAACTCCAAACCCGTGGAGGACAAGGA

TGCTGTGGCCTTCACCTGTGAACCTGAGACTCAGGACGCAACCTACCTGTG

GTGGGTAAACAATCAGAGCCTCCCGGTCAGTCCCAGGCTGCAGCTGTCCA

ATGGCAACAGGACCCTCACTCTATTCAATGTCACAAGAAATGACACAGCA

AGCTACAAATGTGAAACCCAGAACCCAGTGAGTGCCAGGCGCAGTGATTC

AGTCATCCTGAATGTCCTCTATGGCCCGGATGCCCCCACCATTTCCCCTCT

AAACACATCTTACAGATCAGGGGAAAATCTGAACCTCTCCTGCCACGCAG

CCTCTAACCCACCTGCACAGTACTCTTGGTTTGTCAATGGGACTTTCCAGC

AATCCACCCAAGAGCTCTTTATCCCCAACATCACTGTGAATAATAGTGGAT

CCTATACGTGCCAAGCCCATAACTCAGACACTGGCCTCAATAGGACCACA

GTCACGACGATCACAGTCTATGCAGAGCCACCCAAACCCTTCATCACCAG

CAACAACTCCAACCCCGTGGAGGATGAGGATGCTGTAGCCTTAACCTGTG

AACCTGAGATTCAGAACACAACCTACCTGTGGTGGGTAAATAATCAGAGC

CTCCCGGTCAGTCCCAGGCTGCAGCTGTCCAATGACAACAGGACCCTCAC

TCTACTCAGTGTCACAAGGAATGATGTAGGACCCTATGAGTGTGGAATCC

AGAACGAATTAAGTGTTGACCACAGCGACCCAGTCATCCTGAATGTCCTC

TATGGCCCAGACGACCCCACCATTTCCCCCTCATACACCTATTACCGTCCA

GGGGTGAACCTCAGCCTCTCCTGCCATGCAGCCTCTAACCCACCTGCACA

GTATTCTTGGCTGATTGATGGGAACATCCAGCAACACACACAAGAGCTCT

TTATCTCCAACATCACTGAGAAGAACAGCGGACTCTATACCTGCCAGGCC

AATAACTCAGCCAGTGGCCACAGCAGGACTACAGTCAAGACAATCACAGT

CTCTGCGGAGCTGCCCAAGCCCTCCATCTCCAGCAACAACTCCAAACCCG

TGGAGGACAAGGATGCTGTGGCCTTCACCTGTGAACCTGAGGCTCAGAAC

ACAACCTACCTGTGGTGGGTAAATGGTCAGAGCCTCCCAGTCAGTCCCAG

GCTGCAGCTGTCCAATGGCAACAGGACCCTCACTCTATTCAATGTCACAA

GAAATGACGCAAGAGCCTATGTATGTGGAATCCAGAACTCAGTGAGTGCA

AACCGCAGTGACCCAGTCACCCTGGATGTCCTCTATGGGCCGGACACCCC

CATCATTTCCCCCCCAGACTCGTCTTACCTTTCGGGAGCGAACCTCAACCT

CTCCTGCCACTCGGCCTCTAACCCATCCCCGCAGTATTCTTGGCGTATCAA

TGGGATACCGCAGCAACACACACAAGTTCTCTTTATCGCCAAAATCACGC

CAAATAATAACGGGACCTATGCCTGTTTTGTCTCTAACTTGGCTACTGGCC

GCAATAATTCCATAGTCAAGAGCATCACAGTCTCTGCATCTGGAACTTCTC

CTGGTCTCTCAGCTGGGGCCACTGTCGGCATCATGATTGGAGTGCTGGTTG

GGGTTGCTCTGATATAGCAGCCCTGGTGTAGTTTCTTCATTTCAGGAAGAC

TGACAGTTGTTTTGCTTCTTCCTTAAAGCATTTGCAACAGCTACAGTCTAA 145138.doc -69- 201015069

AATTGCTTCTTTACCAAGGATATTTACAGAAAAGACTCTGACCAGAGATC

GAGACCATCCTAGCCAACATCGTGAAACCCCATCTCTACTAAAAATACAA

AAATGAGCTGGGCTTGGTGGCGCGCACCTGTAGTCCCAGTTACTCGGGAG

GCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGTGGAGATTGCAGTGAG

CCCAGATCGCACCACTGCACTCCAGTCTGGCAACAGAGCAAGACTCCATC

TCAAAAAGAAAAGAAAAGAAGACTCTGACCTGTACTCTTGAATACAAGTT

TCTGATACCACTGCACTGTCTGAGAATTTCCAAAACTTTAATGAACTAACT

GACAGCTTCATGAAACTGTCCACCAAGATCAAGCAGAGAAAATAATTAAT

TTCATGGGACTAAATGAACTAATGAGGATTGCTGATTCTTTAAATGTCTTG

TTTCCCAGATTTCAGGAAACTTTTTTTCTTTTAAGCTATCCACTCTTACAGC

AATTTGATAAAATATACTTTTGTGAACAAAAATTGAGACATTTACATTTTC

TCCCTATGTGGTCGCTCCAGACTTGGGAAACTATTCATGAATATTTATATT

GTATGGTAATATAGTTATTGCACAAGTTCAATAAAAATCTGCTCTTTGTAT AACAGAAAAA Sequence No. 103 Matrix Metalloproteinase 2 >gi丨11342665丨ref |NM_004530.1丨 Human Matrix Metalloproteinase 10 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) (^11^ «>2),1111^^八丨4?€11 forward_引子 matches [1713..1732] | qPCR reverse _ bow scorpion matches [1793..1775] 丨qPCR probe with [1751.. 1773] Matching

TGTTTCCGCTGCATCCAGACTTCCTCAGGCGGTGGCTGGAGGCTGC GCATCTGGGGCTTTAAACATACAAAGGGATTGCCAGGACCTGCGGCGGCG GCGGCGGCGGCGGGGGCTGGGGCGCGGGGGCCGGACCATGAGCCGCTGA GCCGGGCAAACCCCAGGCCACCGAGCCAGCGGACCCTCGGAGCGCAGCC CTGCGCCGCGGACCAGGCTCCAACCAGGCGGCGAGGCGGCCACACGCAC CGAGCCAGCGACCCCCGGGCGACGCGCGGGGCCAGGGAGCGCTACGATG GAGGCGCTAATGGCCCGGGGCGCGCTCACGGGTCCCCTGAGGGCGCTCTG Q TCTCCTGGGCTGCCTGCTGAGCCACGCCGCCGCCGCGCCGTCGCCCATCAT CAAGTTCCCCGGCGATGTCGCCCCCAAAACGGACAAAGAGTTGGCAGTGC AATACCTGAACACCTTCTATGGCTGCCCCAAGGAGAGCTGCAACCTGTTT GTGCTGAAGGACACACTAAAGAAGATGCAGAAGTTCTTTGGACTGCCCCA GACAGGTGATCTTGACCAGAATACCATCGAGACCATGCGGAAGCCACGCT GCGGCAACCCAGATGTGGCCAACTACAACTTCTTCCCTCGCAAGCCCAAG TGGGACAAGAACCAGATCACATACAGGATCATTGGCTACACACCTGATCT GGACCCAGAGACAGTGGATGATGCCTTTGCTCGTGCCTTCCAAGTCTGGA GCGATGTGACCCCACTGCGGTTTTCTCGAATCCATGATGGAGAGGCAGAC ATCATGATCAACTTTGGCCGCTGGGAGCATGGCGATGGATACCCCTTTGA CGGTAAGGACGGACTCCTGGCTCATGCCTTCGCCCCAGGCACTGGTGTTG GGGGAGACTCCCATTTTGATGACGATGAGCTATGGACCTTGGGAGAAGGC CAAGTGGTCCGTGTGAAGTATGGCAACGCCGATGGG GAGTACTGCAAGTT CCCCTTCTTGTTCAATGGCAAGGAGTACAACAGCTGCACTGATACTGGCC GCAGCGATGGCTTCCTCTGGTGCTCCACCACCTACAACTTTGAGAAGGAT GGCAAGTACGGCTTCTGTCCCCATGAAGCCCTGTTCACCATGGGCGGCAA 145138.doc -70- 201015069

CGCTGAAGGACAGCCCTGCAAGTTTCCATTCCGCTTCCAGGGCACATCCTA TGACAGCTGCACCACTGAGGGCCGCACGGATGGCTACCGCTGGTGCGGCA CCACTGAGGACTACGACCGCGACAAGAAGTATGGCTTCTGCCCTGAGACC GCCATGTCCACTGTTGGTGGGAACTCAGAAGGTGCCCCCTGTGTCTTCCCC TTCACTTTCCTGGGCAACAAATATGAGAGCTGCACCAGCGCCGGCCGCAG TGACGGAAAGATGTGGTGTGCGACCACAGCCAACTACGATGACGACCGCA AGTGGGGCTTCTGCCCTGACCAAGGGTACAGCCTGTTCCTCGTGGCAGCC CACGAGTTTGGCCACGCCATGGGGCTGGAGCACTCCCAAGACCCTGGGGC CCTGATGGCACCCATTTACACCTACACCAAGAACTTCCGTCTGTCCCAGGA TGACATCAAGGGCATTCAGGAGCTCTATGGGGCCTCTCCTGACATTGACCT TGGCACCGGCCCCACCCCCACACTGGGCCCTGTCACTCCTGAGATCTGCA AACAGGACATTGTATTTGATGGCATCGCTCAGATCCGTGGTGAGATGTTCT TCTTCAAGGACCGGTTCATTTGGCGGACTGTGACGCCACGTGACAAGCCC ATGGGGCCCCTGCTGGTGGCCACATTCTGGCCTGAGCTCCCGGAAAAGAT TGATGCGGTATACGAGGCCCCACAGGAGGAGAAGGCTGTGTTCTTTGCAG GGAATGAATACTGGATCTACTCAGCCAGCACCCTGGAGCGAGGGTACCCC AAGCCACTGACCAGCCTGGGACTGCCCCCTGATGTCCAGCGAGTGGATGC CGCCTTTAACTGGAGCAAAAACAAGAAGACATACATCTTTGCTGGAGACA AATTCTGGAGATACAATGAGGTGAAGAAGAAAATGGATCCTGGCTTTCCC AAGCTCATCGCAGATGCCTGGAATGC CATCCCCGATAACCTGGATGCCGT CGTGGACCTGCAGGGCGGCGGTCACAGCTACTTCTTCAAGGGTGCCTATT ACCTGAAGCTGGAGAACCAAAGTCTGAAGAGCGTGAAGTTTGGAAGCATC AAATCCGACTGGCTAGGCTGCTGAGCTGGCCCTGGCTCCCACAGGCCCTT CCTCTCCACTGCCTTCGATACACCGGGCCTGGAGAACTAGAGAAGGACCC GGAGGGGCCTGGCAGCCGTGCCTTCAGCTCTACAGCTAATCAGCATTCTC ACTCCTACCTGGTAATTTAAGATTCCAGAGAGTGGCTCCTCCCGGTGCCCA AGAATAGATGCTGACTGTACTCCTCCCAGGCGCCCCTTCCCCCTCCAATCC CACCAACCCTCAGAGCCACCCCTAAAGAGATCCTTTGATATTTTCAACGCA GCCCTGCTTTGGGCTGCCCTGGTGCTGCCACACTTCAGGCTCTTCTCCTTTC ACAACCTTCTGTGGCTCACAGAACCCTTGGAGCCAATGGAGACTGTCTCA AGAGGGCACTGGTGGCCCGACAGCCTGGCACAGGGCAGTGGGACAGGGC ATGGCCAGGTGGCCACTCCAGACCCCTGGCTTTTCACTGCTGGCTGCCTTA GAACCTTTCTTACATTAGCAGTTTGCTTTGTATGCACTTTGTTTTTTTCTTT GGGTCTTGTTTTTTTTTTCCACTTAGAAATTGCATTTCCTGACAGAAGGACT CAGGTTGTCTGAAGTCACTGCACAGTGCATCTCAGCCCACATAGTGATGG TTCCCCTGTTCACTCTACTTAGCATGTCCCTACCGAGTCTCTTCTCCACTGG ATGGAGGAAAACCAAGCCGTGGCTTCCCGCTCAGCCCTCCCTGCCCCTCCT TCAACCATTCCCCATGGGAAATGTCAACAAGTATGAATAAAGACACCTAC TGAGTGGC serial No. 104 proprotein convertase Caobox Protease/Kaixin Type 5 >gi丨20336245丨ref丨NM_006200.2丨 Human Proprotein Convertase Subtilisin/Kaixin Type 5 (PCSK5), mRNA| qPCR Advance-Introduction and [2677. .2697] Matching | qPCR reverse _ primer matching [2821..2801] | qPCR probe matching [2737..2765]

CGGAGGGAGCGCTGGGAGCGAGCAAGCGAGCGTTTGGAGCCCGGG 145138.doc -71- 201015069

CCAGCAGAGGGGGCGCCCGGTCGCTGCCTGTACCGCTCCCGCTGGTCATC

TCCGCCGCGCTCGGGGGCCCCGGGAGGAGCGAGACCGAGTCGGAGAGTC

CGGGAGCCAAGCCGGGCGAAACCCAACTGCGGAGGACGCCCGCCCCACT

CAGCCTCCTCCTGCGTCCGAGCCGGGGAGCATCGCCGAGCGCCCCACGGG

CCGGAGAGCTGGGAGCACAGGTCCCGGCAGCCCCAGGGATGGTCTAGGA

GCCGGCGTAAGGCTCGCTGCTCTGCTCCCTGCCGGGGCTAGCCGCCTCCTG

CCGATCGCCCGGGGCTGCGAGCTGCGGCGGCCCGGGGCTGCTCGCCGGGC

GGCGCAGGCCGGAGAAGTTAGTTGTGCGCGCCCTTAGTGCGCGGAACCAG

CCAGCGAGCGAGGGAGCAGCGAGGCGCCGGGACCATGGGCTGGGGGAGC

CGCTGCTGCTGCCCGGGACGTTTGGACCTGCTGTGCGTGCTGGCGCTGCTC

GGGGGCTGCCTGCTCCCCGTGTGTCGGACGCGCGTCTACACCAACCACTG

GGCAGTCAAAATCGCCGGGGGCTTCCCGGAGGCCAACCGTATCGCCAGCA

AGTACGGATTCATCAACATAGGACAGATAGGGGCCCTGAAGGACTACTAC

CACTTCTACCATAGCAGGACGATTAAAAGGTCAGTTATCTCGAGCAGAGG

GACCCACAGTTTCATTTCAATGGAACCAAAGGTGGAATGGATCCAACAGC

AAGTGGTAAAAAAGCGGACAAAGAGGGATTATGACTTCAGTCGTGCCCA

GTCTACCTATTTCAATGATCCCAAGTGGCCCAGCATGTGGTATATGCACTG

CAGTGACAATACACATCCCTGCCAGTCTGACATGAATATCGAAGGAGCCT

GGAAGAGAGGCTACACGGGAAAGAACATTGTGGTCACTATCCTGGATGAC

GGAATTGAGAGAACCCATCCAGATCTGATGCAAAACTACGATGCTCTGGC

AAGTTGCGACGTGAATGGGAATGACTTGGACCCAATGCCTCGTTATGATG

CAAGCAACGAGAACAAGCATGGGACTCGCTGTGCTGGAGAAGTGGCAGC

CGCTGCAAACAATTCGCACTGCACAGTCGGAATTGCTTTCAACGCCAAGA

TCGGAGGAGTGCGAATGCTGGACGGAGATGTCACGGACATGGTTGAAGC

AAAATCAGTTAGCTTCAACCCCCAGCACGTGCACATTTACAGCGCCAGCT

GGGGCCCGGATGATGATGGCAAGACTGTGGACGGACCAGCCCCCCTCACC

CGGCAAGCCTTTGAAAACGGCGTTAGAATGGGGCGGAGAGGCCTCGGCTC

TGTGTTTGTTTGGGCATCTGGAAATGGTGGAAGGAGCAAAGACCACTGCT

CCTGTGATGGCTACACCAACAGCATCTACACCATCTCCATCAGCAGCACT

GCAGAAAGCGGAAAGAAACCTTGGTACCTGGAAGAGTGTTCATCCACGCT

GGCCACAACCTACAGCAGCGGGGAGTCCTACGATAAGAAAATCATCACTA

CAGATCTGAGGCAGCGTTGCACGGACAACCACACTGGGACGTCAGCCTCA

GCCCCCATGGCTGCAGGCATCATTGCGCTGGCCCTGGAAGCCAATCCGTTT

CTGACCTGGAGAGACGTACAGCATGTTATTGTCAGGACTTCCCGTGCGGG

ACATTTGAACGCTAATGACTGGAAAACCAATGCTGCTGGTTTTAAGGTGA

GCCATCTTTATGGATTTGGACTGATGGACGCAGAAGCCATGGTGATGGAG

GCAGAGAAGTGGACCACCGTTCCCCGGCAGCACGTGTGTGTGGAGAGCAC

AGACCGACAAATCAAGACAATCCGCCCTAACAGTGCAGTGCGCTCCATCT

ACAAAGCTTCAGGCTGCTCGGATAACCCCAACCGCCATGTCAACTACCTG

GAGCACGTCGTTGTGCGCATCACCATCACCCACCCCAGGAGAGGAGACCT

GGCCATCTACCTGACCTCGCCCTCTGGAACTAGGTCTCAGCTTTTGGCCAA

CAGGCTATTTGATCACTCCATGGAAGGATTCAAAAACTGGGAGTTCATGA

CCATTCATTGCTGGGGAGAAAGAGCTGCTGGTGACTGGGTCCTTGAAGTT

TATGATACTCCCTCTCAGCTAAGGAACTTTAAGACTCCAGGTAAATTGAA

AGAATGGTCTTTGGTCCTCTACGGCACCTCCGTGCAGCCATATTCACCAAC

CAATGAATTTCCGAAAGTGGAACGGTTCCGCTATAGCCGAGTTGAAGACC

CCACAGACGACTATGGCACAGAGGATTATGCAGGTCCCTGCGACCCTGAG

TGCAGTGAGGTTGGCTGTGACGGGCCAGGACCAGACCACTGCAATGACTG

TTTGCACTACTACTACAAGCTGAAAAACAATACCAGGATCTGTGTCTCCA

GCTGCCCCCCTGGCCACTACCACGCCGACAAGAAGCGCTGCAGGAAGTGT

GCCCCCAACTGTGAGTCCTGCTTTGGGAGCCATGGTGACCAATGCATGTCC 145138.doc -72- 201015069

TGCAAATATGGATACTTTCTGAATGAAGAAACCAACAGCTGTGTTACTCA

CTGCCCTGATGGGTCATATCAGGATACCAAGAAAAATCTTTGCCGGAAAT

GCAGTGAAAACTGCAAGACATGTACTGAATTCCATAACTGTACAGAATGT

AGGGATGGGTTAAGCCTGCAGGGATCCCGGTGCTCTGTCTCCTGTGAAGA

TGGACGGTATTTCAACGGCCAGGACTGCCAGCCCTGCCACCGCTTCTGCG

CCACTTGTGCTGGGGCAGGAGCTGATGGGTGCATTAACTGCACAGAGGGC

TACTTCATGGAGGATGGGAGATGCGTGCAGAGCTGTAGTATCAGCTATTA

CTTTGACCACTCTTCAGAGAATGGATACAAATCCTGCAAAAAATGTGATA

TCAGTTGTTTGACGTGCAATGGCCCAGGATTCAAGAACTGTACAAGCTGC

CCTAGTGGGTATCTCTTAGACTTAGGAATGTGTCAAATGGGAGCCATTTGC

AAGGATGCAACGGAAGAGTCCTGGGCGGAAGGAGGCTTCTGTATGCTTGT

GAAAAAGAACAATCTGTGCCAACGGAAGGTTCTTCAACAACTTTGCTGCA

AAACATGTACATTTCAAGGCTGAGCAGCCATCTTAGATTTCTTTGTTCCTG

TAGACTTATAGATTATTCCATATTATTAAAAAGAAAAAAAAAAGCCAAAA AG Sequence No. 105

Carboxypeptidase N, peptide 2,83 kD gin > § 185 54966 卜 6 丨 ^ ^ _ 087 8.1 丨 human carboxypeptidase 1 ^, polymorphous

2,83 kD (CPN2), mRNA

ATGGGTTGTGACTGCTTCGTCCAGGAGGTGTTCTGCTCAGATGAGG

AGCTTGCCACCGTCCCGCTGGACATCCCGCCATATACGAAAAACATCATC

TTTGTGGAGACCTCGTTCACCACATTGGAAACCAGAGCTTTTGGCAGTAAC

CCCAACTTGACCAAGGTGGTCTTCCTCAACACTCAGCTCTGCCAGTTTAGG

CCGGATGCCTTTGGGGGGCTGCCCAGGCTGGAGGACCTGGAGGTCACAGG

CAGTAGCTTCTTGAACCTCAGCACCAACATCTTCTCCAACCTGACCTCGCT

GGGCAAGCTCACCCTCAACTTCAACATGCTGGAGGCTCTGCCCGAGGGTC

TTTTCCAGCACCTGGCTGCCCTGGAGTCCCTCCACCTGCAGGGGAACCAGC

TCCAGGCCCTGCCCAGGAGGCTCTTCCAGCCTCTGACCCATCTGAAGACA

CTCAACCTGGCCCAGAACCTCCTGGCCCAGCTCCCGGAGGAGCTGTTCCA

CCCACTCACCAGCCTGCAGACCCTGAAGCTGAGCAACAACGCGCTCTCTG

GTCTCCCCCAGGGTGTGTTTGGCAAACTGGGCAGCCTGCAGGAGCTCTTCC

TGGACAGCAACAACATCTCGGAGCTGCCCCCTCAGGTGTTCTCCCAGCTCT

TCTGCCTAGAGAGGCTGTGGCTGCAACGCAACGCCATCACGCACCTGCCG

CTCTCCATCTTTGCCTCCCTGGGTAATCTGACCTTTCTGAGCTTGCAGTGG

AACATGCTTCGGGTCCTGCCTGCCGGCCTCTTTGCCCACACCCCATGCCTG

GTTGGCCTGTCTCTGACCCATAACCAGCTGGAGACTGTCGCTGAGGGCAC

CTTTGCCCACCTGTCCAACCTGCGTTCCCTCATGCTCTCATACAATGCCATT

ACCCACCTCCCAGCTGGCATCTTCAGAGACCTGGAGGAGTTGGTCAAACT

CTACCTGGGCAGCAACAACCTTACGGCGCTGCACCCAGCCCTCTTCCAGA

ACCTGTCCAAGCTGGAGCTGCTCAGCCTCTCCAAGAACCAGCTGACCACA

CTTCCGGAGGGCATCTTCGACACCAACTACAACCTGTTCAACCTGGCCCTG

CACGGTAACCCCTGGCAGTGCGACTGCCACCTGGCCTACCTCTTCAACTGG

CTGCAGCAGTACACCGATCGGCTCCTGAACATCCAGACCTACTGCGCTGG

CCCTGCCTACCTCAAAGGCCAGGTGGTGCCCGCCTTGAATGAGAAGCAGC

TGGTGTGTCCCGTCACCCGGGACCACTTGGGCTTCCAGGTCACGTGGCCG

GACGAAAGCAAGGCAGGGGGCAGCTGGGATCTGGCTGTGCAGGAAAGGG

CAGCCCGGAGCCAGTGCACCTACAGCAACCCCGAGGGCACCGTGGTGCTC

GCCTGTGACCAGGCCCAGTGTCGCTGGCTGAACGTCCAGCTCTCTCCTTGG 145138.doc •73· 201015069

CAGGGCTCCCTGGGACTGCAGTACAATGCTAGTCAGGAGTGGGACCTGAG

GTCGAGCTGCGGTTCTCTGCGGCTCACCGTGTCTATCGAGGCTCGGGCAGC

AGGGCCCTAGTAGCAGCGCATACAGGAGCTGGGGAAGGGGGCTTTGGGG

CCTGCCCACGCGACAGGTAGGGGCGGAGGGGAGCTGAGTCTCCGAAGCTT GGCTTT Sequence No. 106 Hyaluronic Acid and Proteoglycan Linker Protein 4 >gi丨30794471丨ref丨NM_023002.1丨 Human Hyaluronic Acid and Protein

Polysaccharide-linked protein 4 (HAPLN4), mRNA

CGGGGGCCGCGCGGGCAAGATGGTGTGCGCTCGGGCGGCCCTCGG

TCCCGGCGCGCTCTGGGCCGCGGCCTGGGGCGTCCTGCTGCTCACAGCCC

CTGCGGGGGCGCAGCGTGGCCGGAAGAAGGTCGTGCACGTGCTGGAGGG

TGAGTCGGGCTCGGTAGTGGTACAGACAGCGCCTGGGCAGGTGGTAAGCC

ACCGTGGTGGCACCATCGTCTTGCCCTGCCGCTACCACTATGAGGCAGCC

GCCCACGGTCACGACGGCGTCCGGCTCAAGTGGACAAAGGTGGTGGACCC

GCTGGCCTTCACCGACGTCTTCGTGGCACTAGGCCCCCAGCACCGGGCATT

CGGCAGCTACCGTGGGCGGGCTGAGCTGCAGGGCGACGGGCCTGGGGAT

GCCTCCCTGGTCCTCCGCAACGTCACGCTGCAAGACTACGGGCGCTATGA

GTGCGAAGTCACCAATGAGCTGGAAGATGACGCTGGCATGGTCAAGCTGG

ACCTGGAAGGCGTGGTCTTTCCCTACCACCCCCGTGGAGGCCGATACAAG

CTGACCTTCGCGGAGGCGCAGCGCGCGTGCGCCGAGCAGGACGGCATCCT

GGCATCTGCAGAACAGCTGCACGCGGCCTGGCGCGACGGCCTGGACTGGT

GCAACGCGGGCTGGTTGCGCGACGGCTCAGTGCAATACCCCGTGAACCGG

CCCCGGGAGCCCTGCGGCGGCCTGGGGGGGACCGGGAGTGCAGGGGGCG

GCGGTGATGCCAACGGGGGCCTGCGCAACTACGGGTATCGCCATAACGCC

GAGGAACGCTACGACGCCTTCTGCTTCACGTCCAACCTGCCGGGGCGCGT

GTTCTTCCTGAAGCCGCTGCGACCTGTACCCTTCTCCGGAGCTGCGCGCGC

GTGTGCTGCGCGTGGCGCGGCCGTGGCCAAGGTGGGGCAGCTGTTCGCCG

CGTGGAAGCTGCAGCTGCTAGACCGCTGCACCGCGGGTTGGCTGGCCGAT

GGCAGTGCGCGCTACCCCATCGTGAACCCGCGAGCGCGCTGCGGAGGCCG

CAGGCCTGGTGTGCGCAGCCTCGGCTTCCCGGACGCCACCCGACGGCTCT

TCGGCGTCTACTGCTACCGCGCTCCAGGAGCACCGGACCCGGCACCTGGC

GGCTGGGGCTGGGGCTGGGCGGGCGGCGGCGGCTGGGCAGGGGGCGCGC

GCGATCCTGCTGCCTGGACCCCTCTGCACGTCTAGGCTGGGAGTAGGCGG

ACAGCCAGGGCGCTTGACCACTGGTCTAGAGCCCTGTGGTCCCCTGGAGC

CTGGCCACGCCCTTGAAGCCCTGGACACTGGCCACATTCCCTGTGGTCCCT

TACAAACTAACTGTGCCCCTGGGGTCCCTGAAGACTGGCTAGTCCTGGCA

GAACAGTACTTTGGAGTTCCCTGGAGCCTGGCCAGCCCTCACCTCTTCTGG

ATAGAGGATTCCCCCAACTCCCCAACTTTCTCCATGAGGGTCACGCCCCCT

GAGGACCTCAGGAGGCCAGCAGAACCCGCAGGCTCCTGAAGACTGGCCA

CGCCTCCTGAGACCACTTGGAAACAGACCAACTGCCCCCGTGGTCGCCTG

GTGGCTGGACCCCCGGGATTGACTAGAGACCGGCCGTACACCTTCTGCAT

CTCACTGGAGACTGAACACTAGTCCCTTGCGGTCACGTGGGACACTGGGC

GCCTCCTCCTCCCCCTCCTCCTCACCTGGAGAGACTACAGGAACTTCAGGG

TCACTCCCCGTGGTCACATGGAGGTTGTGGGCCGAGGCGCTTATTTTCCCT

TATGGTGACCTGAGTCCTGGAGACTCCCATTCTCCCCCTCTCCCTGAGAGT

CCCCTGCAGTTTCTGGGTAACAGGGCACACCCCTCTAGTTTCATGGGCGAG

CACCCCCATCTGCCACCTCAGACTGACACACAGCCAGCTGGCTCACTTACT 145138.doc •74- 201015069

GGGGGCCACGTCCCACCCCTCAGATATTTCTTTGAAGGGAGAGCAAACCC ACCCTGTCCTCTGACGTCCCTTTCCCAACTGTCACCAAACAGACCATCTTC CCAGGCCTGGGGACCGGTAAGATCCATGTCACTAGTTATGCAGAGCAGTT GCCTTGGGTCCCACTGTCACCAAGGCAACCAGTCCTGCTGCTACCTGTCAC CTAGAGTCACACACCCCTTCCCTCATCAGGCACACCCATGAAGACAGTGC CTCCCTCCTCCAGCTGTAACCATGGATACCACACATTTCTCATCTCATTGG CCCCCACCCCAGAGACCTCCACCTCAACTTCTGGCTGTCCCTACCCTGACT CACCGCCATGGAGATCACCCTCCCCGAAGCTGTCGCCAGGGTGACCCAAC ATCCAGTTCTCCGGCTCTCACCATGGAAACAAACTGTCCCTGTCCCCAGGC CCACTCCAGTTCCAGACCACCCTCCATGCTCCACCCCCAGGCGGTTTGGAC CCCACCACTGTTGCCATGGTGACCAAACTCTGGAGTCCGAGGTAACAGAA CACCTGTCCCCCTAGGCTTTTCCTTGTGGACAACGGGGCCCTGTTCACCAA GCTGTTGCCATAGAGACTGTCAACGTTGTCCTCATGACAACCAGACTTCCA GTTCTCAGGAACTTCTCATTGTGGGCCAGAAGTCCTGGGTGCCTCCTACTA GGGCTACCCTACTGCACCCCATCAGGGGCCTGATGGCTGCCCCTTCCCCAG ACAGGGCTGGACTTCTGGAGCTGCTAAGCCACCCTCCGTTTGCACGTTAAC TCTATGCCGGATAGCAGCTGTGCACGAGACAATCTTGCAACACCCGGGCA TGTTTGTCGTCGTCCTACAAATGAGGAAACCGAGCCTATGGCGTGCCCTG GTCTGTTGAGATATGCAAGCACTGAGCTCCTCTTTTGTCCTCTGAGACCCC ATCTCCATTCTCACCCAGT TCCTCTCTCCTTCCCTGACCCCCACCCACATTT CCCTCCTTAGAGATCCAGGAGGGATGGAATGTTCTTTAAAATTCAACACC CACCAGGCTCTAAGCGGCGATCTGTGCTAAGAGGTCAGGACCCAGCCGAA GTCCTCGGCGTTGACAGGCAGCTGGGGGGACATGATCCATGGACAAGGCC ATCCCGGCCGTGGGAGACCCCAGTCCCGAAGTCTTGCCTGCAGGAGTACT GGGGTCCCCCTGGGGCCCTCTTTACTGTCACGTCATCTCTAGGAAACCTAT CTCTGAGTTTTGGGACCAGGTCGGTTTGGGTTTGAATTCTGCCTCTTCTTGC TCACTGTGTGACCAAGTGACAAACTCCTTCTGAACCTGTGTTCTCeCACTG TACCAGGGCTGTTCTGTGGTCCCCGTGAGTGCCAAGCATACAGTAGGGGC TCAATAAATCCTTGT bad ij Sequence No. 107 immunohistochemical tissue blocks were cut from 8 uM frozen sections, and placed on APES slide. The tissue was fixed in acetone for 10 minutes before air drying. The slides were then immersed in 0.3% hydrogen peroxide in methanol for 10 minutes and rinsed with phosphate-buffered saline (PBS). The non-specific binding sites were blocked by culturing the slides in 20% serum from appropriate animals and flushing again with PBS. Primary antibodies diluted in PBS containing 1% serum were then added to the slides. After 1 hour of incubation, the slides were again washed with PBS and then incubated with secondary antibodies for 1 hour. After rinsing with PBS, the secondary 145138.doc •75- 201015069 antibody was detected using diaminobenzidine tetrahydrochloride dissolved in Tris buffered saline (TBS), followed by TBS and water. The slides were then stained with hematoxylin and counted under a light microscope. In certain embodiments, staining based on the cancer marker of the present invention can be used to localize gastric tumors in situ. At least one marker can be shaped into an amyloid structure that can be colored using Congo red or an equivalent non-specific powder-like protein. Testing Gastric Cancer Markers in Liquid I In several specific embodiments, it may be desirable to obtain samples from blood, plasma, serum, peritoneal fluid obtained using, for example, peritoneal washing, or other body fluids, such as urine. , lymph, cerebrospinal fluid, gastric fluid, or stool samples for GTM determination. Methods for the determination of oligonucleotides, proteins, and peptides in fluids are generally known in the art. Nucleotide detection can be performed using hybridization methods such as Northern blotting, Southern dot method, or microarray or qPCR. Methods for detecting proteins include, for example, enzyme-linked immunosorbent assay (ELISA), antibody-containing protein wafers, suspension bead radioimmunoassay (RIA), Western blotting, and lectin binding. However, to understand the release, a sandwich-type enzyme-linked immunosorbent assay (eusa) can be used to quantify the fluid content of the GTM. For plasma assays, a 5 microliter aliquot of a suitably diluted sample or serially diluted standard GTM was added to a well of a microtiter plate with 75 microliters of peroxidase-conjugated anti-human GTM antibody. After incubation for 30 minutes at 3 ° C, the wells were rinsed with 〇〇 5% in Tween 2 in phosphate buffered saline (PBS) to remove unbound antibody. The binding complex of GTM and anti-GTM antibody was then incubated with o-phenylenediamine containing 145138.doc •76·201015069 H2〇2 for 15 minutes at 30 °C. The reaction was stopped by the addition of 1 M H2S04, and the absorbance at 492 nm was measured using a microtiter plate reader. It is understood that the anti-GTM antibody may be a monoclonal antibody or a plurality of antiserum. It is also known that any other body fluids can be properly studied. Certain markers that appear in the blood or serum are known. These include osteogenic proteins (Hotte et al, Cancer 95(3): 507-510 (2002)), pro-knee-specific antigens (Martin et al, Prostate Cancer Prostatic Dis. (March 9, 2004) (public) Case No. PMID: 15007379), Thyroglobulin (Hall et al., Laryngoscope 113(1): 77-81 (2003); Mazzaferri et al., J. Clin. Endocrinol. Metab. 88(4): 1433-14421 (2003) )), matrix metalloproteinases-2 and -9 (Kuo et al, Clin. Chem. Acta. 294(1-2): 157-168 (2000)), CEA and TIMPl (Pellegrini et al, Cancer Immunol. Immunother. 49(7): 3.88-394(2000)). Therefore, because some of the above markers are also useful GTM markers, plasma, serum or other fluids can already be assayed for their detection and quantification because of many proteins. It is (1) secreted by cells, (2) detached from the cell membrane, or (3) lost from the cells when the cells die, so other GTMs may also be present in body fluids such as plasma, serum, and the like. In a particular embodiment of the invention, it will be useful and desirable to detect GTM in a conveniently obtained sample and may be a diagnosis The basis of gastric cancer. Western analysis uses TriReagent and 胍HC1 extraction to extract proteins from gastric tissue. The non-liquid phase extracted from RNA TriReagent is mixed with 1.5 volumes of 145138.doc -77- 201015069 ethanol, and The DNA and OCT media were removed by centrifugation. Mix 0.5 ml of the supernatant with 0.75 ml of isopropanol' at room temperature for a few minutes, then centrifuge. Rinse the pellet with 1 ml of 0.3 M in 95% ethanol. 3 times, rinsed once with ethanol alone' and then resuspended in 5 μl of microliters of 1% SDS. Proteins were quantified and electrophoresed on SDS polyacrylamide gel using standard methods. Briefly, using standard methodology, The cells were transferred using BioRad&-dot electrophoresis, and the separated proteins were transferred to a PVDF membrane. The membrane was then blocked with a solution containing skim milk powder for 30 minutes, followed by incubation with primary anti-caries for 2 hours at room temperature. After washing, the membrane was incubated with the secondary antibody for 1 hour at room temperature. After the final rinse, the bound antibody was developed using an ECL detection system (Amersham Biosciences). Providing a sample of serum known method, and then the serum sample was then knife qe analysis, using a direct nucleotide probes or antibody raised against the protein of interest, marker detection is accomplished in the serum. The immune dot method, including Western blot analysis, may be particularly useful for determining whether a protein that is otherwise expressed is present in serum. In addition, other Zhao liquids may also contain markers, and include peritoneal fluid, cerebrospinal fluid, and the like. It is not necessary to be useful for the secreted marker 'in physiological sense'. Rather, any mechanism by which a marker protein or gene enters the serum may be effective in producing a detectable, detectable amount of marker. Therefore, it can be: I. The normal secretion of the raw protein from the cell, the secretion of the membrane protein from the serosa, or the secretion of the alternative form of the protein expressed therein, and the death of the cell (cell 祠 zero) can produce sufficient Useful markers. 145138.doc •78· 201015069 There is increasing support for the use of Qiqing markers as a tool for diagnosing and/or assessing the efficacy of treatment for various cancer types.

Yoshikawa et al. (Cancer Letters, 151:81-86 (2000)) describe tissue inhibitors of matrix metalloproteinase-1 in blood pooling in patients with gastric cancer.

Rudland et al. (Cancer Research 62: 3417-3427 (2002)) describe osteogenic proteins as proteins involved in metastasis in human breast cancer.

Buckhaults et al. (Cancer Research 61: 6996-7001 (2002)) describe certain secretory and cell surface genes that are expressed in colorectal tumors.

Kim et al. (JAMA 287(13): 1671 · 1679 (2002)) describe osteogenic proteins as potential diagnostic biomarkers for ovarian cancer.

Hotte et al. (AJ. American Cancer Society 95(3): 507-512 (2002)) describe plasma osteogenic proteins as proteins detectable in human body fluids and are associated with certain malignancies.

Martin et al. (Prostate Cancer Prostatic Dis. March 9, 9 (PMID: 15007379) (abstract)) describes the use of human kallikrein 2, prostate-specific antigen (PSA) and free PSA for prostate cancer detection. Marker.

Hall et al. (Laryngoscope 113(1): 77-81 (2003) (PMID: 12679418) (abstract)) describes the predictive value of serum thyroglobulin in squamous cell carcinoma.

Mazzaferri et al. (J. Clin. Endocrinol. Metab. 88(4):1433- 1441 (2003) (abstract)) describe thyroglobulin as a possible monitoring method for patients with thyroid cancer.

Whitley et al. (Clin. Lab. Med. 24(1): 29-47 (2004) (abstract)) 145138.doc -79-201015069 describes scorpion globulin as a serum marker for thyroid cancer.

Kuo et al. (Clin Chim. Acta 294(1-2): 157-168 (2000) (summary)) describe serum matrix metalloproteinases-2 and -9 in patients infected with HCF and HBV.

Koopman et al. (Cancer Epidemiol. Biomarkers Prev 13(3): 4 8 7-491 (2004) (abstract)) describe osteogenic proteins as biomarkers for pancreatic cancer.

Pellegrini et al. (Cancer Immunol. Immunother. 49(7): 3 88-394 (2000) (abstract)) describe the measurement of soluble carcinoembryonic antigen and TIMP1 as markers for in situ colorectal cancer. Therefore, we have identified a number of genes and/or proteins that can be used to develop reagents, devices and kits for the detection and assessment of gastric cancer. One or more stomach markers can be used alone or in combination to provide a reliable molecular test for gastric cancer. EXAMPLES The examples described herein are merely illustrative of specific embodiments of the invention. Other embodiments, methods, and types of assays are within the skill of those skilled in the art of molecular diagnostics and need not be described in detail herein. Other specific embodiments within the skill of the art are considered as part of the present invention. Example 1: Confirmation of malignant sputum of the stomach Fig. 2 shows a table showing the results of a study using 38 kinds of gastric malignant markers selected by the above criteria. Figure 2 includes the gene's symbol ("symbol"), MWG recruitment number, NCBI mRNA reference sequence number, protein reference sequence number, fold change between tumor and non-tumor gene expression, relative to other in microarray analysis. The fold change level of the gene, the original Student's t-test result adjusted without 145138.doc -80 - 201015069, the Bonferroni-adjusted p-value of the bee fruit', and the result of the 2-sample Wilcoxon test. The median fold change (tumor: non-malignant tissue) ranged from 1.6 to 7, and the intermediate variation in the fold change range ranged from _16,995 to -25,783. The largest possible change in the fold change level was _29,718. For the markers shown, the statistical significance of their specificity as cancer markers is extremely high. Bonferroni-adjusted p-values, usually below 10.6 or lower, indicate the use of these markers. The diagnosis is highly correlated with gastric cancer. The three cysteinyl protease inhibitors (CST1, CST2 and CST4) are highly homologous and, unless otherwise stated, the same recruitment on the array Nucleic acid is expressed and collectively referred to as "CST1,2,4" Using SMART Suite Software (European Molecular Biology Laboratory (Eur〇pean)

Molecular Biology Laboratory))' predicts that all of the proteins described in Figure 2 have signal peptides. It is known that the signal skin is such that the synthetic protein is quasi-fine φ extracellular compartment and thus can be secreted into the interstitial fluid from which it can approach the blood. In fact, some of the proteins of the invention have been detected in serum. Each of the genes depicted in Figure 2 showed more than two oligo-acid changes in intensity levels on an array consistent with CEA, which is the most commonly used marker for monitoring clinical implementation of gastric cancer. Things. Example 2: qPCR analysis Using qPCR, a subset of the genes presented in Figure 3 was obtained, and a more sensitive and accurate quantification of the gene expression was obtained. For the 23 I45138.doc -81-201015069 genes (Fig. 2) confirmed by microarray analysis, analysis was obtained from 46 tumors and 49 non-malignant samples, and no results were obtained in Fig. 3. Figure 3 includes gene symbols, intermediate fold changes between cancer and normal tissues, and % tumor samples showing a degree of expression that exceeds 95% of the performance in non-malignant samples. Twelve tumor samples and nine normal samples were excluded from the analysis because of high (>75%) normal cell contamination, high degree of necrosis (>40%), or poor hybridization signals on the microarray. The intermediate fold change of these 23 genes (tumor tissue compared with the performance of intermediate non-malignant tissue) 'range from 3 to 525 times (Figure 3) Genes ASPN, CST1, 2, 4, LOXL2, TIMP1, SPP1, SFRP4, INHBA The extent of performance of THBS2 and SPARC, with a case of ^9〇0/〇, was greater in lumen tumors than 95% of the non-malignant range (Figure 3). As for the remaining genes, in the >50% of the samples, the performance in the tumor was greater than 95%. Each tumor overexpresses at least 7 genes over 95%, indicating that the combination of markers will guide a wide range of all gastric tumors. Poor Example 3: Confirmation of Array Data Using qPCR Array data was confirmed using quantitative, real-time PCR (qPCR) using probes of 24 genes on face tumors and non-malignant samples. Of the 24 genes studied, 20 showed a strong correlation between the two technologies. Four of these analytes are shown in Figures 4a-4d, which depict a graph of the relative performance of four selected cancer markers using array and qPCR methods. Regarding each of the graphs in Fig. 4, the horizontal axis represents the array log2 fold change in gene expression, and the vertical axis represents the qpCR l〇g2 fold change in gene expression. We found a strong correlation between the two methods to represent the covariant relationship between the two methods. Strong correlation generation 145138.doc -82- 201015069 Table microarray fold change analysis and qPCR are appropriate methods for detecting changes in the expression of gastric cancer marker genes and can therefore be used as accurate and sensitive screening methods. It can also be seen from Figures 4a-4d that qPCR can be more sensitive than array methods in detecting changes in performance. Therefore, qPCR may be particularly useful where it is particularly desirable to have an early detection. Figures 5a-5w depict a comparison of the frequency of each of a series of 23 genes (vertical axis) and the log-fold change in the gene expression (horizontal axis), including normal tissue (open columns) and tumor tissue. (Black column p We were surprised to find that each of these 23 genes, between normal and tumor tissue, is fairly separated in frequency distribution, reflecting a low degree of overlap between the frequency distribution curves. For example, Figure 5b The results of CST 124 are described, where only one normal sample is observed to have a degree of performance in the tumor range. In other cases (eg, Figure 5n; for PRS11), each frequency profile is relatively narrower' And there is some degree of overlap. However, even with this marker, the intermediate log2 fold change still shows that the magnitude of the gene expression is φ when separated. In other cases (eg Figure 5a; ASPN), although there is some overlap, Between the normal and tumor samples, the 1 〇g2 multiple of the performance is still clearly separated. Figure 6 shows that compared with the normal sample, it shows a significant increase in tumor samples (&q Uot; the number of genes that overexpressed ") (vertical axis), and the histogram of the individual styles tested. In each case, the tumor samples showed an increased degree of performance of multiple genes. The minimum number of genes that are expressed is 7 'found in sample El23. These findings indicate that in the case where multiple genes are overexpressed relative to normal tissue, the reliability of cancer detection may be 145138.doc -83 - 201015069 may be Extremely high, the diagnosis of cancer is made clearer. However, in some cases, the performance of a single marker gene is elevated enough to guide the diagnosis of cancer. We have previously and currently used to detect serum markers of gastric cancer, The CEA comparison is based on the difference in intensity levels of the array data between the tumor and the normal sample. This comparison was confirmed using qPCR data from the marker and CEA. Figures 7a-7c depict the expression of the gene with the tumor marker CEA In contrast, in individual tumor samples and non-malignant samples, the relative log2 of the markers (compared to the preparation of reference RNA). CEA is currently the most commonly used to monitor the stomach. Serum markers for cancer progression. Point 0 is defined as the intermediate standard performance of each marker. It can be seen that there is a large overlap between the performance of the CEA gene (CEACAM5) in the tumor sample and the normal sample. The overlap is significantly less than in the gastric cancer markers ASPN, CSPG2, CST1, 2, 4, IGFBP7, INHBA, LOXL2, LUM, SFRP4, SPARC, SPP1, THBS2, TIMP1, Adelicon, LEPRE1 and EFEMP2. The other markers in Figures 7b-7c, ASAH1, SFRP2, GGH, MMP12, KLK10, TG, PRSS11, and TGFBI, overlap between tumor expression range and non-malignant tissue performance range, and are more overlapping than the above markers However, still less than CEA, it is pointed out that all of the novel markers described herein are quantitatively superior to CEA and thus provide a more reliable diagnosis. To minimize the effects of variable tissue manipulation, use qPCR data from tumors and non-malignant tissue samples derived from the same patient to calculate swelling I45138.doc -84- 201015069 Tumor: normal (non-malignant) The fold changes. This type of pairwise analysis corrects the difference in background levels of gene expression in different individuals and minimizes the impact of tissue manipulation on RNA quality. For example, if the excised stomach is at room temperature for 1 hour, the transcripts from normal and tumor samples will degrade to the same extent. Figure 8 summarizes the extent to which markers are determined by qPCR, but uses paired data from the same individuals (i.e., tumors and non-malignant samples). Figure 8 also includes performance data for the six genes not included in Figure 3. Additional genes for study were ΜΜΡ2, CGR11, TGFB1, PCSK5, SERPINB5 and SERPINH1. The confirmed information and probes are shown in Figures 1 and 2. Figure 8 shows the median sputum of 29 gastric cancer markers in these 40 patients with "paired" samples: Ν fold change and maximum τ··Ν fold change. Twenty-seven of the 29 markers have a marker greater than or equal to the prior art, CEA's intermediate Τ: Ν difference. The 29/29 marker has a higher percentage of paired samples in which the performance in the tumor sample exceeds the performance in the normal sample. Figures 9a-9d depict dot plots of data from tumors and normal tissues from the same individual. Each point represents a fold-change in the performance of the marker in the tumor tissue relative to the performance in the non-malignant tissue. All of the markers for the study had better resolution of tumor and non-tumor tissue than CEA. Three markers, CST1, 2, 4, ASPN and SFRP4, were shown between the paired tumor and the normal sample. Out of 1 〇〇% resolution. That is, for each of the markers, each tumor tissue has a greater performance than the corresponding non-tumor sample from the same individual. Among many other markers, such as Adelikon, CSPG2, EFEMP2, IGFBP7, INHBA, 145138.doc -85 - 201015069 LOXL2, LUM, SERPINHl, SPARC, SPP1, TGFbl, THBS2 and TIMP1, all only in 2 or 3 individual cases} Tumor tissue performance is lower than non-tumor tissue. Therefore, for those markers, the probability of any pair of tumors and non-tumor tissue will produce false negatives is relatively low (eg 3 of 40 ' or 7.5%; 2 of 40) Or 5%, one of 40, or 2.5%). Therefore, even with the other markers listed immediately above, the use of multiple samples from individual patients will yield reliable diagnostic information. The gene sequences of these markers are shown above, as well as the positions of the primers and probes used to detect them. To determine if the overexpression of the marker gene is not related to the stage of the gastric tumor, a pairwise change in the T:N log2 fold is plotted against the tumor stage (Fig. l〇a-10ad). For the 26 markers listed in Figure 8, it was observed that there was no phase dependence on the tumor stage. These markers are overexpressed in a similar manner in early and late stages of the tumor. However, 'KLK10 showed a more consistent overexpression in the tumors of stage 1 and stage 2' while PCSK5 and SERPINB5 showed a more consistent overexpression in stage 4 tumors. Therefore, KLK10, PCSK5, and SERPINB5 can be used to determine the stage of gastric tumors. In a similar assay, pairs of T:N log2 fold changes were plotted against the Lauren classification (diffuse or intestinal fistula) of the tumor. Figures 11a-llad show that regardless of whether the tumor type is enteric (I) or diffuse (D), 29 GTMs can distinguish between tumor and non-tumor tissue. Example 4: Use of Multiple Markers 145138.doc -86 - 201015069 As indicated above, certain markers showed the ability to distinguish between tumors and non-tumor tissue in 100% of the samples. Other markers, also described above, can be used in combination to achieve a very high degree of discrimination between tumors and non-tumor tissue. Figure 12 depicts a 3-dimensional plot of the performance of the three markers serpinhI, CST1, 2, 4 and INHBA, expressed as a log2 T:N fold change for a series of gastric tumor samples and non-malignant stomach samples. There is complete separation between the two sets of samples. The reliability of the tumor and non-tumor samples was continuously resolved using the marker combination by the statistical analysis outlined in Figure 13. This analysis compares the standard distribution of data generated using qPCR gene expression from paired tumors and non-malignant samples to show increased sensitivity to test for identifying tumor and non-malignant samples (with 95% The impact of fixed specificity). Although there are a few of the 29 markers (as shown in Figure 8), when used alone in this assay, there are more than 9 〇, 95 or 99% sensitivities but a combination of two or two markers A large number of combinations can achieve high sensitivity. For example, a combination of 50 three markers will identify tumor and non-tumor samples with a sensitivity of 99% and a specificity of 2 95%. Example 5: Detection of Gastric Cancer Tumor Proteins In a further embodiment, GTM proteins can be tested as a basis for diagnosis. In some cases, the concentration of mRNA in a particular sample, such as a sample without cells, may not be readily detectable by microarray or qPCR. Thus, in certain embodiments, detection of GTM proteins can be accomplished using antibodies directed against whole proteins, protein fragments (peptides) or protein cores. Methods for Detecting and Quantifying Proteins and Peptides 145138.doc -87- 201015069 The present methods are known in the art and can include methods that rely on specific antibodies raised against the protein or peptide. Individual antibodies and multiple antisera can be made using methods well known in the art and need not be further described herein. To demonstrate that GTM proteins can be used to distinguish between tumor and non-tumor tissue, obtain anti-SPARC (R&D Systems; catalogue AF941), THBS2 (Santa Cruz Biotechnology Inc; catalog #sc-7655), CSPG2 (Calbiochem; catalog Commercially available antibodies of No. 428060) and IGFBP7 (R&D Systems; Catalog No. AF1334). An additional polyclonal antibody against the hemoperamic acid protease inhibitor SN peptide sequence 50-66(C) FAISEYNKATKDDYYRR, SEQ ID NO: 108 can be raised in rabbits (Alpha Diagnostic International Inc; San Antonio). These antibodies are used in immunohistochemistry or Western analysis of tumors and non-malignant gastric tissues. These markers all show strong tumors at the protein level: normal differences. This confirms that the overexpression of these genes observed at the RNA level can also occur at the protein level. Figure 14 shows Western blot analysis of total protein extracted from two pairs of tumors and non-malignant tissues using antibodies against proteins encoded by SPARC, CST1 (cysteine protease inhibitor SN), IGFBP7 and THBS2. For each marker, the signal in the tumor sample was significantly higher than in the non-malignant sample. The antibodies raised by the cysteine protease inhibitor SN detected three major bands, which were consistent with molecular weights of approximately 34, 45 and 65 kDa, respectively. The lowest molecular weight band is shown in Figure 14. The protein species is larger than the control cysteine 145138.doc -88 - 201015069 protease inhibitor SN protein, suggesting that the protein is produced by tumors that have undergone post-translational modification or multimerization. Regardless of the mechanism responsible for the difference in the molecular weight of the cst protein, Figure 14 demonstrates that the CST performance is low in non-tumor tissues, but is readily observed on the tumor-derived protein dots. Figure 14 also shows that the SPARC protein is substantially expressed in tumor tissue to a greater extent than non-tumor tissue. The SPARC protein has a slower gel mobility than the protein tannin in the serum-detected form (Figure 15) and also represents a different post-translational modification of the protein card produced by the malignant gastric cells. Regardless of the mechanism responsible for any such modification, SPARC was found to be overexpressed in tumor tissue relative to non-malignant tissue, representing spAR (: is a useful protein marker "similarly, IGFBP7*THBS2 also shows relative to non-malignant Tissue 'overexpresses in tumor tissues. Immunohistochemical analysis of tumors and non-malignant tissues can be performed using antibodies against proteins encoded by CSPG2 (Foxicon) and CST1 (cysteine protease inhibitor SN). Immunohistochemical analysis of tissues against antibodies against Fuchsil confirms strong staining in tumor tissues, but not in extracellular matrices of non-malignant tissues. Anti-cysteine protease inhibitor SN antibody, in tumor cells Strong staining was observed around the lateral side. In non-malignant cells, staining with this antibody was weakened and observed only on the mucosal surface of the tissue and the lining of the gastric pit. This confirmed that in non-malignant cells, the command The cysteine protease inhibitor 8]^ protein goes to the extracellular mucosal surface without entering the extracellular space. Therefore, not only in the tumor group In the woven medium, the cysteine protease inhibitor 145138.doc -89· 201015069 SN protein is produced in a higher amount than the non-malignant tissue, and unlike the protein produced by non-malignant tissue, the cysteine protease inhibition of the tumor Agent SN is in direct contact with the tissue vasculature. To extend these observations, use a monoclonal antibody (R&D Systems; catalogue MAB1285) to introduce a cysteine protease inhibitor from the supernatant of the gastric cancer cell line AGS. SN immunoprecipitation (Fig. 16). A large amount of cysteine protease inhibitor SN was detected in the supernatant, which was confirmed to be produced by gastric epithelial cells and secreted from the protein. Example 6: Analysis of tumor markers in jk clear As for the marker that can be used for selective screening, it is desirable that the marker be present in the serum in an amount sufficient to detect. Certain proteins described in Figure 8 can be secreted from the gastric cancer into the blood to a detectable extent. A marker known to be secreted from the stomach tumor into the blood to a detectable extent is TIMP 1. However, if a protein is secreted or detached from any cell surface other than the mucosal surface' It will come into contact with the interstitial fluid, where it may enter the blood supply directly via the capillaries or via the lymphatic system. Therefore, any GTM that is shed will be present in the blood. Osteoblasts, thyroglobulin have been previously described. 'and members of the MMP and kallikrein family' are elevated in the serum of patients with epithelial cancer rather than gastric cancer. However, TIMP1 has previously been observed to increase in the serum of patients with gastric cancer. These findings suggest that in this study The selection criterion, that is, the excessive expression of secreted proteins in tumor tissues but not non-malignant tissues, can be effectively used to detect markers in serum, and thus may have substantial clinical use 'no tissue or organ required Health check. It is apparent from Figure 15 that serum SPARC has a different molecular weight (described herein in 145138.doc-90.201015069 Western blot method), wherein tumor SPARC has a lower molecular weight than SPARC produced by blood cells. Therefore, even if SPARC is produced by tumor and non-tumor blood cells, the presence of tumor SPARC can be determined using a molecular size determined by Western analysis or using an antibody specific for glycosylated proteins produced by tumor cells. In other studies, we tested the cysteine protease inhibitor SN in the supernatant of the gastric cancer cell line AGS. Figure 16 depicts a Western analysis of supernatants from medium alone or from φ self-cultivating AGS cells. The band run on the right side of Figure 16 shows a dense band consistent with the cysteine protease inhibitor SN. Therefore, we conclude from Figure 10 that the GTM of the present invention is suitable for diagnosing gastric cancer in the early, middle or late stages of the disease. Although certain marker proteins can be glycosylated, in some cases, changes in glycosylation patterns can lead to errors in the form of GTMs that lack the usual glycosylation pattern. Thus, in certain embodiments of the invention the GTM immunogen may comprise a deglycosylated GTM or a deglycosylated ❹ GTM fragment. Deglycosylation can be accomplished using one or more glycosylases known in the art. Alternatively, a GTM cDNA, such as a prokaryotic cell strain, including Escherichia coli, can be expressed in a glycosylation-deficient cell strain, thereby producing a glycosylated protein or peptide. It is also known that the degree and quality of glycosylation may be sensitive to the presence of the necessary precursors of the sugar side chains. Therefore, in the absence of the necessary sugar, "normal" glycosylation may not occur, but short or inverted side chain sugars may be formed. Such glycosylation variants can be used as immunogens to generate antibodies of different types to the marker genes. 145138.doc -91- 201015069 In addition, certain GTMs can form homo- or heterodimers, or other types of multimeric forms. For example, statin 0 is a 47 kDa protein that forms a 97 kDa molecular weight homodimer (activin A) and a 92 kDa heterodimer with a 45 kDa protein inhibitor yang (the heterologous The dimer is called activin AB). Thus, Western analysis or other types of assays can be understood that provide molecular weight that is not necessarily limited to detecting the monomeric form of the GTM. Rather, it is quick to know that any form of GTM can be detected, regardless of molecular weight. Therefore, the detection of GTM in a multimeric form can be easily used to diagnose the presence of gastric cancer. In addition, for those gtm that are selective for the stage (1-4) or type (diffuse or intestinal) of gastric tumors. In other words, detection of a multimeric form can provide an appropriate standard for assessing the stage or type of gastric cancer. Once antibody or antiserum against GTM is produced, such antibody preparations can be used in a variety of ways. First, the GTM protein or peptide can be quantified using an enzyme-linked immunosorbent assay (ELISA) or a radioimmunoassay (RiA) method. Immunohistochemistry can be performed in tissues using immunohistochemistry. These methods are all known in the art 'and need not be further described herein. Example 7: Loads containing GTM-raised nucleotides *1 Other specific embodiments of the invention include fragments that can be used in vitro to express a marker gene or a protein thereof ("a marker peptide") or a marker gene product Carrier. For example, a vector having an oligonucleotide encoding a GTMs can be produced. Many of these carriers are based on standard carriers known in the art. The invention also encompasses vectors which can be used to transfer a variety of cell lines to produce a GTM-producing cell line which can be used to produce a desired amount of gtMs for the development of specific antibodies or other reagents for detecting GTMs, or for use in standard 145138.doc. • 92· 201015069 The determination of the development of GTMs. It will be appreciated that such vectors are constructed by inserting into the vector an oligonucleotide comprising a complete open-reading framework encoding a portion of the white matter to be expressed or a portion of such an open-editing construct comprising a promoter gene region, Or a plurality of promoter regions, operably linked to the nucleotide sequence, and a start codon, an open coding framework, and a stop codon. Methods of producing a representation carrier are known in the art and need not be repeated herein. It is also understood that one or more selectable markers can be inserted into the expression vector to allow for the selection of a cell line containing the expression vector of interest. In addition, a leader sequence known in the art can be inserted into the framework to direct secretion, internal storage or insertion into the membrane of the protein or protein fragment in the expression cell. Example 8: Transfer of cells infected with GTM containing sputum in additional embodiments, cells that can express GTMs, GTM fragments or peptide markers are provided. Prokaryotic and eukaryotic cells can be used. For example, E. coli (prokaryotic cells) can be used to produce large amounts of GTMs that lack mature glycosylation (if a particular GTM is normally glycosylated). COS cells, 293 cells, and various other eukaryotic cells can be used to produce glycosylated GTMs, or have a suitable fold, and thus a three-dimensional structure of the native form of the GTM protein. Methods of transferring infections of such cells are known in the art and need not be further described herein. Example 9: Kits Based on the findings of the present invention, several types of test kits can be produced. First, a kit with a pre-loaded detection molecule (or "capture reagent") 145138.doc -93- 201015069 device can be manufactured. In a specific embodiment for detecting GTM mRNA, such devices may include a substrate (eg, glass, ruthenium, quartz, metal, etc.) on which a capture reagent is present and can be hybridized to the mRNA to be detected. Glycosylate. In some embodiments, direct detection of mRNA can be accomplished by hybridizing mRNA (labeled with cy3, cy5, radioactive or other markers) to the oligonucleotide on the substrate. In other embodiments, detection of mRNA can be accomplished by first making complementary DNA (cDNA) of the desired mRNA. The labeled cDNA can then be hybridized to the nucleic acid on the substrate and detected. Regardless of the test method used, it is desirable to compare the standard measurements of the GTM performance and performance of the test. For example, standardization of RNA expression can be performed on total cellular DNA, on RNAs that are expressed in composition (e.g., ribosomal RNA), or on other related invariant markers. Antibodies can also be used as capture reagents in kits. In some embodiments, a substrate (e.g., a multi-well plate) can have a dedicated GTM capture reagent attached thereto. In some embodiments, the kit can have a blocking reagent. Blocking agents can be used to reduce non-specific binding. For example, non-specific oligonucleotide binding can be reduced using excess DNA derived from any convenient source that does not contain GTM oligonucleotides, such as salmon sperm DNA. Excessive blocking proteins, such as serum albumin, can be used to reduce non-specific antibody binding. A number of methods are known for detecting oligonucleotides and proteins, and any strategy for specifically detecting GTM-binding molecules can be used and is considered to be within the scope of the invention. In specific embodiments that rely on antibody detection, GTM proteins or peptides can be expressed on a per cell basis, or on a total cell, tissue or fluid protein, fluid volume, tissue mass (weight) based on 145138.doc •94-201015069 . In addition, relatively high levels of serum protein, such as albumin, may be used to indicate that GTM in serum may include capture reagents (eg, probe plant rinse solutions (eg, SSC, others) in addition to the substrate. Salts, buffer solutions, detergents and the like) and detection parts (such as cy3, cy5, radioactive markers and their analogues). The kit may also include instructions for use and packaging. The invention is illustrated by way of example, but it will be appreciated that other embodiments are directed to the use of the disclosed identifiers, without departing from the scope of the invention. Industrial Applicability Method for detecting GTM family members, including the use of microarrays and/or instant Detection of nucleic acids by PCR, detection of proteins f and & 组合 "The compositions and methods can be used to make diagnostic devices and kits, diagnose diseases, evaluate the efficacy of treatment" and produce suitable for measuring GTM family members Reagents for the performance of the sample clock. [Simplified description of the drawings] The present invention will be described with reference to the specific embodiments thereof, and with reference to the drawings, wherein Figure 1 is a table showing the oligonucleotide sequences of the gastric cancer markers and markers of the present invention. Figure 2 is a table showing the results obtained by the microarray method. Figure 3 shows the results obtained by quantitative PCR. 145138.doc •95· 201015069 Figures 4a-4d illustrate the relationship between the log2 multiple results obtained using the microarray and the qPCR method, where the data is concentrated in the intermediate normal state of the four gastric cancer markers. On the non-malignant ("normal") sample, and the black triangle is the tumor sample. Figure 4a: ASPN. Figure 4b: SPP1. Figure 4c: SPARC. Figure 4d: MMP12. Figure 5a-5w shows relative frequency Histogram of log2 fold change data for quantitative PCR studies obtained from various tumor markers. Figure 5a: ASPN; Figure 5b: CST1, 2 &4; Figure 5c: CSPG2; Figure 5d: IGFBP7; Figure 5e: INHBA; 5f: LOXL2; Fig. 5g: LUM; Fig. 5h: SFRP4; Fig. 5i: SPARC; Fig. 5j: SPP1; Fig. 5k: THBS2; Fig. 51: TIMP1; Fig. 5m: Adlican; Fig. 5n: PRS11; Figure 5〇: ASAH1; Figure 5p: SFRP2; Figure 5q: GGH; Figure 5r: MMP12; Figure 5s: KLK10; Figure 5t: LEPRE1; Figure 5u · · TG; Figure 5v: EFEMP2 and Figure 5w: TGFBI. Figure 6 is a histogram showing the number of markers having a higher performance than 95% of the normal performance. The results were based on qPCR data and the results for each tumor sample were shown separately. Figures 7a-7c are graphs showing the relative l〇g2 expression of markers in individual tumor samples and non-malignant samples compared to the gene expression of the tumor marker CEA. CEA is currently the most commonly used serum marker for monitoring gastric cancer. Figure 8 shows a table supplementing Figure 3. Figure 8 summarizes the extent to which candidate tumor markers are determined by qPCR, but using paired data (i.e., tumors from the same individual ("T") and non-tumor ("N") samples, provided T:N ratio. Figure 8 also includes 145138.doc -96- 201015069 including markers other than Figure 3, namely MMP2, CGRll, TGFB1, PCSK5, SERPIMB5, SERPINH1. As for the comparison, the degree of performance of the established serum marker gene CEACAM5 (CEA) was also shown. 27 of the 29 indicators had intermediate T:N differences greater than or equal to CEA. In addition, the 29/29 marker has a higher percentage of paired samples compared to CEA, where performance in tumor samples exceeds performance in normal samples. The three markers, CST1, 2, 44, ASPN and SFRP4, showed a 100% difference between the paired tumor and the normal sample. The gene sequences of these markers, as well as the primer and probe positions to detect them, are presented here. Figures 9a-9d depict individual and intermediate T:N fold change data for 29 gastric cancer markers using paired samples in 40 patients. Figures 10a-10ad illustrate graphical representations of tumor stage and l〇g2 fold changes in the performance of CEA and other GTMs of the invention. Figure l〇a: Adelicon; Figure 10b: ASPN; Figure 10c: CSPG2; Figure 10d: CST1, 2, 4; Figure 10e: EFEMP2; Figure 10f: GGF; Figure 10g: INHBA; Figure 10h: IGFBP7; 10i ·· KLK10 ; Figure 10j : LEPRE1 ; Figure 10k : LUM ; Figure 101 : LOXL2 ; Figure 10m : MMP12 ; Figure 10η : TIMP1 ; Figure 10〇 : ASAH1 ; Figure 10p : SPP1 ; Figure 10q : SFRP2 ; Figure 10r : SFRP4 Figure 10s: SPARC; Figure 10t: PRSS11; Figure 10u: THBS2; Figure 10v: TG; Figure 10w: TGFBI; Figure 10x: CGR11; Figure 10y: SERPINH1; Figure l〇z: MMP2; Figure 10aa: PCSK5; : SERPINB5; Figure l〇ac: TGFB1 and Figure 10ad: CEA (CEACAM5). • 97- 145138.doc 201015069 Figures 11a-llad depict diagrams of tumor type (diffuse (D) or intestinal (I)) and l〇g2 fold changes in the presentation of the 29 GTM and CEA of the present invention.囷11a: Adelicon; Figure lib: ASPN; Figure lie: CSPG2; Figure lid: CST1, 2, 4; Figure lie: EFEMP2; Figure lif: GGH; Figure llg: INHBA; Figure 11h: IGFBP7; KLK10; Figure 11 j: LEPRE1; Figure Ilk: LUM; Figure 111: LOXL2; Figure 11m: MMP12; Figure 11n: TIMP1; Figure 11〇: ASAH1; Figure lip: SPP1; Figure 11q: SFRP2; 11s : SPARC ; Figure lit : PRSS11 ; Figure 11u : THBS2 ; Figure llv : TG ; Figure llw : TGFBI ; Figure llx : CGR11 ; Figure lly : SERPINH1 ; Figure llz : MMP2 ; Figure llaa : PCSK5 ; Figure llab : SERPINB5 ; Llac : TGFB1 and llad : CEA (CEACAM5). Figure 12 depicts a three-dimensional illustration of three markers SERPINH1, CST1, 2, 4 and INHBA in a series of gastric tumor samples and non-malignant stomach samples. Figure 13 depicts a table showing the effect of multiple markers on the ability to accurately discriminate between tumor tissue and non-malignant tissue. This form is derived from the normal distribution derived from the qPCR data. Figure 14 is a western blot of four tumor markers derived from tumor and non-tumor tissue. Figure 15 is a Western blot of the tumor marker SPARC in gastric tumor tissue and in serum. Figure 16 is an immunoblotting depicting a cysteine kinase inhibitor (cystatin) SN in the supernatant of the gastric cell line AGS. 145138.doc • 98 · 201015069 Sequence <110>New Zealand Business Pacific Aegis Technology Co., Ltd.

Guilford, Pairy J.

Holyoake, Andrew J. <120> marker for detecting gastric cancer <130> PEBL-1006WO0 <140><141> 2004-08-13 <150> US 60/487,906 <151>2003 -07-17 <160> 108 <170> Patentln version 3.2 Reference <210> 1 <211> 26 <212> DNA ' <213> Human. <400> 1 aaatacaaaa ggacacattc aaagga 26 <210> 2 <211> 20 <212>DNA <213> Human <400> 2 gccagtggaa tgatgttccc 20

<210> 3 <211> 19 <212> DNA <213>human <400> 3 19 agtcccagcc caacttgga

<210> 4 <211> 17 <212> DNA <213> Human <400> 4 gtggcaatgc cgctgaa 17 <210> 5 145138 - Sequence Listing.doc 201015069 <211> 18 <212> DNA <213> Human <400> 5 caggtcagca agggcacc <210> 6 <211> 24 <212> DNA <213> Human. <400> 6 acaacatgat atgtgctgga ctgg <210> 7 <211> 24 <212> DNA <^3> Human <400> 7 cttgagtaca acgctgacct cttc <210> 8 <211> 24 <212> DNA Human <400> 8 gattcttgtc catagtgcat ctgc <210> 9 &lt ;211> 19 <212> DNA <213> Human <400> 9 aggccagctt ctgcttgga <210> 10 <211> 23 <212> DNA <213> Human <400> 10 gcctctctgc tgatgacata cgt <;210> 11 145138 - Sequence Listing. doc 201015069 <211> 21 <212> DNA <213> Human <400> 11 ccagaccacc ttataccagc g <210> 12 <211> 17 <212> DNA <;213>Human<400> 12 cgcagaacgc ctgcaaa

<210> 13 <211> 18 <212> DNA <213> Human <400> 13 cgctagcagc gacxacct <210> 14 <211> 23 <212> DNA <213> Human <400> 14 tctbxctgt acactggcag ttc <210> 15 <211> 19 <212> DNA <213> Human <400> 15 tcgggaggcc cgttagtaa <210> 16 <211> 23 <212> DNA <213> Human <400> 16 t£gaaggact acacggccta tag <210> 17 145138 - Sequence Listing.doc 201015069 <211> 20 <212> DNA <213> Human <400> 17 gacggttcct cgcagttcaa <210> 18 <211> 16 <212> DNA <213> Human <400> 18 <210> 19 <211> 21 <212> DNA <213> Human <400> 19 tccacgcatt ttccaggata a &lt ;210> 20 <211> 22 <212> DNA <213> Human <40Q> 20 ggtccatgtc atcaccaatg tt <210> 21 <211> 21 <212> DNA <213> Human <400>; twenty one

Aaaaatcttt gccggaaatg c <210> 22 <211> 20 <212> DNA Human <400> 22 ttgatggcat cgctcagatc <210> 23 145138 - Sequence Listing.doc 201015069 <211> 23 <212> DNA Human <;400> 23 tgcttctgcia attctgatat gga <210> 24 <211> 23 <212> DNA <213>Human<400> 24 tcttggcatt ttctacaaca ggg <2I0> 25 φ <211> 24 <212> DNA <213>Human<400> 25 gggaacttcg tagatctgga aaga <210> 26 <211> 25 <212> DNA <213> Human <400> 26 tgacagcaac aactcagtag gaaaa <21Q> 27 ❶ < 211 > 22 <212> DNA <213> Human <400> 27 tcacagctca agtacacctg gg <210> 28 <211> 20 <212> DNA <213> Human <400> 28 gagag£atgc cttggagggt <210> 29 145138 - Sequence Listing. doc 201015069 <211> · 23 <212> DNA <213> Human <400> 29 ccgtgacaca gttctgcna cag <210> 30 <211> 21 <212> DNA <213>Human. <400> 30 ccaatcaatg c Caggaagag a <210> 31 <211> 17 <212> DNA <213> Human <400> 31 ccctgatcgc cgagttg <210> 32 <211> 25 <212> DNA <213> Human <;400> 32 agtgacagca tcaaaactca aattg <210> 33 <211> 20 <212> DNA <213> Human <400> 33 ggacctgtgg aagtatccgc <210> 34 <211> 25 <212> DNA <;213>Human<400> 34 acaggacatc atacatggtt tcaaa <210> 35 145138 - Sequence Listing.doc 201015069 <211> 23 <212> DNA <213> Human <400> 35 ttttgcaggc ttcacatacc ttt <210&gt 36 <211> 18 <212> DNA <213>Human<400> 36 gaaaaagcgg gtggtgca <210> 37 φ <211> 24 <212> DNA <213> Human <400> Aaggagattc cagctgtcac tttc <210> 38 <211> 28 <212> DNA <213>human<400> 38 taggtttggt catagatagg tcctgagt

<210> 39 <211> 22 <212> DNA <213> Human <400> 39 tgtaaaccgc tccacttcac at <210> 40 <211> 25 <212> DNA <213> Human <400> 40 ttctgtcctt cctagtccct ttagg <210> 41 145138 - Sequence Listing.doc 201015069 <211> 21 <212> DNA <213> Human <40Q> 41 aagccgaatt tgctagttgc a <210> 42 <211> 22 <212> DNA <213>Human<400> 42 tctgcaagtt catcccctct tt <210> 43 <211> 21 <212> DNA <213>Human<400> 43 agtcctggcc gttgaaatac c <210&gt 44 <211> 19 <212> DNA <213>Human<400> 44 tgtcacgtgg cgtcacagt <210> 45 <211> 34 <212> DNA <213> Human <400> 45 ttggaaatga Gtgcaaaccc tcttgataat aatg <210> 46 <211> 23 <212> DNA <213> Human <400> 46 aggaacagtt gcttgcggcc age <210> 47 145138 - Sequence Listing.doc 201015069 <211> 29 <212> DNA <213>Human<400> 47 agccagaact gcaga Agaaa cagttgtgc <210> 48 <211> 29 <212> DNA <213> human <400> 48 ttcactggag gtcaatt£ca cagcagaat <210> 49 <211> 26 <212> DNA <2I3>Human<400> 49 agcaaggtcc ttccatagtg acgcco <210> 50 <211> 25 <212> DNA <213>Human<400> 50 cttgccagag tgactctgga ggccc <210> 51 ❷ <211> 30 <212> DNA <213> Human <400> 51 ccateacaga tcattacatc caggtcctca <210> 52 <211> 36 <212> DNA <213> Human <400> 52 taaggattca aaccatttgc caaaaatgag tctaag <Z10> 53 145138 - Sequence Listing. doc 201015069 <211> 33 <212> DNA <213> Human <400> 53 cgtaattctt ctggatgtct ccttcacatt ctg <210> 54 <211> 30 <212> DNA <213>Human<400> 54 tcagtccctg tatggagacc caaaagagaa <210> 55 <211> 33 <212> DNA <213>Human<400> 55 caagatgacc aagatgtata aagggttcca age <210> 56 <211><212> D NA < 213 > Human <400> 56 tgtctgaacc gcaccagcca agagaata <210> 57 <211> 22 <212> DNA <213> Human <400> 57 ctgccagcca ccgaggaagc tc <210> 58 <211&gt 22 <212> DNA <213>Human<400> 58 tggaccagca ccccattgac gg <210> 59 145138 - Sequence Listing.doc 201015069 <211> 31 <212> DNA <213> Human <400> 59 agtgttaatt ccaatcactt caccgtccag g <210> 60 <211> 27 <212> DNA <213> Human <4〇0> 60 aggcccaaga ccggctacat cagagtc

<210> 61 <211> 25 <212> DHA <213> Human <400> 61 tctggcagat tccgatgccc cacaa <210> 62 <211> 20 <212> DNA <213> Human <400> 62 ccaggccagg agcagctcgg <210> 63 <211> 21 <212> DNA <213>Human<4O0>. 63 tgactccagg cccgcaatgg a <210> 64 <211> 25 <212> DNA <;213>Human<400> 64 cagcctccag ccaacagacc tcagg <210> 65 .145138 - Sequence Listing.doc 201015069 <211> 29 <212> DNA <213>Human<400> 65 acagaatgta gggatgggtt aagcctgca 29 <;210> 66 <211> 23 <212> DNA <213> Human <400> 66 ttcaaggacc ggttcatttg gcg 23 <210> 67 <211> 1778 <212> DNA <213> Human <400> 67 tagaagttta caatgaagtt tcttctaata ctgctcctgc aggccactgc ^ctggagct 60 cttcccctga acagctctac aagcctggaa aaaaataatg tgctatttgg tgagagatac 120 ttaeaaaaat tttatggcct tgagataaac aaacttccag tgacaaaaat gaaatatagt 180 ggaaacttaa tgaaggaaaa aatccaagaa atgca gcact tcttgggtct gaaagtgacc 240 gggcaactgg acacatctac cctggagatg atgcacgcac ctcgatgtgg agtccccgat 300 ctccatcatt tcagggaaat gccagggggg cccgtatgga ggaaacatta tatcacctac 360 agaatcaata attacacacc tgacatgaac cgtgaggatg ttgactacgc aatccggaaa 420 gctttccaag tatggagtaa tgttaccccc ttgaaattca gcaagattaa cacaggcatg 480 gctgacattt tggtggtttt tgcccgtgga gctcatggag acttccatgc ttttgatggc 540 aaaggtggaa tcctagccca tgcttttgga cctggatctg gcattggagg ggat £ cacat 600 ttcfiatgagg acgaattctg gaclacacat tcaggaggca caaacttgtt cctcactgct 660 gttcacgaga ttggccattc cttaggtctt ggccattcta gtgatccaaa ggctgtaatg 720 ttccccacct acaaatatgt cgacatcaac acatttcgcc tctctgctga tgacatacgt 780 ggcattcagt ccctgtatgg agacccaaaa gagaaccaac gcttgccaaa tcctgacaat 840 tcagaaccag ctctctgtga ccccaatttg agttttgatg ctgtcactac cgtgggaaat 900 aagatctttt tcttcaaaga caggttcttc tggctgaagg tttctgagag.accaaagacc 960 -12- 145138- sequence Listing .doc 201015069

agtgttaatt taatttcttc cttatggcca accttgccat ctggcattga agctgcttat 1020 gaaattgaag ccagaaatca agtttttctt tttaaagatg acaaatactg gttaattagc 1080 aatttaagac cagagccaaa ttatcccaag agcatacatt cttttggtit tcctaacttt 1140 gtgaaaaaaa ttgatgcagc tgtttttaac ccacgttttt ataggaccta cttctttgta 1200 gataaccagt attggaggta tgatgaaagg agacagatga tggaccctgg ttatcccaaa 1260 ctgattacca agaacttcca aggaatcggg cctaaaattg atgcagtctt ctattctaaa 1320 aacaaatact actatttctt ccaaggatct aaccaatttg aatatgactt cctactccaa 1380 cgtatcacca aaacactgaa aagcaatagc tggtttggtt gttagaaatg gtgtaattaa 1440 tggtttttgt tagttcactt cagcttaata agtatttatt gcatatttgc tatgtcctca 1500 gtgtaccact acttagagat atgtatcata aaaataaaat ctgtaaacca taggtaatga 1560 ttatataaaa tacataatat tttteaattt tgaaaactct aattgtccat tcttgcttga 1620 ctctactatt aagtttgaaa atagttacct tcaaagcaag ataattctat ttgaagcatg 1680 ctctgtaagt tgcttcctaa catccttgga ctgagaaatt atacttactt ctggcataac 1740 taaaattaag tatatatatt ttggctcaaa taaaattg 1778 < 210 > 68 <211> 184 0 < 212 > DNA < 213 > human < 400 > 68 tccacacaca caaaaaacxt gcgcgtgagg ggggaggaaa agcagggcct ttaaaaaggc 60 aatcacaaca acttttgctg ccaggatgcc cttgctttgg ctgagaggat ttctgtlggc 120 aagttgctgg attatagtga ggagttcccc caccccagga tccgaggggc acagcgcggc 180 ccccgactgt ccgtcctgtg cgctggccgc cctcccaaag gatgtacccai actctcagcc 240 agagatggtg gaggccgtca agaagcacat tttaaacatg ctgcacttga agaagagacc 300 cgatgtcacc cagccggtac ccaaegcggc gcttctgaac gcgatcagaa agcttcatgt 360 gggcaaagtc ggggagaacg ggiatgtgga gatagaggat gacattggaa ggagggcaga 420 aatgaatgaa cttatggagc agacctcgga gatcatcacg tttgccgagt caggaacagc 480 caggaagacg ctgcacttcg agatttccaa ggaaggcagt gacctgtcag tggtggagcg 540 -13- 145138- sequence Listing .doc 201015069 tgcagaagtc tg ^ tettoc taaaagtccc caaggcxaac a ££ aa » Ssa craaagtcac 咖catcccccctc ttccagcagc asa^caccc gcagggcagc t^gac^as gggaasaegc 660 cgaggaagtg ggcttaaagg gggagaggag tgaactgttg ctctctga&a aagtagtaga 720 qgci^ga^g secacctggc a^gtcitccc tgtctccagc agcatccagc ggttgctgga 780 cc agggoag agctcoctgg acgttcggat tgcctgtgag caftgccagg %% tggcgc 840 cagcttggtt dcctgggca gaaagaagag gag £ g & Kaas ggaaasasaa 900 gggcggaggt'gaaggtgggg caggag ^ aga tgageaaaag sagcagtcgc a ^ gaccttt 960 cclcatgctg caggccx% gc agtctg ^ p ccaccctcat cgccggcstc ggcggggctt 1020 ggagtgtgat ggcaagg & a acatctgc% ta ^ aaacag ttctttgtca gtttcaagga 1080 catcggctgg aatgactega tcattpctcc ctct ^ gctat catgocaact actgcgapgg 1140 agccatalag caggcacete ceaelcctea ctetccflcc actcaataat 1200 catoaaocac taccgcatec geggccatae cccctttecc a ^ artcaaat cetectetet 12 ^ 0 gca ^ aagctgagaocca enough cca thief stactatsatga ^ gtmaacatcatcaa 1320 aa ^ acait cagaaatea tceteKteea gtcieegtec tcatagaett gccca ^ coa 13 ^) gegegaaaee gagcaagajgt tgtccasasa agac ^ gtggc aaaatp ^ ga aatttttaag 1440 gtttctgagttaaccagaaaaatasaaattaaaaacaaaacaaaacaaaaaaaaaaacaa 1500 aaaaaaacaa aagtaaatta aaaacaaacc tgai ^ aaaca ga ^ aa ^ ag atgaaggaag 1560 a ^ tggaaat cttagcctgc cttegccagg gctcagagat gaa ^^ tga agagacagat 1620 tggg ^ ggaa agggagaatg gtguiccctt tatttcttct gaaatcacac tgat facatc 1680 ^ ttgtttaa acggggtatt gtccttlccc cccttgaggt tcccttgtga gcttgaatca 1740 accaatctga tctgcagtag tgtggactag aacaacccaa atagcatcu gaaagocatg 1800 agtttgaaag ggcccatcac aggcactttc ctagcctaat 1840 < 2I0 > 69 < 211 > 2384 < 212 > DNA < 213 > human < 400 > 69 tccacacaca caaaaaacct gcgcgtgagg Ggggaggaaa agcagggcct ttaaaaaggc 60 aaioacaaca. acttttgctg ccaggatgcc cttgctttgg ctgags^at Uctgttg^: 120 -14- 145138-sequence table.doc 201015069

aagttgctgg attatagtgasgagttcccc caccccagga tccgaggggc acagcgcggc 180 axcgadgt ccgtcctgtg cgctg ^ cgc cctcccaaag gatgtaccca actctcagcc 240 agagatggtg gasgccgtca agaagcacattttaaacatg oiscacttga sg ^ gagacc 3 (X) cgatgtcacc ca £ cc £ gtac ccaaggcggc gcttcigaac gcgatcagaa agctteatgt H) gggcaaaetc ggggi ^ aacg ggtatgt ^ a gatagagsat gacattggaa ggagggcaga 4 ^ ) aatgaatgaa cttatgs ^ gc agacctegga g & tcatcacg tttgccg ^ t caggaxagc 480 caggaagacg ctgcacttcg agatttccaa ggaaggcagt ggcxtgtcag tggtggagcg 540 tgcagaagtc tggctcttcc taaaagtccc caaggccaac aggaccagga ccaaagtcac 600 catccgcctc ttccagcagc agaagcaccc gcagggcagc ttg £ acacag gggaagaggc 660 cgaggaagtg ggcttaaagg gggagaggag tgaactgtts dctctgaaa a ^ tagtaga 720 cgctcggaag agcacctggc atgtcttccc igtctcca ^: agcatccagc ggt^ctgp 7^) ccagggcaag agctccctgg acgttcggat ^cctgtgag cagtgo»gs agastggcgc 840 cagcttggtt cttctgggca agaagaagaa gaaagaasa; gaggggsaag ggaaaaagaa 900 g£S〇£Saggt gaaggtgggg caggagcaga tgaggaaaag gagcagtcgc acagacctn 960 cctcatgctg caggcccggc ag tctgaaga ccaoxtcet cgccggcstc ggcggggctt 1 coffee £ sagtgtgat £ gcaa £ stcaacatctsctgtaagaaacagttctttstcastttcaa £ ^ i 1080 catoggcteg aateac ^ ea tcattectcc clctggctat cate < gMCt acttgraggg H40 teactgcccg aeccatatae c ^ ficacetc cgpgtcctca ctgte ^ tcc actcaacagt 1200 calraaccac taccgcatgc g ^ gccatai cccct ^ gcx aacdoaat cgtgct ^ tgt 1260 gccgctgcca ccgcaccccg cc ^^ agcg gccgtcgctg cgcgccctgc tcctcggqgc 1320 cgc ^ ggc want c thief tectgc tcc enough cce your ctcttcc tcctcntcgg acacct £ billion £ g 1380 cccctgcgag ccggccbxt gcccgcccct gcccccgc ^ ggctgcct ^: tgeeceagac 1440 cc ^ cgacpcs tgcjepa ^ t gccctatgtg cecocecg ^ c aeegcgagc tstecggggg 1500 tgs Bauer ego; ggcagegggt ac ^ cgcgcc gggcatggag tgcgtgaaga ^ x ^ caagag 1560 gceeaagggt aaagccgggg cagcagccgg cggtccgggt gtaagcsgcg tg ^ cg ^ tg 1620 caagagccgc tacccggtgt geggeage ^ cggcaccacc tacccgascg getspeage ^ I coffee gscgcgccgcc agaagaggg ccgagagccg cggggagsag gccala »cc aggtea ^ aa 1740 -15- 145138 - Sequence Listing. doc 201015069 gggcacctsc gagcaaggtc cttccatagt gacgcccccc aaggacatct ggaatgtcac 1800 tggtgcc cag gtgtacttga gctgtgaggt catcggaatc ccgacacctg tcctcatctg I860 gaacaaggta aaaaggggtc actai £ s ^ gt tcaaaggaca £ aactcct £ c ctggtgaccg 1920 ggacaacctg gccattcaga cccggggtgg cccagaaaag catgaagtaa ctggctgggt 1980 gctggtatct cctctaagta ag ^ aagatgc ^ gagaatat gagtgccatg catcx ^ attc 2040 ccaaggacag gcttcagcat cagcaaaaat tacagtggtt gatgccttac atgaaatacc 2100 agtgaaaaaa ggtsaaggtg ccgasctata aacctccaga atattattag tctgcatggt 2160 taaaagtast categataac tacattacct gttcttgcct aataagtttc ttttaatcca 2220 atccactaac actttagtta tattcact £ g ttctacacag agaaatacaa aataaagatc 2280 acacatcaag actatctaca aaaatttatt atatatttac agaagaaaag catgcatatc 2340 attaaacaaa taaaatactt tttatcacaa aaaaaaaaaa aaaa 2384 < 210 > 70 < 211 > 1280 < 212 > DNA <213>Human<40Q> 70 tgccgcagcc ccc^cccgoc cgcagagctt ttgaaaggcg scgggaggcg gcgagcgoca 60 tggccagtcc gggctgcctg ctgtgcgtgc tgggcctgct actctgcggg gcggcgagcc 120 tcgagctgtc tagaccccac ggcgacaccg ccaagaagcc catcatcgga atattaatgc 180 aaaaat£ccg taataaagt ca ^ aaaaact atgga ^ ata ctatattgct gcgtcctatg 240 taaagtactt ggagtc ^ ca ggtgcgags ^ ttgtacx ^ gt aaggctggat cttacagaga 300 aagactatga aatacttttc aaatctatta atgsaatcct tttccctgga ggaagtgttg 360 acctca £ acg ctcagattat gctaaagtgg ccaaaatatt ttataacttg tccatacaga 420 gttugatga t £ ga £ actat tttcctgtgt ggggcacatg ccttggattt gaagagcttt 480 cactgctgat tagtggagag Tgcttattaa ctgccacaga tactgttgac gtggcaatgc S40 cgctgaaclt cactggaggt caa^gcaca gcagaatgtt ccagaattu cctactsagt 600 tgttgctgtc attagcagta gaacctctga ctgcxaattt ccataagtgg agcctctccg 660 tgaagaattt tacaatgaat gaaaagttaa agaagttttt caatgtctta actacaaata 720 •16· 145138·sequence table.doc 201015069

cagatggcaa gattgagttt attu ^ acaa tggaaggata taagtatcca gtatatggtg 780 tccagtggca tccagagaaa gcaccttatg agtggaagaa tttggatggc atttcccat £ 840 cacctaatgc tgtgaaaacc gcatmatt tagcagagtt ttttgttaat gaagctegga 900 aaaacaacca tcattttaaa tctgaatctg aagaggagaa agcattgatt tatcagttca 960 gtccaattta tactggaaat atttcttcat ttcagcaatg ttacatattt gattgaaagt 1020 cttcaatttg ttaacagaec aaatttgaat aattccatga ttaaactgtt agaataactt 1080 gctactcatg gcaagattag gaagtcacag attcttttct ataatgtgcc Tg£〇tctgat 1140 tcttcattat gtat£t£act atttatataa cattagataa ttaaatagtg agacataaat 1200 agagtgcttt ttcatggaaa agccttctta tatctgaaga ttgaaaaata aatttactga 1260 aatacaaaaa aaaaaaaaaa 1280 <210> 71 <211> 2993 <212> DNA <213>, human <400>; 71 ^ ggtggcgggt ggctggcggt tccgttaggt c ^ ag ^ agc ga ^ gcggta cgcgcgttga 60 agctgctgac cacactgctg gctgtcgtgg ccgctgccto ccaagccgag gtcgagtccg 120 aggcaggatg gggcatggtg acgcctgatc tgctcttcgc cgaggggacc gcagcctacg 180 cgcgcgggga ctggcccggg gtggtcctga gcatggaacg ggcgctgcgc tcccgggcag 240 ccctccgcgc ccttcgccti cgctgccgca cccagtgtgc cgccgacttc ccgtgggagc 300 reference tggaccccga ctggtccccc agcccggccc aggcctcggg cgccgccgcc ctgcgcgacc 360 tga £ CttCtt CgggggCCtt ctgcgtcgcg CtgCCtgCCt £ CgCC £ CtgC ctcgggccgc 420 cggccgccca ctcgctcagc gaagagatgg agctggagtt ccgcaagcgg agcccctaca 480 actacct £ 〇a ggtcgcctac ttcaagatca acaagttgga gaaagct £ tt gctgcagcac 540 acaccttctt cgtgggcaat cctgagcaca tg £ aaatgca gcagaaccta gactattacc 600 aaaccatgtc tggagtgaag gaggccgact tcaaggatct tgagactcaa ccccatatgc 660 aagaatttcg actgggagtg cgactctact cagaggaaca gccacaggaa gctgtgcxx: c 720 acctagaggc ggcgctgcaa gaatactttg tggcctatga ggagtgccgt gccctctgcg 780 aagggcccta tgactacgat ggctacaact accttgagta caacgctgac ctcttccagg 840 • 17 · 145138- sequence table .doc 201015069 ccatcacaga tcattacatc Caggtcctca actgtaagca gaactgtgtc acggagcttg 900 cttcccaccc aagtcgagas aagccxtttg aagacttcct cccatcgcat tataattatc 960 tgcagtttgc ctactataac attgggaatt atacacaggc tgttgaatgt gccaagacct 1020 atcttc^tt cttccccaat gacgaggtga ^ aaccaaaa tttggcctat tatgcagcta 1080 tgcttggaga agaacacacc agatccatcg gcccccgtga gaglsccaag gagtaccgac 1140 agcgaa £ 〇ct actggaaaaa gaactgcttt tcttc ^ ctta tgatgttttt ggaattccct 1200 ttgtggatcc ggattcatgg actccaggag aagtgatu ^ caagagattg caaga ^ iaac 1260 agaagtcaga acgggaaaca gcx ^ tacgca tctcccagga gat ^ ggaac cttatgaagg 1320 aaatcgasac ccttstggaa gagaagacca aggagtcact gga ^ tgagc agactgaccc 1380 ggsaase ^ g ccccctgctg tatgaaggca tcagtctcac catgaactcc aaactcc ^ a 1440 atggttccca ficgggtggtg atggacggcg taatctctga ccacgagjgt caggagc ^ c 1500 agagactgac caatgtggca gcaacctcag ga £ at £ gcta ccggggtcag acctecccac 1560 atactcccaa tgaaaagttc tatggtgtca ctgtcttoaa agccctcaag ctggggcaag 1620 aaggcaaagt tcctctgcag ag ^ cccacc tgtactacaa Cgtgacggag aagg^ggc 1680 gcatcatgga gtcctacttc cgcctggata cgcccctcta cttttcctac tctcatctgg 1740 tgtgccgcac tgccatcgaa gaggtccagg cagagaggaa ggatgatagt catccagtcc 1800 acgtggacaa ctgcatectg aatgccgaga ccctcgtg% tgtcaaagag cccccagcct 1860 acaccttcx^g cgactacagc gccatccttt acctaaatgg £ gacttcgat ggcggaaact 1920 tttatttcac tgaactggat gccaagaccg tgacggcaga sgtgcagcct cagtgtggaa 1980 gagccgtgsg attctcttca ggcactgaaa acccacat ££ agt £ aag £ ct gtcaccaggg 2040 ggcagcgctg tgccatcgcc ctgtggttca ccctggaccc tcgacacagc gagcgggtga 2100 gagcagctcg agcgggtgag agcasctggt gctgtggtga cccgttccca sagcgccctt 2160 ggtttgcctt tctcttcccc aaatcccatt gccagtggct gagacacgaa aggagcactt 2220 gggacacx: ag ctccaacgcc ctgtcattat ggtcacattg ccttgtcctc cctgggcctg 2280 ctgtgaacgg gatccaggtg gggaaagagg tcaagacagg gagcgatgct gagttcttgg 2340 ttccctcctt gggccccact tcagctgtcc ttttccagag agtaggacct sctgggaagg 2400 agatgagcct ggggccatta aggaaccttc cttgtcccct gggaagtagc agctgagaga 2460 • 18 _ 145138 · sequence Listing .doc 201015069 tagcgagtgt ctggagcgga ggcctctctg aatgggcagg ggtttgtcct tgcaggacag 2520 ggtgcaggca gatgacctgg tgaagatgct cttcagccca gaagaga ^ g tcctctccca 2S80 ggagcagcccctgga^cccagcagggcccccccgaacacgcacaagagtctctctcagg 2640 cagtgaatcg aagcccaagg atgagctatg acagcgtcca ggtcagacgg atg ggtgact 2700 agacccatgg agaggaactc ttctgcactc tgagctggcc agcccctcgg ggctgcagag 2760 cagtgagcct acatctgcca ctcagccgag gggaccctgc teacagcctt ctacatggtg 2820 ctactgctct tggagtggac atgaccagac accgcacccc ctggatctgg ctgagggctc 2880 aggacacagg cccagccacc cccaggggcc tccacaggcc gctgcataac agcgatacag 2940 tacttaagtg tctgtgtaga caaccaaaga ataaatgatt catggttttt ttt 2993

≪ 210 > 72 < 211 > 736 < 212 > DNA < 2] 3 > human < 400 > 72 ggctctcacc ctcctctcct scasctccag ctttgtgctc tgcctctgag gagaccatgg 60 cccggcctct gtgtaccctg ctactcctga tggctaccct ggctggggct ctggcctcga 120 gctccaagga ggagaatagg ataatcccag £ tggcatcta tgatgcagac ctcaatgatg 180 agtgggtaca gcg ^ ccctt cacttcgcca tcagcgagta caacaasscc accgaagatg 240 agtactacag acgcccgctg caggtgctgc gagccaggga gcagaccttt ggggggg ^ a 300 attacttctt cgacgtagag gtgggccgca ccatatgtac caagtcccag cccaact ^ g 360 acacctgtgc cttccalsaa cagccagaac tgcagaagaa aca £ ttgtgc tctttcgaga 420 tctacgaagt tccctgggag gacagaatg ^ ccctggtgaa ttccaggtgt caagaagcct 480 aggggtctgt gccaggccag teacaccgac caccacccac tcccacccac tgtagtgctc 540 ccacca: tgg actggtggcc cccaccctgc ggeaegcctc axatgtgcc tgtgccaaga 600 gacagacaga gaaggctgca ggagtccm gttgctcagc agggcgctct gccctccctc 660 cttccttctt gcttctaata gacctg £ tac atggtacaca cacccccacc tcctgcaatt 720 aaacagtagc atcgcc 736 < 21〇 > 73 • 19- 145138- sequence Listing .doc 201015069 < 2 11 > 2820 <! 2 2 > DNA < 213 > human < 400 > 73 ggcgggttcg cgccccgaag gctgagagct ggcgctgctc gtgccctgtg tgccagacgg 60 cggagctccg cggccggacc ccgcggcccc gctttgctgc cgactggagt ttgggggaag 120 aaactotcct gcgccccaga agatttcttc ctcggcgaag ggacagcgaa ^ gatgagggt 180 g £ ca ££ aaga saaggcgctt tctgtctgcc ggggtcgcag cgcgzgzg ^ g cagtgccatg 240 ttcctctcca tcctagtggc gctgtgcctg tggctgcacc tggcgctggg cgtgcgcggc 300 gcgccctgcg aggcggtgcg catccctatg tgccggcaca tgccctggaa catcacgcgg 360 atgcccaacc acctgcacca cagcacgcag gagaacgcca tcxtggccat cgagcagtac 420 gaggagctgg t £ gacgtgaa ctgcagcgcc gtgctgc ^ t tcttettetg tgccat £ tac 480 gcgcccattt £ caccctgga gttcctgcac gaccctatca agccgtgcaa gtcggtgtgc S40 caac £ cgcgc gcgacgacts cgagccccte atgaagatgt acaaccacag ctggccx ^ gaa 600 agcctggcct gcgacgagct gcctgtctat gaccgtggcg t £ tgcatttc gcotgaagcc 660 atcgtcacgg acctcccgga ggatgttaag tggatagaca tcacaccaga cat £ at £ gta 720 cagsaaasgc ctcttgatgt tgactgtaaa cscctaa & x: ccsatcggtg caag ^ taaa 780 aaggtgaagc caactt tggc aacgtatctc agcaaaaact acagctatgt tatteatgcc 840 aaaataaaag ctg ^ cagag gagtggctgc aatgaggtca caac ^ stggt ggatgtaaaa 900 gagatcttca agtcctcatc acccatccct cgaactcaag tcocgctcat tacaaattct 960 tcttgccagt stccacac ^ cctgccccat caaga ^ ttc tca ^ at £ tg ttac £ a £ tgg 1020 cgttcaagga ^ atgcttct tgaaaattgc ttagttgaaa aa ^ gagaga tcagcttagt 1080 aaaagatcca tacagtggga agagaggctg caggaacagc ggagaacagt tcaggacaag 1140 aagaaaacag ccgggcgcac cagtcgtagt aatcccccca aaccaaaggg aaagcctcct 1200 gctca ^ aaac cagccagtcc caagaagaac attaaaacta ggagtgccca gaagagaaca 1260 aacccgaaaa gagtgtgagc taactagttt ccaaagcgga gacttccgac tlccttacag 1320 gatgaggctg sgcattgcct gggacagcct atgtaaggcc atgtgcccct tgccctaaca 1380 actcac ^ ca gtgctcttca tagacacatc ttgcagcatt tdctiaagg ctatgcttca 1440 gtttttcttt gtaagccatc Acaagccata gtggtaggtt tgccctttgg tacagaaggt 1500 •20- 145138-sequence table.doc 201015069

gagttaaagc tggtggaaaa ggcttattgc attgcattca gagtaacc ^ tgtgcatact 1560 ctagaagagt agggaaaata atgcttgtta caattcgacc taatatgtgc attgtaaaat 1620 aaatgccata tttcaaacaa aacacgtaat ttttttacag tatgttttat taccttttga 1680 tatctgttgt tgcaatgtta gt ^ atgtttt aaaatgtgat gaaaatataa tgtttttaag 1740 aaggaacagt agtggaatga atgttaaaag atctttatgt gtttatggtc t £ 〇agaagga 1800 tttttgtgat gaaaggggat tttttgaaaa attagagaag tagcatatgg aaaattataa 1860 tgtgtttttt taccaatgac ttcagtttct gtttttagct agaaacttaa aaacaaaaat 1920 aataataaag aaaaataaat aaaaaggaga ggcagacaat gtctggattc ctgttttttg 1980 gttacctgat ttccatgatc a ^ atgcttc ttgtcaacac cctcttaagc agcaccagaa 2040 acagtgagtt tgtctgtacc attaggagtt aggtactaat tagttggcta atgctcaagt 2100 attttatacc cacaagagag gtatgtcact catcttactt cccaggacat ccaccctgag 2160 aataatttga caagcttaaa aatggcx: ttc atgtgagtgc caaattttgt ttttcttcat 2220 agaggagtta aatataaatg tacagagagg ttaaatattt tctttgccta aatacatgtg 2280 aaagttgagt tccacctctg aaaigagaat tacttgacag ttgggatact ttaatcagaa 2340 aaaa agaact tatttgcagc attttatcaa caaatttcat aattgtggac aattggaggc 2400 atttatttta aaaaacaatt ttattggcct tttgctaaca cagtaagcat gtattttata 2460 aggcattcaa taaatgcaca acgcccaaag gaaataaaat cctatctaat cctactctcc 2S20 actacacaga ggtaatcact attagtattt tggcatatta ttctccaggt gtttgcttat 2580 gcacttataa aatgatttga acaaataaaa ctaggaacct gtatacatgt gtttcataac 2640 ctgcctcctt tgcttggccc tttattgaga taagttttcc tgtcaagaaa gcagaaacca 2700 tctcatttct aacagctgtg ttatattcca tagtatgcat tactcaacaa actgttgtgc 2760 tattggatac Ttaggtggtt tcttcactga caatactgaa taaacatctc accggaatic 2820 <210> 74 <211> 2480 <212> DNA <213>human <400> 74 agtactaaca tggactaatc tgtgggagca gtttattcca gtatcaccca gggtgcagcc 60 •21 · 145〗 38 - Sequence Listing.doc 201015069 Acaccaggac tgt£ttgaag £gtgtttttt ttcttttaaa tgtaatacct cctcatcttt 120 tcttcttaca cagtgtctga gaacatttac attatagata agtagtacat ggtggataac 180 ttctactttt aggaggacta ctctcttctg acagtcctag act£gtcttc tacactaaga 240 caccatgaag gastatgtgc tcctattat t cctggctttg tgmgcca aacccttctt 300 tagcccttca cacatcgcac tgaagaatat gatgctgaas gata ^ gaag acacagatga 360 tgatgatgat gatgatgatg atgatgatga tgatgatgag gacaactctc tttttccaac icccaaccaa 540 cattccattt gatactcgaa tgcttgatct tcaaaacaat aaaattaagg 420 aasagascca aga ^ gccatt tttttccatt tgatctgttt ccaatgtgtc cattt £ gatE 480 tcag ^ ctat tcacgagttg tacattgctc agatttaggt t ^ acctcag aaatcaaaga 600 aaatgatttt aaaggactca cttcacttta tggtctgatc ctgaacaaca acaafictaaa 660 gaagattcac ccaaaagcct ttctaaccac aaagaagt% c & assdgi atetgtocca 720 caatcaacta agtgaaatac c ^ K ^ aatcttcccaaaica tta ^ agaac tcagaattca 780 tgaaaataaa gttaagaaaa tacaaaagga cacattcaaa ggaa ^ aats ctttacacst 840 tttgsaaatg agtscaaacc ctcttgataa taatgggata gagccagggg catttgaaK 900 ggtgacggtg ttccatatca gaattgcaga agcaaaactg acctcagdc Ctaaaggctt 960 accaccaact ttattggagc ttcacttas& ttataataaa atttcaacag tggaacttga 1020 £gattttaaa cgatacaaag aactacaaag gctgsgccta sgaaacaaca aaatcacaga 1080 tatcgaaaat gggagtcttg ctaacatacc acgtgtgaga gaaatacat t tggaaaacaa 1140 taaactaaaa aaaatccctt caggattacc agagttgaaa tacctccaga taatcttcct 1200 tcattctaat tcaattgcaa gagtgggagt aaatgacttc tgtccaacag tgccaaagat 1260 gaagaaatct ttatacagtg caataagttt attcaacaac ccggtgaaat act £ ggaaat 1320 gcaacctgca acatttcgtt gtgttttgag cagaatgagt gttcagcttg ggaacttt £ g 1380 aatgtaataattagtaattggtaatgtccatUaatataagattcaaaaatccctacatt 1440 tggaatactt gaactctatt aataatggta gtattatata tacaagcaaa tatctattct 1500 caagtggtaa gtccactgac ttattttatg acaagaaatt tcaacggaat tttgccaaac 1S60 tattgataca taagg£ttga gagaaacaag catctattgc agUtctttt tgcgtacaaa 1620 tgatcttaca taaatctcat scttgaccat tcctttcttc ataacaaaaa agtaagatat 1680 -22- 145138-sequence table.doc 201015069

tcggQtttaacactttgttatcaagcatatmaaaaagaactgtactgtaaa ^ gaat 1740 gcttgactta gcaaaatttg ^ ctctttca tttgctgtta gaa ^ tacaga aOaacaaag 1800 acagtaat £ tgaagae ^ attacs: tattcttattctttagtaadlgggtagtac ^ t i860 aatattttta atcatettaa agta ^ attt gatataatct tattgaaatt accttalcat 1920 gtctotgagc ccg ^ ntat gttcaaaact aatttcttaa aataaagcct tcagtaaatg 1980 ttcat & cca acttgatm tgctactcat aagagctg ^ t ^ gggctat agcatatgct 2 < M) tmtttttttaattattacctgatttaaaaatctetgtaaaaacgtgtagtgtocata 2100 aaatctgtaa ctcgcatttt aatgatccgc tattataagc tttta ^ agc atgaaaattg 2160 ttaggctatat ^ cattgccacttcaactctaa ^ aatatttt ^ iatatecctagga 2Ώ0 agaccttgct tggaagagcc tggacactaa caatictaca cmattgtc tcttcaaata 2280 cstatssact isataactct gasaaacaca tctagtiitaa c ^ aataaec asagcatcaa 2340 attaaacagacagaaaa; gaaagctctatataaatgctcaga £ ttctttatgtatttctt 2400 attggcattc aaca ^tgta aaatcagaaa acagggaaat tttcattaaa aatat^gtt 2460 tgaaataaaa aaaaaaaaaa 2480 <210> 75 <211> 1887 <212> DNA <213> Human <400>75®c^;sc8£ccc Ctccggccgc gggcgcagcg ggececteg tggagctscg aags^cagg 60 tccggceeec ggggt^c^ c^gcac^g ctccggadc ^cxx^cca sggcggcggc 120 tec^gc^ggagsgcg^st foot ggccacgt miscellaneous 勉 (over the ball 180 ggaggcgagg cg (%^cggc gcagcagcca ggagcgcas C^agctgga cccocagagc 2^0 cgcg(^gc^ cgc^cagtt ccaggaagga tgttaccttt gscptgaca gtg^aatcc 300 tgctgc^ct cccxacgggt caggcts^cc caa%g£gg agtcacaagg cragactetg 360 aastscagca tcagctcctg c(xs&cccct tccagccagg ccaggagcag clcggactlc 420 tgcagagcta cctaa ^ gga ct2ggaagga cagaagtgca actggagcat ctgagccggg 480 agcaggttct cctctzcctc tttgccctcc atgactatga ccagagtgga ca ^ gats 540 gcc ^ gagct gctgtccatg ttgacagctg ctctggcccc tggagctgcc aactctccta 600 -23- 14513 8- sequence Listing .doc 201015069 ccaccaaccc ggtgatattg atagtggaca aagtgctcga gacgcaggac ctgaatgggg 660 atgggctcat gacccctgct gagctcatca acttcccggg agtagccctc aggcacgtgg 720 Agcccggaga gccccttgct ccatctcctc aggagccaoa agctgttgga aggcagtccc 780 tattagctaa aagcxcatta agacaagaaa cacaggaagc ccctggtccc agagaagaag 840 caaagggcca ggtagaggcc agaaggga gt ctttggatcc tgtccagfiag cctgggggcc 900 a £ gcaga £ gc tgatggagat gttccagggc ccagagggga agctgagggc ca ^ cagagg 960 ctaaaggaga tgcccxtggg ccx ^ gagggg aagctgggsg ccaggcagag gctgaaggag 1020 atgccccc £ g gcoca £ aggg gaagc ^ ggg gcc ^ ggcaga ggccagggag aatggagagg 1080 aggccaa ^ a acttccaggg gaaacactgg agtctaagaa cacccaaaat gactttgagg 1140 tgcacattgt tcaagte ^ ig aatgatgaga tctagalctt gaagatacas gtaccccacg 1200 accat〇tet gtgccccc% tctggtccca gtaggtatca gstctttctg tgca accctctcag aggaacgggg t aagtetcagt gccagaacat aagccctgaa gtgggcaggg saaatgtacg ctgggacaag 1260 £ ^ tcag 1320 ggagacccta agttaagggg cagattacca ataaagaact gaateaattc atecccccffi 1380 gccacctctc tacccgtcca gcctgcccag ^ gggaccg 1440 aaaggacagg gatgccficct gcccagtgtt tctgggcctc Acggtgctcc ggcagcagag 1500 cgcatggtgc tagccatggc cggctgcaga ggacccagtg aggaaagcto agtctatccc 1S60 tgggccccaa accctcaccg gttccccctc acctggtgtt cagacacccc atgctctcct 1620 gcagctcagg gcaggtgacc ccatccccag taatattaat catcactaga actttttgag 1680 agccttgtac acatcaggca tcat£ctggg cattttatat atgattttat cctcacaata 1740 attctgiagc caagcagaauggttccatt tgacagatga agaaattgag gcagattgcg 1800 ttaagtgctg taccctaagg tgatatgcag ctaattaaat ggcagatttg aaaaaaaaaa I860 aaaaaaaaaa aaaaaaaaaa aaaaaaa 1887 < 210 > 76 < 211 > 1580 < 212 > DNA < 213 > human < 400 > 76 catcctgcca cccctagcct tgctggggac gtgaaccctc Tccccgcgcc tgggaagcct 60 -24· 145]38·sequence table.doc 201015069

tcttggcacc ggg ^ ccgga gaaiccccac ggaagcc ^ tsccaaaaggg algaaa ^ K 120 ggcgtttcgg g ^ cigggag aagc ^ gtat tccagggcxx ^ ctcoapgc aggaatctgg 180 ga < xcaggag tgccagcctc accx ^ cgcag atcotggcx: a tgagagctcc gcacclccac 240 ctetccgccg cctctggc £ c ccgggc ^ tg gcgaagctgc tgccgctgct gatggcgc ^ 300 ctctgggccg caga £ gc £ gc gctgctcccc caaaacgaca cgcgctt £ ga ccx ^ gaagcc 360 tatggctccc cgtgcgcgcg cggctcgcag ccctggcagg tctcgctcti caacggccte 420 tcgttccact scgcgggtgt cctggt ^ ac cagagttggg tgctgacggc cgcgcactgc 480 ggaaacaagc cactgtg ^ c tcgagtagg ^ gatgaco ^ c tgctscttct tca £ gsagag 540 cagctccgcc gg ^ c ^ ctcg ctctgttitc catcccaagt accaccagjgg ctcaggccco 600 atcctgccaa ggcgaacgga t ^ agcacgat ctcatgt ^ c tgaagctggc caggcccgta 660 g ^ ctggggc cccgcgtccg ggccctgc% ct & xctBcc gditgclca gaxgg% ^ 720 cag ^ ccagg ttsctggctg gggcaccac £ gccgcccgga gag ^ aagta caacaagggc 7 ^) ctiacctgct ccagcatcac tatcct ^ igc cctaaagagt Gtgagg^t ctaccctg^: S40 gtg£tcacca acaacatgat atgt£〇tgga ctggacqggg gcc%gaccct^ccagagt 900 gactctgsag gccccct^tc^tgacga g aocctccaag gcatcctcte gtigggtgtt 960 tacccd: gts ^ tc ^ ccca gcalc ^ agd gtctacaccc agatctgcaa atacstfgtcc 1020 tggatcaataaagtcat ^ ctccaac ^ iocagatgctacsctccagctgaficcasat 1080 gttatgctcc tgdgatcca gatgccc ^ a £ gctccatcg tccatcctct tcctcoccafi 1140 tcggc ^ a ^: tctixcct% available cactgt tcaaacctct gccficcctcc ac ^ ctctaa 1200 acatcteox {c ^ racceca ^ ccoccacc tacccx ^ dclioctgt 1260 aaatgcagga aaggtttatt ccagagaagc caggaagccg gtcatcacxc 13% agcctctgag agc ^ Uac ^ ggggtcaccc aacctgactt cdctgcx ^ c tocclgctgt 13K) ^ gacttlsg gcaagccaag rgcccictct gaacclcagt tt < xtcatct scaa & a ^ gg 1440 aacaatgacg tgccm: tc ttagacatgt Tgtgaggasa ctaigatata a^^tat 1500 gtaaatcitc atggtgattg tcatgtaagg cttaacacag tgggtggtga gttetgacta 1560 aaggttacct gitgtcgtga 1580 <21〇> 77 •25· 145138-sequence table.doc 201015069 <211> 1443 <212> DNA <213> Human <;400> 77 accagcggca gaccacaggc agggcagagg cacgtctggg tcccctccct ccttcctatc 60 ggcgaotccc aggatcctgg ccatgagagc tcxgcacctc cacctctccg ccgcctctgg 120 cgcccg ggct ctggc £ aagc tgctgccgct gctgaiggcg caactctggg ccgcagaggc 180 ggcgc ^ ctc ccccaaaacg acacgcgctt ggaccccgaa gcctatggct ccccg ^ cgc 240 gcgcggctcg cagccx: tsgc aggtetcsct cttcaacggc ctctcgttcc actgcgcggg 300 tgtcctggtg gaccagagtt gggtgctgac ggccgcgcac t £ 〇ggaaaca agccactgtg 360 ggctcsagta ggggatgacc acctgctgct tcttcaggga gagcagctcc gccggaccac 420 tcgctctgtt gtccatccca agtaccacca gsgctcaggc cccatcctgc caaggcgaac 480 ggatgagcac gatetcatgt tgctgaasct ggccaggccc gtastgctgs ggccccgcgt 540 ccsggccctg cagcttccct accgctgt £ c teagcccgga gacc & stgcc aggttgctgg 600 ctggggcacc acggccgccc geagagtgaa gtacaacaag ggcctgacct gcU: cagcat 660 cactatcctg agccctaaag agtgtga £ gt cttctaccct ggcgtggtca ocaacaacat 720 gatatgtgct ££ dctg £ & cc ggggccagga cccttgccag sgtgsctctg Gaggccccct 780 ggtctgtgac gagaccctcc aaggcatect ctcg^gggt gtttacccct jgtggctc^c 840 ccagcatcca gctgtctaca cccagaictg caaatacatg tcctggatca ataaagtcat 900 acgctccaac tgatccagat gctacgctcc agctgatcca gatgttatgc tcc^c^at 960 ccagatgccc ag aggctcca tcgtccatcc tctto ^ ccc cagtcggc ^ aacictaxc 1020 ttstctgcac tgttcaaacc tctgccgccc tccacacctc taaacatctc (xctctcacc 1080 tcattcoccc acctatcccc attctctgcc tgtactgaag ctgaaatgca ggaagtggtg 1140 gcaadggttt attccagaga agccasgaag ccggtcatca cccagcctct gagagcagtt 1200 actggggtca cccaacctga cttcctctgc cactccctgc tgtgtgactt tgggcaagcc 1260 aagtgccctc tctgaacctc astttcctca tctgcaaaat gggaacaatg acgtgcctac 1320 ctcttagaca tgttgtgagg agactatgat ataacaigtg tatgtaaatc Ttcatggtga 1380 ttgtcatgta aggcttaaca cagtgggtgg tgagttctga ctaaaggtta cctgttgtcg 1440 tga 1443 • 26- 145138 · Sequence Listing _doc 201015069 <210> 78 <211> 782 <212> DNA <213> Human <400>

aggggcctta gcgtgccgca tcgccgagat ccagcgccca gagagacacc agagaaccca 60 ccatggcccc ctttgagccc ctggcttctg gcatcctgtt gttgctgtgg ctgatagccc 120 ccagcagggc ctgcacctgt gtcccacccc acccacagac ggccttctgc aattccgacc 180 tcgtcatcag ggccaagttc gtggggacac cagaagtcaa ccagaccacc ttataccagc 240 gttatgagat caagatgacc aafiatgtata aagggttcca agccttaggg gatgccgctg 300 acatccggtt cgtctacacc cccgccatgg agagtgtctg cggatacttc cacaggtccc 360 acaaccgcag cgaggagttt ctcattgctg gaaaactgca ggatggactc ttgcacatca 420 ctacctgcag tttcgtggct ccctggaaca gcctgagctt agctcagcgc cggggcttca 480 ccaagaccta cactgttggc tgtgaggaat gcacagtgtt tccctgttta tccatcccct 540 gcaaactgca gagtggcact cattgcttgt g £ acggacca gctcctccaa ggctctgaaa 600 agggcttcca gtcccgtcac cttgcct £ cc tgcctcggga gccagggctg tgcacctggc 660 agtccctgcg gtcccagata £ cctgaatcc tgcccggagt ggaactescag cctgcacagt 720 gtccaccctg ttcccactxc catctttctt ccggacaatg aaataaagag ttaccacxca 780 gc 782 <210> 79 <212> DNA <213> Human <400> 79 £ttgcctgtc tct aaacccc tccacattcc cgcggtcctt cagactgccc ggagagcgcg 60 ctctgcctgc cgcctgcctg cctgccactg a ££ gttccca gcaccatgag ggcctggatc 120 ttctttctcc tttgcctggc cgggagggcc ttggcagccc ctcagcaaga agccctgcct 180 gatgagacag aggtggtgga agaaactgtg gcagaggtga ctgaggtatc tgtgggagct 240 aatoctgtcc aggtggaagt aggagaattt gatgatggtg cagaggaaac cgaagaggag 300 gtggt £ gcgg aaaatccctg ccagaaccac cactgcaaac acggcaaggt gtgcgagctg 360 -27- 145138 - sEQUENCE LISTING .doc 201015069 gatgagaaca acacccccat gtgcgtgtgc caggacccca cca £ ctgccc agcccccatt 420 ggcgagtttg agaaggtgtg cagcaa ^ ac aacaagacct tc ^ ctcttc c ^ ccacttc 480 tttgccacaa agtgcaccct gsagggcacc aagaagggcc acaagctcca cctggactac 540 atcgggcctt gcaaatacat ccccccttgc ctg £ actctg agctgaccga attccccctg 600 cgcatgcggg actggctcaa gaacgtcctg gtcaccctgt atgagaggga tgaggacaac 660 aaccttctga ctgagaagca gaagctscgs gtgaagaaga tcxatgagaa tgagaagcgc 720 ctggaggcag gagaccaccc cgtggagctg ctggcccggg aottcgagaa ^aactataac 780 atgtacatct tccctgtaca ctggcagttc ggccagctgg accagcaccc cattgacggg 8 40 tacctctccc acacc £ agct ggctccactg cgtgctcccc tcatccccat ggagcattgc 900 accacccgct ttttcgagac ctgtgacctg gacaatgaca agtacatcgc cctggatgag 960 tgggccsgct gcttcggcat caagcagaag gatatcgaca aggatcttgt gatctaaatc 1020 cactccttcc acastaccgg attctctctt taaccctccc cttcgtgttt cccccaatgt 1080 ttaaaatgtt tggatggttt gttgttctgc ctggagacaa ggtgctaaca tagatttaag 1140 tgaatacatt aacggtgcta aaaatgaaaa ttctaaccca agacatgaca ttcttagctg 1200 taacttaact attaaggcct tttccacacg catCaatagt cccatttttc tcttgocatt 1260 tgtasctttg cccattgtct tatt ££ 〇aca tgggtggaca cggatt: tgct gggctctgcc 1320 ttaaacacac attgcagctt caacttttct ctttagt £ tt ctgtttgaaa ctaatactta 1380 ccgagtcaga ctttgtgttc atttcatttc agggtcttgg ctgcctgtsg gcttccccag 1440 gtggcctgga ggtgggcaaa gggaastaac agacacacga tgttgtcaag gatggttttg 1500 ggactagagg ctcagtggtg ggagagatcc ctgcagaacc caccaaccag aa〇 £ t £ gttt 1560 Gcctgs^gct gtaactgaga gaaagattct ggggctgtgt tatgaaaata tagacattct 1620 cacata^gcc cagocatca ccatttcctc ctttaccttt cagtgcagtt tcttttcaca 1680 ttaggctgtt ggttcaaact tttgggagca cggactgtca gttctctggg aagtggtcag 1740 cgcatcctgc agggcttetc ctcctctgtc ttttggagaa ccagggctct tctcaggggc 1900 tctagggact gccaggctgt ttcagccagg aaggccaaaa tcaagagtga gatgtagaaa 1860 gttgtaaaat agaaaaagtg gagttggtga atcggttgtt ctttcctcac atttggatga 1920 ttgtcataag gtttttagca tgttcctcct tttcttcacc ctcccctttt ttcttctatt 1980 • 28 - 145138- sequence table .doc 201015069

cttcaaag ttaatgggat igtcggatct cacaggctga gaactcgttc 2040 acctccaagc atttcatgaa aaagctgctt cttattaatc atacaaactc tcaccat £ at 2100 gtgaagagtt tc ^ aaatcc tteaaaataa aaagtaatga cttagaaact gccttcctgg 2160 £ t £ atttgca tgtgtcttag tcttagtcac cttattatcc tgacacaaaa acacatgagc 2220 atacatgtct acacatgact acacaaatgc aaacx soft a pull caaga: tttgc aaacacatta tgcttttgca 2280 cacacacacc tstacacaca caccggcatg tttatacaca gggagtgtat ggtlcctgta 2340 agcactaagt tagctgtttt catttaatga cctgtggttt aacccttttg atcactacca 2400 ccattatcag caccagactg agcagctata tccttttatt aatcatggtc attcattoat 2460 tcattcattcacaaaatatttatgatgtatttactctgcacca £ gtcccat £ ccaa £ cac 2S20 tggggacaca gttatggcaa agtagacaaa gcatttgttc atttggagct tasagtccag 2580 gaggaataca ttagataatg acacaatcaa ataUiaattg caagatgtca caggtgtgat 2640 gaaggga £ ag tasgagagac catgagtatg tgtaacagga £ gacacagca ttattctagt 2700 gctgtactgt tccgtacggc agccactacc cacatgtaac tttttaagat ttaaatttaa 2760 attagttaac attcaaaacg cagctcccca atcacactag caacatttca agtgcttgag 2820 a gccatgcatgattagts £ ttaccctattgaatag £ tca £ aagtagaalcttttcatcat 2880 cacagaaagt tctattggac agtgctctte tagatcatca taa ^ claca gagcactttt 2940 caaagctcatgcatgttcatcatgttagtgtegtattttgagctggggtttt £ agactcc 3000 ccttagagat agagaaacag acccaagaaa tg ^ ctcaat tgcaatgggc cacataccta 3060 gafctccaga tgtcatttcc cctctcttat maagttat gttaagatta ctaaaacaat 3120 aaaagctcct aaaaaatcaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 3178 < 210 > 80 < 211 > 2691 < 212 > DNA < 213 > human < 400 > 80 gcttgcccgtcggtcgctag ctogctcggt gcgcgtcgtc ccgctccatg gcgctcttcg 60 tgcggctgct ggctcto £ cc ctggctctgg ccctgggccc cgccgcgacc ctggcgggtc 120 ccgccaagtc gccctaccag ctggtgc ^ c agcacagcag gctccggggc cgccagcacg 180 -29- 145138 · sequence Listing .doc 201015069 ffxxcmsli gtgtgctste caga^gt^ tt£gcactaa taggaag^cm^ccaact 240 gcaagc^tg gtaa^aagg aaaatetgtg @aaatcaac agtcato^c tacgag^t 3(X) gta^tggm tsaaaagglc cdggg^aga asgctgtoc agoiscccia ccadctcaa 360 pccctssga st ^t^at ccaccaccac tcagctgtac dcggaccsca 420 cg^ga^gct g Agccctg^ siggaggggc ccggcasck caccatctio ^ccctagca 48Q acgaggcc% ^cctccxxg cca^c^aag ^ctgg^tc cdg^cagc aa^caaca S40 ttgagctgct caatgccctc qgctaccata tggtggg^g gcgag^g 600 tgaaacac^g (^tgaccdc acctctatgt acc^aattc c^ Tcatccag atccaccacc na atcctaa^g gatlgtaact gtgaac^gtg cccggctca saaagpc^c cacca^a 720 cca祀gggst gg male cacctc aic^ata^g tcatctccac catcaccaac a^atccagc 780 ^gatcattga gaicgaggac acctttgc^ga ccct£c%g^ tgc^sctgca ^ ggeo 840 tcaacacgat gcttsaaest aacggcc ^ acaqsctdt ggcoccpoc aa ^ sgcct 900 tcgagaagat ccctag (ga £ actit ^ aacc £ talcctsgg qgacccagaa gixctgagag 960 aootgctgaa caao: acatc dgaagtcag ctatgt £ tgc tgaagccatc £ tsgcggg ^ 1020 ig ^ taga £ accctgg2g ggcacgacac tggaggtegg ct ^ agcgjgg gacat ^ tca] 080 ctatcaacgg gaaggcgatc atctsccaata aagacatcrt agccaccaac ggggtgatcc 1140 ^ tacattga tgagctac ^ atcccagact ^ gccaagac actatttgaa Uggctgcafi 1200 agtccgatgt gtccacagcc attgacxttt tcagacaagc cggcxtcggc aatcaictct 1260 ctggaagtga £ 〇sgttgacc ctcctg £ ctc ccctgaattc tgtaticaaa satggaac ^ c 1320 ctccaattga tgcccataca aggaattlgc ttegpacca cataat ^ Laa gaccagctgg 1380 cctctaagta tctgtaccat ggacs ^ accc tggaaactct ^ gcggcaaa aaactgagag 1440 tttttgttta tegtaatagc ctctgcattg agaaagct £ catcgcggcc c ^ gacaaga 1S00 gggggaggta cggsaccctg tlcacgatss accssgtgct gaccccccca atggggactg 1560 tcatggatgt cctgaaggga gacaatcgct ttagcatgct ggtagctgcc atccagtctg 16¾) caggactgac ggagaccctc aaccgggaag gagtctacac agtcotgct cccacaaatg 1620 aagccttccg agccctgcca ccaagaiaac ggagcagact cttgggagat gccaaggaac 17^ ttgccaacat cctgaaatac cacattggtg atgaaatcct gsttagcgga ggcatcg£gg 1800 -30- 145138 · Sequence Listing.doc 201015069

ccctggtgcg gctaaagtct ctccaaggtg acaagctgga agtcagcttg aaaaacaatg 1860 tggtgagtgt caacaaggag cctgttgccg agcctgacat catggccaca aatggcgtgg 1920 tccatgtcat caccaat £ tt ctgcagcctc cagccaacag acctcaggaa agaggggatg 1980 aacttgcaga ctctgcgctt eagatcttca aacaagcatc agcgttttcc agggcttccc 2040 agaggtctgt £ billion £ actagcc cctgtctatc aaaagttatt agafaggatg aagcattagc 2100 ttgaagcact acaggaggaa tgcaccacgg cagctctccg ccaatttctc tcagatttcc 2160 acagagactg tttgaatgtt ttcaaaacca agtatcacac tttaatgtac atgggccgca 2220 ccataatgag atgtgagcct tgtgcatgtg £££ gaggagg gagagagatg tactttttaa 2280 atcatgttcc ccctaaacat ggctgttaac ccactgcatg cagaaacttg gatgtcactg 2340 cctgacattc acttccagag aggacctatc ccaaatgtgg aattgactgc ctatgccaag 2400 tccctggaaa aggagcttca gtattgtggg gctcataaaa catgaatcaa gcaatccagc 2460 ctcatgggaa gtcctggcac agtttttgta aagcccttgc acagctggag aaatggcate 2520 attataagct atgagttgaa at £ ttctgtc aaatgtgtct cacatetaca cgtggcttgg 2580 aggcttttat ggggccctgt ccaggtagaa aagaaatggt atgtagagct tagaittecc 26 40 tattgtgaca gagccatggt gtgtttgtaa taataaaacc aaagaaacat a 2691

<210> 81 <211> 1757 <212> DNA <213> Humans <400> 81 caagcttggc acgagggcag gcattgcccg agccagccga gccsccagag cc^ggccg 60 cgcgsgt£tc gcsggcccaa ccccaggatg ctcccx:tec£ cctcctgcct acccgggtot 120 ctactgctct gggcgctgct actgtt £ ctc ttgggatcag cttctcctca ggattctgaa 180 gagcccgaca gctacacgga atgcacagat ggctatgagt ££ gacccaga cagccagcac 240 tgccgggatg tcaacgagtg tctgaccatc cctgaggcct gcaaggggga aatgaagtgc 300 atcaaccact acgggggcta cttetgcctg ccccgctccg ctgxgtcat caacgaccta 360 cacggcgagg gacccccgcc accagtgcct cccgctcaac accccaaccc ctgcccacca 420 ggctatgagc ccgacgatca ggacagct £ t gtggatgtgg acgagtgtgc ccaggccctg 480 cacgact £ t £ gccccagcca ggactgccat aacttgcctg gctcctatca gtgcacctgc 540 -31- 145138 · sequence Listing .doc 201015069 cctgatggtt accgcaagat cgsgcccgag tstgtssaca tagacgagtg ccgctaccgc 600 tactgccagc accgctgcgt gaacctgcct ggctccttcc gctgccagtg cgagccgggc 660 ttccagctgg ggcctaacaa ccgctcctgt gtlgatgtga acgagtgtga ca ^ ggggcc 720 ccatgcgagc agcgctgctt caactcct at gggaccttcc tgtfitcgctg ccaccagggc 780 tatgagctgc atcgggatgg cttctcctgc agtgatatt £ atfiagtgtag ctactcca £ c 840 tacctctgtc agtaccgctg cftcaacgag ccaggccgtt tctcctgcca ctgcccacag 900 ggttaccagc tgctggccac acgcctctgc caagacatts atgagtgtsa £ tc ^ ggtgc £ 960 caccagtgct ccgaggccca aacctgtgtc aacttccatg ggggctaccg ctgcg ^ gac 1020 accasKxgct gcgtggagcc ctacatccag gtctetg ^ a accgctgtct ctgcccggcc 1080 tccaaccctc tatstceaga gcasccttca tccattgtgc accgctacat gaccatcacc 1140 tcggagcgga £ a £ tacccgc tgacgtgttc cagatccagg cgacctccgt ctacocc ^ t 1200 gcctacaatg cctttcagat ccgtgctgga aactcgcags eggactttta cattaggcaa 1260 atcaacaacg tcagcgccat sctggtcctc scccggccgg tgacgggccc ccgggagtac 1320 Stgctggacc tggagatggt caccatgaat tccctcatga gctaccgggc cagctctgta 1380 ctgaggctca ccgtctttgt aggggcctac accttctgag gagcaggagg gagccacxct 1440 ccctgcagct accctagctg Aggaggctgt tgtgaggggc agaatgagaa aggcccaggg 1500 gcccccattg acaggagctg ggagc£ctgc accacgagct tcagtcaccc cgagaggaga 1560 ggaggtaacg aggagggcgg actccaggcc c Cggcccaga gatttggact tggctggctt 1620 gca^gggtcc taagaaactc cactctggac agcgccag£a giccctgggt tccattccta 1680 actctgcctc aaactstaca ttt£gataag ccctagtagt tccctggscc tgtttttcta 1740 taaaac^agg caactgg 1757 <210> 82 <211> 1804 <212> DNA <213> Human <;400> 82 gtatcactca gaatctggca gccagttccg tcctgacaga gttcacagca tatattggtg 60 gattcttgtc catagtgcat ctgctttaag aattaacgaa agcagtgtca agacagtaag 120 -32- 145138-sequence table.doc 201015069

£ attcaaacc atttgccaaa aatgagtcta agtgcattta ctctcttcct ggcattgatt 180 ggtggtacca giggccagta ctatgattat gattttcccc tatcaattta tgggcaatca 240 tcaccaaact gtgcaccaga atgtaactgc cctgaaagct acccaagtgc catgtactgt 300 gatgagctga aattgaaaag tgtaccaatg gtgcctcctg gaatcaagta tctttacctt 360 aggaataacc agattgacca tattgatgaa aaggcctttg agaatgtaac tgatctgcag 420 tggctcattc tagatcacaa ccttctagaa aactccaaga taaaagggag agttttctct 480 aaattgaaac aactgaagaa gctgcatata aaccacaaca acctgacaga gtct £ tgggc 540 ccacttccot aatctctgga g £ atctgcag cttactcata acaagatcac aaagctgggc 600 tcttttgaag gattggtaaa cctgaccttc atccatctcc agcacaatcg gctgaaagag 660 gatgctgttt ca £ ctgcttt taaaggtctt aaatcactcg aataccttga cttgagcttc 720 aatcagatag ccagactgcc ttctggtctc cctgtctctc ttctaactct ctacttagac 780 aacaataaga tcagcaacat ccctgatgag tatttcaagc gttttaatgc attgcagtat 840 ctgcgtttat ctcacaacga actggctgat agtggaatac ctggaaattc tttcaatgtg 900 tcatccctgg ttgagctgga Tctgtcctat aacaagctta aaaacatacc aactgtcaat 960 gaaaaccttg aaaac tatta cctggaggtc aateaacttg agaagtttga cataaagagc 1020 ttctgcaaga tcctggggcc attatcctac tccaagatca agcatttgcg tttggatggc 1080 aatcgcatct cagaaaccag tcttccaccg gatatgtatg aatgtctacg tgttgctaac 1140 fiaagtcactc ttaattaata tctgtatcct ggaacaatat tttatggtta tgtttttctg 1200 tgtgtcagtt ttcatagtat ccatatttta ttactgttta ttacttccat gaattttaaa 1260 atct £ aggga aatgttttgt aaacatttat tttctttaaa gaaaagatga aaggcaggcc 1320 tatttcatca caagaacaca cacatataca cgaatagaca tcaaactcaa tgctttattt 1380 gtaaatttag tgttttttta tttctactgt caaatgatgt gcaaaaccit ttactggttg 1440 catggaaatc agccaagttt tataatcctt aaatcttaat gttcctcaaa gctlggatta 1500 aatacatatg gatgttactc tcttgcacca aattatcttg atacattcaa atttgtctgg 1560 ttaaaaaata ggtggtagat attgaggcca agaatattgc aaaatacatg aagcttcatg 1620 cacttaaaga agtattttta gaataagaat ttgcatactt acctagtgaa acttttctag 1680 aattattttl cactctaagt catgtatgtt tctctttgat tatttgcatg ttatgtttaa 1740 -33 · 145138_ .doc sequence table 201015069 taagctacta gcamtaaa acatagcaaa ^aaarnaa aaaaaaaaaa aa Aaaaaaaa 1800 1804 <210> 83 <211> 3290 <212> DNA <213> Human <400> 83 age ggccg gaccgggcgg geggageegg acccpcg rain ctectgcggg gegateggge 60 cgggccgctg ccgcgccatg gactcccgtg tcc^cctga gdcc&^xt cactgagtgg 120 ccacccccaa agtgdscca geegaggeag cccccagcao tgaccatgtc tattatggec 180 cacagcccca. ccacegecgt ggtc ^ agtc atc ^ atcc tcat ^ ccat cgcggccctg 240 ❹ ggggccttga tcctgggctg c ^ gtgctac c ^ ggctgc agegcatcag ccagtcagag 300 gaegaggaga gcatcstggg £ gaig ££ gag accaaggaac ccttcdgct gg ^ cagtat 360 tc £ gccaagg gaccgtgcgt Ggaga^aag gccaagctga ^actcccaa cggcccgg^i 420 itccdcggtx £agccag£at gcaaggctcc tggtectgu l^cagccggc caagag^gc 480 tgsgagggjgc aaaaccat^ gga^ege^ ctgtetgaga ggaagggc^ acacttgclg 540 gcatggcctc ^cgggjcttc gtcatcgcat gcactgatgc ccggggaoct ggo^icctg 6(X) ggct ^ccct cggcctccas gtgaggctgc ccat^cags ca^gggcag gcdgacctt 660 sc^ggsctc atggccctgt agegettt^ tiaettgaat gtctagctga gcctgtOd; 720 gatggageta ctactgtaat gcgtgaacta acaaacctgt gaactgtaaa taggcccctg 780 gaagcacgtg ettaageedt tttaaaaate teatetageg cacat ^ ggac 840 tggtattctjg gctgtactaa tgacaagc ^ agtmgacc ctg & amp tttgctgatt; igggtc atsggcttgt 900 ££ aggcccac gccacactcg gca ^ gggtct ctcaigtgtg tccatctgqi tgta ^ tcaa 93) ggaagtgagatgccaaatggggtcttgaggc ^ accagttggggtgatgggtgatctc 1020 t ^ cttcatta gtcatgggtg gaagaaaaac cacacccco: gcacccctcc gttctt & tg 1080 catagactca cttgttaaat agcafittct £ ttsagaet & g agttadgca eggaagoac 1140 cggacctgix igggagccag tgaagggcga eteaegecac gcgtcctgga ggc ^ ccagc 1200 Steettgtag cagagcagtt tcttgccgc ^ tggstettea gc ^ sccaas ccocaao »1260 accctccacc ccgagtsaas gettegetsa aattgctttg gtcctcatag agcc ^ tggt 1320 -34- 145138- sequence Listing .doe 201015069

ggct ^ tttt ggtctgaaac ccacttggcc caggaaagag aaaaggttgt atgttttgtg 1380 ttggtgtttc ctattttctg cactggaggg gaggggactg ttgaggttct gtcttttttc 1440 ttcttttcct cttccctett cacatcactt ggcttccttt cctctctgat gaccgtccgc 1500 ctatggggtt ctgacttcac ttlcctcagc gggtctccag tcccctgacc cagctctaaa 1560 ggcacttagg acccagggaa catttctcac gtgcacattc ccctaagagc caccagactg 1620 cttcctgcca gcctgtgctt gcggcaggga gccg ^ ggcag ggcagaggtg aacttgaagt 1680 tcaggacttg actotcccac aggtggtgag ctggtggctc tctggtgagc tagtgtctcc 1740 acagcctgtc tccaaggcct ccocta ^ ta catttcastg agctcacttt gatttttaat 1800 cccaccacaa gcacatacta attttattta ^ attcaaat g ^ actcgtg cctgcccatc 1860 cctgtaatag atggaa ££ tc agccccgga taaccacaea gcactggccc ttcatggc% 1920 agctcasagc tctgicctcc tgctcagact aaaggcacct cctctggcct cacccaagcc 1980 tcttctaaaa accatgttga atgaatccac gttctggaac cccgaggcgg gagaagtagg 2040 gasctgttcg tttaagcagc atacacctaa Attgggggtt taaacattaa gtaggagctt 2100 Igggtggaag agggacagcc ggctgggcca cctgagcaga aggtggtaat gaaacacctc 2160 agctgggctc ttgggagacc ttaggaagca ggagaggcaa cacctctggc tactga ^ gt 2220 gtggcaagttcagaagaggtggtggt £ gggtaggcgtgatgtcagcagaa £ ccctgoagg 2280 ctgggtgggc aggacacgtg gtggg ^ cca clgaaaccag gcctaggaeg gagaacaagt 2340 tccaaaggtgccgactggaagaagggggtaaaagtttectttggtgagtgagaaaa £ gct 2400 SSggcgtgtg atccatcccc tcacgtttca gaacttocag gctttctacc tcgactctca 2460 cx: acagccag cacatacacc taggctgttt ttccttcctc cacacctgag ggacgcagca 2520 acagctagga tctgcatttt caggttccga gcctgacccc tggaactgac cagcgctcga 2580 ttgtcasccttggcctgsg £ ttttgaccttgcca £ tgaagtttcggtmgaagteatta 2640 aatgtcactt cctcatcagt ttcacttctg gaggttttct tatcctactc cctggtgcca 2700 gggacgtacc tgggagtttg aatcaggccc atttgagcgt ggcagccgts ttgggtgaag 2760 Etccggggctcggtgaggcactgggggggttttcgggaggaaaatgaaaatgcttctaga 2820 atgagtgaac cacatcatag ctctcx ^ t tttttcaata gctacttttt ttagcagaca 2880 ocagagccac actcaaatgg ctaagtaggt tatgacctct ctggattatt tttgaatgcc 2940 • 35 · 145138- sequence table -doc 201015069 caactgttgc attcaagttt At tgactaat aagaaattaa gcaQratcc t^atcac 3000 tgcagaagcaacagtgggggcac ^ gggagggaactetliacactgagccactaaaatals 3060 gact suppression takes gacaaat c This aaacgg ac ^ dac tgtatt enough c tcaaagctac caasctgatt 3 i as caastt ^ ls caataagtgg aaggptgtc alccttcttc aatm ^ ct gaatgacatt 31 of ttctagacot ctgagaaaat cittattUK tttt: aataaattte aataaaattt 3240 gcat & astat attcccaaaa aaayqa ^ aaa aaaaaaagan Aa^aaaaaaa 3290 <210> 84 <211> 1616 <212> DNA <2i3> human

<400> 84 ❹ ctccotgtgt tsgtggagga tgtctgoagc a^attta^ ttet^gga^; sct^^t 60 cagcagcagc aggaggaggc agagcaca^ atcgic^ga ccagactcgt dcaggccag 120 ttgca^U ctcagccaaa cgccg^xaa ggaa^ctca dac^tgag aat^c^ tg 180 atttgcmt gcctcctagg calcacctgt gorataccag tu ^ aca ^ i ^ atlctgga 240 agttc ^ agg aaaagcagct ttacaacaaa tacccagatg ctgtggccac al ^ taaac 300 cct ^ tcccat ctcagaagca gaatctccta gccccacaga cccttccaag taagtccaac 360 gaaa ^ caggaclcca ttgactcgaa cgactctgat catg accacatgga tgatalggat gatgaaga ^ atgatgacca tgtggacagc 420 ^ itgtap% acactgatga Udcaccag 480 tctgatgagt cteaccattc tgatgaatct ga ^ aactgg tcactgattt teccacgga; 540 ctgccafcaa ccgaagtttt cactccagtt gtecccacag tagacacata tgatggcc ^ 600 ggtgatagtg tggtttatgg actgaggtca aaatctaaga agmogcag acctgacatc 6Θ0 cagtaccctg atgctacaga cgaggacatc accicacaoi tsgaa ^ cga ggagttgaat 720 ggt £ 〇ataca aggccatccc cgttgcccag gacctgaacg cgccttctga ttgggacagc 780 cgtgggaagg acagltatga aacgagtx ^g ctggatg^x: agagtgctga aacccacagc 840 cacaagcagt ccasattata taa^ggaaa gcc Aatgats agagcaatga gcattccgat 900 g^attgata gtcaggaact ttccaas^^: agccgtgaai tccacagcca tgaatttcac 960 agccatgaag atatgctggt tstagacccc aaaagtaagg aagaagataa acacctgaaa 1020 145〗 38-sequence table.doc -36· 201015069

tttcgtattt ctcatgaatt agatagtgca tcttctgagg tcaattaaaa ggagaaaaaa 1080 tacaatttct cactttgcat ttagtcaaaa gaaaaaatgc tttatagcaa aatgaaagag 1140 aacatgaaat gcttctttct cagtttattg gttgaatg ^ tatctatttg agtctggaaa 1200 taactaatgt gtttgataat tagtttagtt tgtggcttca tggaaactcc ctgtaaacta 1260 aaagcttcag ggttatgtct atgttcattc tatagaagaa atgcaaacta tcactgtatt 1320 ttaatatttg ttattctctc atgaatagaa atttatgtag aagcaaacaa aatactttta 1380 cccacttaaa aagagaatat aacattttat gtcactataa tcttttgttt tttaagttag 1440 tgtatatttt gttgtgatta tctttttgtg gtgtgaataa atcttttatc ttgaatgtaa 1500 taagaatttg gtggtgtcaa ttgattattt gttttcccac ggttgtccag caattaataa 1560 aacataacct tttttactgc ctaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1616 < 210 > 85 < 211 > 11185 < 212 > DNA < 213 > human < 400 > 85 a gctgccccga gcctttctgg ggaagaactc Caggcgtgcg gacgcaacag ccgagaacat 60 taggtgttgt ggacaggagc tgggaccaag atcttcggcc agccccgcat cctcccgcat 120 cttccagcac cgtcccgcac cctccgcatc cticcccggg ccaccacgct tcctatgtga 180 cccgcctgj ^ caacgccgaa cccagtcgcg cagcgctgca gtgaattttc cccccaaact 240 _ gcaataagcc gccttccaag gccaagatgt tcataaatat aaagagcatc ttatggatgt 300 Xin gttcaacctt aatagtaacc catgcgctac ataaagtcaa agtgggaaaa agcccaccgg 360 tgagggsctc cctctctgga aaagtcagcc taccttgtca tttttcaacg atgcctactt 420 tgccacccag ttacaacacc agtgaatttc tccgcatcaa atggtctaag attgaagtgg 480 acaaaaatgg aaaagatttg aaagagacta ctgtccttgt ggcccaaaat ggaaatatca 540 agattggtca ggactacaaa gggagagtgt ct £ tgcccac acatcccgag gctgtgggcg 600 atgcctcxct cactgt £ gtc aagctgctgg caagtgatgc gggtctttac cgctgtgacg 660 tcatgtacgg gattgaagac acacaagaca cggtgtcact gactgtggat ggggttgtgt 720 ttcactacag ggcggcaacc agcaggtaca cactgaattt tgaggctgct cagaaggctt 780 gtttggacgt tggggcagtc atagcaactc cagagcagct cttt £ 〇tgcc tatgaagatg 840 • 37- 145138- sequence Listing .doc 201015069 gatttgagca £ tgtgacgca Ggctggctgg ctgatcagac tgtcagatat cccatccggg 900 ctcccagagt aggctgttat ggagataaga tgggaaaggc aggagtcagg acttatggat 960 tccgttctco ccaggaaact tacgatgtgt attgtta tgt ggatcatctg gatggtgatg 1020 tgttccacct cactgtcccc agtaaattca ccttcgagga ggctgcaaaa gagtgtgaaa 1080 accaggatgc caggctggca acagtggggg aactccaggc ggcat £ gagg aacggctttg 1140 accagtscga ttacgggtgg ctgtcggatg ccagcgtgcg ccaccctgtg actgtggcca 1200 ggscccagtg tggaggtggt ctacttgggg tgagaaccct gtatcgtttt gagaaccaga 1260 caggcttccc tccccctgat agcagatttg atgcctactg ctttaaacct aa ^ gaggcta 1320 caaccatcga tttgagtatc ctc £ cacaaa ctgcatcacc cagtttatcc aaagaaccac 1380 aaatggtttc tgatagaact acaccaatca fccctttagt cctgtcattc 1440 caacagagtt ccctcccgtg g £ aaatattg tcagttttga acagaaagcc acagtccaac 1500 ctcaggctat cacasatagt ttagccacca aattacccac acctactggc agtaccaaga 1560 agccct £ gga tatggatgac tactcacctt ctgcttcagg acctctt £ ga aagctagaca 1620 tatcagaaat taaggaagaa £ t £ 〇tccaga gtacaactgg cgtctctcat tatgctacgg 1680 attcatggga tggtgtegtg £ tgatgaatta Aagataaac aaacacaaga atcgettaca cagattgaac 1740 aaatagaagt gggtcctttg gtaacatota tggaaatctt aaagcacatt ccttccaagg 1800 aattccct£t aactgaaaca ccattggtaa ct gcaagaat gatcctggaa tccaaaactg 1860 aaaagaaaat ggtaagcact gtttctgaat tggtaaccac aggtoactat ggattcacct 1920 tgggagaasa ggatgatgaa gacagaacac ttacagttgg atctgatgag agcaccttga 1980 tctttgacca aattcctgaa gtcattacgg tgtcaaagac ttcag ^ igac accatccaca 2040 ctcatttaga agacttggag tcagtctcag catccacaac tgtttcccct ttaattatgc 2100 ctgataataa tggatcatcc atggatgact gggaagagag acaaactagt ggtaggataa 2160 cggaagagtt tcttggcaaa tatctgtcta ctacaccttt tccatcacag catcgtacag 2220 aaatagaatt gtttccttat Tctggtgata aaatattagt agaEggaatt tccacagtta 2280 tttatccttc tctacaaaca gaaatgacac atagaagaga aagaacagaa acactaatac 2340 cagagatgag aacagatact tatacagatg aaatacaaga agagatcact aaaagtccat 2400 ttatgggaaa aacagaagaa gaagtcttct ctgggatgaa actctctaca tctctctcag 2460 -38- 145138 · Sequence Listing.doc 201015069

agccaattca tgttacagag tcttctgtgg aaatgaccaa gtcttttgat ttcccaacat 2S20 tgataacaaa gttaagtgca gagccaacag aagtaagaga tatggaggaa gactttacag 2580 caac ^ cagg tactacaaaa tatgatgaaa atattacaac agtgcttttg gcccatggta 2640 ctttaagtgttgaagcagccactgtatcaaaatggtcatgggatgaagataatacaacat 2700 ccaag〇cm ^ gtc ^ cagaa < xttcagcctcttcaaaattsccccctgccttactca 2760 caactgtggggatgaatggaaaggataaagacatcccaagtttcactgaagategagcag 2820 atgaatttac tcttattcca gatagtactc aa ^ agcagtt agaggaggtt actgatgaag 2880 acatagcagc ccatggaaaa ttcacaatta gatttcagcc aactacatca actggtattg 2940 cagaaaagtc aactttgaga pttctacaa ctgaagaaaa agttccacct atcacaagca 3000 ctgaaggcca agtttatgca accatggaag gaagtgcttt gsgtsaagca gaagatgtgg 3060 acctctctaa gccagtatcc actgttcccc aatttgcaca cacttcagag stggaaggat 3120 tagcatttgt tagttatagt agcacccaag agcctactac ttatgtasac tcttcccata 3180 ccattcctct ttctstaatt cccaagaoag actgg £ gagt sttagtacci tctgttccat 3240 cagaagatga agttctaggt gaaccctctc aagacatact tgtcattgat cagactcgcc 3300 Ctgaagcgac tatttctcca gaaactatga gaacaacaaa aatcacagag ggaacaactc 3360 aggaagaattcccttggaaagaacagactgcagagaaaccagttoctgctctcagttcta 3420 cagcttggac tcccaaggag gcagtaacac cactggatga acaagagggo galggatcag 3480 catatacastctctgaagatgaattgttgacaggttctgasagggtcccagttttagaaa 3540 caactccagt tggaaaaatt gatcacagtg tgtcttato: accaggtgct gtaactgagc 3600 acaaagtgaa aacagatgaa gtggtaacac taacaccacg catt ^ ggcca aaagtatctt 3660 taagtccagg gcctgaacaa aaatatgaaa cagaaggtag tagtacaaca ggatttacat 3720 catctttgag tccttttagt acccacatta cccascttat ggaagaaacc actactgaga 3780 aaacatccct agaggatatt gatttaggct caggattaU tgaaaagccc aaagccacag 3840 aactoataga attttcaaca atcaaagtca cagttccaag tgatattacc actgccttca 3900 gttcagtaga cagacttcac acaacttcag cattcaagcc atcttccgcg atcactaaga 3960 aaccacctct catcgacagg gaacctggtg aagaaacaac cagtgacatg gtaatcattg 4020 Eagaatcaac atctcatgtt cctcccacta cccttgaaga tattgtagcc aaggaaacag 4080 -39- 145〗 38- sequence Listing .doc 201015069 aaaccgatat tgatagagag tatttcacga cttcaagtcc tcctgctaca cagcx :aacaa 414 0 gaccacccac tgtggaasac aaagaggcct ttggacctca ggcgctttct ac£〇cacagc 4200 ccccagcaascacaaaatttcaccctgacattaatgtttatattattgaggtcagagaaa 4260 ataagaca£g tcgaatgagt gattteagtg taat^gtca tccaatagat tcagaatcta 4320 aagaagatga acx:ttgtagt gaagaaacag aliccagtgca tgatctaa^ gdgaaattt 4380

aagaagaaga gtgtgcaaat gctactgatg tgacaaccac cccatctgtg cagtacataa 4500 atgggaagca tctcgUacc actgtgccca aggacccaga agc ^ cagaa gctaggcgts 4560 gccastttsaaagtgtt £ caccttctcagaatttck: ggacagcK; igaaagtgatactc 4620 atccatttgtaatagccaaaacggaattgtctactgctetscaacctaatgaatctacag 4680 aaacaactga gtt ^ tgaa gttacal ^ agcct ^ gac ttaccctgaa acatcagaac 4740 atttttcasetss ^ gcctgat £ ttttccccacagtcc ^ attcca ^ aggaatttgaaa 4S00 gtggaacagccaaaaaaggggcagaatcagtcacagagagagatactgaagt ^ gteatc 4860 a £ gcacatga acatactgaa cctgtatctc tgtttcctga ag ^ tettca ggagagatts 4920 ccatt £ acca agaatctcag aaaatagcct ttgcaa £ ggc tacagaagta acatttggtg 4980 aagaggtaga aaaaagtact tctgtcacat acactcocac tatagttcca agttctgcat S040 cagcatatgt ttcagaggaa gaascagtta ccctaatagg aaatccttgg ccagatgacc 5100 tgttgtctac caaagaaagc tgggtagaag caactcctag acaagttgta gagctctcag 5160 ggagttcttcgattccaattacagaaggctctggaga ^ cagaagaagatgaagatacaa 5220 tgttcaccat Ggtaactgat ttatcacaga gaaatactac ^atacactc attactttag 5280 acactagcag gataatcaca gaaagctttt ttgaggt tcc tgcaaccacc atttatccag 5340 tttctgaaca accttctgca aaagtgg ^ c ctaccaagtt tgtaagtgaa ac ^ acactt 5400 ctgagtggat Occagtacc actgttgagg aaa ^ aaaag gaaggaggag gagggaacta 5460 caggtacggcttctacatttgaggtatattcatctacacagagatcggatcaattaattt 5520 taccctttgaattagaaagtccaaatgtagctacatctagtgattcaggtaccagsaaaa 5580 gttttatgtc cttgacaaca ccaacacagt ctgaaaggga aatgacagat tctactcctg 5640 tctttacaga aacaaataca ttagaaaatt gaccactgag cacagcagta 5700 • 40 · 145138 · Sequence Listing tgggggcaca. Doc 201015069

tccatcaacc tggggttcag gaagggctga ccactctccc acgtagtcxt gcctctgtct 5760 ttatggagca gggctctgga gaagctgctg ccgacrcaga aaccaccact gtttcttcat 5820 tttcattaaa cgtagagtat gcaattcaag ccgaaaagga agtagctggc actttgtctc 5880 cgcatgtgga aactacattc tccactgagc caacaggact ggttttgagt acagtaatgg 5940 aca £ agtagt tgctgaaaat ataacxxaaa catcca ££ ga aatagtgatt tcagagcgat 6000 taggagaacc aaattatggg gcagaaataa g £ ggcttttc cacaggtttt cctttggagg 6060 aagatttcag tggtgacttt agagaataot caacagtgtc tcatcccata gcaaaagaag 6120 aaacggtaat gatggaa £ gc tctggagatg cagcatttag ggacacccag acttcaccat 6180 ctacagtacc tacttcagtt cacatcagtc acatatctga ctcagaagga cccagtagca 6240 ccatggtcag cacttcagcc ttcccctggg aagagtttac atcctcagct gagggctcag 6300 gtgagcaact ggtcacagtc agcagctctg ttgttccagt gcttcccagt gctgtgcaaa 6360 agttttctgg tacagcttcc tccattatcg acgaaggatt gggagaagt £ ggtactgtca 6420 atgaaattga tagaagatcc accattttac caacagcaga agtggaaggt acgaaagctc 6480 cagtagagaa ggaggaagta aaggtcagtg gcacagtttc aacaaacttt ccccaaacta 6540 tagagcca £ 〇caaattatgg tctaggcaag aagtcaaccc tgtaagacaa gaaattgaaa 6600 gtgaaacaac atcagaggaa caaattcaag aagaaaagtc atttgaatcc cctcaaaact 6660 ctcctgcaac agaacaaaca atctttgatt cacagacatt tactgaaact gaactcaaaa 6720 ccacagatta ttctgtacta acaacaaaga aaacttacag tgatgataaa gaaatgaagg 6780 aggaagacac ttctttagtt aacatgtcta ctccagatcc agatgcaaat ggcttggaat 6840 cttacacaac tctccctgaa gctactgaaa agtcacattt tttcttagct actgcattag 6900 taactgaatc tataccagct gaacatgtag tcacagattc accaatcaaa aaggaagaaa 6960 gtacaaaaca ttttccgaaa ggcatgagac caacaattca agagtcagat actgagctct 7020 tattctctgg actgggatca ggagaagaag ttttacctac tctaccaaca gagtcagtga 7080 attttactga agtggaacaa atcaataaca cattatatcc ccacacttct caagtggaaa 7140 gtacctcaag tgacaaaatt gaagacttta acagaatgga aaatgtggca aaagaagttg 7200 gaccactcgt atctcaaaca gacatctttg aaggtagtgg gtcagtaacc agcacaacat 7260 taatagaaat tttaagtgac actggagcag aaggacccac ggtggcacct ctccctttct 7320 • 41 - 145138- sequence Listing .doc 201015069 ccacggacat cggacatcct caaaatcaga ct gtcaggtg ggcagaagaa atccagacta 7380 gtagaccaca aaccataact gaacaagact ctaacaagaa ttcttcaaca gcagaaatta 7440 acgaaacaac aacctcatct actgattttc tggctagagc ttatggtttt gaaatggcca 7500 aasaatttgt tacatcagca ccaaaaccat ctgacttgta ttatgaacct tctggagaag 7560 gatctggagaagtggatattgttgattcatncacacttctgcaactactcagscaac ^ a 7620 sacaagaaag cagcaccaca tttgtttctg atgggtccct ggaaaaacat cctgaggtgc 7680 caagcgctaaagctgttactgctgatggattcccaacastttcagtgatgc ^ cctcttc 7740 atu ^ ga £ cagaacaaaagctcccct £ atocaacta £ cacactgtcaaatacag ^ Lcat 7800 atgagaggtc cacagacggt agtttccaag accstttcas ggaaticgag gattccacct 7860

aggatttaatattgacaattacagagagtaccaiccttgaaattctacctgagc ^ acat 7980 cggataaaaa tactatcata satattgatc atactaaacc tgtgtatgaa gacattcttg 8040 gaatgcaaac agatatagat acagaggtac caicagaacc acatgacagt aatgatgaaa 8100 gtaatgatga cagcactcaa gttcaagaga tctatgaggc agctgtcaac 8160 ctgaggaaac attt £ a ££ gc tctgctgat £ ttctggctag ctacactcag gcaacacatg 8220 atgaatcaat gacttatgaa gatagaagcc aactasatca catgggcttt cacttcacaa 8280 ctggsatccc tgctcctagc acagaaacag aattagacgt tCtactlccc acggcaacat 8340 ccctgccaat tcctcgtaag tetgccacag ttattccaga gattjaaua ataaaagctg 8400 aagcaaaagc cctggatgac atgtttgaat caagcacttt gtctgatggt caaectattg 8460 cagaccaaag tgaaataata ccaacattgs gccaatttga aaggactcag gaggagtatg 8520 aagacaaaaa acatgctggt ccttcttttc agccagaatt ctcttcagga gctgaggagg 8580 cattagtaga ccatactccc tatctaagta ttgctactac ccaccttatg gatcagagtg 8640 taacagaggt gcctgatgtg atggaaggat ccaatccccc atattacact gatacaacat 8700 tagcagtttc aacatttgcg aagttgtctt ctca £ acacc atcatctccc Ctcactatct 8760 actcaggcag tgaagcct Ct ggacacacag agatccccca gcccagtgct ctgccaggaa 8820 tagacgtcgg ctcatctgta atgtccccac aggattcttt taaggaaatt catgtaaata 8880 ttgaagcaac tttcaaacca tcaagtgagg aataccttca cataactgag cctccctctt 8940 • 42· 145138 · Sequence Listing.doc 201015069

tatctcctga cacaaaatta gaaccttcag aagatgatgg taaacctgag ttattagaag 9000 aaatggaagc ttctcccaca gaacttattg ctgtggaagg aactgagatt ctccaagatt 9060 tccaaaacaa aaccgatggt caagtttctg gagaagcaat caagatgttt cccaccatta 9120 aaacacctga ggctggaact gttattacaa ctgccgatga aatt ^ aatta gaaggtgcta 9180 cacagtggcc acactctact tctgcttctg ccacctatgg ggtcgaggca ggtgtggtgc 9240 cttggctaag tccacagact tctgagaggc ccacgctttc ttcttctcca gaaataaacc 9300 ctgaaactca agcagcttta atcagagggc aggattccac gatagcagca tcagaacagc 9360 aagtggcagc gagaattctt gattccaatg atcaggcaac agtaaaccct gtggaattta 9420 atactgaggt tgcaacacca ccattttccc ttctggagac ttctaatgaa acagatttcc 9480 tgattggcat taatgaagag tcagtggaag gcacggcaat ctatttacca ggacctgatc 9540 gctgcaaaat gaacccgtgc cttaacggag gcacctgtta tcctactgaa acttcctacg 9600 tatgcacctg tgtgccagga tacagcggag accagt £ tga acttgatttt gatgaatgtc 9660 actctaatcc ctgtcgtaat ggagccactt gtgttgatgg ttttaacaca ttcaggtgcc 9720 tctgccttcc aagttatgtt ggtgcacttt gtgagcaaga taccgagaca Tgtgactatg 9780 gctgg cacaa attccaaggg cagtgctaca aatactttgc ccatcgacgc acatgggatg 9840 cagctgaacg ggaatgccgt ctgcagggtg cccatctcac aagcatcctg tctcacgaag 9900 aacaaatgtt tgttaatcgt gtgggccatg attatcagtg gataggcctc aatgacaaga 9960 tgtttgagca tgacttccgt tsgactgatg gcagcacact goaatacgag aattggagac 10020 ccaaccagcc agacagcttc ttttctgctg gagaagactg tgttgtaatc atttggcatg 10080 agaatggcca gtggaatgat gttccctgca attaccatct cacctatacg tgcaagaaag 10140 gaacagttgc ttgcggccag ccccctgttg tagaaaatgc caagaccttt ggaaagatga 10200 aacctcgtta tgaaatcaac tccctgatta gataccactg caaagatggt ttcattcaac 10260 gtcaccttcc aactatccgg tgcttaggaa atggaagatg ggctatacct aaaattacct 10320 gcatgaaccc atctgcatac caaaggactt attctatgaa atactttaaa aattcctcat 10380 cagcaaagga caattcaata aatacatcca aacatgatca tcgttggagc cggaggtggc 10440 aggagtcgag gcgctgatcc ctaaaatggc gaacatgtgt tttcatcatt tcagccaaag 10500 * tcctaacttc ctgtgccttt cctatcacct cgagaagtaa ttatcagttg gtttggattt 10560 • 43- 145138- sequence table. Doc 201015069

t ^ gaccacc gttcagtcat tttgggttsc cgtgctccca aaacamta aatgaaagta 10620 ttggcattca aaaagacagc agacaaaatg aaagaaaatg agagcagaaa gtaagcattt 10680 cc ^ gcctatctaatttctttagttttctatttgcctccagtgcagtccatttcctaatgt 10740 ataccagcctactgtactatttaaaatgctcaattteagcaccgatggccatgtaaataa 10800 ga ^ atttaatgtt £ attttaatcctgtatataaaataaaaagtcacaat £ agtttgggc 10860 atatttaatg atgattatgg agccttagag gtctttaatc att £ gttcgg ctgcttttat 10920 gtagmagg ctsgaaatgg tttcacttgc tctttgac ^ tcagcaagac tgaasa ^ gc 10980 ttitcctgga Cagctagaaa acacaaaatc t^taggtca ttgcacctat ctcagccata 11040 ggtgcagttt gcttctacat ga^ctaaag gctgcgaatg ggatcctgat ggaactaagg 11100 actccaatgt cgaactcttc WLgc\gczt tcctttttct tcacttacaa gaaaggcctg 11160 aatggaggac ttttctgtaa ccagg 1118S

<210> 86 <211> 2503 <212> DNA

<213> Human I <400> 86

Esactttgaa atccaacccg gtcacctacc cgcgcgdctg tgtccacgga tggcacgaaa 60 gccaagcgag tccccctgcc gagctactcg cgtccgcciK: ctcccaagct gagctotgct 120 ccgcccacct sagtccttcg ccagttagga £ gaaacacag ccgcttaatg aactgctgca 180 tcgggctggg agagaaagct cgcgggtccc accgggcctc ctacccaagt ctcagcgcgc 240 ttttcaccga ggcctcaatt ctgggatttg gcagctttgc tgtgaaagcc caatggacag 300 aggactgcag aaaatcaacc tatcctcctt ca ^ gaccaac gtacagaggt gcagttccat 360 gStacaccat aaatcttgac ttaccaccct acaaaagatg gcatgaatts atgct ^ aca 420 aggcaccaat gctaaaggtt atagtgaatt ctctgaagaa tatgataaat acattcgtgc 480 caa £ tggaaa agttatgcag gtggtggatg aaaaattgcc tggcctactt ggcaacttte 540 ctggcccttt tgaagaggaa atgaagggta ttgccgctgt tactgatata cctttaggag 600 agattatttc attcaatatt ttttatgaat tatttaccat ttgtacttca atagtagcag 660 aagacaaaaa aggtcatcta atacatggga gaaacatgga ttttggagta tttcttgggl 720 • 44 · 145138- sequence table. Doc 201015069

ggaacataaa taatgatacc tgggtcataa ctgagcaact aaaaccttta acagtgaatt 780 tggatttcca aagaaacaac aaaactgtct tcaaggcttc aagctttgct ggctatgtgg 840 gcatgttaac aggattcaaa ccaggactgt tcagtcttac actgaatgaa cgtttcagta 900 taaatggtgg ttatctgggt attctagaat g £ attct £ gg aaagaaagat gccatgt £ ga 960 tagggttcct cactagaaca gttctggaaa atagcacaag ttatgaagaa gccaagaatt 1020 tattgaccaa gaccaagata ttggccccag cctactttat cctgggaggc aaccagtctg 1080 gggaaggttg tgtgattacacgagacagaa aggaatcatt ggatgtatat gaactcgatg 1140 ctaagcaggg tagatggtat gtggtacaaa caaattatga ccgttggaaa catcccttct 1200 tccttgatga tcgcagaacg cctgca suppression ga tgtgtctgaa ccgcaccagc caagagaata 1260 tctcatttga aaccatgtat gatgtcctgt caacaaaacc tgtcctcaac aagctgacx: g 1320 tatacacaac cttgatagat gttaccaaag gtcaattcga aacttacctg cgggactgo: 1380 ctgacccttg tataggttgg tgagcacacg tctggcctac a £ aatgcggc ctctgagaca 1440 tgaagacacc atctccatgt gaccgaacac tgcagctgtc Tgaccttcca aagactaaga 1500 ctcgcggcag gttctctttg agtcaaaagc ttgtcttcgt ccatctgttg acaaatgaca 1560 gacct ttttt tttcccccat cagttgattt ttcttattta cagataactt ctttagggga 1620 agtaaaacag tcatctagaa ttcactgagt tttgtttcac tttgacattt ggggatct £ g 1680 tgggcagtcg aaccatggtg aactccacct ccgtggaata aatggagatt cagcgtgggt 1740 gttgaatcca gcacgtctgt gtgagtaacg g £ acagtaaa cactccacat tcttcagttt 1800 ttcacttcta cctacatatt tgtatgtttt tctgtataac agccttttcc ttctggtlct 1860 aactgctgtt aaaattaata tatcattatc tttgctgtta ttgacagcga tataatttta 1920 ttacatatga ttagagggat gagacagaca ttcacctgta tatttctttt aatgggcaca 1980 aaatgggccc ttgcctctaa atagcacttt ttggggttca agaagtaatc agtatgcaaa 2040 gcaatctttt atacaataat tgaagtgttc cctttttcat aattactgta cttcccagta 2100 accctaagga agttgctaac ttaaaaaact gcatcccacg ttctgttaat ttagtaaata 2160 aacaagtcaa agacttgtgg aaaataggaa gtgaacccat attttaaatt ctcataagta 2220 gcattcatgt aataaacagg tttttagttt gttcttcaga ttgataggga gttttaaaga 2280 aattttagta gttactaaaa ttatgttact gtatttttca gaaatcaaac tgcttatgaa 2340 -45- 145138- Sequence table.doc 201015069 aagtactaat agaacttgtt aacctttcta accttcacga ttaactgtga aatgtacgtc 2400 atttgtgcaa £ accgtttgt ccacttcatt ttgtataatc acagttgt £ t tcctgacaot 2460 caataaacag tcattggaaa gagtgccagt cagcagtcat gca 2503 < 210 > 87 < 211 > 2341 < 212 > DNA < 213 > human < 400 > 87 ggctcttctt tgcctctgct ggagtccggg gagtggcgtt ggctgctaga gcgatgccgg 60 gccggagttg c £ tcgcctta gtcctcctgg ctgccgccgt cagctgtgcc gtcgcgcagc 120 acgcgccgcc gtggacagag £ ac ^ cagaa aatcaaccta tcctccttca ssaccaacgt 180 acagaggtgc agttccatsg tacaccataa atcttgactt accaccctac aaaagatfigc 240 atgaattgat gcttgacaag gcaccaatgc taaaggttat agtgaattct ctgaagaata 300 tgataaatac attcgtgcca agtsgaaaag ttatgcagst ggtggatgaa aaattgcctg 360 gcctacttgg caactttcct ggccctttts aagaggaaat gaagggtatt gccgctgtta 420 otgatatacc ttta ££a£ag attatttcat tcaatatttt ttatgaatta tttaccattt 480 gtacttcaat agtagcagaa gacaaaaaag gtcatctaat aca^ggaga aacaiggatt 540 ttggagtatt tcttgggtgg aacataaata atgatacctg ggtcataact gagcaactaa 600 aacctttaac agfgaatttg gatttccaaa gaaacaacaa aactgtcttc aaggcttc aa 660 gctttgctgg ctatg ^ ggc atgttaacag gattcaaacc aggactgttc agtcttacac 720 tgaatgaacg tttcagtata aatgg ^ gtt atctggetat tctagaatsg attctgggaa 780 agaaagatgc ca ^ tggata gggtlcc ^ a ctagaacagt tctggaaaat agcacaagtt 840 atgaagaagc caagaattta ttgaccaaga ccaagatatt ggccccagcc tacttlatcc 900 tgggaggcaa ccagtctggg gaaggttgtg tgattacacg agacagaaag gaatcattgg 960 atgtatalga actcgatgct aagcagggta gatggta ^ t ^ gtacaaaca aatta ^ acc 1020 gttsgaaaca tcccttcttc cttgatgatc gcagaacgcc tgcaaagatg tgtctgaacc 1060 gcaccag < xa agasaatatc tcatttgaaa ccatgtatga tgtcctg ^ a acaaaacctg 1140 tcctcaacaa gctgao: gta tacacaacct tgata £ atgc taccaaaggt caattcgaaa 1200 cttacctgcg ggactgccct gacc ^ ttgta taggttgstg agcacacgtc t £ gcctacag 1260 • 46 · 145丨38-Sequence List.doc 201015069

aatgcggcct ctgagacatg aagacaccat ctccatgtga ccgaacactg cagctgtctg 1320 accttccaaa gactaagact cgcggcaggt tctctttgag tcaaaa £ ctt gtcttcgtcc 1380 atctgttgac aaatgacaga cctttttttt tcccccatca gttgattttt cttatttaca 1440 gataacttct ttaggggaag taaaacagtc atctagaatt cactgagttt ttcagttttt cacttctacc tacatatttg tgtttcactt 1500 tgacatttgg ggatctggtg ggcagtcgaa ccatggtgaa ctccaoctcc gtggaataaa 1560 tggagattca gcgt £ ggtgt tgaatccagc acgtctgtgt gagtaacggg acagtaaaca 1620 ctccacattc tatgttttlc tgtataacag 1680 ccttttcctt ct £ gttctaa ctgctgttaa aattaatata tcatlatctt tgctgttatt 1740 gacagcgata taattttatt acatatgatt agagggatga gacagacatt cacctgtata 1800 tttcttttaa tgggcacaaa atgggccctt gcctctaaat agcacttttt ggggttcaag 1860 aagtaatcag tatgcaaagc aatcttttat acaataattg aagtgttccc tttttcataa 1920 ttactgtact tcccagtaac cctaaggaag ttgctaactt aaaaaactgc atcccac ^ t 1980 ctgttaattt agtaaataaa caagtcaaag acttgtggaa aataggaagt gaacccatat 2040 tttaaattct Cataagtagc attcat£taa taaacaggtt tttagtttgt tcttcagatt 2100 gat Agggagt tttaaa£aaa ttttagtagt tactaaaatt atgttactgt attettcaga 2160 aatcaaactg cttatgaaaa gtactaatag aacttgttaa cctttctaac cttcacgatt 2220 aactgtgaaa tgtacgtcat ttgtgcaaga ccgtttgtcc acttcatttt gtataatcac 2280 agttgtgttc ctgacactca ataaacagte attggaaaga gtgccagtca gcagtcatgc 2340 a 2341

≪ 210 > 88 < 211 > 2039 < 212 > DNA < 213 > human Shu < 400 > 88 ccggccctcg ccctgtccgc cgccaccgcc gccgccgcca gagtcgccat gcagatccxg 60 cgcgccgctc ttctcccgct gctgctgctg ctgctggcgg cgcccgcctc ggcgcagctg 120 tcccgggccg gccgctcggc gcctttg £ cc gccgggtgcc cagaccgctg cgagccggcg 180 cgctgcccgc cgcagccgga gcacigcgag ggcggccggg cccgggacgc gtgcggctgc 240 -47 · 145138- sequence Listing .doc 201015069 tgcgaggtgt gcggcgcgcc cgagggcgcc gcgtgcggcc ^ casgaggg cccgtgcggc 300 gaggggct £ c agtgcgtggt gcccttcggg gtgccagcct cggtxacggt gcggcggcgc 360 gcgcaggccg scctctgtgt gtgcgcxagc agcgagcogg tgtg〇 £ gcag cgacgccaac 420 acctacgcca acctgtgcca gctgcgcgcc gcca ^ ccgcc £ cto〇 £ agag gctgcaccgg 480 ccgccggtca tcgtcctgca gcgcggagcc tgcggccaag ggcaggaaga tcccaacagt 540 ttgcgccata aatataactt tatcgcggac glggtggaga agatcgcccc ^ ccgtggtt 600 catatcgaat tgtttcgcaa gcttecgttt tctaaacgag agg ^ ccggt ggctagtggg 660 tctgggttta ttgtgt〇 £ ga aga ^ gactg atcgtgacaa a ^ cccacgt ggtgaccaac 720 aagcaccggs tcaaagttga gctgaagaac ggtgccactt acgaagrcaa aatcaaggat 780 gtggatgaga aagcagacat cgcactcatc aaaattgacc accagggcaa gdgcctgtc 840 ctgctgcttg gccgctcctc agagctgcgg ccgggagagt tcg ^ gtegc catcggaagc 900 ccgttttccc ttcaaaacac agtoaccacc gggatcgtga gcaccaccca gcgaggcggc 960 aaagagctgg ggctccgcaa ctcagacatg gactacatcc agaccgacgc catealcaac 1020 tatggaaact cgggaggccc gttagtaaac ctggacggtg aa £ tgatt ££ aattaacact 1080 ttgaaagtga cagctggaat ctccotgca atcccatctg ataasattaa aaagttcctc 1140 acggagtccc atgaccgaca ggccaaasga aaagccatca ccaagaagaa gtatattggt 1200 atccgaatga tgtcactcac gtccagcaaa gccaaagagc tgaaggaccg gcaccgggac 1260 ttcccagacg tgatctcagg agcgtatata attgaagtaa ttcct £ atac cccagcagaa 1320 gctggtggtc tcaaggaaaa cgacgtcata atcagcatca atggacagtc cgtggtctcc 1380 gccaatgatg tcagcgacgt cattaaaagg gaaagcaccc tgaacatggt ggtccgcagg 1440 ggtaatgaag atatcatgat cacagtgatt cccgaagaaa ttgacccata ggcagaggca 1500 tgagctggac ttcatgtttc cctcaaagac tctcccgtgg Atgacggatg aggactctgg 1560 gctgctggaa taggacactc aagacttttg actgccat tt tgtttgttca gtggagactc 1620 cctggccaac agaatccttc ttgatagttt gcaggcaaaa caaatgtaat gttgcagatc 1680 cgcaggcaga agctctgccc ttctgtatcc tatgtatgca gtglgctttt tcttgccagc 1740 ttgggxatt cttgcttaga cagtcagcat ttgtctcctc ctttaactga £ tcatcatct 1800 tastccaact aatgcagtcg atacaatgcg tagatagaag aagccccacg ggagccagga 1860 -48- 145138- Sequence Listing .doc 201015069 tgggactget cgtgtt ^ tg cttttctcca agtcagcacc caaaggtcaa Tgcacagaga 1920 cccxgggtgg stgagcgctg gcttctcaaa cggccgaagt tgcctctttt aggaatctct 1980 ttgfiaattgg gagcacgatg actctgagtt tgag^atta aagtacttct ^cacattg 2039

<210> 89 <211> 1387 <212> DNA

Human I <400> 89 ccgg£tc£ga gccocccgga gctgcg〇£cg ggcttgcagc gcctcgcccg cgctgtcctc 60 CCggtgtCCC gCttCt〇C£C gccccagccg CCg£Ct£C〇a £CttttC£gg sccccg^gtc 120 gcacccagcg aagagagcgg gcccgggaca agctcgaact ccggccgcct cgcccttccc 180 9 c £ gctccgct ccctctgccc cctcggggtc £ cgcgcccac gatgctgcag ggccctggct 240 cgctgctgct gctcttcctc gcctcgcact gctgcctggg ctcggcgcgc gggctcttcc 300 tctttggcca gcccgacttc tcctacaagc gcagcaattg caagcccatc cctgccaacc 360 tgcagctgtg ccacggcatc gaataccaga acatgcggct gcxxaacctg ctgggccacg 420 agaccatgaa ggaggtgctg gagcaggccg gC £ 〇ttg £ at cccgctggtc atgaagcagt 480 gccacccgga caccaagaag ttcctg ^ gct cgctcttcgc ccccgtc ^ c ctcgatgacc 540 tagacgagac ca ^ cagcca tgccactcgc tctgcgtgca ggtgaaggac c ^ ctgcgccc 600 cggtcatgtc cgccttcggc ttcccc ^ gc ccgacatgct tgagtgcgac cgtttccxx ^ 660 aggacaacga cctttgcatc cccctcgcta gcagcgacca cctcc% cca gccaccgagg 720 Φ aagctccaaa ggtatgtgaa gcctgcaaaa ataaaaatga t £ atgacaac gacataatgg 780 aaacgctttg taaaaatgat ti ^ cactsa Aaataaaagt ga aggagata acctacatca 840 accgagatac caaaatcatc ctggagacca agagcaagac oatttacaag c ^ aacggtg 900 tgtccgaaag ggacctgaag aaatcggtgc tgtggctcaa agacagcttg cagtgcacct 960 gtgaggagat gaacgacatc aacgcgccct atctggtcat gggacagaaa cagggtgggg 1020 agctggtgat cacctcggtg aagcggtggc agaaggggca gagagagttc aagcgcatct 1 (^ 0 cccgcagcat ccgcaagctg c ^ tgctagt cccggcatcc tgatgsctcc gacaggcctg 1140 ctccagagca cggctgacca tt ^ tgctcc gggatctcas ctcccgttcc ccaagcacac 1200 tcctagctgc tccagtctca gcctggEcag atccccctg ccttttgcac gtttgcatcc 1260 • 49. 145138 · sequence Listing .doc 201015069 ccascatttc ctgagttata a ££ 〇cacagg ag ^ gat ^ gc tgttttcaa: taaaggaaaa 1320 gcccacccga atcdgtaga aatattcaaa ctaataaaat catgaatatt tcta ^ aagt 1380 ttaaaaa 1387 <210> 90 <2U> 1092 <212> DNA <213> Human <400> 90 t£tccctgsa attetgggac actggctggg gtt^ag^g agaagcxagt acctacctgg 60 ctgcaggate aagctggcca g^gcttctt ggdttgtgg ctcagcxttg ^gtggcct 120 ggctcagagc gacacgagcx c^ Acacgga ggagtcctat tcagaclggg gccttcggca 180 cctccg ggga agctttgaat ccgtcaatag ctacttcgat tctxttetgg agc ^ ctggg 240 agggaagaatgga ^ gtcagtacaggtgccgata ^ gaaaggcaccaatgcccagacc 300 tggctacaag ccccaagagc ccaatggctg cggctcctat ttcctgggtc tcaaggtacc 360 agaaagtatg gacttgggca ttccagcaat gacaaag ^ c ^ caaccagc tggatgtetg 420 ttatgacact tgcgstscca acaaatatcg ctgtgatgca aaattccgat ggtgtctcca 480 ctcgatctgc tctgacctta agcggagtct gggctttgtc tccaaagtgg aagcagcctg 540 tgattccctg gttgacactg tgttcaacac cgtgtggacc ttgggctgcc gcccctttat 600 gaatagtcag cgggcagctt gcatctgtgc agaggaggag aaggaagagt tatgaggaag 660 aagtgattcc ttcctggttt tgagtgacac cacagctgtc agccttcaa £ atetcaagtc 720 ttcgagteag cgtgactoat toattcttcc aacagtttgg acaccacaaa scaggagaaa 780 gggaaoattt ttctacagct ggaaagtgag tcctatcctt tgaggaaatt tgaaaaaaga 840 catgga £ t £ g tttgaaagct actettcatt taagactgct ctccccaacc aagacacatt 900 tgcctggaaa ttcagttctt agcttaaaga ctaaaatgca agcaaaccct gcaattcctg 960 Sacctgatag ttatattcat gagtgaaatt gtggggagtc casccatttg ggaggcaatg 1020 actttctgct sgcccatgtt tcagttgcca g Taagcttct cacatttaat aaagtgtact 1080 ttttagaaca tt ' 1092 <210> 91 145138 - Sequence Listing. 〇-50- 201015069 <211> 1807 <212> DNA <213> Human <400> 91 gcac^ggga agasg^it Ccgacccggg gaaggtcgct sggcagggcg agt^ggaaa 60

gcggcagccc ccgccgcccc cgcagcccct tctoctectt tctcccacgt octatotECc 120 tctcgctgga ggcc ^ gccg tgcagcatcg aagacaggag gaactggagc ctcatlggcc 180 ggcccggggc gccggcdcg ggcttaaata ^ agctccgg gdc ^ gctg ggaoc ^ g ^: 240 gc ^ ccgscc gc ^ lccqgc tidcctgcc g ^ tgatgg ^ aaacxmgc ccggccscx% 300 ccctgggcaa ggccx & ^ gc gct ^ tcc tggccac & t cggcgccgcc ggocagc ^ tc 360 t ^ ggegaga gtcc ^^ t ix ^ gccagag ccccsgccaa atacagcatc accttcacgg 420 ^ caagtsgag ccagacggcc ttccccaagc agtaccccct gttccgoxc cctgcgcagt 480 ggtcttcgct sctsggggcc gcgcata ^ t ccgaciacag catgtggagg aasaaccagt 540 acgtcagtaa cg £ gctscgc gacttlgcgg agcgcggcga ggcctgggcg ctgatsaagg 600 agatcga£gc ggcgggg£a£ gcgctgcaga ^s^c^gc ^tgttttc£ gcgcccgccg 660 tccccagcgg cacc^cag acgtcggc^g %ctgga^t gpa^gcs^g cac^c^ 720 tctegtttgt gg^cgcatc gt^ccagcc ccgae^ Gtt cgtgggcgtg pcagcxtjgg 780 acctg^cga cg^ggaccgt tggcgggaac agecggc^ ggacc^c ccctacgacs 840 ccgggacgga cagcggcttc accttctcct ccccmctt cgccaccatc a^c^poa 900 cegtgaccga gataacgtcc tcctctocca gccacccggc caactccdc ^ct acccgc 9 ^) ggctgaaggc cctgcx ^ ccc atcgccaggg tgac ^ tggt gcggc ^ cga cagagcccca 1020 gggccttcat oxtcccgcc ccagtectgc caatg Township tt gtagacagog 10SO colc% ttcc agaaac ^ ccg ctggactgcg ^ gtdccct g ^ gtcgto: tggggactgt Ϊ140 gcggaggcca c ^ tgggagg ctcgggacca agagcaggac tcgc available to cggstcc ^ o 1200 ccgccaacaa cgigd £ cccc tgccccgagc tcgaagaasa ££ ctgagtgc £ tccc ^ ata 1260 actgcgtcta agaccagagc cccgcagccc ctggggcccc cggagccatg gggtgtcggg 1320 ggctcctgtg caggctcatg ctgcaggcgg ccgaggcaca gggggtttcg cgctgctcct 1380 gaccgcggts aggcc ^ gcc gaccatctct gcactgaags gcxtctggt ggccggcacs 1440 ggcattggga aacagcctcc tccttlccca accttgcttc ttaggggccc ccg ^ tcccg 1500 - 51-145138 · sequence Listing .doc 201015069 tctgctctca gcctcctcct cc ^ caggal aaagtcatcc ccaaggctcc agctactcta 1560 aattatggtc tccttataag ttattgctgc tocaggagat tgtccttcat cetccagggg 1620 cctggctccc acgtggt ^; agatacctca gacctggtgc tctaggctgt gctgagccca 1680 ctctcccgag ggcgcatcca agcgsgggcc acttgagaagtgaataaat £ gggcggtttc 1740 ggaagcgtca gtgtttccat gttatggatc tctctgcgtt tgaataaa Ga ctatctctgt 1800 tgctcac 1807 <210> 92 <211> 1077 <212> DNA <213> Human <400> 92 cccgcccccg ccccttcc£a gcaaactttt ggcacccacc gcagccx^agc £cgcgttcgt 60 £ctccscagg gcgcgcctct ctccgccaat gccaggcgcg cgggggagcc attassaggc 120 gaggagagag gagggcgcag cteccgccca gcccagccct gcccagccct gcccggaggc 180 agacgcgccg gaaccgggac gcgataaata tgcagagcgg aggcttcgcg cagcagagcc 240 cgcgcgccgc ccgctccggg ^ ctgaatcc aggcgtgggg acacgagcca ggcgccgccg 300 ccggagccag cggagccggg gccagagccg gagcgcgtcc gcgtccacgc agccgccggc 360 C ££ (xa £ 〇ac ccagggccct gcatgccagg tcgttggagg tggcagcgag acatgcaccc 420 ggcccggaag ctcctcagcc tcctcttcct catcctgatg ggcactgaac tcactcaaaa 480 taaaagagaa aacaaagcag aeaasatggg agggccagag agcgagagga agaccacagg 540 agagaagaca ctgaacgagc ttcccttgtt ttgcctggaa gcccacgctg gctccctggo 600 tctgcccagg atgtgcagtc caaatcccaa tccagcagtg gggttatgtc gtcccgctta 660 ccctcagagc ccttctcctg gtgctgccca gacgaicagc cagtccctcc tggagaggtt 720 ctgcatggcc tctaggagag aasttttctt ggcccca gga aggcctggtg gagggtggtg 780 gttgtgcact gttgctggac agatgcattc attcatgtgc acacacacac acacacatgc 840 acacacaggg gagcagatac ctgcagagaa gagccaacca £ gtcctgatt agtggcaagc 900 t £ accacaa agggctatgc ctgtgtctta ttgdgacacc ttggcaaaga gatggctgat 960 tctgggtggtcctggacatggcx: gcacccaagggccctccaagccttaatggcaccctga 1020 145138 · Sequence Listing .doc 201015069 agcctccatg cccaggccaa aagatgcttt tcctccctaa aaaaaaaaaa aaaaaaa 1077 < 210 > 93 <211> 4229 <212> DNA <213>human<400> 93 ggggccccag tggccgccgc ggagcgaggt tgcctggaga gagcgcctgg gcgcagaagg 60 £ttaac£g£c cac〇£ggggc tcgcagagca g£asg£tgct ctcggacggt gtstccccca 120 ctgcactcct gaacttggag gacagggtcg ccgcgaggga cgc; agagagc accctecacg 180 cccagatgcc tgc ^ tagttt ttgtgaccag tccgctects cctecccctg gggcagtaga 240 gggggagcga tggagaactg gactegoagg ccctggctgt atctgc ^ ct gcttctgtcc 300 9 ctecctcagc tctgcttgga tcaggag ^ g ttgtecssac actctettca gacacctaca 360 gaggagggcc agggccccga aggtgtctgg ggaccttggg tccagtgggc ctcttgctcc 420 cagccctgcg gg gtgggggt gcagcgcagg agccggacat gtcagctccc tacagtscag 480 ctccacccga gtctsccxt ccctccccgg cccccaagac atccagaagc cctcctcccc 540 cggggccagg gtcccagacc ccagacttct ccagaaaccc tcoccttgta c ^ gacacag 600 tctcggggaa ggggtggccc acttcgaggt cccgcttccc acctagggag a £ aggagacc 660 caggagattc ga £ 〇ggccag gaggtcccgg cdc £ agacc ccatcaagcc ag ^ atgttc 720 ggttatggga gagtgccctt tgcattgcca ctgcaccgga accgcaggca ccctcggasc 780 ccacccagat c ^ agctgtc cctgatctct tctagaggsg aa £ ag £ ctat tccgtcccct 840 Φ actccaagag cagagccatt ctccgcaaac ggcagccccc aaactgagct ccctcccaca 900 gaactgtctg tccacacccc atccccccaa gcagaacctc taagccctga aactgctcag 960 acagaggtgg cccccagaac caggcctgcc cccctacggc ateaccccag agccca £ gcc 1020 tctggcacas agcccccctc acccacgcac tccttagpg aaggtggctt cttcc £ tgca 1080 tcccctcagc cacgaaggcc Aagttccxag ggttsggcca gtcccca^t agcagggaga 1140 cgccctgatc cttttccttc ggtccctcgg ggccgaggcc agcagggcca agggccttgg 1200 ggaacggggg ggactoctca cgggccccgc ctggagcctg accctcagca cccgg£〇gcc 1260 tggctgcccc tgctgagca a cggccxccat gccagctccc tctggagcct cttt ^ ctecc 1320 agtagcccta ttccaagatg ttctggggag agtgaacagc taagagcctg cagccaa £ cg 1380 -53- 145138 · Sequence Listing .doc 201015069 ccctgccccc c ^ a ^ ca ^ c agacccccgg goxtgcagt gc @ »gcctt t ^ ctcccag 1440 gaattcatgg gccagctgta tcagtgggag cccttcactg aagtcca ^ g cbxcagcgc 1500 tgtgaactga actgccggcc ccgtggctb: cgdicta ^ tccguacsc tgaaaaggtc 1560 caggatgggaccc ^ tgtca ^ ctggagcccctsaczictg ^^ ssacgctstctg 1620 agccccggct gtgatgggat octtggc ^ t ggcag ^ gtc (^ ttsgc ^ tspgtctgt 1680 ggggeteate attctaccte icecdtgttlcgggeaacc tcactpccg androgen level pcccc 1740 ctgggctatc agaagatctt gtggattcca gcg ^ pagcd : ^ gcgg ^ ca gattgcccag 1S0Q ctcceeccta ectccaacta ccteecactt cetppca ^ gpggccetfc catoatcaat I860 ggeaactggg ds ^ gatcc ccc ^ ggt »: tacaroecca scgggaocgt ctttcgatat 1920 aaccgtcctc ccagggagga gggcaaaggg gagagtctgt c ^ ctsaagg ccccaccacc 1980 cagcdglis a ^ tclatat s ^ tticag psgaaaeoc c ^ ec ^ ttt t&teagtat %40 gtcatctctt c^ctcctcc aatcc^gag rao^caccc cagagc<»cc tgtccoccag 2100 cttcagccggagamgagg^ggagccc ccact ^ ctccggcaccocscccagcocgg 2160 accccaggca csctcragcg tcag ^ jgcgg ataxccaga ^ axgcxoc s ^ xcatccc 2220 aggacacccc tggggtctcc asctgcgtac ^ gaaacgag tsggacactc tgratgctca 22S0 gcgtcctgcg ggaaaggtgt ctggcgcccc attttcctct gcatctcccs; isagtc ^ ga 2340 gaggaactgg atgaacgct ^ ctgtgocgcg ggtgccaggc ccccasccte ccctgaaccc 2400 tgccacggca ccccatgccc cccatactgg gaggctsscg agtgsacatc ctscagccgc 2460 tcctgtggcc cc £ gcaccca gcaccgccag ctgcastscc ggcasgaatt tggggggggt 2520 ggctcc ^ gg tgcccccgga gcgctstgp catctccccc ggcccaacat cacccagtct 2580 tgccagctgc gcctctgtgg ccattgeeaa gttggctcte cttg ^ gcca gtgctecgtg 2640 cggtgcggcc ggeeccaeag aa ^ ccggcag gttogctgtg t ^ gsaacaa cg £ tgat £ aa 27 (X) gtgagcgagc aggagtgtgc gtca ^ cccc ccscagcccc ccagcagaga ggcctgtgac 2760 atsgggccct gtactactgc ctggttccac agcgactgga gctccaastg ctcagccgas 2820 tgtgggac ^ g gaatccagcg gcgctctgtg gtotgo:. ttg gsagt £ g £ gc agccctcggg 2380 cca ^ ccagg gssaagcagg agcaggaact ggecaeaect gtccaacagg aagccggcoc 2940 cstgacatgc gcgcctgcag cctggggccc tstgagagaa ct Tggcgctg gtacacaggs 3000 -54- 145138-sequence table.doc 201015069

❹ ccctggggtgagtgctcctecsaaigtggctctggcacacagcgtasagacatcatctgt 3060 gtatccaaac tggggacgga gttcaacg ^ acttctccga gcaactgttc tcacctcccc 3120 aggccccctg ccct £ 〇agcc ctgtcaaggg caggcctgcc aggaccgatg gttttccacg 3180 ccctggagcc catgttctcg ctcct £ ccaa gggggaacgc agacacggga ggtccagtgc 3240 c ^ a £ caccaa (xagaccctcagcacccgatgccctcctcaac] gcggccctccaggaag 3300 cgcccctgta acagccaacc ctgcagccag cgccctgatg atcaatgcaa ggacagctct 3360 ccacatt £ cc ccctggtggt acaggcccgg ctctgcgtct acccctacta cacagccacc 3420 tgUgccgc ^ cttgcscaca tgtcctggag cggtctcccc aggaiccctc ctgaaagggg 3480 tccggggcacc ^ tcacggtttictgtgccaccatc £ gtcacccattgatc £ gcccactct 3540 £ aaccccciggclctecagcc ^ tcccagtctcagcag £ gatgtcctccagg ^ acagag 3600 ggtggcaagg tgactgacac aaagtgactt tcagggctgt getcaggccc atgtggtggt 3660 gtgatgggtg tgtgcacata tgcctcasgt gtgcttttgg gactgcatgg atatgtgtgt 3720 gctcaaacgt gtatcacttt tcaaaaagag gttacacaga ctgagaagga Caagacctgt 3780 ttccttgaga ctttcctagg tggaaaggaa agcaagtctg cagttccttg ctaatctgag 3840 ctacttagag tgtggt ctcc ccaccaactc cagttttgtg ccxtaagcct catttetcat 3900 gticasaccicacalcttctaagcc £ ccct £ ^ tctctgaccccttctcatttecctagt 3960 atctc ^ gccc ctgcotccct aattagctag ggc ^ gggtc agccactgcc aatcctgcct 4020 tactcaggaaggcaggaggaaagagactgcctctccagagcaasgcccagctgggcagag 4080 ggtgaaaaag agaaatgtga gcatccgctc ccccaccacc cc ^ xcagcc cctagcccca 4140 ctccctgcct cc ^ aaatgg ttcccaccca gaactaattt atttmatt aaagatgstc 4200 atgacaaa ^ aaaaaaaaaa aaaaaaaaa 4229 <210> 94 <211> 5826 <212> DNA <213> Human <400> 94 gaggaggaga cggcatccag tac^ag^g ctggacttgg acccctgcag cagccctgca 60 caggagaasc g£〇atataaa gccgcgctgc ccgggagccg ctcggccacg tccaccggag 120 -55- 14513 8 - sEQUENCE LISTING .doc 201015069 catcctgcac tgcagggccg £ tctctcgct cx ^ gcagagc cf ^ cgccttt ctgactcggt 180 ccggaacact gaaaccagtc alcactgcat ctttttggca aaccaggagc tcagctgcag 240 ga £ gcaggat ggtctggagg ctggtcctgc tggctctgtg ggtgtggccc agcacgcaag 300 ctsgtcacca ggacaaagac acgaccttcg accttttcag tatca ^ caac atcaaccsca 360 agaccattgg cgccaagcag ttccgcg ggc ccgaccccgg cgtgccggct taccgcttcg 420 tgcgctttga ctacatccca ccggtgaacg cagatgacct cagcaagatc accaagatca 480 tgcggcagaa ggagggcttc ttcctcacgg cccagctcaa gcaggacggc aagtccaggg 540 gcacgctgtt ggctct ^ gag ggccccggtc tctcccagag gcagttcgag atcgtctcca 600 acggccccgc ggacacgctg gatctcacct actggattga cggcacccgg catgtggtct 660 ccctggagga cgtcggcctg gctgactcfic agtggaagaa cgtcaccgtg ca £ gtggctg 720 gcgacaccta cascttgcac gtgggctgcg acctcataga cagcttcgct ctggacgagc 780 ccttctacga gcacc ^ cag gcggaaaaga gccggatgta cgtggccaaa ggctctgcca 840 gagagagtca cttcasBSEt ttgcttcaga acgtccacct agtgtttgaa aactctgtgg 900 aagatattct aagcaagaag ggttgccagc aaggccaggg agctgagatc aacgccatca 960 gtgagaacac aga £ acectg cgcc ^ ggtc cgcatgtcac caccgagtac st ££ gcccca 1020 gctc £ gagag gaggcccgag gtgtgpgaac gctpgt £ < ^ a sgagct £gga aacatgstcc 1080 aggasctcto ggggcicca: £tcctqgtsa accagcteag pgagaacctc aasagast£t 1140 cgaa^ataa ccagtttctc ^ggagctca ttggtggccc tcctaagaca aggaacatgt 1200 cagcttgctg gcagga^gc cggttctttg cgga aaa ^ a aacgtgggtg gtggacagct 1260 gcaccacgtg tacctgcaag aaatttaaaa ccatttgcca ccaaatcacc tgcccgcctg 1320 caacctscgc cagtsccatcc tttgtsgaag £ cgaatgctg cccttcctgc ctccactcgg 1380 tggacgstga ggagggctgg tctccgtggg cagagtggac ccagtgctcc gtgacgtgtg 1440 gctctgggac ccagcagaga ggccggtcct glgacgtcac cagcaacacc tgcttggggc 1500 cctccatcca gacacgggct tgcagtctga gcaagtgtga cacccgcatc cggcaggacg 1560 gcggctggag ccactggtca ccttggtctt catgctctgt gacctgtgga gttggcaata 1620 tcacacgcat Ccgtctctgc aactccccag tgccccagat ggggggcaas aattgcaaag 1680 ggagtgsccg ggagaccaaa gcctsccagg gcgccccatg cccaatcgat ggccgctgga 1740 -56- 145138 · Sequence Listing.doc 201015069 ❹

gcccctggtc cccgtggtcg gcctgcactg teacctgtgc cggtgggatc cgfigagcgca 1800 cccgggtct £ caacagccctgagcctcastacggagggaaggcctecgtgggggatgtgc 1860 a ££ agc £ tca gatgtgcaac aagaggagct gccccgtgga tggctgttta tccaacccct 1920 gcttcccggg agcccagtgc agcagcttcc ccgatgggtc ctsgtcatgc ggctcctgcc 1980 ctgt ^ gcttcttgggcaatggcacccactgtgaggacctggacgagtgtgccctggtcc 2040 ccgacatctg cttctccacc agcaaggtgc ctcgctgtgt caacactcag cctggcttcc 2100 act £ cctgcc ct £ cccgccc cgatacagag ggaaccagcc cgtcggggtc £ gcctggaag 2160 cagccaagac ggaaa ^ caa gtgtgtgagc ccsaaaaccc atgcaaggac aagacacaca 2220 actgccacaa gcacgcggag tgcatctacc tgggccactt cagcgacccc atgtacaa £ t 2280 gcgagtgcca gacaggctac gcgggcgacg ggctcatcts cegggaggac tcggacc ^ g 2340 ac £ gctggcc caaccteaat ctggtctgcg ccaccaacgc cacctaccac tgcatcaagg 2400 ataactgccc ccatctgcca aattctgggc asgaagactt tgacaaggac gggattggcg 2460 atgoctgtga tgatgacgat gacaatgacg gtgtgaccga Tgagaaggac aactgcc^c 2520 tcctcttcaatccccgccaggctgactatgacaaggatgasett££ggaccgc^tgaca 2580 actgccctta cgt scacaac cctgcccaga tcgacacaga caacaatgga gagggtgacg 2640 cctgctccgt ggacattgat ggggacgatg tcttcaatga acgagacaat tgtccctacg 2700 tctacaacac tgaccagagg gacacggatg gtgacggtgt gggggatcac tgtgacaact 2760 gccccctggt gcacaaccct gaccagaccg acgtggacaa tgaccttgtt ggggaccagt 2820 gtgacaacaa cgaggacata gatgacgacg gccaccagaa caaccaggac aactgcccct 2880 acatctccaa cgccaaccag gctgaccatg acagagacgg ccagggcgac gcct £ t £ acc 2940 ctgatgatga caacgatggc gtccccgatg acagggacaa ctgccggctt gtgttcaacc 3000 cagaccagga ggacttggac ggtgatggac ggggtgatat ttgtaaagat gattttgaca 3060 atgacaacat cccagatatt gatgatgtgt stcctgaaaa caatgccatc agtgagacag 3120 acttcaggaa cttccagatg gtccccttgg ateccaaagg gaccacccaa attgatcxxa 3180 actgggtcat tcgccatcaa ggcaaggagc tggttcagac agccaaotcg gaccxcg ^ a 3240 tcgctgtagg ttttgacgag tttgggtctg tggacttcag tggcacattc tacgtaaaca 3300 ctgaccggga cgacgactat gccggctlcg tctttggtta ccagtcaagc zgccgcm 3360 -57- 145138 · Sequence table.doc 201015069 atgtggtgat stfisaagcas £tgacgcaga cctactggga ggaccagccc acscgggcct 3420 atggctactc cggcgtgtcc ctcaaggtgg tgaactccac cacggggace ggcg & gCQCC 3480 tgaggaacgc gctgtggcac a〇 £ gggaaca cgccgg ££ ca ggtgcgaacc ttatggcacg 3540 accccaggaa cattggctgg aaggactaca cggcctatag gtggcacctg actcacaggc 3600 ccaagaotgg ctacatcaga gtcttagtgc atgaaggaaa acaggtcatg gcagactcag 3660 gacctatcta tgaccaaacc tacgctggcg ggcggctggg tctatttgtc ttctctcaag 3720 aaatggtcta tttctcagac ctcaagtacg aatgcagaga tatttaaaca agatttgctg 3780 catttccggc aatgccctst scatgccatg gtccctagac accteagttc attgtsgtcc 3S40 ttgtggcttc tctctctagc agcacctcct gtcccttgac cttaactctg atggttcttc 3900 acctcctgcc agcaacccca aacccaagtg ccttcagagg aiaaatatca atggaactca 3960 gagaCgaacatctaacccactaga ^ gaaaccagtKgg ^ atatatgagactttatitgs 4020 agtgaaaatt pggcatgcca ttacattgct ttttcttgtt tgtttaaaaa gaatgacgtt 4080 tacatataaaatstaattacttattgtatttat £ ^ taia ^ gagttgaa £ ggaata (% 4140 tgcataagccattat £ &taaattaagcatgaaaaatat^ct£aactacttt!ggt£ctt 4200 aaagttgtca ctattcttga attasagtte ctctacaatg acacacaaat cccattaa at 4260 aaa ^ ataaa caagggtcaa ttcaaatt ^ g aagtaatgtt ttagt & agga gagattagaa 4320 gacaacaggc atagcaaatg acataagcta ccgat ^ act aatcggaaca tgtaaaacag 4380 ttacaaaaat aaacgaactc tcctcttgtc ctacaatgaa agccctcatg tgcagtagag 4440 atgcagtttc atcaaagaac aaacatectt scaaatgggt gtgacgcset tccagatgtg 4500 gatttg £ caa aacctcattt aa £ taaaag £ ttagcagagc aaagtgcggt gctttagctg 4560 ctgcttgtgc cgctgtggcg tcggggaggc tcctgcctga gcttccttcc ccagctttgc 4620 tgcctgagag gaaccagagc anacgcacag gcc £ gaaaag gcgcatctaa cgcgtatcta 4680 ggctttggta actgcggaca agttgctttt acctgatttg atgatacatt teattaa £ gt 4740 tccagttataaatattttgttaatatttattaagtgactatagaatgcaactccatttac 4800 cagtaactta ttctaaatat gcctagtaac acatatgtag tataatttct agaaacaaac 4860 atctaataagtatataatcctgtgaaaatatgaggcttgataatattaggttgtcacgat 4920 gaascatsctagaagctgtaacasaatacatagagaataatgaggagtttatgatggaac 4980 -58 - 145138- sequence Listing .doc 201015069

cttaaatata taatgttgcc agcfiatttta gttcaatatt atctatctgc 5040 tgtatatgga atlcttttaa ttcaaacgct gaaaagaatc agcatttagt cttgccaggc 5100 acacccaata atcagtcatg tgtaatat £ c acaagtttgt ttttgttttt gttttttttg 5160 ttggttggtt tgtttttttg ctttaagttg catgatcttt ctgcaggaaa tagtcactca 5220 tcccactcca cataaggggt ttagtaagag aagtctgtct gtctgatgat ggatag £ ggg 5280 caaatctttt tcccctttct gttaatagtc atcacatttc tat £ ccaaac aggaacaatc 5340 cataacttta etcttaatgt tgttactgtt acacattgca mtgataaa attaattttg ttgtttcctt 5400 tgaggttgat square £ tt £ t £ ttg ttgttttgct gcacttttta cttttitgcg tgtggagctg 5460 tattcccgag accaacgaag cgttgggata cttcattaaa tgtagcgact gtcaacagcg 5520 tgcaggtttt ctgtttctgt gttgtggggt caaccgtaca atggtgtggg agtgacgatg S580 atgtgaatat ttagaatgta ccatattttt tgtaaattat ttatgttttt ctaaacaaat 5640 ttatcgtata ggctgatgaa acgtcatgtg ttttgccaaa gactgtaaat atttatttat 5700 gtgttcacat ggtcaaaatt tcaccactga aaccctgcac Ttagctagaa cctcattttt 5760 aaagattaac aacaggaaat aaattgtaaa aaaggttttc tatacatgaa aaaaaaaaaa 5820 aaaaaa 5826 < 210 > 95 < 211 > 9645 < 212 > DNA < 213 > human < 40Q > 95 atgcccaagc gcgcgcactg gggggccctc tccgtggtgc tgatcctgct ttggggccat 60 ccgcgagtgg cgctggcctg ccc £ 〇atcct tgtgcctgct ac £ tccccag cgaggtccac 120 tgcacgttcc gatccctggc ttccgtgccx; gctggcattg ctagacacgt ggaaagaate 180 aatttggggt ttaatagcat acaggccctg tcagaaacct catttgcagg actgaccaag 240 ttggagctac ttatgattca cggcaatgag atcccaagca tccccgatgg agctttaaga 300 eacctcagct ctcttcaggt tttcaagttc agctacaaca agctgagagt gatcacagga 360 cagaccctcc ag ££ tctctc taacttaatg aggctgcaca ttgaccacaa caagatcgag 420 tttatccacc ctcaagcttt caacggctta acgtctctga ggctactcca tttggaagga 480 aatctcctcc accagctgca ccccagcacc ttctccacgt tcacattttt ggattatttc 540 • 59- 145〗 38_Listing list.doc 201015069 agactctcca ccataaggca cctctactta gcagagaaca tggtiagaac tcttcctgcc 600 agcatgcttc egaacatgcc gcttctggag aatcttmct tgcagggaaa tccgtggacc 660 tgcgattgtg agatgagatg gtttttggaa tgggatgcaa aatccagagg aattctgaag 720 tgtaaaaagg acaaagctta tgaaggcggt cagttgtgtg caatgtgctt cagtccaaag 780 aagttgtaca aacatgagat acacaagctg aaggacatga cttgtctgaa gccttcaata 840 gagtcccctc tgagacagaa caggagcagg agtattgagg aggagcaaga acaggaagag 900 satggtggca gccagctcat cctggagaaa ttccaactgc ccca £ t £ gas caictctttg 960 aatat £ accgac £ agcacgegaacatggtgaacttg0ctgtgacatcaagaaaccaat £ 1020 ga ^ tgtaca agattcactt gaaccaaacg gatcctccag atattgacat aaatgcaaca 1080 fttgccttgs actttgagtg tccaatgacc cgagaaaact at £ aa2u @ ct aiggaaattg 1140 atagcatact acagtgaagt tcccgtgaag ctacacagag agctcatg ^ cagcaaagac 1200 cccagagtcagctaccagtacaggcaggatgctgatgaggaagctctctactacacaggt 1260 Stgasa ^ ccc a £ atu ^ t £ 〇agaaccagaa tg ^ tca ^ c agccatccat a ^ tatecag 13¾) ctgaaccgac gtcagagtac ggccaagaag gtgctac ^ tt cctaotacac ccagtattc ^ 1380 caaacaatat Ccacacaaaga tacaaggcag gctcggggca gaagctgsst aatgat^ag 1440 cctagtggag ctgtgcaaag agatcagact gtcctggaag ggggtccatg ccagttsagc 1500 tgcaacgtga aagcttctga ga^tccatct atcttct£gg tgcttccaga tsgctccatc 1560 ctgaaagc£〇ccatggatga cccagacasc a agttctcca ttctcascag ^ gctggctg 1620 aggatcaagt ccatggagcc atctgactca ggcttgtacc agtgcattgc tcaagtgagg 1680 gatgaaatgg accgcatggt atatagggta cttgtgcagt ctccctccac tcagccagcc 1740 gagaaagaca cagtgacaat tggcaagaac ccaggggagt cggtgacatt gccttgcaat \ 20Q gctttagcaa tacccgaagc ccaccttagc tggattcttc caaacagaag gataattaat 1860 gatttggcta acacatcaca tgtatacatg ttgccaaatg gaactctttc catccma ^ 1920 gtccaagtca gtgatagtgg ttactacaga tgtgtggc ^ teaaccagca aggggcagac 1980 Catmacgg tgggaatcac agtgaccaag aaagggtctg gcttgccatc caaaagaggc 2040 agacgcccag gtgcaaaggc tctttccaga gtcagagaag acatcgtgga ggatgaaggg 2100 ggctcgggca tgggagatga agagaacact tcaaggagac ttetgcatcc aaaggaccaa 2160 •60· 145138-sequence table.doc 201015069

gaggl £ ttccteaaaacaaa £ gatgatgccatcaatggagacaagaaagccaagaaa £ gg 2220 agaagaaagc tgaaactctg gaagcaticg gaaaaagaac cagagacm tgrtgcagaa 2280 ggtcgcagag tgtttgzBXc tagacgaagg ataaacatgg caa ^ aaaoa gattaatccg 2340 gagcgctggg ctgatatttt agccaaagtc cgtgggaaaa atctccctaa gsgcacagaa 2400 gtacccocgt Igattaaaac cacaagrcct ccatccttga gcct ^ aagt c ^ accacct 2460 tt ^ xtgctgtttctcccccctcsepa ^ tatg ^ cagacagtaaccag ^ ctga & saa 2520 tcctcagcag atgtacctct acttggtgaa gaagag < ^ cg ttttgggtac catttcctea 2S80 gccascatgg ^ ctagaacacaacca (^ at £ gagttaticttgttgaaa; tgaastaaca 2640 agcacacctc tggaggaagt tgttgatg & c ctttetgaga agactgagga g & tz & ct & co 2700 actgaaggag accfsaaggs {acagcagcc cctacactta tatctgagcc t ^^ aacca 2760 tct^tactc^cacac^agacaca£totet^aaagccc%ccatgaagagacggca 2820 acagagggttggtctgcagcagatgdggategtcacc^agco^caiccagtgagtat 2880 gagcctocattggatgctstctccttssctgagtctgagccca^caatactt^accca 2940 gatttgga ct&agtcaca accagatgag gaiaasa wonderful aaga^acac cfttecaou: 3000

Tcta^ataggggaacc^tstcccas^caa^acatctacaagsactgacagacaac 3120 a&xaccug tgaaaagteg tcta^caacs^^cacct tactgaltaa 3180

sssa ^ ssL aatateccae agggasacoc cacacactcc 3240 a ^ gttc ^ dgagt @ ^ ccaapg8gcaaauxatcacmgccliactccacactg 3300 ggtalaatga gcagta coffee iccagttaag as ^ cctgcgg aaaccacagt tggtaccctc 3360 ctegacaaag acaccac ^ agtaacaaca acaccaaggc aaaaagttgc tccgtcatcc 3420 ^ ca ^ agca cic &; aaagagaiet tc & amp ctcaeacact xcttc tcgaajggaga co ^ acggga saaggaeatt acgccccaao 3480 aaattccscc accggcacaa gcaaacccca «xcacaactt ttgccccatc agagactttt 3540 tciactcaac caactcaagc acctg ^ att aagatttcaa gtcaagtgga gaettctctg 3600 gt ^ ctacag ct ^ ggtgga taacacagu aataccccca aacagugga aat ^ agaag 3660 ^ tgcagaac ccacatccaa gggaacacca cggagaaaac acgggaagag gccaaacaaa 3720 categatata ccccttctac agtgagctea ag ah: gtc ^ g gatccaagc ^ cagcccttct 37 committed • 61 · 145138- sequence table .doc 201015069 ccagaaaata aacatagaaa cattgttact cccagttcag aaactatact tttgcctaga 3840 actgtttctc tgaaaactga gggcccttat gatux ^ g attacatgac aaccaccaga 3900 aaaatatatt catcttaccc taaagtccaa gagacacttc cagtcacata taaacccaca 3960 tcagatggaa aagaaattaa ggatgatgtt gccacaaatg ttgacaaaca t Aaaagtgac 4020

actatgggag aattiaagga agaatcctct cc ^ taggct ttccaggaac tccaacctgg 4140 aatccctcaa ggacggccca gcctgggagg ctacagacag acatac ^ gt taccacdct 4200 ggggaaaato ttacagaccc tccccttctt aaagascttg aggateteea tttcacttcc 4260 gagtttttgt cctctttgac agtotccaca ccatttcacc aggaagaagc tjggttcncc 4320 acaactctct caagcaiaaa ag ^ gagg ^ gcdcaagtc aggcagaaac caccaccctt 4380 gatcaagatc atcttsaaac cactgt ^ gct attctcc ^ ctgaaactag accacagaat 4440 cacaccccta ctgc ^ ccg gatgaaggag ccagcatcct cgiaxxatc cacaattctc * 4S00 atgtctttgg gacaaaoc ^ caccactaag ccagcacttc ccagtccaag aatalcteaa 4560 gcatctagag attccaagga aaa ^ ttdc ttgaattatg tggggaatcc agaaacagaa 4620 gcaaccccaf tcaacaatga aggaacacag catatgtcag ggccaaatga attatcaaca 4680 ccctcttccg accgggatgc atttaacttg tctacaaagc tggaattgsa aaagcaagta 4740 tttggtagta ££ a £ tctacc acstggccca Gatagccaac gccaggatgg aagagdcat 4800 gcttctcatc aactaaccag agtcxx;tgcc aaacccatcc taccaacagc aacagtgagg 4860 ctacctgaaa tgtccacaca aajgcgcttcc agatactttg taacttccca gtcacctcgt 4920 cactggacca aca aaccgga aataactaca tatccttctg gggctttgcc agagaacaaa 4980 cagtttacaa ctccaagatt atcaagtaca acaattcctc tcccattgca catgtccaaa S040 cccagcattc ctagtaagtt tactgaccga agaactgacc aattcaatgg ttactccaaa 5100 gtgtttggaa ataacaacat ccctgaggca agaaacccag ttggaaagcc tcccagtcca 51Θ0 agaattcctc attattccaa tggaagactc cctttcttta ccaacaagac tctttctttt 5220 ccacagttgg gagtcacccg gagaccccag atacccactt ctcctgcccc agtaatgaga 5280 gagagaaaag ttattccagg ttcctacaac aggatacatt cccatagcac cttccatctg 5340 gactttggcc ctccggcacc Tccgttgttg cacactccgc agaccacggg atcaccctca 5400 -62- 145138-sequence table.doc 201015069

actaacttac agaatatccc tatggtctct tccacccaga gttctatctc ctttataaca 5460 tcttctgtoc agtcctcagg aagcttccac cagagcagct caaagttctt tgcaggagga 5520 cctcctgcat ccaaattctg gtctcttggg gaaaagcccc aaatcctcac caagtcccca 5580 cagactgtgt ccgtcaccgc tgagacagac actgtgttcc cctgtgaggc aacaggaaaa 5640 ccaaagcctt tcgttacttg gacaaaggtt tccacaggag ctcttatgac tccgaatacc 5700 aggatacaacggtttsaegttctcaagaacggtaccttagtgatacggaaggttcaagta 5760 caa £ atc £ aggccagtatatgtgcaccgccagcaacctgcacggcctggacaggatggtg S820 gtcttgctttcggtcaccgtgcagcaacctcaaatcctagcctcccactaccaggacgtc 5880 actgtctacc tgggagacac cat ^ caa ^ gaj ^ tctgg ccaaagggac cccagccccc 5940 caaatttcct ggatcttccc tgacaggagg gtgtgscaaa ctgtgtcccc cgtggag ^ c 6000 cgcatcaccc tgcacgaaaa ccggaccctt tccatcaasg aggcgtcctt ctcagaoaga 6060 ggcgtctata a ^ tgcgtggc cagcaatgca eccggggcgg acagcctggc catccgcctg 6120 cacgtggcgg cactgccccc cgttatccac caggagaagc tggagaacat ctcgctgccc 6180 ccggggctea gcattcacat tcactgcact gccaaggctg cgcccctgcc cascgtgcgc 6240 tgggtgctcggggacggtaccca satccgcccctcgcagctcctccacgggaact ^ ttt 6300 gttttccccaacgggacgctctacatccgcaacctcg ^ cccaaggacagcggscgctat 6360 gagtgcstgsccgccaacctggtagsctccgcgcgcaggacggtgcasctgaacgtgcag 6420 cgtgcagcag cx ^ acgcgcg catcac ^ ggc acctccccgc ggagg ^: £ ga qgtcaggtac 6480 ^ aggaaccctcaagc ^ gactgcagcgcctcgggggacccc ^ gccgcgcaticctctgg 6540 aggctgccgt ccaagaggat gatc ^ acgcg ctcttcagtt tt £ atagca £ aatcaaggtg 6600 tttgccaatg ggaccxtggt ggtgaaatca gtgacggaca aagatgccgg agattacctg 6660 tgcgtagctc gaaataaggt ^ gtgatgac tacgtggt £ c tcaaagtgga tgtggtgatg 6720 aaaccggcca agattgaaca caaggaggag aacgaccaca aagtcttcta cgggggtgac 6780 ctgaaagtgg actgtgtggc caccgggctt cccaatcccg agatctcctg gagcctccca 6840 gacgggagtc tggtgaactc cttcatgcag tcggatgaca gcggtggacg cacxaagcgc 6900 tatgtcgtct tcaacaatgg gacactctac tttaacgaag tggggatgag ggaggaagga 6960 gactacacct gctttgctga aaatcaggtc gggaaggacg agatgagagt cagagtcaag 7020 -63- 145 ] 38-Sequence table.doc 201015069 gtggtgacagcgcccgccaccatccggaacaagacttacttggcggttcaggtgccctat 7080 ggagacgtsg tcact gtagc ctgtgaggcc aaaggagaac ccatgcocaa ggtgacttgg 7140 ugtccccaaccaacaaggtgatccccacctcctctgagaagtatcagatatacca ^ gat 7200 ggcactctcc ttattcagaa agcccagcgt tetgacascg gcaactacac ctecctggte 7260 aggaacagcg cgggagagga taggaagacg gtgtsgattc acgtcaacgt xagccaccc 7320 aagatcaacg gtaaccccaa ccccatcacc accgtgcggg agatagcagc cgggggcagt 7380 cggaaactga ttgactgcaa agotgaaggc atccccaccc cgagggtgtt aigggctttt 7440 cccgagggtg tggttc ^ qc agctccatac tatgeaaacc £ gatcact £ t ccatggcaac 7S00 ggttccctgg acatcaggag tttgaggaag agcgactccg tccagctggt atgcat ^ gca 7560 cgcaacgagg gaggggaggc gaggttgatc stgcagctca ctgtcctgga gccca ^ gag 7620 aaacccatct tccacgaccc gatcagcgag aasatcacsg ccatgg ^ gg ccacaccatc 7680 agcctcaaclgctctgccgcgg £ gaccccgacacccagcctggt £ tgggtcctteccaat 7740 ggcaccgatc tgcagagtgg acagcagctg cagcgcttct accacaaggc tgacggca ^ 7800 ctacacatta gcggtctctc ctcggtggac gctggggcct accgctgcgt ggcccgcaat 7860 gccgctggcc acacggagag Gctggtctcc ctgaagstgg gaotgaagcc asaagcaaac 7920 aagcagtatc ataacctggt cagcatcatc a atggtgaga ccctgaagct cccctgcacc 7980 cctcccgggg ctgggcaggg acgtttctcc tggacgctcc ccaatggcat gcatctggag 8040 ggcccccaaa ccctgggacg cgtttctctt ctggacaatg gcaccctcac ggttcgtgag 8100 gcctcggtgt ttgacagggg tacctatgta tgcaggatgg agacggagta cggcccttcg 8160 gtcacxagca tccccgtgat tgtgatcgcc tatcctcccc ggatcaccag cgagcccacc 8220 ccggtcatct acacccggcc cgggaacacc gtgaaactga actgcatggc tatggggatt 8280 cccaaagctg acatcacgtg ggagttaccg gataagtcgc atctgaaggc aggggttcag 8340 gctcgtctgt atggaaacag atttcttcac ccccasggat cactgaccat ccagcatgcc 8400 acacagagag atgccggctt ctacaagtgc atggcaaaaa acattctcgg cagtgactcc 8460 aaaacaactt acatccacgt cttctgaaat gtggattcca gaatgattgc ttaggaactg 8520 acaacaaagc £ gggtttgta agggaagcca ggttggggaa taggagctct taaataatgt 8580 gtcacagtgc atggt ££ 〇ct ctggtgggtt tcaagttgag gttgatcttg atctacaatt 8640 • 64 · 145 · 38〗 sequence table .doc 201015069

gttgggaaaa ggaagcaatg cagacacgag aaggagggct cagccttgct gagacacttt 8700 cttt ^ tgtttacatcateccaggggcttcattcagggtgtct £ tgctctgac ^ caatt 8760 tttcttcttttgcaaatgccaclcgactgccttcataa £ cgtccatag £ atatcl £ agga 8820 acattcatcaaaaataagccatagacatgaac ^ acacctcactaccccattgaagacgca 8880 tcacctagtt aacctgctgc agtttttaca tgatagactt tgttccagat tgacaagtca 8940 tctttcagtt atttixtotg tcacttoaaa actccagctt gcccaataag gatttagaac 9000 cagagtgact gatatatata tatatatttt aattcagagt tacatacata cagctaccat 9060 tttatatgaa aaaagaaaaa catttcttcc tggaactcac tttttatata atgttttata 9120 tatatatttt ttcctttcaa atcagacgat gagactagaa ggagaaatac tttctstctt 9180 attaaaatta ataaattatt ggtctttaca agacttggat acattacagc agacatggaa 9240 atataatttUaaaaatttc tctccaacct ccttcaaatt cagtcaccac tgttataita 9300 ccttctccag gaaccctcca stggggaagg ctgcgatatt agatttoctt gtatgcaaag 9360 ttttt £ ttga aagctgt £ ct cagaggaggt gagaggagag gaaggagaaa actgcatcat 9420 aactttacag aatlgaatct agastcttcc ccgaaaagcc cagaaacttc tctgcagtat 9480 Ctggcttgtc catctggt ct aaggtggctg cttcttcccc agccatgagt cagtt ^ c 9540 ccatgaataa tacacgacct g ^ tatttcca tgactgcttt actstatttt taaggtcaat 9600 atactgtacatttgataataaaataatattctcccaaaaaaaaaa 9645 < 210 > 96 0 < 2U > 694 < 212 > DNA < 213 > human < 400 > 96 gcctccgagg agaccatggc ctggccxctg tgCBCcotgc tgctcctgct ggccacccag 60 gctgtggccc tggcctggag cccccaggag gaggacagga taatcgaggg tggcatctat 120 gatgcagacc tcaatgatga gcgggtacag cgtgcccttc actttgtcat cagcgagtat 180 aacaaggcca ctgaagatga gtactacaga cgcctgctgc gggtgctacg agccagggag 240 cagatcgtgg gcsgggtEaa ttacttcttc gacatagagg tggficcgaac catatgtacc 300 aagtcccagc ccaacttgga cacctgtgcc ttccatgaac agccagaact gcagaagaaa 360 • 65- 145138- sequence Listing .doc 201015069 cagttgtgct ctttccagat ctacgaagtt Ccctgggagg aca£aat£tc cctggtgaat 420 tccaggtgtc aagaagccta gggatctgtg ccagg£dgtc acactgacca cctcctactc 480 ccaccccttg tagtgctccc acccctggac tggtggcccc caccctgtgg gaggtctccc 540 cat£cacctg cagcaggaga agacagagaa ggctgcagga ggcctttgtt gctcagcagg 600 ggactc tgcc ctccctcctt ccttttgctt ctcatagccc tgglacatgg tacacacacc 660 cccacctcct gcaattaaac agtagcatca cctc 694 < 210 > 97 < 211 > 782 < 212 > DNA < 213 > human < 400 > 97 gggctccctg cctcgggctc tcaccctcct ctcctgcagc tccagctttg tgctctgcct 60 ctgaggagac catggcccag tatctgagta ccctgctgct cctgctggcc accctagctg 120 tggccctggc ctggagcccc aaggaggagg ataggataatcccgggtggc atctata ££ g 180 cagacctcaa tgatgagt ^ g gtacagcgtg cccttcactt c ^ ccatcasc gagtataaca 240 aggccaccaa agatgactac tacagacgtc cgctgcgggt actaagagcc aggcaacaga 300 ccgttggggg ggtgaattac ttcttcgacg tagaggtggg ccgcaccata tgtaccaagt 360 cccagcccaa ctt £ gacacc tgtgccttcc atgaacagcc agaactgcag aagaaacagt 420 tgtgctcttt cgagatctac gaagttccct gggagaacag aaggtccctg gtgaaatcca 480 ggtgtcaaga atcctagg it a tctgtgccag gccattcgca ccagccacca cccactccca 540 ccccctgtag tgctcccacc cctggactgg tggcccccac cctgcgggag gcciccccat 600 gtgcctgcgc caagagacag acagagaagg ctgcaggagt cctttgttgc tcagcagggc 660 gctctgccct ccctccttcc ttctt£cttc taatagc Cct ggtacatggt acacaccccc 720 ccacctcctg caattaaaca gtagcatcgc ctccctctga aaaaaaaaaa aaaaaaaaaa 780 aa 782 <210> 98 <211>3432-<212> DNA <213> Human <400> 98 -66 - 145138 - Sequence Listing.doc 201015069

actccagcgc gcggctaxt acgcttggtg cttgctttct ccagccatcg gagaccagag 60 cc £ ccccctc tgctcgagaa aggggctcag cggcggcgga agcggag £ gg gaccaccgtg 120 gagagcgcgg tcccagcccg gccactgcgg atccctgaaa ccaaaaa £ ct cctgctgctt 180 ctgtaccccg cctgtccctc ccagctgcgc agggcccctt cgtg £ gatca tcagcccgaa 240 gacagggatg gagaggcctc tgtgctccca cctctgcagc t £ 〇ctggcta tgctggccct 300 cctgtccccc ctgagcctgg cacagtatga cagctggccc cattaccccg agtacttcca 360 gcaaccggct cctgagtatc accagcccca ggcccccgcc aacgtggcca agattcagct 420 gcgcctggct gggcagaaga ggaagcacag cgagggccgg gtggaggtgt actateatgg 480 ccagtggggc accgt £ tgcg atgacgactt ctccatccac gctgcccacg togtctgccg 540 ggagctgggc tatgtggagg ccaagtcctg gactgccagc tcctcctacg gcaagggaga 600 agggcccatc tggttagaca atctccactg tactggcaac gaggcgaccc ttgcagcatg 660 cacctccaat ggctggggcg tcactgactg caagcacacg gaggatgtcg gtgtggtgtg 720 cagcgacaaa aggattcctg ggttcaaatt Tgacaattcg ttgatcaacc agatagagaa 780. cctgaatatc caggtggagg acattcggat tcgagccatc ctctcaacct accgcaagcg 840 caccccagtg at ggagggct acgtgga ^ gt gaaggagggc aagacctgga agcagatctg 900 tgacaagcac tggacggcca agaattcccg cgtggtctgc ggcatgtttg gcttccxtgg 960 ggagaggaca tacaatacca aagtgtacaa aatgtttgcc tcacggagga agcagcgcta 1020 ctggccattc tccatggact gcaccggcac agaggcccac atctccagct gcaagctggg i〇g〇cccccaggtg tcactggacc ccatgaagaa tgtcacctgc gagaatgggc tgccggccgt 1140 ggtgagttgt gtgcctgggc aggtcttcag ccctgacgga ccctcgagat tccggaaagc 1200 atacaagcca gagcaacccc tggtgcgact gagaggcggt gcctacatcg gggagggccg 1260 cgtggaggtg ctcaaaaatg g ^ aatgggg gaccgtctgc gacgacaagt g ^ acctggt 1320 gtcggccagt gtggtctgca gagagctggg ctttgggagt gccaaagagg cagtoactgg 1380 ctcccgactg gggcaaggga tcggacccat ccacctcaac gagatccagt gcacaggcaa 1440 tgagaagtcc attatagact gcaagttcaa tgccgagtct cagggctgca accacgagga 1500 ggatgctggt gtgagatgca acacccctgc catgggcttg cagaagaagc tgcgcct £ aa 1560 cggcggccgc aatccctacg agggccgagt ggaggtgctg gtggagagaa acg £gtccct 1620 -67- 145138 · Sequence Listing.doc 201015069 tgtgtggggg atggtgtgtg gccaaaactg gggcatcgtg gaggcca tgg tggtctgccg 1680 ccasctgggc ctgggattcg ccagcaacgo cttccaggag acctggtatt ggcacggaga 1740 t £ tcaacagc aacaaagtgg tcat £ agtgg agtgaagtgc tcgggaacgg agctgtGcct 1800 £ gc £ 〇actgc cgccacga ^ gggaggacgt £ gcc ^ cxcc cagggcg £ ag tgcagtacgg 1860 ggccggagtt scctgctcag tgacctggte ctcaatgcgg agatggtgca 1920 gcagaccacc tacctggagg accggcccat gttcatgctg cagtgtgcca tggaggagaa 1980 ctgcctctcggcctc ^ sccgcscagaccgaccccaccacgggctaccgcc ^ ctcctgcg 2040 cttctcctcc cagatccaca acaatggcca gtccgacttc cggcccaaga acggccgcca 2100 cgc £ tggatc tggcacgact gtcacaggca ctaccacagc atggaggtgt tcacccacta 2160 tgacctgctgaacctcaaisgcaccaaggtggcagagggccacaaggccagcttctgctt 2220 gga £ gacacagaatgt £ aa £ gagacatccagaagaattacga £ tgt £ ccaacttt: gecga 2280 tcagggcatcaccatgggctgct £ g £ acatgtacc £ ccatgacatcgactgccagtgggt 2340 tgacatcactgacgtgccccctggagactacctgttccaggttgttattaaccccaactt 2400 cgaggttgca Gaatccgatt actcxaacaa catcatgaaa tgcaggagcc sctatgacgg 2460 ccaccgcatc tggatgtaca actgccacat aggtggttcc ttcagcgaag agae^gaaaa 2520 aaagttt gag cacttcagcg ggctettaaa caaccagctg tccccgcagt aaagaagcct 2S80 gcgtggtcaa ctectgtctt caggccacac cacatcttcc atgggacttc cccccaacaa 2640 ctgagtctga acgaatgcca cstgccctca cccagcccgg cccccaccct gtccagaccc 2700 ctaca £ ctgt gtctaagctc ag £ aggaaag ggaccctccc atca〇cat £ gggggctgct 2760 acctgaccct tggggcctsa gaaggccttg ggggggtggg gtttgtccac agagc ^ ctg 2820 gagcagcacc aagagccagt cttgaccggg atgaggccca cagacaggtt gtcatcagct 2880 tgtcccattcaagccaccgagctcaccacagacacagtssagccgcgctct ^ tcx ^ gtg 2940 acacgtggac aaatgcgggc tcatcagccc occcagagag ggtca ^ ccg aaccxx ^ ttt 3000 ctcctcctct taggtcattt tcagcaaact tgaatatcta gacctetctt ccaatgaaac 3060 cctccagtct attatagtca catagataat ggtgccacgt gttttctsat ttggtea ^ ct. 3120 cagacttggt gcttecctct ccacaacccc caccccttgt ttttcaagat actattatta 3180 tattttcaca gacttttgaa gcacaaattt attggcatit aatattggac atctgggccc 3240 • 68 - J45] 38-sequence table.doc 201015069 ttggaagtao aaatctaagg aaaaaccaac ccactgtgta agtgactcat cttcctgug 3300 t^caattct gtgggttttt gattcaacgg tgctataacc agg Gtcctgg gtgacagggc 3360 gctcactgas caccatgtgt catoacagac acttacacat acttgaaact tggaataaaa 3420 gaaagatttatg 3432 <210> 99 <211> 8448 <212> DNA <213> human <400>

£ cagtggttt ctcctcxttc ctcccaggaa gggccaggaa aatggccct £ gtcctggaga 60 tcttcaccct gctggcctcc atctgctggg tgtcggccaa tatcttcgag taccaggttg 120 atgcccagcc ccttcgtccc tgtgagctgc agagggaaac ggcctttctg aagcaagcag 180 actacgtgcc ccagtgtgca gaggatggca scttccagac tgtccag ^ c cagaacgacg 240 gccgctcctg ctggtgtgtg gg ^ caacg gcagtgaagt gptgggcagc aggcagccag 300 gacggcctgt ggcttgtctg tcattttgtc aectacagaa acagcagatc ttactgagtg 360 gctacattaa caacacagac acctcctacc tccctcagt ^ tcaggattca ggggactacg 420 cscctsttca gt £ tgatgt £ cagcatgtec agtgctggtg tstggacgca gaggggatgg 480 aggtgtatgg gacccgccag ctggggaggc caaagcgatg tccaaggagc tgtgaaataa 540 gaaatcgtcg tcttctccac ggggtgggag ataagtcacc accccagtgt tctgcggagg 600 gagagtttat gcctgtccag tgcaaatt ^ tca ^ accac agacatga ^ atttttgatc 660 tggtccacag ctacaacagg tttccagatg catttgtgac cttcagttcc ttccagagga 720 ggttccotga ggtatctggg Tattgccact gtgctsacag ccaagggcgg gaactggctg 780 agacaggttc ggagttgtta ctggatgaaa tttatgacac catttt^ct ggcctggacc 840 ttccttccac cttcactgaa ac caccctgt accggatact gcagagacgg ttcctcgcag 900 ttcaatcagt catctotggc agattccgat gccccacaaa atgtgaag ^ gagcggttta 960 cagcaaccag ctttggtcac ccctatgttc caagctgccg ccgaaatggc gactatcagg 1020 cggtgcagtg ccagacggaa gggccctgct g £ tgtstgga cgcccagggg aaggaaatgc 1080 atggaacccs gcagcaaggs g ^ ccgccat cttgtgctga aggccaatct tgtgcctccg 1140 aaaggcagca ggccttgtcc agactctact ttgggacctc aggctacttc agccagcacg 1200 -69- 145138- sEQUENCE LISTING .doc 201015069 acctgttctc ttccccagag aaaagatggg cctctccaag agtagccaga tttgccacat 1260 cctgcccacc cacgatcaag gagctctttg tgsactctgg gcttctccgc ccaatggtgg 1320 agggacagag ccaacagttt tctgtctcag aaaatcttct caaagaagcc atccgagcaa 1380 tttttccctc ccgagggctg gctcgtcttg cocttcagtt taccaccaac ccaaafagac 1440 tccagcaaaa cctttttgga gggaaatttt tggtgaatgt tjggccagttt aacttgtctg 1500 gagcccttgg cacaagaggc acatttaact tcagtcaatt tttccagcaa cttggtcttg 1560 caagcttctt gaatggaggg agacaagaag Atttgsccaa gocactctct gtgggattag 1620 attcaaattc ttccacagga acccxtgaag ctgctaagaa ggatggtact atgaataagc 1 680 caactgtggg cagctttggc tttgaaatta acctacaaga gaaccaaaat gccctcaaat 1740 tccttgottc tctcctggag cttecagaai tcctictctt cttgcaacat gctalctc% 1800 tgccagaaga tgtggcaaga gamaggtg atgtgatgga aacggtacte gactcxcaga 1860 cctgtgasca g ^ acctgaa a ^ sctatttg tcccatcatg cacgacagaa ggaagctatg 1920 aggatgtcca atgqmtcc ggagag ^ ct gg ^ tgtgaa ttectggggc aaag ^ gcttc 1980 caggctcaag agtcagagat ggacagccaa ggtgccccac agactg ^ aa aagcaaaggg 2040 ctcgcatgca aagcctcatg ggcagccagc ctgctsgctc caccttgttt gtccctfctt 2100 gtactagtga gggacatttc ctgcctgtcc agtgcttcaa ctcagagtgc taagtgttg 2160 atgctgaggg tcaggccatt cctggaactc saagtgcaat agggaasccc aagaaatgcc 2220 ccacgccctg tcaattacas tctgagcaag ctttcctca £ gacg £ tgcag gccctgctct 2280 ctaactccag catgctaccc accctttccg acacctacat cccacastgc agcaccgatg 2340 ggcagtggag acaagtgcaa tgcaatgggc ctcctgagca ggtcttcgag ttgtaccaac 2400 . gatgggaggc tcagaaoaag ggccaggatc tgacgcctgc caa£ctgcta stgaagatca 2460 tgagctacag agaagcagct tccggaaact tcagtctctt tattcaaagt ctgtatgagg 2520 ctg£cc agca agatgtcttc ccggtgctgt cacaataccc ttctctgcaa gatgtcccac 2580 tagcagcact ggaagggaaa cggccccagc ccagggagaa tatcctcctg gagccctacc 2640 tettctggca gatcttaaat ggccaactca gccaataccc ggggtcctac tcagacttca 2700 gcactccttt ggcacatttt gatcttcgga tgtggatgag gctggccaag 2760 aactggaagg aatgcggtct gagccaagca agctcccaac gtgtcctggc tcctgtgagg 2820 • 70 · 145138- sequence table actgctggtg .doc 201015069

aagcaaagct ccgtgtactg cagttcatta gggaaacgga agagattgtt tcagcttcca 2S80 acagttctcggttccctct ££ ggga £ agtttcx: ^ gtsgccaagggaatccggctgag £ a 2940 atgaggacct cggccttcct ccgctcttcc cgccccggga ggctctcgcg gagtttctgc 3000 gtgggagtga ttacgccatt cgcctggcgg ctcagtctac cttaagcttc tatcagagac 3060 gccgcttttc cccggacgac tcggctggag catccgccct tct ^ cggtcg gscccctaca 3120 tgccacagtg tgatgcgttt ggaagttggg agcctgtgca gtgccacgct gggactgggc 3180 actgctggtg tgtagatgag aaaggagggt tcatccctgg ctcactgact gcccgctctc 3240 tgcagattccacagtgcrcgacaaxtgcgagaaatctcgaaccagtgggctgctttcca 3300 sttggaaaca ggctagatcc caagaaaacc catctccaaa agacctgttc gtcccagcct 3360 gcctagaaac aggagaatat £ 〇caggctgc d ££ 〇ateggg ggctggcacc tggtgtgtgg 3420 accctgcatc aggagaagag ttgcggcctg gctcgagcag cagtgcccag tgcccaagcc 34S0 tctgcaatgt gctcaagagt ggagtcctet ctaggagagt cagcccaggc tatgtcccag 3540 cctgcagggc agaggatggg ggcttttccc cagigcaatg tgaccaggcc cagggcagct 3600 gctggtgtgt Catggacagc ggagaagagg tgcctgggac gcgcgtgacc gggggccagc 3660 (xgcct g ^ a gagcccgcgg tgtccgctgc cattcaacgc gtc ^ gaggtg gttggtggaa 3720 caatcc ^ tg tgagacaatc tcgggcccca caggctotgc catgcagcag tgccaattgc 3780 tgtgccgcoa aggctcctgg agcgtgtttc caccagggcc attgatat £ t agcctggaga 3840 gcggacgctg ggagtcacag ctgcctcagc cccg £ gcctg ccaacggccc cagctgtggc 3900 agaccatcca gacccaaggg cactttcagc tccagctccc gccgggcaag atgtgcagtg 3960 ctgactacgc gggtttgctg cagactttcc aggttttoat att ^ atgag ctgacagccc 4020 gcggcttc ^ ccagatccag gtgaagactt ttggcaccct ggtttccatt cctgtctgca 4080 acaactcctc tgtgcaggtg ggttgtctga ccagggagcg ttta £ gaetg aatgttacat 4140 ggaaatcacg gcttgaggac atcccagtgg cttctcttcc tgacttacat gacattgaga 4200 gagccttggt gggcaaggat ctccttgggc gcttcacaga tctgatccag agtggctcat 4260 tccagcttcatctggactccaagacgttcccagcggaaaccatccgcttcctccaagggg 4320 accactttgg cacctctcct aggacacggt ttgggtgctc ggaaggattc taccaagtct 4380 tgacaagtga ggccagtcag gacggactgg gatgcgttaa gtgccatgaa ggaagctatt 4440 -71- 145138 - Sequence Listing.doc 201015069 cccaagat£aggaatgcattcctt£toctgttggattctaccaa£aacag £cagggagct 4500 tggcctgtgtcccatgtcctgtgggcagaacsaccatttetgccgga^tttcagccaga 4560

V ctcac ^ t cactgactgt cagaggaacg aagcaggcct gcaat £ ^ ac cagaat ^ cc 4620 agtatcgagccagccaga9ggacaggggcag ^ gga £ tggcc »ct £ ^ tsgacggcgagg 4680 ggcggaggct £ ccatggtgggaaacagd £ gcccctctt £ aggactcacagtgtttgat £ a 4740 tgcagaagtt tgagaaggtt ocaeaatcaa agg ^ atctt cgacgccaat gctcc ^ tgg 4800 ctstcagatccaaagttcctgattctgagttccccgtgat £ ca £ tgcttsaca £ att ^ a 4860 cagaggacga ggcctgcago ttcttcaccg tgtccacgac ggagccagag atttcctgtg 4920 atttctatgc ttggacaagt gacaatgttg cclecatgac ttctsaccas aaacgaga ^ 4980 cact £ g £ gaa ctcaaaggcc accagctttg gaagtcttcg ctgccaggtg aaagtgagga 5040 gccatggtca agattctcca gctgtgtatt tsaaaaaggg ccaa ^ gatcc accacaacac 5100 tteagaaacg ctttgaaccc actggtttcc aaaacate ^ tu: tggatt £ tacaacccca 5160 ttgtgttctc agcctcagga gccaatctaa ccgatgctca cctcttctgt cttcttgcat S220 gcgacc £ tga tctgtgttgc gatggcttcs tcctcacaca ggttcaagga ggtgccaica 5280 tctgtSSStt gctgagctca cccagtgtcc tgctttgtaa tgtcaaagac tggatggatc 5340 cctctgaagc ctgggctaat gctacatgtc ctggtgtgac atatgaccag gagagccacc 5400 aggtgatatt gcg tcttgga gaccaggagt tctgacaccc ttagaaggaa 5460 ctcaagacac ctttaccaat tttcagcagg tttatctag gaaagattct gacatggggt 5520 ctcggcctga gtctatggga tgtagaaaaa acacagtgcc aaggccagca ^ tccaacag 5580 aagcaggttt gacaacagaa cttttctccc ctgtggacct caaccaggtc attgtcaatg S640 gaaatcaatc actatccagc cagaagcact ggcttitcaa gcacctgttt tcagcccagc 5700 aggcaaacct atggtgcctt tctcgttgtg tgcaggagca ctctttctgt cagctcgcag 5760 U agataacagagagtgcatccttgtacttcacct £ caccctctaccca £ agscacagg ^ tcatcaagag t 5820 gtgatgacat catggagtcc aatacccagg gctgcagact gatcctgcct cagatgccaa. 5880 aggccc ^ tt ccggaagaaa gttatactgg aagataaagt gaagaacttt tacactcgcc 5940 tgccgttcca aaaactgatg gggatatcca ttagaaataa agtgccca ^ tctgaaaaat 6000 ctatttctaatgggttctttgaatgtgaacgacggtgcgatgcggacccatgctgcactg 6060 -72 · 145138 · sequence Listing .doc 201015069

gctttggatttctaaatgtttcccagttaaaaggaggagaggtgacatgtcteactctga 6120 acagcttggg aattcagatg tgca £ tgagg agaatggagg agcctggcgc attttggact 6180 gtggctctcc tgacat ^ aa gtccacacct atcccttcgg atggtaccag aagcccattg 6240 ctcaaaataatgctc ^ cagtmtgccctttggttgttctgccttccctcacagagaaag 6300 tgtctetgga atcgtggcag tccctggccc totettcagt ggttgttgat ccatccatta 6360 ggcactt ^ atgttgcccatgtcascactgctgccaccagcaatttctctgctgtccgag 6420 coffee fotEttt gtcggaatgt tcccaac Post township cctgtct catcaccact ctgcaaaccc 6480 aactcggggc ^ tgagatgt atgttctatg ctgatactca aagctgcaca catagtctgc 6540 agggtcggaa ctgccgactt ctgcttcgtg aagaggccac ccacatctac cggaagccag 6600 gaatctotct gctcagctat gaggcatctg taccttctgt gcccatttcc acccatggcc 6660 ggctgctsgg caggtcccag gccatccagg tgggtacctc atggaagcaa gtggaccagt 6720 tccttggagt tccatatgct gccccgcccc tggcagagag gcacttccag gcaccagagc 6780 ccttgaactg gacag £ ctcc tgggatgcca gcaagccaag £ gccagctgc tsgcagccag 6840 gcaccagaac atccacgtct cctggastca gtgaagattg tttgtatctc aatgtgttca 6900 tccctcagaa% %£cccct aac Hyun cgtctg tgctggtgtt cttccacaac accatggaca 6960 Sgpgg ^ gag ^ aasgatggccggctatcgacggctccttct ^ gctgctgttggcaacc 7020 tcate £ tggt cactgccagc taccgagtgg gtgicttcsg cttcctgagt ictggatccg 7080 £ a £ agg ^ agtggcaactgggggctgctggaccaggtggcggctctgacc ^ g £ tgcaga 7140 cccacatccg aggatttg £ C ggggaccctc ggcgcgtgtc cctggcagca gaccgtggci 7200 gggctgatgt ggccagcatc caccttctca cggccagggc caccaactcc caacttttcc 7260 ggagagctgt gctgatggga ggctccgcac tctccccggc cgccgtcatc agccatgaga 7320 gggctcagca gcaggcaatt gctttggcaa aggasgteag ttgccccatg tcatccagcc 7380 aagaagtggt gtcctgcctc cgccagaagc ctg (raatgt cctcaatgat gcccagacca 7440 agctcc ^ gccgtgagtggccctttccactactgggg ^ ctgtgatcgatggccacttcc 7500 tccglgagcc tccagccaga gcactgaaga ggtctttatg ggtagaggtc gatctgctca 7560 ttgggagttc tcaggacgac gggctcatca acagagcaaa ggctgtgaag caatttgagg 7620 aaagtcgagg ccggaccagt agcaaaacag ccttttacca ggcactgcag aattctctgg 7680 • 73· 145Π8· Sequence Listing.doc 201015069 gt£gcgagga ctcagatgcc cgcgtcgagg c^ctgctac a^£tattac tctctggagc 7740 actcc acgga tgactatgcc tccttctccc gggctctgga gaatsccacc cgggactact 7800 ttatcatctg ccctataato gacatggcca gtgcctgggc aaagagggcc cgaggaaacg 7860 tcttcatgta ccatgctcct gaaaactacg gccatggcag cctggagctg ctggcggatg 7920 ttcagtttsccttggggcttcccttctacccagcctacgflggggcagttttctctggagg 7980 agaa £ agcctgtcgctgaaaatcatgcagtactmcccactlcatcdgatcagsaaatc 8040 ccaactaccc ttatgagttc tcacggaaag tacccacatt tgcaacccoc tggcctgact 8100 ttgtacccc £ tgctggtgga gagaactaca aggagttcag tgagctgctc cccaatcgac 8160 agggcctgaa saaagccgac t ^ ctccttct ggtccaagta catctcgtct ctgaagacat 8220 ctgca£atgg aeccaaeggc gggcagtcag cagagagtga agaggaggag ttgacggc^ 8280 gatctgggct aagagaagat ctcctaago: tccaggaacc aggctctaag acctacagca 8340 agtgaccagc ccttsagctc cxcaaaaacc tcacccgagg ctgcccacta tggtc^ctt 8400 tttctctaaa atagttactt accttcaata aagtatctac atgcggtg 8448

<210> 100 <211> 5025 <212> DNA

≪ 213 > Human I < 400 > 100 gcagtggttt ctcctccttc ctcccaggaa gggccaggaa aatggccctg gtcctggaga 60 tcttcaccct gctggcctcc atctsctggg tgtcggccaa tatcttcgag taccaggttg 120 atgcccagcc ccttc £ tccc tgtgagctgc agagggaaac ggcctttctg aagcaagcag 180 actacgtgcc ccagtgtgca gaggatggca gcttccagac tgtccagtgc ca £ aac £ acg 240 gccgctcct £ ct £ gtgtgtg ggtgccaacg scagtgaagt gctgggcagc aggcagccag 300 gacggcctgt sgcttgtctg tcattttgtc agctacagaa acagcagatc ttactgagtg 360 gctacattaa cagcacagac acctcctacc tccctcagtg tcaggattca ggggactacg 420 cgcct £ ttca gtgtgatgtg cagcatgtcc agtgctggtg tgtggacgca gaggggatgg 480 agstgtatgs gacccgccag ctggggaggc caaagcgatg tccaaggagc tgtgaaataa S40 faaatcgtcg tcttctccac ggggtgggag ataagtcacc accmstst tctfcggagg 600 • 74 ·

145138 - Sequence Listing doc 201015069

gagagtttat gcctgtccag tgcaaatttg tcaacaccac agacatga ^ atttttgate 660 tggtccacag ctacaacagg tttccagatg catttgtgac cttcagttcc ttccagagga 720 ggttccctga ggtatctggg tattgccact gtgctgacag ccaagggcgg gaactggctg 780 agaca ^ ttt ggagttgtta ct ^ a ^ aaa t ^ atgacac catmtgct ggcctggacc 840 ttcctlccac cttcactgaa accaccctgt accggatact gcagagacgg ttcctcgcag 900 ttcaatcagt catctctggc agattccgat gccccacaaa atgtgaagtg gagcggttta 960 cagcaaccag cCttggtcac ccctatgttc caagct ^ ccg ccgaaatggc gactatcasg 1020 cggtgcagtg ccagacggaa gggccctgct ggtgtgtgga cgcccagggg aafigaaatgc 1080 atggaacccg gcagcaa ^ g £ a £ ccgccat cttgtgctga aggccaatct tgtgcctccg 1140 aaasgcagca ggccttgtcc agactctact ttgggacctc aggctacttc agccagcacg 1200 acctgttctc ttccccagag aaaagatggg cctctccaag agta £ 〇caga tttgccacat 1260 cctgcccacc cacgatcaag gagctctttg tggactctgg Gcttctccgc ccaatggtgg 1320 agggacagag ccaacagtti tctgtctcag aaaatcttct caaagaagcc atccgagcaa 1380 tttttccctc ccgagggctg gctcgtcttg cccttcagtt taccaccaac ccaaagagac 14^0 tccagcaaaacctm t £ gagggaaatttttgg ^ aat £ ttggccagtt £ aacttgtct £ 1500 gagcccttgg cacaagaggc acatttaact tcag ^ aatt tttccagcaa cttggtcttg 1560 caagcttctt gaatggaggg agacaagaag att ^ gccaa gccadctct gtgggattag 1620 attcaaatic ttccacagga acccctgaag ctgctaagaa gga ^ gtact atgaataagc 1680 caac ^ tggg cagctnggc at ^ aaatta acctacaaga gaaccaaaat gocctcaaat 1740 tccttgcttc tctcct £ ga £ cttccagaat tccttetctt cttgcaacat gctatctct £ 1800 tgccagaaga tgtggcaaga gatttaggtg algtgatgga aacggtactc gactcccaga 1860 cctgtgagca gacacctgaa aggctatttg tcccatcatg cacgacagaa ggaagctatg 1920 aggatgtcca atgcttttcc ggagagtgct gglgtgtgaa ttcctggggc aaagagcttc 1980 caggctcaag agtcagagat ggacagccaa ggtgccccac agactgtgaa aagcaaag £ g 2040 ctcgcatgca aagcctcatg ggcagccagc ctgctggctc caccttgttt gtccctgctt 2100 gtactagtga ggsacatttc ctgcctgtcc Agtgcttcaa ctcagag^c tactgtgt^ 2160 atgctgaggg tcaggccatt cc^iactc gaag^caat agggaagccc aagaaa^cc 2220 •75- 145138·sequence table.doc 201015069 ❿ ccacsccctg tcaattacag tctgagcaag ctttcdcag gacggtgcag gccctgc tct 2280 acctccctcc gcggagcagc cagacaecga ^ gccccggc cgggggcagg ggggacgccc 2340 cgtccgggscaccccccccggctctgagccgcccgcggggccggcctcggcccggagcgg 2400 aggaaggagtcgccgaggagcagcctga £ gccccagagtctgagac £ agccgccgccgcc 2460 cccgccact £ cggggaggag ggggaggagg agcgggagga gggacgagct ggtcgggaga 2S20 agaggaaaaa aacttttgag acttttccgt tgccgc ^ gg agcx ^ gaggc gcgsggacct 2580 cttggcscga cgctgccccg cgaggaggca ggacttgggg accccagacc gcctcccttt 2640 gccgccgggg acgct ^ ctc cctccctgcc ccctacacgg Cgtccctcag gcgcccccat 2700 tccggaccag ccxtcgggag icgccgaccc ggccteccgc aaagacmt ccccagacct 2760 cg^cgcacc ccc^cacgc cgccttcatc cccggcctgt ctcctgagcc cccgcgcatc 2820 ctagaccctt tctoctccag gasacggatc tctctccgac ctgccacaga tcccctattc 2880

agacaccccc ggtccaagcc tcccctccac cactgcgccc ttctccctga ggagcctcag 3000 cmccctcs aggcxxtcct acctttt ^ cc gggagacccc cagcccctgc aggggcgggg 3060 cctccccacc acaccagcx ^: ^ tlcgcgct ctcggcagtg ccggggggcg ccgcctcccc 3120 catgccgccc tccgggctgc ggctgctgcc gctgctgcta ccgctgctgt ggctactggt 3180 gctgacgcct ggcccgccgg ccgcgggact atccacctgc aagactatcg acatggagct 3240 ggtgaagcgg aagcgcatcg aggccatccg cggcca ^ atc ctgtccaagc tgcggctegc 3300 cagccccccg agccaggggg aggtgccgcc cggcccgctg cccgaggccg tgctcgccct 3360 gtacaacagc acccgcgacc gggtggccgg ggagagtgca gaacoggagc ccgagcctga 3420 ggccgactac tacgccaagg aggtcacccg cg ^ ctaa ^ gt ££ aaaccc acaacgaaat 3480 ctatgacaag ttcaagcaga gtacacacag catatatatg ttcttcaaca catcagagct 3540 ccgagaagcg gtacctgaac ccgtgttgct ctcccgggca gagctgcgtc tgctgaggag 3600 gctcaagtta aaagtggagc agcacgtgga gdgtaccag aaatacagca acaattcctg 3660 gcgatacctc agcaaccggc tgctggcacc Cagcgactcg ccagagtggt tatcttttga 3720 tgtcaccgga gttgtgcgg agtggitgag ccgtggaggg gaaattgagg gctdcgcct 3780 tagcgcccac Tgctcctgts acagcaggga taacacactg caagtggaca tcaacgggtt 3840 -76- 145138 - Sequence Listing.doc 201015069 ❹

cactaccggc cgccgaggtg acctggccac cattcatggc atgaaccggc ctt ^ ctgct 3900 tctcatggcc accccgctgg asagggccca gcatctgcaa agctcccggc accgcciagc 3960 cctggacacc aactattgct tcagctccac ggaga ^ aac tgctgcgtgc ggcagctgta 4020 cattgacttc c £ caa £ gacc tcggctggaa gtggatccac gagcccaagg gctaccatgc 4080 caacttctgc ctcgggccct gcccctacat ttggagcctg gacacgcagt acagcaaggt 4140 cctggccctg tacaaccagc ataacccggg cgccteggcg gcgccgtgct gcgtgccgca 4200 ggcgctggag ccgctgccca tcgtgtacta cgtgggccgc aagcccaagg tggagcagct 4260 gtccaacatg atcgtgcgct cctgcaagtg cagctgaggt cccgccccgc cccgccccgc 4320 cccggcaggc ccggccccac cccgccccgc ccccgctgcc ttgcccatg £ g £ gctgtatt 4380 taaggacacc gtgccccaag cccacctggg gccccattaa agatggagag aggactgcgg 4440 atctctgtgt cattgggcgc ctgcctgggg tctccatccc ^ ac ^ ttccc ccactcccac 4500 tccctctctc tccctctctg cclcctcctg cctgtclgca ctattccttt goccggcatc 4560 aaggcacagg £ G^cagtgg ^aacactac tgtagttaga tctamatt gagcaccttg 4620 ggcactgttg aagtgcctta cattaatgaa ctcattcagt caccatagca acactctgag 4680 atggcagg gactctgataacacccattttaaaggttgaggaaacaagcccagagaggtta 4740 agggaggagt tcctgcccac caggaacctg ctttagtggg ggatagtgaa ^ aagacaata 4800 aaagatagta gttcaggcca ggcggsgtgc tcacgcctgt aatcctagca cttttgggag 4860 gcagagat £ g gaggatactt gaatccaggc atttgagacc agcctgggta acatagtgag 4920 accctatctc tacaaaacac ttttaaaaaa tjgtacacctg tggtcccagc tactctggag 4980 gctaaggt £ g gaggatcact tgatcctggg ag £ tcaaggc tgcag S02S < 210 > 101 < 211 > 2208 < 212 > DNA < 213 > human < 4O0 > 101 tctttggctt tttttggcgg agctggggcg ccctocggaa gcgtttccaa ctttccagaa 60 gtttctcggg acgggcagga gggggtgggg actgccatat atagatcccg ggagc ^ ggg 120 agcgggctaa gagtagdatc gt £ tcgcggc tcgagagcga gagtcacgtc ccggcgctas 180 cccagcccga cccaggccca ccgtggigca cgcaaaccac ttcctggcca tgcgctccct 240 -77· 145138-Sequence table.doc 201015069 cctgcttctc agcgccttct gcctcctgga ggcggccctg sccgccgagg tgaagaaacc 300 tgcagccgca gcagctcctg gcactgcgga gaagttgagc cccaaggcgg ccacgcttgc 360 cgagcgcagc gccggcctgg ccttcagctt gtaccaggcc atggccaagg accag gcagt 420 ggagaacatc ctggtgtcac ccgtggtggt ggcctcgtcg ctagggctcg tgtcgctggg 4B0 cggcaaggcg accacggcgt cgcaggccaa ggcagtgctg agcgccgagc agctgcgoga S40 cgaggaggts cacgccggcc tgggcgagct gctgcgctca ctca £ 〇aact ccacggcgcg 600 caacgtsacc t ££ aagctgg gcagccgact gtacggaccc agctcagtga gcttcgctga 660 tgacttcgtg cgcagcagca agcagcacta caactgcga £ cactccaaga tcaacttccg 720 cgacaagcgc agcgcgctgc agtccatcaa cgagtgggcc gcgcagacca ccgacggcaa 780 gctgcccgag gtcaccaagg acgtggagcg cacggacggc gccctgctag tcaacgccat 840 gttcttcaag ccacactggg atgagaaatt ccaccacaag atggtggaca accgtggctt 900 ca ^ gtgact cggtcctata ccgtgggtgt catgatgatg caccggacag gcctetacaa 960 ctactacgac gacgagaagg aaaagctgca aatcgtggag atgcccctgg cccacaagct 1020 ctccagcctc atcatcctca tgccccatea cgtggagoct ctcgagcgcc t ^ aaaagct 1080 gctaaccaaa gagcagctga agatctg £ at ggggaagatg cagaagaagg ctgt ^ ccat 1140 ctccttgccc aagggtgtgg tggaggtgac cca^acctg cagaaacacc tggctgggct 1200 gggcctgact gaggccattg acaagaacaa ggccgdctts tcacgcatgtcaggcaagaa 1260 gga cctgtac ctggccagcg tgttccacgc caccgccttt ga £ ttggaca cagatggcaa 1320 cccctttsac caggacatct acgggcgcga ggagctgcgc agccccaagc tgttctacgc 1380 cgaccacccc ncatcttcc tagtgcggga cacccaaagc ggctccc ^ c tattcattgg 1440 gcscctggtc cggcctaagg gtgacaagat gcgagacgag ttatagggcc tcaggstgca 1500 cacaggatgg caggaggcat ccaaaggctc ctgagacaca tgggtgctat tggggttggg 1560 £ Sggaggtga ggtaccagcc ttsgatactc catgg £ gtg £ gggtggaaaa acagaccggg 1620 gttcccgtgt gcctgagcgg accttcccag ctagaattca ctccacttgg acatgggccc 1680 cagataccat gatgctgagc ccggaaactc cacatcctgt gggacctggg ccatagtcat 1740 tctgcctgcc ctgaaagtcc cagatcaagc ctgcctcaat cagtattcat atttatascc 1800 aggtaccttc tcacctgtga gaccaaattg agctaggggg gtcagccagc cctcttctga 1860 -78 · 145138 · sequence Listing .doc 201015069 cactaaaaca cctcagctgc ctccccagct ctatcccaac ctctcccaac tataaaacta 1920 g £ tgctgcag cccctgggac caggcacccc Cagaatgacc tggccgcagt gaggcggatt 1980 gagaaggagc tcccaggagg ggcttctggg cagactctgg tcaagaagca tcgtgtct^g 2040 cgttfitgggg atgaactttt tgttttgttt cttcc Ttttt tagttcttca aagataggga 2100 gggaaggggg aacatgagcc tttgttgcta tcaatccaag aacttatttg tacatttttt 2160 ttttcaataa aacttttcca atgacatttt gttggagcgt ggaaaaaa 2208 <210> 102 <211> 2566 <212> DNA <213> human ❹ <400>

ggcacgagtt gtgctcctcg cttgcctgtt ccttttccac gcattttcca ggataactgt 60 gactccaggc ccgcaatgga tgccctgcaa eta forget caaatt cggcttttgc cgttgatetg 120 ttcaaacaac tatgtgaaaa ggagccactg ggcaatgtcc tcttctetcc aatctgtctc 180 tccacctetc tgtcacttgc tcaagtgggt gctaaaggtg acactgcaaa tgaaattgga 240 caggttcttc atttt £ aaaa tgtcaaagat ataccctttg gatttcaaac agtaacatcg 300 gatgtaaaca aacttagttc cttttactca ctgaaactaa teaagegget etaegtagae 360 aaatctctga atctttctac agagttcak: agetetaega agagacccta tgcaaaggaa 420 ttggaaactg ttgacttcaa agataaattg gaagaaacga aaggtcagat caacaactca 480 attaaggatc tcacagatgg ccactttgag aacattttag ctgacaacag tgtgaacgac 540 cagaccaaaa tccttgtggt taatgctgcc tactttgttg gcaagtggat gaagaaattt 600 cctgaatcag aaacaaaaga tcatcctact acccaaggat 780 atgtcctttc agactcaaca agacagacac caaaccagtg 660 cagatgatga acatgga £ gc cacgttctgt atgggaaaca ttgacagtat caattgtaag 720 atcatagagc ttccttttca aaataageat ctcagcatgt gtggaggatg agtccacagg Ettggagaag attgaaaaac aactcaactc agagtcactg 840 tcacagtgga ctaatc ccag caccat £ gcc aatgccaagg tcaaactctc cattccaaaa 900 tttaaggtgg aaaagatgat tgatcccaag gcttgtctgg aaaatctagg gctgaaacat 960 atcttcagtg aagacacatc tgatttctctggaatgteag agaccaaggg agtggcccta 1020 -79 · 145138 · Sequence Listing .doc 201015069 tcaaat £ tta tccacaaagt gtgcttagaa ataactgaag atggtgggga ttccatagas 1080 gtgccaggag cacggatcct gcagcacaag gatgaattga atgc ^ acca tccctttatt 1140 tacatcatca ggcacaacaa aactcgaaac atcattttct t ^ gcaaatt ctgttctcct 1200 taagtggcat agcccat £ tt aagtcctccc tgacttttct gtggatgccg atttc ^ taa 1260 actctgcatc cagagattca ttttctagat acaataaatt gctaa ^ ttg ctggatcagg 1320 aagccgccag tacttgtcat atgtagcctt cacacagata sacctttttt tttttccaat 1380 tctatctttt gtttcctttt ttcccataas acaatgacat acgcttttaa tgaaaaggaa 1440 tca〇 £ ttaga ggaaaaatat ttat ^ atta Tttgtcaaat tgtccggggt agttggcaga 1500 aatacagtct tccacaaaga aaattcctat aasgaagatt tggaasctct tcttcccagc 1560 actatgcttt ccttctttgg gatagagaat gtCccagaca ttctcgcttc cctgaaagac 1620 tgaagaaagt gtag^catg ggacocacga aactgocc^ fictccag^a aact^ ggca 1680 catgc ^ agg ctactatagg tccagaagte cttatgttaa gccctggcag gcaggtsttt 1740 attaaaattc tgaattttgg ggattttcaa aagataatat tttacataca ctgtatgtta 1800 tiigaacttca tggatcagat ctggggcagc aacctataaa tcaacacctt aatatgctgc 1860 aacaaaatgt a £ aatattca gacaaaatgg atacataaas actaagtagc ccataagggg 1920 tcaaaatttg ctgccaaatg cgtatgccac caacttacaa aaacacttcg ttcgcagagc 1980 ttttcagatt gtggaatgtt ggataaggaa ttatagacct ctagtagctg aaatgcaaga 2040 ccccaagagg aagttcagat cttaatataa attcactttc atttttgata gctgtcccat 21CX) ctggtcatgt ggttggcact agactggtgg caggggcttc tagctgactc gcacagggat 2160 tctcacaata gccgatatca gaatttgtgt tgaaggaact tgtctcttca tctaatatga 2220 tagcgggaaa aggagaggaa actactgcct ttagaaaata taagtaaagt gattaaagtg 2280 ctcacgttac cttgacacat agtttttcag tctatgggtt tagttacttt agatggcaag 2340 catgtaaott atattaatag taatttgtaa agttgggtgg ataagctatc cctgttgccg 2400 gttcatggat tacttctcia taaaaaatat atatttacca aaaaattttg tgacattcct 2460 tctcccatct cttccttgac Atgcattgta aataggttct tcttgttctg agattcaata 2520 ttgaatttct cctatgctat ^acaataaa atattat^a actacc 2566 <210> 103 -80 - 145138 · Sequence Listing.doc 201015069 <211> 2974 <2I2> DNA <213> Human <400>

ctcagggcag agggaggaaggacagcagac cagacagtca cagcagcctt gacaaaacgt 60 tcctggaact caagctcttc tccacagagg aggacagagc agacagcaga gaccatggag 120 tctccctcgg cccctcccca cagatggtgc atcccctggc agaggctcct gctcacagcc 180 tcacttctaa ccttctggaa cccgcccacc actgccaagc tcactattga atccacgccg 240 ttcaatgtog cagaggggaa ggaggtgctt ctacttgtcc acaatctgcc ccagcatctt 300 tttggctaca gct £ gtacaa aggtgaaaga gtggatggca accgtcaaat tataggatat 360 gtaataggaa ctcaacaagc taccccaggg cccgcataca gtggtcgaga gataatatac 420 cccaatgcat ccctgctgat ccagaacatc atccagaatg acacaggatt ctacacccta 480 cacgtcataa agtcagatet tgtgaatgaa gaagcaactg gccagttccg ggtatacccg 540 gagctgccca agccctccat ctecagcaac aactccaaac ccgtggagga caaggatgct 600 gtggccttca cctgtgaacc tgagactcag gacgcaacct acctgt £ gtg ggtaaacaat 660 cagagcctcc cggtcagtcc caggctgcag ctgtccaatg gcaacaggac cctcactcta 720 ttcaatgtca caagaaatga cacagcaagc tacaaatgtg aaacccagaa occagtgagt 780 gccaggcgca gtgattcagt catcctgaat gtcctctatg gcccggatgc ccccaccatt 840 tcccctctaa acacatctt a cagatcaggg gaaaatctga acctctcctg ccacgcagcc 900 tctaacccac ctgcacagta ctctt £ gttt gtcaatggga ctttccagca atccacccaa 960 gagctcttta tcx: ccaacat cact £ tgaat aatagtggat cctatacgtg ccaagcccat 1020 aactcagaca ctggcctcaa taggaccaca gtcacgacga tcacagtcta tgcagagcca 1080 cxxaaaccct tcatcaccag caacaactcc aaccccgtgg aggatgagga tgctgtagcc 1140 ttaacctgtg aacctgagat tcagaacaca acctacctgt ggtgggtaaa taatcagagc 1200 ctcccggtca gtcccaggct gcagclgtcc aatgacaaca ggaccctcac tctactcagt 1260 gtcacaagga atgatgtagg accctatgag tgtggaatcc agaacgaatt aagtgtlgac 1320 cacagcgacc cagtcatcct gaatgtcctc tatggcccag acgaccccac catttccccc 1380 tcatacacct atlaccgtcc aggggtgaac ctcagcctct cctgccatgc agcxtctaac 1440 ccacctgcac agtaticttg gctgattgat gggaacatcc agcaacacac acaagagctc 1500 -81- 145138 · sequence Listing .doc 201015069 tttatctcca acatcactga gaagaacagc g £ actctata cctgccaggc caataactca 1560 £ccagt£gcc acagcaggac tacagtcaae acaatcacag tctc^C££a gctgcccaag 1620 ccctcx;atct ccagcaacaa ctccaaaccc gt^aggaca agga^ctgt g gccttcacc 1680 tgtgaacctg aggctcagaa cacaacctac ctgtggtggg taaatggtca gagcctccca 1740 gtcagtccca ggctgcagct gtccaatggc aacaggaccc tcactctatt caatgtcaca 1800 agaaatgacg caagagccta tgtatgtgga atccagaact cagtgagtgc aaaccgcagt 1860 gacccagtca ccctggatgt cctctatggg ccggacaccc ccatcatttc ccccccagac 1920 tcgtcttacc tttcgggagc gaacctcaac ctctcctgcc actcggcctc taacccatcc 1980 ccgcagtatt cttggcgtat caat £ ggata ccgcagcaac acacacaagt tctctttatc 2040 gccaaaatca cgccaaataa taacgggacc tatgcctgtt ttgtctctaa cttggctact 2100 ggocgcaata attccatagt caagagcatc acagtctctg catctggaac ttctcc ^ gt 2160 ctotcagctg gggc ^ actgt cggcatcatg auggagtgc tggttggggt tgctctgata 2220 tagcagccct ggtgtagttt ctteatttca ggaagactga cagttgtttt gcttcttcct 2280 taaagcattt gcaacagcta cagtctaaaa ttgcttcttt accaaggata tttacagaaa 2340 agactctgac cagagatcga gaccatccta £ ccaacatc £ tgaaacccca tctctactaa 2400 aaatacaaaa atgagctggg cttggtggcg cgcacctgta gtcccagtta ctcgsgasgc 2460 tgaggcagga gaatcgcttg aacccfggag g^gat% cs^agocc agatcgcacc 2 520 actgcactcc agtctggcaa cagagcaaga ctccatctca aaaagaaaag aaaagaagac 2580 tctgacctgt actcttgaat acaagtttct gataccactg cactgtctga gaatttsccaa 2640 aactttaatg aactaactsa cagcttcatg aaactgtcca ccaagatcaa gcagasaaaa 2700 taattaatttcatsggactaaatgaactaa ^ aggattgctgattctttaaatgtcttgt 2760 ttcccagatt tcagsaaact ttttttcttt taagctatcc actcttacag caatttgata 2820 aaatatactt ttgtgaacaa aaattgagac atttacattt tctcoctatg tggtcgctcc 2880 agacttgggaaactattcatgaatatttatattgtatggtaatatagttattgcacaagt 2940 tcaataaaaa tctgctctit gtataacaga aaaa 2974 < 210 & gt 104 <211> 3069 • 82· 145138· Sequence Listing.doc 201015069 <212> DNA <213> Human <400> 104

tgtttccgct gcatecagac ttcctcaggc ggtggctgga ggctgcgcat ctggggcttt 60 aaacatacaa agggattgcc aggacctgcg gcggcggcgg cggcggcggg ggctggggcg 120 cgggggccgg accatgaficc gctgagccgg gcaaacccca ggccacxgag ccagcggacc 180 ctcggagcgc agccctgcgc cgcggaccag gctccaacca ggcggcgagg cggccacacg 240 caccgagcca gcgacccccg ggcgacgcgc ggggccaggg agcgctacga tggaggcgct 300 aatggcccgg ggcgcgctca cgggtcccct gagg £ square £ Ctc tgtctcctgg gctgcctgct 360 gagccacgcc gccgccgcgc cgtcgcccat catcaagttc cccfi £ square £ atg tcgcccccaa 4 ^) aacg £ acaaa gagttsscag tgcaatacct gaacaccttc tatggctgcc ccaaggafag 480 ctgcaacctg tttgtgctga aggacacact aaagaagatg casaagttct ttsgactgcc 540 ccagacaggt gatcttgacc afaataccat cgagaccatg cggaagccac gctgcggcaa 600 cccagatgtg gccaactaca acttcttccc tcgcaagccc aagtgggaca agaaccagat 660 cacatacagg atcattggct acacacctsa tctggaccca gagacagtgg atsatgcctt 720 tgctcgtgcc ttccaagtct ggascgatgt gaocccactg Cgcttttctc ^atccatga 780 tggagaggca gacatcatga tcaactt^g ccgc^ggag catggc^alg gatacccctt 840 tgacggtaag ga cggactcc tggctcatgc cttcgccxca g ^ actggtg t ^ ggggasa 900 ctcccatttt gatgacgatg agctatsgac cttgggagaa ££ 〇caagtgg tccgtgtgaa 960 gtatggcaac gccgatgggg agtac ^ caa gttccccttc ttgttcaatg gcaaggagta 1020 caacagctgc actgatactg gccgcagcga ^ gcttcctc tggtgctcca ccacct ^ aa 1080 ctttgagaag gatggoaagt acggcttctg tccccatgaa gccctsttca ccatgggceg 1140 caacgctgaa ggacagccct gcaagtttcc attccgcttc cagggcacat cctatgacag 1200 ctgcaccact gagggccgca cggatggcta ccgctggtgc ggcaccactg aggactacga 1260 ccgcgacaag aagta ^ gct tc ^ ccctga gaccgccatg tccactgttg gtgggaactc 1320 agaaggtgcc ccctgtgtct tccccttcac tttcctgggc aacaaatatg agagctgcac 1380 cagcgccggc cgcagtgacg gaaagatgtg gtgtgcgacc acagccaact acgatgacga 1440 ccgcaa £ t £ g £ gcttctgcc ctgaccaags gtacagcctg ttcctcgtgg cagcccacga 1500 • 83 - 145138·序表.doc 201015069 gtttij^oac scca^S£g〇tggagcacte ccaapccct £gggccctga ts^acccat 1560 ttacacct^accaagaactlccgtc^Dcc^gatgacatcaassgcattcaggag^t 1630 cta^ggcc ictcc^a ttgsmtgg cacrggcocc acccccacac tgggocctgt 1680 cactcc ^ ag atctgcaa ^: agpcaUs ^ ^ t ^ atggc atcgctcaga tccgtggtga 1740 gatct ^ cttc Cteaaggacc g ^ tcamg gc ^ ctgtg acgcc ^ gtg acaagcccat 1800 ggggcccds ctggtggcca ^ agctccxg gaaaagattg a ^ cggtam i860 cgaggcccca caggaggaga aggctgtgtt cttlgcaggg aatgaatact ggatctacte '1920 agccagcacc ctggagc ^g ggtaccccaa gccactgacc a£cctsss&c tgccxxctga 1980 tgtocagcga gts^tgccg ccttta^tg gagc^aaa^ aa footgacat acatctt^c 2040 tggagacaaa ttctggagat ^cs^t&ggn gaagaag^aa atggaKx:tg gc^cccaa 2100 gctcategca gatgcc^ ga a ^ gccatccc cptaacctg gatgccgtcg ^ ggacc ^ oa 2160 gggcggcggtcacagctactlcttc ^ gggt ^ lattacctgaagc ^ gagaaccaaas 2220 tc ^ aagagc gtgaagttt ^ gaagc ^ tcaa atccgact ^ g cta ^ gctgct gagc ^ gccc 2280 quiet djcccac aggcccttcc tdxc ^ tgc cttcgataca ccg ^ cdEg agaactagag 2340 aaggacccgg A^gsscctgg ca^cgts^c dcagctcta cagctaatca gcattctcac 2400 tcctaa;tgg taamaaga ttccagagas boat to add c cggtgcccaa gaalagatgc 2460 tgactgtact o:tcccaggc gccccdccc cc£ccaatco OKscaaocct capgccacc 2520 cctaaagaga tccmsata ttttcaacgc agcccl^cU t£ Sctgcoo tsst £ ^ £ cc 2580 ac ^ ttcaggctcttctcctttcacaaccttctgtggctcacasaacccttggagccaat 2640 ggagactgtcccaagaggscactegtggcccgacagoctg ^ acasggcagtggg ^ ags 2700 scatggccag gtggccactc cagacccctg gctotcact gctssctgcc ttagaacctt 2760 tcttacatta ^ agtttgct Ugta ^ cac tttgtdttt tctttgggtc ttgttttttt 28 ^) tttccactta gaaat ^ cat ficctgacag aaggactcag gttgtctgaa gtcactgcac 2880 agtgcaictc agcccacata stsatggttc ccctgttcac tctacttagc Atgtoxt^: 2940 cgagtctctt ctccactgga tggaggaaaa ccaa£〇:gtg scttcc^gct cagccctccc 3(XX) tgcccctecx ttcaaccatt ccccatggga aatgtcaaca agtatgaata aagacaccta 3060 ctgagtggc 3069 84- U5138·sequence table.doc 201015069 9 A class 1053299T ^17^^7 1* n 1 11 < 2 < 2 < 2 < 2 < 400 > 105 cggagggagc gctgggagcg agcaagcsag cgtttggaec a% £ gccagc agagggggcg θΰ cccggtcgct goagtaccg ctcccgctgg tcalctccgc cgcgctcg® ggccccggga 120 ggagcgagac square £ agtcggag agtccgggag ccaagccm cpaacccaa ctgcggagga 180 cgcccgcox actoagcctc ctcctgcgtc ogagccgggg agcate ^ cg Agcgccxcac 240 gggcxggaga gctgggagca ca gg & xcgg c ^ ccccagg ga ^ gtctag gagccggcgt 300 a & ggctcfict £ 〇tctgctcc ctgccg £ g £ c tagccgc ^ tc ctgcxgateg ccqggggc ^ 360 reference cgagct ^ gg cggcccgggg c ^ ctcgccg ggcggcgcag gccgsagaag tt ^ gttgtsc 420 gcgcccUag tgcgcggaac cagccagcga gcgag ^ gagc agcgaggcgc cgggaccatg ggct ££ g £ ga gccgctgctg ctgoxggga cgtttggaec tjgct ^ tgcgt sctggcgctg 540 ctcgggggct gcctgctccc cstgtgtcgg acgcgcgict acaccaacca ctgggcagtc 600 aaaatcgccg ggggcttccc ggaggccaac cgtatcgcca gcaagtacgg attcatcaac 660 ataggacaga taggggccct gaaggactac taccacttot ^ catagcag 720

780 840 cagictacot atQcaaiga teccaa ^ g cccagc ^ tgt ^ tetalicactscagtgac 900 ❹ aatacacatc cc ^ ccagic ^ aca ^ aat ategaaggag cc ^ gaagag a ^ cbicacg 960 ggaaagaaca ttgtggtcac taicctggat gacggaatlg agagaaccca 1020 atgcaaaact aegatgetet ggcaagttgc gaegtsaatg gg ^ itgactt ggacccaatg 1080 cctcgttatg atgcaagcaacgagaacaag catgggactc gctgtgctgg agaagtggca 1140 gccgctgcaa acaattcgca ctgcacagtc ggaattgett tcaacgccaa gateggagga 1200 gtgegaatse tggaeggaga tgteaeggae at ^ gttgaag caaaate ^ t tagettcaac 1260 occcagcac £ tgcacama cagcgcc ^: tggggcccgg atptgatgg ca ^ actg ^ 132Ω gacggaocag cccccctcac ccggca ^ cc tttgamc% gcgttagaat 1380 ggccti ^ got ctgtgtogt ttgeecatct ggaaatgglg gaaggagcaa agaccactgc 1440 • 85 · 145 · 38〗 sequence table .doc 201015069 tcctgtgats gctacaocaa cagcatctac accatctcca tcagcagcac tgcagaaagc 1500 ggaaagaaac cttggtacct ggaagagtgt tcatecacgc tggccacaac ctacagcagc 1560 gSggagtcct acgataagaa aatcatcact acagatctga sgcagcgttg cacggacaac 1620 cacactggga cgtcagcctc agcccmatg gctgcaggca tcattgcgct ggccctggaa 1 680 gccaiitccgt ttctgacctg gagagacgta cagcatgtta ttgtcaggac ttcccgtgcg 1740 g ^ icatttga acgct ^ tga ctggaaaacc aatgctgctg gttttaa £ gt gagccatcu 1800 tatggatttg gactgat £ ga cgcagaagcc atggtgatgg aggcagagaa gtggaccacc 1860 gttccccggc agcacgtgtg tgtggagagc acagaccgac aaatcaagac aatccgccct 1920 aacagtgcag tgcgctccat ctacaaagct tcaggctgct cggataaccc caaccgccat 1980 gtcaactacc tggagca〇 £ t cgttgtgcgc atcaccatca cccaccccag gagaggagac 2040 ctggccatct aoctgacctc gccctctgga actaggtcte agcttttgsc caacaggcta 2100 ttt ^ atcact ccatggaagg attcaaaaac tgggagttca tgaccattca ttgctgggga 2160 gaaasagctg ctggtgactg g £ tccttgaa gtttatgata ctccctctca gctaaggaac 2220 tttaagactc caggtaaatt gaaagaatgg tctttggtcc tctacggcac ctccgtgcas 2280 ccatattcac caaccaatsa atttccgaaa etggaac ^ gt tccgctatag ccgagttgaa 2340 gaccccacag acgactatgg cacagaggat tatscaggtc cctgc ^ccc tgagtgcagt 2400 gaggttggct gtgacgggcc aggaccagac cactgcaats actgttt^ca ctactactac 24^) aagctgaaaa acaataccag gatctgtgtc tccagctgcc cccctggcca ctaccacgcc 252 0 gacaagaaec gctgcaggaa gtgtgccccc aactgtgagt cctgctttgg gagccatggt 2S80 gaccaatgca tgtcctgcaa atatggatac tttctgaatg aagaaaccaa cagctgtgtt 2640 actcactgcc c ^ atgggtc atatcaggat accaagaaaa atctttsccg gaaatgcagt 2700 gaaaactgca agacatgtac tgaattccat aactgtacag aatgtaggga tgggttaagc 2760 ctgcagggat cccggtgctc tgtctcctgt gaagatggac getatttcaa cggccaggac 2820 tgccagccct gccaccgctt ctgcgccact tgtgctgggg caggagctga tggglgcatt 2880 aactgcacag agggctactt catggaggat gggagatgcg tgcagagctg tagtatcagc 2940 tattactttg accactcttc agagaatgga tacaaatcct gcaaaaaatg tgatatcagt 3000 tgtttgacgt gcaatggccc aggattcaag aactgtacaa gctgccctaf tgggtatctc 3060 145138 · sequence Listing .doc 201015069 ttagacttag gaatgtgtca aatgggagcc atttgcaagg atgcaacgga agagtcctgg 3120 gcggaaggag gcttctgtat gcttgtgaaa aagaacaatc tgtgccaacg gaaggttctt 3180 caacaacttt gctgcaaaac atgtacattt caaggctgag cagccatctt agatttcttt 3240 gttcctgtag acttatagat tattccatat tattaaaaag aaaaaaaaaa gccaaaaag 3299 <210> 106 <211> 1664 <212> DNA <213>Human <400> 106 atgggt^tg actgcttcgt ccaggaggtg ttctgctcag atgaggagct tgccaccgtc 60 ccgctggaca tcccgccata tacgaaaaac atcatctttg tggagacctc gtteaccaca 120 ginseng

ttggaaacca gagctttt ^ g cagtaacccc aacttgacca aggtggtctt cctcaacact 180 cagctctgcc agtttaggcc ££ atgccttt ggggggctgc ccaggctgga ggacctggag 240 £ tcacaggca gtagcttctt gaacctcagc accaacatct tctccaacct gacctcgctg 3 (X) ggcaagctca ccctcaactt caacatgctg £ aggctctgc ccgagggtct tttccagcac 360 ctggctgccc tggagtccct ccacctgca £ gggaaccagc tccaggccct gcccaggagg 420 ctcttccagc ctctgaccca tctgaagaca ctcaacctgg cccagaacct cctggcccag 480 ctcccggagg agctgttcca cccactcacc agcctgcaga ccctgaagct gagcaacaac 540 gcgctctctg gtctccccca gggtgtgttt ggcaaactgg gcagcctgca ggagctottc 600 ctggacagca acaacatctc ggagctgccc cctcaggtgt tctcccagct cttctgccta 660 gagaggctgt ggctgcaacs caacgccatc acgcacctgc cgctctccat ctttgcctcc 720 ctgggtaatc tgacctttct gagcttgcag tggaacatgc ttcgggtcct gcctgccggc 780 ctctttgccc acaccccatg cctggttggc ctgtctctga cccataacca gctggagact 840 gtcgctgagg gcacctttgc ccacctgtcc aacctgcgtt ccctcatgct ctcatacaat 900 gccattaccx: acctcccagc tggcatcttc agagacctgg aggagttggt caaactctac 960 ctgggcagca ac aaccttac ggcgctgcac ccagccctct tccagaacct gtccaagctg 1020 gagctgctca gcctctccaa gaaccagctg accacacttc cggagggcatcttcgacacc 1080 aactacaacc tgttcaacct ggccctgcac ggtaacccct ggcagtgcga ctgccacctg 1140 -87 · 145138- Sequence Listing .doc 201015069 gcctacctct tcaactgsct gcagcagtac dct ^ cggc tectgaacataut ^ cctec 1200 tgc ^ ggoc c ^ cctacct caaaggc ^ g gt ^ Ticccg cct^aiga gaagcagc^g 1260 g&gtixcg lcaccc%£sa ccacuggsc ttcca^tca <%tggccs^ cgaaagcaag 1320 goagggggca gclgs&tci ggctg^cag gaaa££gcag cccggagcca gtgc^tac 1380 agcaaccccg ag^c want gt gg thief Icgcc tg^ocasg cccagtglcs ct^ctgHelp c 1440 gtccagctct ciccttggca gggctccc^ gsactgca^t acaatgctag U^ggag^ 1500 gacotgaget Township gctgogg ttctetgcgg clcaccgtgt ctatcga^c lc^gc£$c;a 1560 gggcccta^ sgcagc^at acagga^ct£ Sss^agESES ctt^gggcc tgcccacgcg 1620 acaggtaggg gcggagg^a gctgzgtc\c cgaagcttgg cut 1664 <210> 107 <211> 3383 <212> DNA <213>human<400> 107 cgggggccgc gcg^aaga tggtgtgcsc tcgggcggcc dcggtcccg Gcgcgdctg 60 ggccgcgg cc tggggcglcc tgctgctcac agcccctscg ggggcgcagc g ^ gccggaa 120 gaaggtcgtg cacgtgctgg aggg ^ agtc gggctcggta gt £ gtacaga cagcgcctg £ 180 gcagg ^ gta agcc ^ cgtg gtggcaccat cgtcttgtxc ^ ccgctacc actatgaggc 240 agccgcccac £ etcacgacs £ cgtcc ££ ct c & agt £ gaca aaggtggtgg acccgctsgc 300 cttcaccgac gtcttcgtgg cactaggccc ccagcaocgE scattoggca gctacc ^ s 360 gcjggSEdsas ctecagggcg acs $ gcc $ 8 ctsgtcctcc ^ caas ^ tcac 420 gctgcaagSK; ^ cgggcsct alpg ^ ga agtcaccaat gagctggaag atgac ^ tgg 480 c & l ^ gtcaag ctggacctgg aaggcgtggt ctUccctac caccxccgtg gaggccgata 540 ca ^ cigacc ttcgcggagg cgcagcgcgc gtgc % cc £ ag caggac ^ gca tcctggcatc 600 tgcagaac ^ g ctscacgcgg coggcgcga csgcctggac t £ gtgcaacg cgggctgett fine gcgcgacggc tcagt £ caat zccccgfiu ccfgccccgg gzgcccxgcg scggcctggg 72Ώ gggg ^ cggg agtgcasggg gcggcgg ^ a tgcx ^ acsgg ggccigcgca actacgggta 780 tc ^ ccataac gccgaggaac ^ tacg ^ gc Cttctgcttc acgtccaacc t&cc^ggcg 840 cgtsttcttc c^aagccgc tgpgacctgt acccttctcc ggagctg(%c gcgcg^tgc 900 -88- 145138-sequence table.doc 201015069

tgcgcgtggc gcggocgtgg ccaaggtggg gcagctgttc gccgc £ tgga agctgcagct 960 gctagaccgc tgcaccgcgg gttggctggc cgatggcagt gcgcgctacc ccatcgtgaa 1020 cccgcgagcg cgctgcggag gccgcaggcc tggtgtgcgc agcctcggct teccggacgc 1080 cacccgacgg ctcttcggcg tctactgcta ccgcgctcca gga £ 〇accgg acc〇 £ gcacc 1140 tggc £ gctg £ gg ^ ggggct gggcgggcgg cggcggctgg gcagggggcgcgcgcgatcc 1200 tgctgcctgg acccctct £ c acgtctagsc tgggagtagg cggacagcca gggc ^ cttga 1260 ccactggtct agagccctgt ggtcccc ^ g agcctggcca cgcccttgaa gccctggaca 1320 ctggccacat tccctgtggt cccttacaaa ctaactgtgc ccctgggstc cctgaagact 1380 ggctagtcct ggcagaacag tacttt £ gag ttccctg £ ag cct £ gccagc cctcacctct 1440 tct £ gataga ggattccccc aactccccaa ctttctccat gaggfitcacg ccccctgagg 1500 accteaggag gccagcagaa cccgcaggct cctgaagact Ggccacgcct cctgagacca 1560 cttggaaaca gaccaactgc ccccgtggtc gcctggtggc tggaccoccg ggattgacta 1620 gagaccggcc gtacaccttc tecatetcac tg£agactga acactagtcc cttgcggtca 1680 cgtgggacac tgggcgcctc ctcctccccc tectcctcac ctggagagac tacaggaact 1740 tcagggtcac tccccgtggt cacatggagg ttgtgggccg aggcgcttat tttcccttat 1800 ggtgacctga gtcc ^ gaga ctcccattct ccccctctcc ctgagagtcc cctgcagttt 1860 c ^ ggtaaca gggcacaccc ctctagtttc at ££ gc £ agc acocccatct gccacctcag 1920 actgacacac agcca £ ctgg ctcacttact gggggccacg tcccacccct cagatatttc 1980 tt ^ aaggga gagcaaaccc accctgtcct ctgacgtccc tttcccaact £ tcaccaaac 2040 agaccatctt cccaggcctg gggac〇 £ gta agatocatgt cactagttat gcagagcagt 2100 tgccttgggt cccactgtca ccaaggcaac cagtcctgct gctacctgtc acctagagtc 2160 acacacccct tccdcatca ggcacaccca tgaagacagt scctccctcc tccagc ^ ta 2 ^ 0 accatggataccacacamctcatctcattggcccccaccccagagacctccaccm 2280 cttctggctg tccctaccct gactcaccgc catggagatc accctccccg aaeclgtcgc 2340 cagggtgacccaacatccagttctccggc ^ ctcaccatggaaacaaactstecc ^ tccc 2400 caggcccact ccagttccag accaccctcc atgctccacc cccaggcggt ttggacccca 2460 Ccactgttgccatggtgaccaaactctggagtccg^gtaacagaacacctgtcccccta 2520 -89 - 145138 - Sequence Listing.doc 201015069 ggcttttcct tgtggacaac ggggccctgt tcaoaagct £ttgccatag agactgtcaa 2580 cgttgtcctc atgacaacca gacttcoagt tcteaggaac ttctcattgt gggccagaag 2640 tcctgggtgc ctcctactag ggctacccta c ^ cacccca tcaggggcct gatggctgcc 2700 ccttccccag acagggot £ g acttctgsas otgctaascc accctecgtt tgcacgttaa 2760 ctctatgccg gatagcagct gtgcacgaga caatcttgca acacccgggc atgtttgtcg 2820 tcgtoctaca aatgaggaaa ccgagcctat ggcgtgccct ggtctgttga gatatgcaag 2880 cactgagctc ctcttttgtc dctgagacc ccalctecat tctcacccag ttcctctotc 2940 cttccctgac cox ^ cccac atttox ^ cc ttagagatcc aggagggatg gaatgttctt 3000 taaaattcaa cacccaccag gctctaa ^ g gcgatctgtg ctaagaggtc aggacccagc 3060 cgaagtcctc ggcgttgaca ggcagc electrically gg gggacatgat ccatggacaa £ gccatcccg 3120 gccetgggagaccccagtcxcsaagtc ^ gcctgcaggagtactggggtccccctggggc 3180 cctctttactstcdcgtcatctctaggmcctatctctgagmtEggaccaggtoggt 3240 ttgggmga attctgcxtc ttcttgctca ctgtgtgacc aagtgacaaa ctccacisa 3300 acct £ ^ ttctcccact £ taccagggct £ ttctg ^ £tccccgtgagtgcca^gcataca 3360 gtaggggctc aataaatcct tgt 3383 <210> 108 <211> 17 ^>\'m <400> 108

Pbe Ala He So: Glu Tyr Asn Lys Ala Thr Lys Asp Asp Tyr Tyr Arg 15 10 15

Arg 90- 145138 - Sequence Listing. doe

Claims (1)

201015069 VII. Patent application scope: 1. A method for detecting gastric cancer, comprising: (a) providing a biological sample; and (b) detecting excessive one or more members of the gastric tumor marker (GTM) family in the sample. Characterization wherein the GTM family member is selected from the group consisting of carboxypeptidase N, polypeptide 2, 83 kDa chain (CPN2), matrix metalloproteinase 12 (MMP12), statin ("INHBA"), insulin-like Growth Factor 7 ("IGFBP7"), γ-Amidoxime Hydrolase ("GGH"), proteoglycan rich in bright Φ amidate ("LEPRE1"), cysteine protease inhibitor S("CST4"), secretory curly-related protein 4 ("SFRP4"), Aspen cloud ("ASPN"), cell growth regulator with EF hand function site 1 ("CGREF1"), Peptide-releasing enzyme 10 ("KLK10"), tissue inhibitor of metalloproteinase 1 ("TIMP1"), secreted acidic cysteine-rich protein ("SPARC"), transforming growth factor, β- Induced ("TGFBI"), containing EGF, etc. - Bollinger Extracellular Matrix Protein 2 ("EFEMP2") 'Rumiken ("LUM"), Sterling ("SNN"), Secretory Phosphoprotein 1 ("SPP1"), Chondroitin Sulfate Proteoglycan 2 ("CSPG2"), N-indoleamine decylamine hydrolase ("AS ΑΗΓ), serine protease 11 ("PRSS11"), secretory curl-related protein 2 ("SFRP2"), phospholipase A2, XIIB group ("PLA2G12B"), statin 2, extracellular matrix protein ("SPON2"), olmolizole 1 ("0LFM1"), platelet reaction containing 1 Protein repeat ("TSRCl'i), thrombospondin 2 ("THBS2"), Adelikan, cysteine protease inhibitor SA ("CST2"), amidoxime oxidase-like enzyme 2 ("LOXL2"), scorpion 145138.doc 201015069 Adenoglobulin ("TG"), transforming growth factor beta ("TGFBl"), serine or cysteine protease inhibitor, level H ( "SERPINH1"), serine or cysteine protease inhibitor, level B ("SERPINB5" ), matrix metalloproteinase 2 ("ΜΜΡ2"), proprotein convertase subtilisin/Kaixin type 5 ("PCSK5") and hyaluronan glycoprotein-linked protein 4 ("HAPLN4"). 2. The method of claim 1, which comprises the further step of: comparing the amount of GTM present in the test sample to the value of a control sample obtained from an individual not having gastric cancer. 3. The method of claim 1, wherein the at least one GTM family member is selected from the group consisting of ampoule oxidase-like enzyme 2 ("LOXL2"), secretory coil-related protein 2 ("SFRP2"), silkamine Acid or cysteine protein inhibitor, level H ("SERPINH1") and serine or cysteine protein inhibitor, level B ("SERPINB5"). 4. The method of claim 1, wherein step (b) comprises detecting the following overexpression: cysteine protease inhibitor SN ("CST1"), aminase oxidase-like enzyme 2 ("LOXL2" ), secretory curl-related protein 2 ("SFRP2"), serine or cysteine protein inhibitor, level H ("SERPINH1") and serine or cysteine protein inhibitor, scale B("SERPINB5n). 5. The method of any one of claims 1 to 4, wherein the detecting step is performed by detecting excessive expression of GTM mRNA. 6. The method of any one of claims 1 to 4, wherein the detecting step is performed by detecting excessive expression of the GTM cDNA. 145138.doc 201015069 7. The method of claim 6, wherein the detecting step is performed using a spring nucleotide complementary to at least a portion of the GTMC DNA. 8. The method of claim 6, wherein the detecting step is performed using a qPCR method using a forward primer and a reverse primer. The method of claim 1 to 4t, wherein the detecting step is performed by detecting excessive expression of the protein. The method of any one of items 1 to 4, wherein the detecting step is performed by detecting excessive expression of the gtm peptide. The method of any one of clauses 1 to 5 wherein the bond is subjected to the detecting step with an antibody against the GTM. 12. The method of claim 1, wherein the detecting step is performed using a sandwich type immunoassay. 13. The method of claim 12, wherein the antibody is a monoclonal antibody. 14. The method of claim 12, wherein the antibody is a plurality of strains, an antiserum. 15. The method of any of the claims, wherein the detecting step is such that Φ is analyzed by ELISA. 16. The method of any one of claims 1 to 4 wherein the test sample is obtained from blood. 17. The method of any one of claims 1 to 4 wherein the test sample is obtained from tissue, urine, gastric juice, serum and feces. 18. A kit for detecting gastric cancer, comprising: a substrate having two or more GTM capture reagents thereon, which is capable of binding to one or more GTMs selected from the group consisting of: a slow enzyme N, a polypeptide 2, 83 kDa chain (CPN2), matrix metalloproteinase 12 (MMpi2), 145138.doc 201015069 statin ("INHBA"), ternal growth factor 7 ("IGFBP7"), γ-glutamine hydrolysis Enzyme ("GGH"), proteoglycan rich in leucine acid ("LEPRE1"), cysteine protease inhibitor S("CST4"), secretory curl-associated protein 4 ("SFRP4&quot ;), Aspen Cloud ("ASPN"), cell growth regulator with EF hand function site 1 ("CGREF1"), kallikrein 10 ("KLK10"), tissue inhibitor of metalloproteinase 1 ("TIMP1"), secreted acidic cysteine-rich protein ("SPARC"), transforming growth factor, β-induced ("TGFBI"), EGF-like, phenanthrene cells Exo-Matrix Protein 2 ("EFEMP2"), Lumiken ("LUM"), Stern ("SNN"), secretory phosphoprotein 1 ("SPPl"), chondroitin sulfate proteoglycan 2 ("CSPG2"), N-mercaptosphingosine guanamine hydrolase ("ASAH1&quot ;), serine protease 11 ("PRSS11"), secretory coil-related protein 2 ("SFRP2"), phospholipase A2, XIIB group ("PLA2G12B"), statin 2, extracellular matrix Protein ("SPON2"), smegmatidine l ("OLFMl), platelet reactive protein repeat containing 1 ("TSRC1"), thrombospondin 2 ("THBS2"), Adeliken , cysteine protease inhibitor SA ("CST2"), adenine oxidase-like enzyme 2 ("LOXL2"), thyroglobulin ("TG"), transforming growth factor beta ("TGFB1&quot ;), a serine or cysteine protease inhibitor, level H ("SERPINH1"), a serine or cysteine protease inhibitor, level B ("SERPINB5"), matrix metalloproteinase 2 ( "ΜΜΡ2"), proprotein convertase subtilisin / Kaixin type 5 ("P CSK5") and hyaluronan glycoprotein-linked protein 4 ("HAPLN4"); a tool for coloring the GTM capture reagent and GTM complex; 145138.doc 201015069 reagent; and instructions for use. 19. The kit of claim 18, wherein the GTM capture reagent is a GTM-specific oligonucleotide. 20. The kit of claim 18, wherein the GTM capture reagent is a GTM-specific antibody that is selective for a GTM oligonucleotide, a GTM protein, or a GTM peptide. Reference 145138.doc